[
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00001",
   "question": "Which of the following is not a mechanism of drug absorption in the GI tract?",
   "options": [
      "Passive diffusion",
      "Facilitated diffusion",
      "Active transport",
      "Filtration"
   ],
   "answer": "Filtration",
   "explanation": "Filtration is not a mechanism for drug absorption in the GI tract; drugs cross membranes mainly by passive diffusion, facilitated diffusion, active transport, or endocytosis."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00002",
   "question": "P-glycoprotein (P-gp) reduces oral drug bioavailability by:",
   "options": [
      "Enhancing passive diffusion",
      "Facilitating uptake into enterocytes",
      "Effluxing drugs from enterocytes back into the lumen",
      "Inhibiting metabolic enzymes"
   ],
   "answer": "Effluxing drugs from enterocytes back into the lumen",
   "explanation": "P-gp acts as an efflux transporter, pumping drugs from enterocytes back into the intestinal lumen, reducing their absorption."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00003",
   "question": "“First-pass metabolism” refers to drug metabolism that occurs primarily in the:",
   "options": [
      "Plasma",
      "Lung",
      "Kidney",
      "Liver and gut wall"
   ],
   "answer": "Liver and gut wall",
   "explanation": "First-pass metabolism involves the enzymatic breakdown of a drug in the liver (and to some extent the gut wall) before it reaches systemic circulation."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00004",
   "question": "Which route of administration achieves therapeutic plasma levels most rapidly?",
   "options": [
      "Oral",
      "Subcutaneous",
      "Intramuscular",
      "Intravenous"
   ],
   "answer": "Intravenous",
   "explanation": "Intravenous administration delivers drug directly into the bloodstream, producing the most rapid rise to therapeutic levels."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00005",
   "question": "A weakly basic drug (pKa 7.8) is given orally. At which site will it be mostly un-ionized and readily absorbed?",
   "options": [
      "Stomach (pH 1–2)",
      "Jejunum (pH 6–7)",
      "Ileum (pH 7.4)",
      "Colon (pH 8)"
   ],
   "answer": "Colon (pH 8)",
   "explanation": "At a pH above its pKa, a weak base is predominantly un-ionized; in the colon (pH ~8), the drug will be largely un-ionized and best absorbed."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00006",
   "question": "A drug infused continuously has a half-life of 12 hours. Approximately how long will it take to reach steady state?",
   "options": [
      "24 hours",
      "36 hours",
      "48 hours",
      "60 hours"
   ],
   "answer": "60 hours",
   "explanation": "It takes about 4–5 half-lives to reach steady state; 5 × 12 hours = 60 hours."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00007",
   "question": "Valproic acid is 90–95% albumin-bound. In hypoalbuminemia, the unbound fraction will:",
   "options": [
      "Decrease – dose must be increased",
      "Decrease – dose must be decreased",
      "Increase – dose must be increased",
      "Increase – dose must be decreased"
   ],
   "answer": "Increase – dose must be decreased",
   "explanation": "With less albumin binding, a greater fraction of free (active) drug is present, so dose should be reduced to avoid toxicity."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00008",
   "question": "Absolute bioavailability (F) is calculated as:",
   "options": [
      "Dose_IV ÷ Dose_oral",
      "AUC_oral ÷ AUC_IV",
      "CL_oral ÷ CL_IV",
      "Vd_oral ÷ Vd_IV"
   ],
   "answer": "AUC_oral ÷ AUC_IV",
   "explanation": "Absolute bioavailability is the ratio of the area under the curve (AUC) after oral dosing to that after IV dosing, corrected for dose if necessary."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00009",
   "question": "The elimination half-life (t½) relates to volume of distribution (Vd) and clearance (Cl) by:",
   "options": [
      "t½ = 0.693 × Vd ÷ Cl",
      "t½ = Vd × Cl ÷ 0.693",
      "t½ = Cl ÷ (0.693 × Vd)",
      "t½ = 0.693 ÷ (Cl × Vd)"
   ],
   "answer": "t½ = 0.693 × Vd ÷ Cl",
   "explanation": "By definition for first-order kinetics, t½ = (0.693 × Vd) / Cl."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00010",
   "question": "During a constant-rate infusion, the steady-state concentration (Css) is determined by:",
   "options": [
      "Infusion rate × Vd",
      "Infusion rate ÷ Cl",
      "Infusion rate × Cl",
      "Infusion rate ÷ Vd"
   ],
   "answer": "Infusion rate ÷ Cl",
   "explanation": "At steady state, infusion rate equals clearance × Css, so Css = infusion rate / Cl."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00011",
   "question": "A loading dose (LD) to rapidly achieve a target plasma concentration is calculated by:",
   "options": [
      "LD = (CL × Css) ÷ F",
      "LD = (Vd × Css) ÷ F",
      "LD = (CL × t½) ÷ Vd",
      "LD = (Vd × t½) ÷ F"
   ],
   "answer": "LD = (Vd × Css) ÷ F",
   "explanation": "A loading dose is based on the volume of distribution and target concentration, adjusted for bioavailability."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00012",
   "question": "The maintenance dose (MD) for a desired steady-state concentration is given by:",
   "options": [
      "MD = (Vd × Css) ÷ F",
      "MD = (Cl × Css) ÷ F",
      "MD = (Vd × t½) ÷ Cl",
      "MD = (Vd × Cl) ÷ Css"
   ],
   "answer": "MD = (Cl × Css) ÷ F",
   "explanation": "Maintenance dosing rate equals clearance times desired concentration, divided by bioavailability."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00013",
   "question": "If a drug’s oral bioavailability is 50%, to achieve the same steady-state concentration as an IV infusion you must:",
   "options": [
      "Halve the oral maintenance dose",
      "Double the oral maintenance dose",
      "Use the same oral maintenance dose",
      "Reduce the dosing interval by half"
   ],
   "answer": "Double the oral maintenance dose",
   "explanation": "With F = 0.5, the oral dose must be doubled to match systemic exposure from IV dosing."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00014",
   "question": "The extraction ratio (E) of a drug is defined as:",
   "options": [
      "Cl × Q",
      "(Cin – Cout) ÷ Cin",
      "(Cout – Cin) ÷ Cout",
      "Vd ÷ t½"
   ],
   "answer": "(Cin – Cout) ÷ Cin",
   "explanation": "Extraction ratio measures the fraction of drug removed during one pass through an eliminating organ: (inlet concentration – outlet concentration) / inlet concentration."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00015",
   "question": "Which of the following drugs exhibits zero-order kinetics at therapeutic concentrations?",
   "options": [
      "Lidocaine",
      "Phenytoin",
      "Gentamicin",
      "Atenolol"
   ],
   "answer": "Phenytoin",
   "explanation": "Phenytoin metabolism can become saturated, leading to a constant amount (not proportion) metabolized per unit time (zero-order)."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00016",
   "question": "Clearance is best defined as:",
   "options": [
      "Volume of plasma cleared of drug per unit time",
      "Fraction of dose eliminated per half-life",
      "Maximum volume of distribution",
      "AUC ÷ Dose"
   ],
   "answer": "Volume of plasma cleared of drug per unit time",
   "explanation": "Clearance represents the volume of plasma from which the drug is completely removed per unit time."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00017",
   "question": "Volume of distribution (Vd) is defined as:",
   "options": [
      "Amount of drug in body ÷ Plasma concentration",
      "Cl × t½ ÷ 0.693",
      "AUC × Dose",
      "Clearance × Half-life"
   ],
   "answer": "Amount of drug in body ÷ Plasma concentration",
   "explanation": "Vd is a theoretical volume that relates the total amount of drug in the body to the plasma concentration."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00018",
   "question": "Which process contributes least to renal drug elimination?",
   "options": [
      "Glomerular filtration",
      "Active tubular secretion",
      "Passive reabsorption",
      "Biliary excretion"
   ],
   "answer": "Biliary excretion",
   "explanation": "Biliary excretion occurs via the liver and intestines, not the kidney."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00019",
   "question": "Phase II metabolism typically involves:",
   "options": [
      "Oxidation by CYP450",
      "Reduction by dehydrogenases",
      "Conjugation with glucuronic acid",
      "Aromatic hydroxylation"
   ],
   "answer": "Conjugation with glucuronic acid",
   "explanation": "Phase II reactions add polar groups (e.g., glucuronidation) to increase water solubility for excretion."
},
 {
   "chapter_id": 1,
   "chapter": "Pharmacokinetics",
   "question_id": "00001-00020",
   "question": "For a drug following first-order kinetics, if you double the dose, the AUC will:",
   "options": [
      "Stay the same",
      "Double",
      "Quadruple",
      "Halve"
   ],
   "answer": "Double",
   "explanation": "With first-order kinetics, AUC (systemic exposure) is directly proportional to dose."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00021",
   "question": "Which parameter reflects the concentration of a drug needed to produce 50% of its maximal effect?",
   "options": [
      "Emax",
      "EC50",
      "KD",
      "TI"
   ],
   "answer": "EC50",
   "explanation": "EC50 is the concentration or dose required to achieve 50% of the maximal effect, and is a measure of potency."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00022",
   "question": "Which term describes the maximal response that a drug can produce, regardless of dose?",
   "options": [
      "Potency",
      "Efficacy",
      "Affinity",
      "Selectivity"
   ],
   "answer": "Efficacy",
   "explanation": "Efficacy refers to the maximum effect a drug can elicit, independent of the dose required to achieve it."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00023",
   "question": "A competitive antagonist will:",
   "options": [
      "Decrease Emax without changing EC50",
      "Increase EC50 without changing Emax",
      "Decrease both EC50 and Emax",
      "Increase Emax without changing EC50"
   ],
   "answer": "Increase EC50 without changing Emax",
   "explanation": "Competitive antagonists shift the dose–response curve to the right (higher EC50) but do not affect the maximal achievable response."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00024",
   "question": "A noncompetitive antagonist will:",
   "options": [
      "Shift curve to the right only",
      "Lower Emax without changing EC50",
      "Raise Emax and EC50",
      "Have no effect on the dose–response curve"
   ],
   "answer": "Lower Emax without changing EC50",
   "explanation": "Noncompetitive antagonists reduce the maximal response (Emax) by binding irreversibly or allosterically, independent of agonist concentration."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00025",
   "question": "Partial agonists:",
   "options": [
      "Produce full Emax when receptors are saturated",
      "Produce submaximal effect even at full receptor occupancy",
      "Have no efficacy",
      "Are identical to competitive antagonists"
   ],
   "answer": "Produce submaximal effect even at full receptor occupancy",
   "explanation": "Partial agonists bind receptors but have lower intrinsic activity, so they never achieve full Emax."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00026",
   "question": "Spare receptors:",
   "options": [
      "Increase efficacy but decrease potency",
      "Decrease both efficacy and potency",
      "Allow maximal response at less than full receptor occupancy",
      "Are only found in enzyme-linked receptors"
   ],
   "answer": "Allow maximal response at less than full receptor occupancy",
   "explanation": "Spare receptors mean not all receptors need be occupied to elicit a maximal effect, increasing apparent potency."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00027",
   "question": "Affinity of a drug for its receptor is most closely related to:",
   "options": [
      "Emax",
      "KD",
      "EC50",
      "TI"
   ],
   "answer": "KD",
   "explanation": "KD is the equilibrium dissociation constant reflecting the concentration at which half of receptors are occupied, directly measuring affinity."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00028",
   "question": "The therapeutic index (TI) is defined as:",
   "options": [
      "LD50/ED50",
      "ED50/LD50",
      "TD50/ED50",
      "ED50/TD50"
   ],
   "answer": "TD50/ED50",
   "explanation": "TI is the ratio of the dose that produces toxicity in 50% of subjects (TD50) to the dose that produces therapeutic effect in 50% (ED50)."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00029",
   "question": "An inverse agonist:",
   "options": [
      "Produces the same effect as an agonist",
      "Reduces basal receptor activity below its constitutive level",
      "Has no effect unless an agonist is present",
      "Acts identically to a competitive antagonist"
   ],
   "answer": "Reduces basal receptor activity below its constitutive level",
   "explanation": "Inverse agonists bind to receptors with constitutive activity and decrease their basal signaling in the absence of agonist."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00030",
   "question": "Functional antagonism occurs when:",
   "options": [
      "Two drugs compete at the same receptor",
      "One drug blocks the effect of another via opposite physiological pathways",
      "A drug is metabolized faster when co-administered",
      "A drug binds irreversibly to a receptor"
   ],
   "answer": "One drug blocks the effect of another via opposite physiological pathways",
   "explanation": "Functional antagonism involves two drugs acting at different receptors or systems but producing opposite effects."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00031",
   "question": "The slope (Hill coefficient) of a dose–response curve indicates:",
   "options": [
      "Maximum effect achievable",
      "Cooperativity of ligand binding",
      "Affinity exclusively",
      "Duration of action"
   ],
   "answer": "Cooperativity of ligand binding",
   "explanation": "The Hill coefficient reflects how binding of one ligand molecule influences the binding of additional molecules (cooperativity)."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00032",
   "question": "A rightward shift in a quantal dose–response curve indicates:",
   "options": [
      "Increased potency",
      "Decreased potency",
      "Increased efficacy",
      "Decreased toxicity"
   ],
   "answer": "Decreased potency",
   "explanation": "A rightward shift signifies that a higher dose is required to produce the same effect in 50% of the population, indicating lower potency."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00033",
   "question": "In a Schild plot, the slope of unity indicates:",
   "options": [
      "Noncompetitive antagonism",
      "Competitive antagonism",
      "Partial agonism",
      "Inverse agonism"
   ],
   "answer": "Competitive antagonism",
   "explanation": "A Schild plot slope of 1 suggests reversible competitive antagonism at the same binding site as the agonist."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00034",
   "question": "Quantal dose–response curves are used to determine:",
   "options": [
      "Individual EC50",
      "Population variability in dose response",
      "Maximum efficacy",
      "Intrinsic activity"
   ],
   "answer": "Population variability in dose response",
   "explanation": "Quantal curves plot the fraction of a population responding at each dose, showing variability and allowing ED50 determination."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00035",
   "question": "Desensitization (tachyphylaxis) refers to:",
   "options": [
      "Increased response with repeated dosing",
      "Decreased response with continuous or repeated exposure",
      "A shift in KD only",
      "Complete loss of receptor expression"
   ],
   "answer": "Decreased response with continuous or repeated exposure",
   "explanation": "Desensitization is a rapid decrease in receptor responsiveness upon sustained agonist exposure."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00036",
   "question": "Allosteric modulators:",
   "options": [
      "Bind the same site as the agonist",
      "Alter receptor activity by binding a different site",
      "Always act as antagonists",
      "Have no effect on efficacy"
   ],
   "answer": "Alter receptor activity by binding a different site",
   "explanation": "Allosteric modulators bind to sites distinct from the orthosteric site and modify receptor response positively or negatively."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00037",
   "question": "An irreversible antagonist:",
   "options": [
      "Competes with agonist and is surmountable",
      "Covalently binds receptor, reducing Emax",
      "Increases potency of agonist",
      "Acts as a partial agonist"
   ],
   "answer": "Covalently binds receptor, reducing Emax",
   "explanation": "Irreversible antagonists permanently inactivate receptors, lowering the maximal response even at high agonist concentrations."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00038",
   "question": "Intrinsic activity describes:",
   "options": [
      "Affinity of a drug",
      "Ability of a bound drug to activate its receptor",
      "Rate of drug metabolism",
      "Duration of receptor binding"
   ],
   "answer": "Ability of a bound drug to activate its receptor",
   "explanation": "Intrinsic activity is the relative efficacy of a drug to produce a response once bound."
},
 {
   "chapter_id": 2,
   "chapter": "Drug–Receptor Interactions and Pharmacodynamics",
   "question_id": "00002-00039",
   "question": "Potency is influenced by:",
   "options": [
      "Only efficacy",
      "Only affinity",
      "Affinity and efficacy",
      "Receptor number only"
   ],
   "answer": "Affinity and efficacy",
   "explanation": "Potency depends on both how tightly a drug binds (affinity) and how well it activates the receptor (efficacy)."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00040",
   "question": "Which neurotransmitter is released by preganglionic neurons in both sympathetic and parasympathetic divisions?",
   "options": [
      "Acetylcholine",
      "Norepinephrine",
      "Epinephrine",
      "Dopamine"
   ],
   "answer": "Acetylcholine",
   "explanation": "Preganglionic fibers in both divisions release ACh onto nicotinic receptors in the ganglia."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00041",
   "question": "Which receptor subtype mediates vasoconstriction when activated by norepinephrine?",
   "options": [
      "α1",
      "α2",
      "β1",
      "β2"
   ],
   "answer": "α1",
   "explanation": "α1 receptors on vascular smooth muscle cause vasoconstriction via Gq-mediated Ca²⁺ release."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00042",
   "question": "Activation of which receptor decreases heart rate?",
   "options": [
      "M2",
      "M3",
      "β1",
      "β2"
   ],
   "answer": "M2",
   "explanation": "M2 receptors on the heart decrease cAMP via Gi, reducing heart rate and AV conduction."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00043",
   "question": "Which enzyme breaks down acetylcholine in the synaptic cleft?",
   "options": [
      "Acetylcholinesterase",
      "Monoamine oxidase",
      "COMT",
      "Butyrylcholinesterase"
   ],
   "answer": "Acetylcholinesterase",
   "explanation": "AChE hydrolyzes acetylcholine into choline and acetate."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00044",
   "question": "Which receptor subtype is found on sweat glands and responds to ACh in sympathetic fibers?",
   "options": [
      "M3",
      "M2",
      "α1",
      "β2"
   ],
   "answer": "M3",
   "explanation": "Sympathetic cholinergic fibers innervate sweat glands via M3 receptors."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00045",
   "question": "Which of the following is NOT a function of the sympathetic nervous system?",
   "options": [
      "Bronchoconstriction",
      "Pupil dilation",
      "Increased heart rate",
      "Glycogenolysis"
   ],
   "answer": "Bronchoconstriction",
   "explanation": "Sympathetic activation causes bronchodilation, not constriction."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00046",
   "question": "Ganglionic blockade would affect which receptor type?",
   "options": [
      "Nicotinic N",
      "Muscarinic",
      "α1-adrenergic",
      "β1-adrenergic"
   ],
   "answer": "Nicotinic N",
   "explanation": "Nicotinic N receptors on autonomic ganglia mediate neurotransmission from pre- to postganglionic neurons."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00047",
   "question": "Which autonomic division predominates in maintaining resting vascular tone?",
   "options": [
      "Sympathetic",
      "Parasympathetic",
      "Both equally",
      "Neither"
   ],
   "answer": "Sympathetic",
   "explanation": "Vascular tone is primarily maintained by sympathetic α1-adrenergic activity."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00048",
   "question": "Which receptor mediates relaxation of bronchial smooth muscle?",
   "options": [
      "β2",
      "β1",
      "α1",
      "M3"
   ],
   "answer": "β2",
   "explanation": "β2 receptor activation increases cAMP, causing bronchodilation."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00049",
   "question": "Activation of which receptor reduces norepinephrine release from sympathetic nerve terminals?",
   "options": [
      "α2",
      "α1",
      "β1",
      "M2"
   ],
   "answer": "α2",
   "explanation": "α2 autoreceptors inhibit further NE release via Gi-mediated pathways."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00050",
   "question": "Which of the following is a sympathetic postganglionic neurotransmitter?",
   "options": [
      "Norepinephrine",
      "Acetylcholine",
      "Dopamine",
      "Serotonin"
   ],
   "answer": "Norepinephrine",
   "explanation": "Most sympathetic postganglionic fibers release NE onto adrenergic receptors."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00051",
   "question": "Which receptor subtype increases insulin secretion when activated?",
   "options": [
      "β2",
      "α2",
      "M2",
      "M3"
   ],
   "answer": "β2",
   "explanation": "β2 activation on pancreatic β-cells enhances insulin release."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00052",
   "question": "Which transporter mediates reuptake of norepinephrine into presynaptic terminals?",
   "options": [
      "NET",
      "MAO",
      "COMT",
      "AChE"
   ],
   "answer": "NET",
   "explanation": "Norepinephrine transporter (NET) is responsible for NE reuptake into presynaptic neurons."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00053",
   "question": "Which receptor subtype primarily increases cardiac contractility?",
   "options": [
      "β1",
      "β2",
      "α1",
      "M2"
   ],
   "answer": "β1",
   "explanation": "β1 receptors on cardiac myocytes increase Ca²⁺ influx, enhancing contractility."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00054",
   "question": "Which receptor mediates pupillary constriction when activated?",
   "options": [
      "M3",
      "α1",
      "β2",
      "M2"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on the sphincter pupillae cause constriction (miosis) via Gq."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00055",
   "question": "Which of the following best describes dual innervation?",
   "options": [
      "Innervation by both sympathetic and parasympathetic fibers",
      "Only sympathetic fibers",
      "Only parasympathetic fibers",
      "Neither"
   ],
   "answer": "Innervation by both sympathetic and parasympathetic fibers",
   "explanation": "Most organs receive input from both divisions, allowing fine control."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00056",
   "question": "Which receptor subtype mediates relaxation of the detrusor muscle of the bladder?",
   "options": [
      "β3",
      "β2",
      "M3",
      "α1"
   ],
   "answer": "β3",
   "explanation": "β3 activation causes detrusor relaxation, promoting urine storage."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00057",
   "question": "Which drug class blocks nicotinic receptors at the neuromuscular junction?",
   "options": [
      "Nondepolarizing neuromuscular blockers",
      "ACE inhibitors",
      "β-blockers",
      "α-blockers"
   ],
   "answer": "Nondepolarizing neuromuscular blockers",
   "explanation": "Agents like tubocurarine compete at NM nicotinic receptors to inhibit muscle contraction."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00058",
   "question": "Which of the following occurs with parasympathetic activation of the gut?",
   "options": [
      "Increased motility",
      "Decreased secretions",
      "Constipation",
      "Bronchodilation"
   ],
   "answer": "Increased motility",
   "explanation": "Parasympathetic M3 receptor activation increases GI motility and secretions."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00059",
   "question": "Activation of β1 receptors leads to increased levels of which second messenger?",
   "options": [
      "cAMP",
      "IP3",
      "DAG",
      "cGMP"
   ],
   "answer": "cAMP",
   "explanation": "β1 receptors are Gs-coupled, activating adenylate cyclase to raise intracellular cAMP."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00060",
   "question": "Which structure acts like a sympathetic ganglion but secretes hormones into the bloodstream?",
   "options": [
      "Adrenal medulla",
      "Paravertebral ganglion",
      "Celiac plexus",
      "Dorsal root ganglion"
   ],
   "answer": "Adrenal medulla",
   "explanation": "The adrenal medulla contains chromaffin cells (modified postganglionic neurons) that release epinephrine and norepinephrine directly into the blood."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00061",
   "question": "Parasympathetic preganglionic fibers originate from which regions of the CNS?",
   "options": [
      "Brainstem and sacral spinal cord",
      "Thoracolumbar spinal cord",
      "Cervical spinal cord only",
      "Lumbar spinal cord only"
   ],
   "answer": "Brainstem and sacral spinal cord",
   "explanation": "Parasympathetic outflow is craniosacral: preganglionic neurons are in the brainstem (cranial nerves III, VII, IX, X) and S2–S4 segments."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00062",
   "question": "Sympathetic preganglionic fibers emerge from which spinal segments?",
   "options": [
      "T1–L2",
      "C3–C7",
      "S2–S4",
      "L3–L5"
   ],
   "answer": "T1–L2",
   "explanation": "Sympathetic outflow is thoracolumbar: preganglionic neurons reside in the intermediolateral cell columns of T1–L2."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00063",
   "question": "In the sympathetic division, preganglionic fibers are typically:",
   "options": [
      "Short and myelinated",
      "Long and unmyelinated",
      "Short and unmyelinated",
      "Long and myelinated"
   ],
   "answer": "Short and myelinated",
   "explanation": "Sympathetic preganglionic fibers are myelinated but relatively short, synapsing in paravertebral or prevertebral ganglia."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00064",
   "question": "Parasympathetic postganglionic neurons are located:",
   "options": [
      "In or near the target organ",
      "Alongside the spinal cord (chain ganglia)",
      "In the dorsal root ganglia",
      "In the adrenal medulla"
   ],
   "answer": "In or near the target organ",
   "explanation": "Parasympathetic ganglia (terminal ganglia) lie close to or within the walls of their effector organs."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00065",
   "question": "The sympathetic chain ganglia are also called:",
   "options": [
      "Paravertebral ganglia",
      "Prevertebral ganglia",
      "Terminal ganglia",
      "Collateral ganglia"
   ],
   "answer": "Paravertebral ganglia",
   "explanation": "The sympathetic trunk runs alongside the vertebral column; its ganglia are termed paravertebral."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00066",
   "question": "Which nicotinic receptor subtype is found on chromaffin cells of the adrenal medulla?",
   "options": [
      "Nicotinic N (NN)",
      "Nicotinic M (NM)",
      "Muscarinic M1",
      "Muscarinic M3"
   ],
   "answer": "Nicotinic N (NN)",
   "explanation": "Chromaffin cells express the neuronal subtype of nicotinic receptors (NN) which respond to ACh from preganglionic fibers."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00067",
   "question": "α1-adrenergic receptors couple to which G-protein to increase intracellular Ca²⁺?",
   "options": [
      "Gq",
      "Gi",
      "Gs",
      "Go"
   ],
   "answer": "Gq",
   "explanation": "α1 receptors are Gq-coupled, activating phospholipase C to generate IP₃ and release Ca²⁺ from the ER."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00068",
   "question": "β2-adrenergic receptors mediate their effects primarily through which second messenger?",
   "options": [
      "cAMP",
      "IP₃",
      "DAG",
      "cGMP"
   ],
   "answer": "cAMP",
   "explanation": "β2 receptors are Gs-coupled, stimulating adenylate cyclase to raise intracellular cAMP levels."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00069",
   "question": "Activation of α2-adrenergic receptors leads to:",
   "options": [
      "Decreased cAMP",
      "Increased cAMP",
      "Increased IP₃",
      "Increased DAG"
   ],
   "answer": "Decreased cAMP",
   "explanation": "α2 receptors are Gi-coupled, inhibiting adenylate cyclase and reducing cAMP formation."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00070",
   "question": "Which nerve provides the majority of parasympathetic innervation to the heart?",
   "options": [
      "Vagus nerve",
      "Phrenic nerve",
      "Splanchnic nerve",
      "Hypoglossal nerve"
   ],
   "answer": "Vagus nerve",
   "explanation": "Parasympathetic fibers to the heart travel via the vagus (cranial nerve X), slowing heart rate."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00071",
   "question": "Which division of the ANS predominates in controlling basal vascular tone?",
   "options": [
      "Sympathetic",
      "Parasympathetic",
      "Both equally",
      "Neither"
   ],
   "answer": "Sympathetic",
   "explanation": "Blood vessels lack significant parasympathetic input; vasomotor tone is maintained by sympathetic α1 activity."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00072",
   "question": "Parasympathetic stimulation of the bladder detrusor muscle occurs via which receptor?",
   "options": [
      "M3",
      "M2",
      "β3",
      "α1"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on the detrusor mediate contraction and promote urination under parasympathetic control."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00073",
   "question": "Which receptor subtype mediates pupillary dilation (mydriasis) under sympathetic activation?",
   "options": [
      "α1",
      "M3",
      "β2",
      "α2"
   ],
   "answer": "α1",
   "explanation": "α1 receptors on the iris dilator muscle contract it, leading to pupil dilation."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00074",
   "question": "Sweat glands receive sympathetic innervation that uses which neurotransmitter?",
   "options": [
      "Acetylcholine",
      "Norepinephrine",
      "Epinephrine",
      "Dopamine"
   ],
   "answer": "Acetylcholine",
   "explanation": "Sympathetic postganglionic fibers to sweat glands are cholinergic, releasing ACh onto M3 receptors."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00075",
   "question": "Which receptor subtype on bronchial smooth muscle causes constriction when activated?",
   "options": [
      "M3",
      "β2",
      "α1",
      "D2"
   ],
   "answer": "M3",
   "explanation": "Parasympathetic M3 receptors increase IP₃, raising Ca²⁺ and causing bronchoconstriction."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00076",
   "question": "Activation of β1-adrenergic receptors in the heart increases:",
   "options": [
      "Heart rate and contractility",
      "Vasodilation",
      "Glycogen synthesis",
      "Salivary secretion"
   ],
   "answer": "Heart rate and contractility",
   "explanation": "β1 receptors on cardiac myocytes enhance Ca²⁺ currents via cAMP, raising both chronotropy and inotropy."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00077",
   "question": "Which autonomic effect is described as complementary rather than antagonistic?",
   "options": [
      "Salivary secretion (parasympathetic: watery; sympathetic: protein-rich)",
      "Heart rate (parasympathetic decreases; sympathetic increases)",
      "Pupil diameter (parasympathetic constricts; sympathetic dilates)",
      "GI motility (parasympathetic increases; sympathetic decreases)"
   ],
   "answer": "Salivary secretion (parasympathetic: watery; sympathetic: protein-rich)",
   "explanation": "Salivary glands under dual innervation produce different secretions: parasympathetic yields a watery fluid, sympathetic a protein-rich fluid, complementing each other."
},
 {
   "chapter_id": 3,
   "chapter": "The Autonomic Nervous System",
   "question_id": "00003-00078",
   "question": "Which term refers to the baseline firing rate of sympathetic fibers at rest?",
   "options": [
      "Sympathetic tone",
      "Parasympathetic tone",
      "Autonomic latency",
      "Neurogenic shock"
   ],
   "answer": "Sympathetic tone",
   "explanation": "Sympathetic tone describes the continuous low-level activity of sympathetic fibers maintaining vascular tone and organ function."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00079",
   "question": "Which direct-acting muscarinic agonist is used to treat urinary retention?",
   "options": [
      "Bethanechol",
      "Carbachol",
      "Pilocarpine",
      "Methacholine"
   ],
   "answer": "Bethanechol",
   "explanation": "Bethanechol selectively activates M3 receptors in the bladder to stimulate detrusor muscle contraction and relieve urinary retention."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00080",
   "question": "Which muscarinic agonist is resistant to acetylcholinesterase and can be used topically in glaucoma?",
   "options": [
      "Pilocarpine",
      "Carbachol",
      "Methacholine",
      "Bethanechol"
   ],
   "answer": "Carbachol",
   "explanation": "Carbachol is a carbamate resistant to AChE and can be applied to the eye to induce miosis and lower intraocular pressure."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00081",
   "question": "Pilocarpine is primarily used in the treatment of which condition?",
   "options": [
      "Asthma",
      "Glaucoma",
      "Myasthenia gravis",
      "Urinary retention"
   ],
   "answer": "Glaucoma",
   "explanation": "Pilocarpine activates M3 receptors in the eye to induce ciliary muscle contraction, increasing aqueous humor outflow and reducing intraocular pressure."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00082",
   "question": "Which agent is used as a diagnostic test for bronchial hyperreactivity?",
   "options": [
      "Methacholine",
      "Bethanechol",
      "Pilocarpine",
      "Carbachol"
   ],
   "answer": "Methacholine",
   "explanation": "Methacholine challenge test induces bronchoconstriction via M3 receptor activation to assess airway hyperresponsiveness in asthma."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00083",
   "question": "Which quaternary ammonium carbamate is used to treat myasthenia gravis?",
   "options": [
      "Neostigmine",
      "Physostigmine",
      "Donepezil",
      "Edrophonium"
   ],
   "answer": "Neostigmine",
   "explanation": "Neostigmine inhibits AChE peripherally, increasing ACh at the neuromuscular junction and improving muscle strength in myasthenia gravis."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00084",
   "question": "Which reversible cholinesterase inhibitor is preferred for prophylaxis against nerve agent poisoning?",
   "options": [
      "Edrophonium",
      "Pyridostigmine",
      "Donepezil",
      "Rivastigmine"
   ],
   "answer": "Pyridostigmine",
   "explanation": "Pyridostigmine is used prophylactically to protect AChE from irreversible organophosphate binding due to its reversible carbamoylation."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00085",
   "question": "Which ultra-short-acting AChE inhibitor is used in the Tensilon test to diagnose myasthenia gravis?",
   "options": [
      "Neostigmine",
      "Edrophonium",
      "Physostigmine",
      "Rivastigmine"
   ],
   "answer": "Edrophonium",
   "explanation": "Edrophonium binds AChE non-covalently with rapid onset and short duration, allowing transient improvement in muscle strength for diagnostic purposes."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00086",
   "question": "Which tertiary amine AChE inhibitor crosses the blood-brain barrier and is used to treat anticholinergic toxicity?",
   "options": [
      "Neostigmine",
      "Physostigmine",
      "Pyridostigmine",
      "Edrophonium"
   ],
   "answer": "Physostigmine",
   "explanation": "Physostigmine is a tertiary carbamate that enters the CNS to reverse central and peripheral anticholinergic effects."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00087",
   "question": "Which selective acetylcholinesterase inhibitor is used as first-line therapy in Alzheimer’s disease?",
   "options": [
      "Neostigmine",
      "Donepezil",
      "Bethanechol",
      "Echothiophate"
   ],
   "answer": "Donepezil",
   "explanation": "Donepezil selectively inhibits AChE in the CNS, enhancing cholinergic transmission and improving cognition in Alzheimer’s patients."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00088",
   "question": "Which cholinesterase inhibitor also inhibits butyrylcholinesterase and is used in mild to moderate Alzheimer’s disease?",
   "options": [
      "Rivastigmine",
      "Edrophonium",
      "Carbachol",
      "Physostigmine"
   ],
   "answer": "Rivastigmine",
   "explanation": "Rivastigmine inhibits both AChE and BuChE, increasing ACh levels in the CNS with a longer duration of action."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00089",
   "question": "Which cholinergic drug is an AChE inhibitor and allosteric modulator of nicotinic receptors used in Alzheimer’s disease?",
   "options": [
      "Galantamine",
      "Donepezil",
      "Neostigmine",
      "Pilocarpine"
   ],
   "answer": "Galantamine",
   "explanation": "Galantamine inhibits AChE and modulates nicotinic receptors to enhance cholinergic neurotransmission in Alzheimer’s disease."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00090",
   "question": "Which irreversible AChE inhibitor is used topically for open-angle glaucoma?",
   "options": [
      "Neostigmine",
      "Echothiophate",
      "Physostigmine",
      "Bethanechol"
   ],
   "answer": "Echothiophate",
   "explanation": "Echothiophate irreversibly inhibits AChE, causing prolonged miosis and decreased intraocular pressure in glaucoma."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00091",
   "question": "Malathion belongs to which class of cholinesterase inhibitors?",
   "options": [
      "Carbamate",
      "Organophosphate",
      "Alcohol",
      "Ester"
   ],
   "answer": "Organophosphate",
   "explanation": "Malathion is an organophosphate insecticide that irreversibly phosphorylates AChE, leading to cholinergic overstimulation."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00092",
   "question": "Parathion, an organophosphate, causes toxicity by:",
   "options": [
      "Reversible AChE inhibition",
      "Irreversible AChE phosphorylation",
      "Blocking muscarinic receptors",
      "Blocking nicotinic receptors"
   ],
   "answer": "Irreversible AChE phosphorylation",
   "explanation": "Parathion and other organophosphates phosphorylate AChE, permanently inactivating the enzyme and increasing ACh levels."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00093",
   "question": "Which drug regenerates acetylcholinesterase inhibited by organophosphates?",
   "options": [
      "Atropine",
      "Pralidoxime",
      "Physostigmine",
      "Neostigmine"
   ],
   "answer": "Pralidoxime",
   "explanation": "Pralidoxime reactivates phosphorylated AChE by cleaving the phosphate-enzyme bond, restoring enzyme function."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00094",
   "question": "Which drug is administered to treat cholinergic crisis caused by AChE inhibitors?",
   "options": [
      "Atropine",
      "Bethanechol",
      "Pilocarpine",
      "Neostigmine"
   ],
   "answer": "Atropine",
   "explanation": "Atropine is a muscarinic antagonist that blocks excessive ACh at muscarinic receptors during cholinergic crisis."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00095",
   "question": "Which mnemonic describes the muscarinic effects of cholinergic overstimulation?",
   "options": [
      "SLUDGE",
      "DUMBBELSS",
      "ABCDE",
      "FASTHUG"
   ],
   "answer": "DUMBBELSS",
   "explanation": "DUMBBELSS stands for Diarrhea, Urination, Miosis, Bronchospasm, Bradycardia, Emesis, Lacrimation, Sweating, Salivation—key cholinergic signs."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00096",
   "question": "Which muscarinic receptor subtype is primarily responsible for increased glandular secretions?",
   "options": [
      "M1",
      "M2",
      "M3",
      "M4"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on exocrine glands mediate increased secretions such as saliva, sweat, and gastric secretions."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00097",
   "question": "Which receptor subtype mediates decreased heart rate when stimulated by ACh?",
   "options": [
      "M1",
      "M2",
      "M3",
      "M4"
   ],
   "answer": "M2",
   "explanation": "M2 receptors in the heart activate Gi to reduce cAMP, slowing heart rate and AV conduction."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00098",
   "question": "Which nicotinic receptor subtype is located at the neuromuscular junction?",
   "options": [
      "Nicotinic N",
      "Nicotinic M",
      "M1",
      "M2"
   ],
   "answer": "Nicotinic M",
   "explanation": "Nicotinic M (muscle type) receptors are found on skeletal muscle end plates and mediate neuromuscular transmission."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00099",
   "question": "Which nicotinic receptor subtype is found on autonomic ganglia and the adrenal medulla?",
   "options": [
      "Nicotinic N",
      "Nicotinic M",
      "M3",
      "M2"
   ],
   "answer": "Nicotinic N",
   "explanation": "Nicotinic N (neuronal type) receptors are present on autonomic ganglia and chromaffin cells of the adrenal medulla."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00100",
   "question": "Which muscarinic agonist increases gastric motility postpartum?",
   "options": [
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine",
      "Methacholine"
   ],
   "answer": "Bethanechol",
   "explanation": "Bethanechol activates M3 receptors in the gastrointestinal tract to enhance smooth muscle contraction and motility."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00101",
   "question": "Which cholinergic agonist is contraindicated in peptic ulcer disease due to increased gastric secretions?",
   "options": [
      "Bethanechol",
      "Pilocarpine",
      "Carbachol",
      "Neostigmine"
   ],
   "answer": "Bethanechol",
   "explanation": "Bethanechol increases gastric secretions via M3 activation, which can exacerbate peptic ulcers."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00102",
   "question": "Which agonist would cause bronchoconstriction, limiting its use in asthmatics?",
   "options": [
      "Pilocarpine",
      "Methacholine",
      "Bethanechol",
      "Carbachol"
   ],
   "answer": "Methacholine",
   "explanation": "Methacholine induces bronchoconstriction via M3 receptor activation in airway smooth muscle."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00103",
   "question": "Miosis induced by cholinergic agonists lowers intraocular pressure by:",
   "options": [
      "Decreasing aqueous humor production",
      "Increasing trabecular outflow",
      "Blocking ciliary epithelium",
      "Dilating the pupil"
   ],
   "answer": "Increasing trabecular outflow",
   "explanation": "Miosis pulls the scleral spur, opening the trabecular meshwork to enhance aqueous humor drainage."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00104",
   "question": "Neostigmine is administered after surgery to reverse which type of neuromuscular blockade?",
   "options": [
      "Depolarizing",
      "Nondepolarizing",
      "Organophosphate-induced",
      "Botulinum toxin–induced"
   ],
   "answer": "Nondepolarizing",
   "explanation": "Neostigmine increases ACh at the NMJ to outcompete nondepolarizing blockers like vecuronium or rocuronium."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00105",
   "question": "Which reversible AChE inhibitor can be used topically in the eye for glaucoma?",
   "options": [
      "Physostigmine",
      "Echothiophate",
      "Neostigmine",
      "Edrophonium"
   ],
   "answer": "Physostigmine",
   "explanation": "Physostigmine applied ocularly inhibits AChE, producing miosis and lowering intraocular pressure."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00106",
   "question": "Which AChE inhibitor has the longest duration of action?",
   "options": [
      "Edrophonium",
      "Neostigmine",
      "Physostigmine",
      "Echothiophate"
   ],
   "answer": "Echothiophate",
   "explanation": "Echothiophate irreversibly inhibits AChE, leading to prolonged cholinergic effects."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00107",
   "question": "Which AChE inhibitor has the shortest duration of action?",
   "options": [
      "Echothiophate",
      "Neostigmine",
      "Edrophonium",
      "Physostigmine"
   ],
   "answer": "Edrophonium",
   "explanation": "Edrophonium binds non-covalently with rapid onset and short duration, making its effect transient."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00108",
   "question": "Which AChE inhibitor does NOT cross the blood–brain barrier?",
   "options": [
      "Physostigmine",
      "Donepezil",
      "Neostigmine",
      "Rivastigmine"
   ],
   "answer": "Neostigmine",
   "explanation": "Neostigmine is a quaternary ammonium compound, limiting its ability to penetrate the CNS."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00109",
   "question": "Carbachol can be used intraocularly to induce miosis during which procedure?",
   "options": [
      "Cataract surgery",
      "LASIK",
      "Corneal transplant",
      "Retinal detachment repair"
   ],
   "answer": "Cataract surgery",
   "explanation": "Carbachol causes rapid miosis to facilitate lens extraction and intraocular lens insertion."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00110",
   "question": "Cholinergic agonists increase bronchial secretions via which receptor subtype?",
   "options": [
      "M2",
      "M3",
      "β2",
      "α1"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on airway submucosal glands mediate increased mucus and fluid secretion."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00111",
   "question": "Which agent is contraindicated in urinary obstruction due to risk of increased bladder pressure?",
   "options": [
      "Bethanechol",
      "Pilocarpine",
      "Carbachol",
      "Neostigmine"
   ],
   "answer": "Bethanechol",
   "explanation": "By increasing detrusor contraction, bethanechol can worsen obstruction and cause bladder rupture."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00112",
   "question": "Excessive indirect cholinergic stimulation at the neuromuscular junction leads to which sign?",
   "options": [
      "Flaccid paralysis",
      "Spastic paralysis",
      "Tremors only",
      "No effect"
   ],
   "answer": "Flaccid paralysis",
   "explanation": "Continuous depolarization by excess ACh at the end plate results in flaccid paralysis due to inactivation of voltage-gated Na⁺ channels."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00113",
   "question": "Miosis caused by cholinergic drugs is mediated by which muscle?",
   "options": [
      "Sphincter pupillae",
      "Dilator pupillae",
      "Ciliary muscle",
      "Orbicularis oculi"
   ],
   "answer": "Sphincter pupillae",
   "explanation": "The sphincter pupillae muscle constricts the pupil when M3 receptors are activated by ACh."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00114",
   "question": "Which receptor subtype stimulates gastric acid secretion when activated?",
   "options": [
      "M1",
      "M2",
      "M3",
      "M4"
   ],
   "answer": "M1",
   "explanation": "M1 receptors on gastric parietal cells and ECL cells mediate increased acid secretion via vagal stimulation."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00115",
   "question": "Vagal stimulation increases which of the following via muscarinic receptors?",
   "options": [
      "Heart rate",
      "AV conduction",
      "Gastric motility",
      "Pupil dilation"
   ],
   "answer": "Gastric motility",
   "explanation": "Vagal and muscarinic activation increases GI motility and secretions but decreases heart rate and conduction."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00116",
   "question": "Which receptor subtype blockade would most directly inhibit both sympathetic and parasympathetic neurotransmission?",
   "options": [
      "Muscarinic",
      "Nicotinic N",
      "Nicotinic M",
      "β-adrenergic"
   ],
   "answer": "Nicotinic N",
   "explanation": "Blocking Nn receptors at autonomic ganglia prevents transmission in both divisions, reducing all autonomic outflow."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00117",
   "question": "Which second messenger is increased by M1 receptor activation?",
   "options": [
      "cAMP",
      "IP3",
      "cGMP",
      "DAG"
   ],
   "answer": "IP3",
   "explanation": "M1 receptors are Gq-coupled, activating phospholipase C to generate IP3 and DAG, leading to intracellular Ca²⁺ release."
},
 {
   "chapter_id": 4,
   "chapter": "Cholinergic Agonists",
   "question_id": "00004-00118",
   "question": "Which class of AChE inhibitors binds covalently to the enzyme and has effects lasting several hours?",
   "options": [
      "Alcohols",
      "Carbamates",
      "Organophosphates",
      "Sulfonamides"
   ],
   "answer": "Carbamates",
   "explanation": "Carbamate inhibitors like neostigmine and physostigmine form a covalent carbamoyl–enzyme intermediate that reverses slowly."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00119",
   "question": "Which muscarinic antagonist is used to dilate pupils during ophthalmic exams?",
   "options": [
      "Tropicamide",
      "Pilocarpine",
      "Bethanechol",
      "Methacholine"
   ],
   "answer": "Tropicamide",
   "explanation": "Tropicamide blocks M3 receptors in the iris sphincter, causing pupil dilation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00120",
   "question": "Which agent is used transdermally to prevent motion sickness by blocking central muscarinic receptors?",
   "options": [
      "Scopolamine",
      "Ipratropium",
      "Glycopyrrolate",
      "Darifenacin"
   ],
   "answer": "Scopolamine",
   "explanation": "Scopolamine crosses the BBB to antagonize central M1 receptors, reducing vestibular stimulation and motion sickness."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00121",
   "question": "Which inhaled quaternary ammonium anticholinergic is used in COPD management?",
   "options": [
      "Ipratropium",
      "Atropine",
      "Scopolamine",
      "Trihexyphenidyl"
   ],
   "answer": "Ipratropium",
   "explanation": "Ipratropium is a quaternary muscarinic antagonist delivered by inhalation to cause bronchodilation in COPD."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00122",
   "question": "Which antimuscarinic reduces salivary secretions perioperatively?",
   "options": [
      "Glycopyrrolate",
      "Bethanechol",
      "Pilocarpine",
      "Atropine"
   ],
   "answer": "Glycopyrrolate",
   "explanation": "Glycopyrrolate blocks M3 receptors on salivary glands, reducing secretions and minimizing aspiration risk."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00123",
   "question": "Which M3-selective antagonist treats overactive bladder?",
   "options": [
      "Oxybutynin",
      "Pilocarpine",
      "Bethanechol",
      "Tolterodine"
   ],
   "answer": "Oxybutynin",
   "explanation": "Oxybutynin antagonizes M3 receptors in the detrusor muscle, reducing involuntary contractions and urgency."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00124",
   "question": "Which antispasmodic agent treats irritable bowel syndrome–related smooth muscle spasms?",
   "options": [
      "Dicyclomine",
      "Atropine",
      "Bethanechol",
      "Methacholine"
   ],
   "answer": "Dicyclomine",
   "explanation": "Dicyclomine antagonizes gut M3 receptors, reducing smooth muscle spasms and pain in IBS."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00125",
   "question": "Which antimuscarinic reduces Parkinsonian tremors by blocking central M1 receptors?",
   "options": [
      "Trihexyphenidyl",
      "Atropine",
      "Ipratropium",
      "Oxybutynin"
   ],
   "answer": "Trihexyphenidyl",
   "explanation": "Trihexyphenidyl blocks central M1 receptors to reduce cholinergic overactivity contributing to tremors."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00126",
   "question": "Which agent produces cycloplegia and mydriasis for eye examination and has a longer duration than tropicamide?",
   "options": [
      "Cyclopentolate",
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine"
   ],
   "answer": "Cyclopentolate",
   "explanation": "Cyclopentolate blocks M3 receptors in the eye, causing cycloplegia and dilation lasting longer than tropicamide."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00127",
   "question": "Which ganglionic blocker decreases both sympathetic and parasympathetic tone?",
   "options": [
      "Mecamylamine",
      "Atropine",
      "Scopolamine",
      "Glycopyrrolate"
   ],
   "answer": "Mecamylamine",
   "explanation": "Mecamylamine blocks nicotinic N receptors at autonomic ganglia, reducing all autonomic outflow."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00128",
   "question": "Which M1-selective antagonist reduces gastric acid secretion and was used to treat peptic ulcer disease?",
   "options": [
      "Pirenzepine",
      "Atropine",
      "Glycopyrrolate",
      "Oxybutynin"
   ],
   "answer": "Pirenzepine",
   "explanation": "Pirenzepine selectively blocks M1 receptors on gastric parietal cells, reducing acid secretion."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00129",
   "question": "Which antimuscarinic agent selectively antagonizes bladder M3 receptors to reduce urinary urgency with fewer cardiac effects?",
   "options": [
      "Darifenacin",
      "Atropine",
      "Pilocarpine",
      "Bethanechol"
   ],
   "answer": "Darifenacin",
   "explanation": "Darifenacin’s selectivity for M3 receptors in the bladder minimizes off-target effects on the heart."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00130",
   "question": "Which ophthalmic antimuscarinic drug is contraindicated in narrow-angle glaucoma due to risk of precipitating angle closure?",
   "options": [
      "Atropine",
      "Pilocarpine",
      "Bethanechol",
      "Carbachol"
   ],
   "answer": "Atropine",
   "explanation": "Atropine causes mydriasis and cycloplegia, which can close the anterior chamber angle and raise IOP."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00131",
   "question": "Which antimuscarinic side effect is most directly responsible for dry mouth?",
   "options": [
      "M3 receptor blockade in salivary glands",
      "M2 receptor blockade in heart",
      "β1 receptor blockade in salivary glands",
      "α1 receptor blockade in salivary glands"
   ],
   "answer": "M3 receptor blockade in salivary glands",
   "explanation": "M3 receptors mediate salivary secretion; their blockade leads to xerostomia."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00132",
   "question": "Which anticholinergic agent does not cross the blood–brain barrier and therefore has minimal CNS side effects?",
   "options": [
      "Glycopyrrolate",
      "Scopolamine",
      "Atropine",
      "Trihexyphenidyl"
   ],
   "answer": "Glycopyrrolate",
   "explanation": "As a quaternary ammonium compound, glycopyrrolate cannot penetrate the CNS, reducing central adverse effects."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00133",
   "question": "Which anticholinergic agent readily crosses the blood–brain barrier and can cause sedation and amnesia?",
   "options": [
      "Scopolamine",
      "Ipratropium",
      "Glycopyrrolate",
      "Darifenacin"
   ],
   "answer": "Scopolamine",
   "explanation": "Scopolamine is a tertiary amine that is lipid-soluble, allowing CNS penetration and central effects."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00134",
   "question": "At low therapeutic doses, atropine primarily causes tachycardia by blocking which receptor?",
   "options": [
      "M2",
      "M3",
      "α1",
      "β1"
   ],
   "answer": "M2",
   "explanation": "Atropine blocks cardiac M2 receptors, inhibiting vagal tone and increasing heart rate."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00135",
   "question": "Excessive antimuscarinic therapy can lead to hyperthermia due to inhibition of sweat glands mediated by which receptor?",
   "options": [
      "M3",
      "M2",
      "α1",
      "β2"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on sweat glands mediate sweating; their blockade impairs heat dissipation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00136",
   "question": "Which drug is used as an antidote for organophosphate poisoning to counteract muscarinic effects?",
   "options": [
      "Atropine",
      "Pilocarpine",
      "Bethanechol",
      "Edrophonium"
   ],
   "answer": "Atropine",
   "explanation": "Atropine competitively blocks excess ACh at muscarinic receptors, reversing cholinergic symptoms."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00137",
   "question": "Which drug reactivates acetylcholinesterase inhibited by organophosphates?",
   "options": [
      "Pralidoxime",
      "Atropine",
      "Scopolamine",
      "Neostigmine"
   ],
   "answer": "Pralidoxime",
   "explanation": "Pralidoxime cleaves the phosphate–enzyme bond, restoring AChE activity."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00138",
   "question": "Which anticholinergic drug is recommended to reduce drooling in patients with neurologic disorders?",
   "options": [
      "Glycopyrrolate",
      "Pilocarpine",
      "Bethanechol",
      "Atropine"
   ],
   "answer": "Glycopyrrolate",
   "explanation": "By blocking M3 receptors in salivary glands, glycopyrrolate decreases hypersalivation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00139",
   "question": "Which anticholinergic is used to reduce bronchospasm in asthma patients with a longer duration than ipratropium?",
   "options": [
      "Tiotropium",
      "Atropine",
      "Scopolamine",
      "Bethanechol"
   ],
   "answer": "Tiotropium",
   "explanation": "Tiotropium is a long-acting muscarinic antagonist (LAMA) that provides prolonged bronchodilation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00140",
   "question": "Which antimuscarinic agent is most specific for M3 receptors, thus minimizing M2-related cardiac effects?",
   "options": [
      "Darifenacin",
      "Atropine",
      "Glycopyrrolate",
      "Trihexyphenidyl"
   ],
   "answer": "Darifenacin",
   "explanation": "Darifenacin’s selectivity for M3 receptors reduces off-target cardiovascular side effects."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00141",
   "question": "Which urinary antimuscarinic is considered safer in elderly patients due to limited CNS penetration?",
   "options": [
      "Trospium",
      "Oxybutynin",
      "Darifenacin",
      "Tolterodine"
   ],
   "answer": "Trospium",
   "explanation": "Trospium is a quaternary ammonium that does not cross the BBB, reducing cognitive side effects."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00142",
   "question": "Which antimuscarinic is effective in treating overactive bladder but associated with the highest incidence of dry mouth?",
   "options": [
      "Oxybutynin",
      "Darifenacin",
      "Solifenacin",
      "Tolterodine"
   ],
   "answer": "Oxybutynin",
   "explanation": "Oxybutynin’s high lipophilicity and nonselective M3 blockade in salivary glands lead to xerostomia."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00143",
   "question": "Which antispasmodic agent used for IBS acts primarily as a muscarinic receptor antagonist?",
   "options": [
      "Dicyclomine",
      "Bethanechol",
      "Pilocarpine",
      "Physostigmine"
   ],
   "answer": "Dicyclomine",
   "explanation": "Dicyclomine blocks M3 receptors in the GI tract, reducing smooth muscle spasms."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00144",
   "question": "Which anticholinergic agent is used to treat peptic ulcer disease by reducing acid secretion?",
   "options": [
      "Pirenzepine",
      "Neostigmine",
      "Edrophonium",
      "Carbachol"
   ],
   "answer": "Pirenzepine",
   "explanation": "Pirenzepine selectively antagonizes M1 receptors on parietal cells, decreasing gastric acid synthesis."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00145",
   "question": "Which anticholinergic drug can cause cycloplegia and mydriasis lasting up to 72 hours?",
   "options": [
      "Homatropine",
      "Tropicamide",
      "Pilocarpine",
      "Bethanechol"
   ],
   "answer": "Homatropine",
   "explanation": "Homatropine’s intermediate duration produces prolonged mydriasis and cycloplegia compared to tropicamide."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00146",
   "question": "Which antimuscarinic drug is used to treat motion sickness and postoperative nausea with a transdermal patch?",
   "options": [
      "Scopolamine",
      "Atropine",
      "Glycopyrrolate",
      "Darifenacin"
   ],
   "answer": "Scopolamine",
   "explanation": "Scopolamine’s central M1 blockade reduces vestibular-induced nausea and vomiting."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00147",
   "question": "Which anticholinergic would be most effective at reducing gastrointestinal motility?",
   "options": [
      "Dicyclomine",
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine"
   ],
   "answer": "Dicyclomine",
   "explanation": "By blocking M3 receptors, dicyclomine decreases GI smooth muscle contractions and motility."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00148",
   "question": "Which antimuscarinic is preferred to manage bradycardia during surgery?",
   "options": [
      "Atropine",
      "Scopolamine",
      "Glycopyrrolate",
      "Pilocarpine"
   ],
   "answer": "Atropine",
   "explanation": "Atropine’s rapid onset and central and peripheral M2 blockade make it ideal for increasing heart rate."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00149",
   "question": "Which receptor subtype blockade leads to decreased bronchial secretions?",
   "options": [
      "M3",
      "M2",
      "M1",
      "M4"
   ],
   "answer": "M3",
   "explanation": "M3 receptors on airway submucosal glands mediate secretion; their blockade reduces mucus production."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00150",
   "question": "Which muscarinic antagonist would most directly increase intraocular pressure?",
   "options": [
      "Atropine",
      "Pilocarpine",
      "Carbachol",
      "Physostigmine"
   ],
   "answer": "Atropine",
   "explanation": "Atropine-induced mydriasis can narrow the anterior chamber angle and reduce aqueous outflow, raising IOP."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00151",
   "question": "In organophosphate poisoning, which combination is used to both reactivate AChE and block muscarinic receptors?",
   "options": [
      "Pralidoxime and atropine",
      "Neostigmine and pilocarpine",
      "Physostigmine and scopolamine",
      "Bethanechol and glycopyrrolate"
   ],
   "answer": "Pralidoxime and atropine",
   "explanation": "Pralidoxime reactivates AChE while atropine blocks life-threatening muscarinic overstimulation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00152",
   "question": "Muscarinic receptor antagonism in the GI tract leads to:",
   "options": [
      "Reduced motility and secretions",
      "Increased motility and secretions",
      "No change",
      "Selective increase of secretions"
   ],
   "answer": "Reduced motility and secretions",
   "explanation": "Blocking M3 receptors in the gut decreases peristalsis and glandular secretions."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00153",
   "question": "Which anticholinergic would likely exacerbate narrow-angle glaucoma?",
   "options": [
      "Tropicamide",
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine"
   ],
   "answer": "Tropicamide",
   "explanation": "By inducing mydriasis, tropicamide can precipitate angle closure and acute glaucoma."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00154",
   "question": "Which antimuscarinic is used off-label to reduce urinary urgency in multiple sclerosis?",
   "options": [
      "Oxybutynin",
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine"
   ],
   "answer": "Oxybutynin",
   "explanation": "Oxybutynin’s bladder M3 antagonism reduces detrusor overactivity in neurogenic bladder conditions."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00155",
   "question": "Which drug is a long-acting muscarinic antagonist (LAMA) used in COPD?",
   "options": [
      "Tiotropium",
      "Atropine",
      "Scopolamine",
      "Glycopyrrolate"
   ],
   "answer": "Tiotropium",
   "explanation": "Tiotropium dissociates slowly from M3 receptors, providing prolonged bronchodilation."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00156",
   "question": "Which muscarinic antagonist can cross the BBB and treat extrapyramidal side effects of antipsychotics?",
   "options": [
      "Benztropine",
      "Ipratropium",
      "Glycopyrrolate",
      "Tolterodine"
   ],
   "answer": "Benztropine",
   "explanation": "Benztropine is a tertiary amine that enters the CNS to restore dopaminergic–cholinergic balance in Parkinsonism."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00157",
   "question": "Which antimuscarinic drug has high selectivity for M1 receptors, reducing central cholinergic activity without much peripheral effect?",
   "options": [
      "Pirenzepine",
      "Atropine",
      "Benztropine",
      "Glycopyrrolate"
   ],
   "answer": "Pirenzepine",
   "explanation": "Pirenzepine’s M1 selectivity targets central and gastric receptors while sparing peripheral M3 receptors."
},
 {
   "chapter_id": 5,
   "chapter": "Cholinergic Antagonists",
   "question_id": "00005-00158",
   "question": "Which muscarinic antagonist in overdose produces flushing, hyperthermia, dry skin, and delirium?",
   "options": [
      "Atropine",
      "Pilocarpine",
      "Bethanechol",
      "Neostigmine"
   ],
   "answer": "Atropine",
   "explanation": "Atropine toxicity manifests as ‘hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter.’"
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00159",
   "question": "Which receptor subtype does phenylephrine primarily activate?",
   "options": [
      "α1",
      "α2",
      "β1",
      "β2"
   ],
   "answer": "α1",
   "explanation": "Phenylephrine is a selective α1-adrenergic agonist, causing vasoconstriction."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00160",
   "question": "At low plasma concentrations, epinephrine preferentially activates which receptor?",
   "options": [
      "α1",
      "α2",
      "β1",
      "β2"
   ],
   "answer": "β2",
   "explanation": "Epinephrine has higher affinity for β2 at low concentrations, causing vasodilation and bronchodilation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00161",
   "question": "Isoproterenol is a nonselective agonist of which receptor class?",
   "options": [
      "β",
      "α",
      "Dopamine",
      "Muscarinic"
   ],
   "answer": "β",
   "explanation": "Isoproterenol stimulates both β1 and β2 receptors without α-adrenergic activity."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00162",
   "question": "Dobutamine is primarily used to increase what parameter in heart failure?",
   "options": [
      "Contractility",
      "Afterload",
      "Heart rate",
      "Diastolic pressure"
   ],
   "answer": "Contractility",
   "explanation": "Dobutamine is a β1 agonist that enhances myocardial inotropy with minimal chronotropic effect."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00163",
   "question": "Mirabegron treats overactive bladder by activating which receptor?",
   "options": [
      "β3",
      "β2",
      "α1",
      "M3"
   ],
   "answer": "β3",
   "explanation": "Mirabegron selectively agonizes β3 receptors in detrusor muscle, promoting relaxation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00164",
   "question": "Amphetamine increases synaptic norepinephrine by:",
   "options": [
      "Promoting release",
      "Blocking α receptors",
      "Inhibiting synthesis",
      "Blocking COMT"
   ],
   "answer": "Promoting release",
   "explanation": "Amphetamine enters presynaptic neurons and displaces NE from vesicles, increasing its release."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00165",
   "question": "Clonidine lowers blood pressure by stimulating which receptor?",
   "options": [
      "α2",
      "α1",
      "β1",
      "β2"
   ],
   "answer": "α2",
   "explanation": "Clonidine is an α2 agonist in the CNS that reduces sympathetic outflow."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00166",
   "question": "Methyldopa is converted to an active metabolite that stimulates which receptor?",
   "options": [
      "α2",
      "α1",
      "β1",
      "β2"
   ],
   "answer": "α2",
   "explanation": "Methyldopa’s metabolites act on central α2 receptors to decrease sympathetic tone."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00167",
   "question": "Ephedrine is classified as a:",
   "options": [
      "Mixed-acting adrenergic agonist",
      "Selective β2 agonist",
      "α1 antagonist",
      "Neurotransmitter"
   ],
   "answer": "Mixed-acting adrenergic agonist",
   "explanation": "Ephedrine has direct agonist activity at α and β receptors and indirectly releases NE."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00168",
   "question": "Tyramine can precipitate hypertensive crisis in patients taking:",
   "options": [
      "MAO inhibitors",
      "β-blockers",
      "ACE inhibitors",
      "Calcium channel blockers"
   ],
   "answer": "MAO inhibitors",
   "explanation": "Tyramine is normally metabolized by MAO; inhibition leads to excess NE release and hypertension."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00169",
   "question": "Albuterol is primarily a selective agonist at:",
   "options": [
      "β2",
      "β1",
      "α1",
      "α2"
   ],
   "answer": "β2",
   "explanation": "Albuterol targets β2 receptors in bronchial smooth muscle for bronchodilation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00170",
   "question": "Which long-acting β2 agonist has high lipophilicity for prolonged action in asthma?",
   "options": [
      "Salmeterol",
      "Metaproterenol",
      "Epinephrine",
      "Isoproterenol"
   ],
   "answer": "Salmeterol",
   "explanation": "Salmeterol’s lipophilicity allows it to remain in airway membranes for extended β2 activation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00171",
   "question": "Formoterol differs from albuterol by being:",
   "options": [
      "Long-acting",
      "Selective for β1",
      "An α agonist",
      "Nonselective"
   ],
   "answer": "Long-acting",
   "explanation": "Formoterol is a long-acting β2 agonist used for maintenance asthma therapy."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00172",
   "question": "Terbutaline is used off-label to:",
   "options": [
      "Delay preterm labor",
      "Treat hypotension",
      "Increase GI motility",
      "Reduce heart rate"
   ],
   "answer": "Delay preterm labor",
   "explanation": "Terbutaline’s β2 activation relaxes uterine smooth muscle to delay labor."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00173",
   "question": "Ritodrine treats preterm labor by activating:",
   "options": [
      "β2 receptors",
      "β1 receptors",
      "α1 receptors",
      "α2 receptors"
   ],
   "answer": "β2 receptors",
   "explanation": "Ritodrine relaxes uterine smooth muscle via β2 receptor stimulation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00174",
   "question": "Oxymetazoline, a topical nasal decongestant, primarily stimulates:",
   "options": [
      "α1 receptors",
      "β2 receptors",
      "α2 receptors",
      "β1 receptors"
   ],
   "answer": "α1 receptors",
   "explanation": "Oxymetazoline’s α1 agonism causes vasoconstriction of nasal mucosa, reducing congestion."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00175",
   "question": "Pseudoephedrine relieves nasal congestion by:",
   "options": [
      "Mixed α agonism and NE release",
      "β2 agonism only",
      "α2 antagonism",
      "M3 activation"
   ],
   "answer": "Mixed α agonism and NE release",
   "explanation": "Pseudoephedrine directly stimulates α receptors and releases NE to constrict nasal vessels."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00176",
   "question": "Fenoldopam treats hypertensive emergencies via:",
   "options": [
      "D1 receptor agonism",
      "β1 receptor agonism",
      "α1 receptor agonism",
      "M3 receptor agonism"
   ],
   "answer": "D1 receptor agonism",
   "explanation": "Fenoldopam’s D1 activation causes renal vasodilation, lowering blood pressure."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00177",
   "question": "Dopamine’s receptor effects at low, moderate, and high doses are:",
   "options": [
      "D1 → β1 → α1",
      "α1 → β1 → D1",
      "β1 → D1 → α1",
      "β2 → D1 → α2"
   ],
   "answer": "D1 → β1 → α1",
   "explanation": "Low dose activates D1 (renal), moderate adds β1 (heart), high stimulates α1 (vasoconstriction)."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00178",
   "question": "Droxidopa is a therapeutic prodrug of:",
   "options": [
      "Norepinephrine",
      "Dopamine",
      "Epinephrine",
      "Phenylephrine"
   ],
   "answer": "Norepinephrine",
   "explanation": "Droxidopa is converted to NE for treating orthostatic hypotension."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00179",
   "question": "Fenoldopam’s main clinical advantage is:",
   "options": [
      "Renal vasodilation",
      "Bronchodilation",
      "Cardiac inotropy",
      "Glycogenolysis"
   ],
   "answer": "Renal vasodilation",
   "explanation": "Fenoldopam selectively dilates renal vessels via D1, improving perfusion and reducing BP."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00180",
   "question": "β-adrenergic receptors couple to which G-protein?",
   "options": [
      "Gs",
      "Gi",
      "Gq",
      "G12/13"
   ],
   "answer": "Gs",
   "explanation": "β receptors activate adenylate cyclase via Gs to increase cAMP."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00181",
   "question": "α2-adrenergic receptors inhibit adenylate cyclase via which G-protein?",
   "options": [
      "Gi",
      "Gs",
      "Gq",
      "G12/13"
   ],
   "answer": "Gi",
   "explanation": "α2 receptors couple to Gi, reducing cAMP formation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00182",
   "question": "α1-adrenergic receptors signal through which G-protein?",
   "options": [
      "Gq",
      "Gi",
      "Gs",
      "G12/13"
   ],
   "answer": "Gq",
   "explanation": "α1 activation of Gq stimulates phospholipase C, increasing IP₃ and DAG."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00183",
   "question": "Activation of α2 receptors on pancreatic β-cells leads to:",
   "options": [
      "Decreased insulin release",
      "Increased insulin release",
      "No change",
      "Increased glucagon release"
   ],
   "answer": "Decreased insulin release",
   "explanation": "α2 receptor stimulation inhibits insulin secretion via decreased cAMP."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00184",
   "question": "β2 receptor activation on pancreatic β-cells causes:",
   "options": [
      "Increased insulin release",
      "Decreased insulin release",
      "Glucagon release",
      "No effect"
   ],
   "answer": "Increased insulin release",
   "explanation": "β2 stimulation enhances insulin secretion by raising cAMP in β-cells."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00185",
   "question": "β1 receptor activation in the kidney increases:",
   "options": [
      "Renin release",
      "ADH release",
      "Glomerular filtration",
      "Tubular reabsorption"
   ],
   "answer": "Renin release",
   "explanation": "β1 receptors on juxtaglomerular cells stimulate renin secretion."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00186",
   "question": "β3 receptor activation in adipose tissue promotes:",
   "options": [
      "Lipolysis",
      "Lipogenesis",
      "Glucose uptake",
      "Cholesterol synthesis"
   ],
   "answer": "Lipolysis",
   "explanation": "β3 receptors stimulate hormone-sensitive lipase, increasing fatty acid mobilization."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00187",
   "question": "β2 receptor–mediated vasodilation in skeletal muscle occurs via:",
   "options": [
      "cAMP increase",
      "IP₃ increase",
      "cGMP increase",
      "DAG increase"
   ],
   "answer": "cAMP increase",
   "explanation": "β2-Gs activation raises cAMP in vascular smooth muscle, causing relaxation."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00188",
   "question": "α1 receptor–mediated vasoconstriction occurs via:",
   "options": [
      "IP₃-mediated Ca²⁺ release",
      "cAMP decrease",
      "cGMP increase",
      "Na⁺ influx"
   ],
   "answer": "IP₃-mediated Ca²⁺ release",
   "explanation": "α1-Gq activation generates IP₃, releasing Ca²⁺ to induce smooth muscle contraction."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00189",
   "question": "α1 activation on the iris radial muscle causes:",
   "options": [
      "Mydriasis",
      "Miosis",
      "Accommodation",
      "Lacrimation"
   ],
   "answer": "Mydriasis",
   "explanation": "α1 stimulation contracts dilator pupillae muscle, dilating the pupil."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00190",
   "question": "β2 activation in bronchial smooth muscle results in:",
   "options": [
      "Bronchodilation",
      "Bronchoconstriction",
      "Mucus secretion",
      "Inflammation"
   ],
   "answer": "Bronchodilation",
   "explanation": "β2-Gs signaling raises cAMP, relaxing airway smooth muscle."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00191",
   "question": "β1 receptor activation in the heart increases:",
   "options": [
      "Heart rate and contractility",
      "Vasoconstriction",
      "Bronchoconstriction",
      "Glycogen synthesis"
   ],
   "answer": "Heart rate and contractility",
   "explanation": "β1-Gs increases cAMP, enhancing sinoatrial firing and myocardial force."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00192",
   "question": "β2-mediated glycogenolysis in the liver is due to:",
   "options": [
      "cAMP activation of protein kinase A",
      "IP₃-mediated Ca²⁺ release",
      "Direct enzyme binding",
      "cGMP increase"
   ],
   "answer": "cAMP activation of protein kinase A",
   "explanation": "β2-Gs increases cAMP, activating PKA to phosphorylate glycogen phosphorylase."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00193",
   "question": "α1 activation in the bladder neck causes:",
   "options": [
      "Urinary retention",
      "Micturition",
      "Diuresis",
      "No effect"
   ],
   "answer": "Urinary retention",
   "explanation": "α1-mediated contraction of the internal urethral sphincter impedes bladder emptying."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00194",
   "question": "β3 receptor activation in the bladder causes:",
   "options": [
      "Detrusor relaxation",
      "Detrusor contraction",
      "Micturition",
      "No effect"
   ],
   "answer": "Detrusor relaxation",
   "explanation": "β3-Gs stimulation relaxes detrusor muscle, increasing bladder capacity."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00195",
   "question": "Norepinephrine is the drug of choice for hypotension in:",
   "options": [
      "Septic shock",
      "Asthma",
      "Bradycardia",
      "Hyperthyroidism"
   ],
   "answer": "Septic shock",
   "explanation": "NE’s potent α1 vasoconstriction and modest β1 support blood pressure in septic shock."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00196",
   "question": "Epinephrine is first-line therapy for:",
   "options": [
      "Anaphylaxis",
      "Hypertension",
      "Angina",
      "Hyperglycemia"
   ],
   "answer": "Anaphylaxis",
   "explanation": "Epinephrine’s α and β effects reverse bronchospasm, hypotension, and edema in anaphylaxis."
},
 {
   "chapter_id": 6,
   "chapter": "Adrenergic Agonists",
   "question_id": "00006-00197",
   "question": "Isoproterenol may be used in complete heart block to:",
   "options": [
      "Increase AV conduction",
      "Decrease contractility",
      "Vasoconstrict",
      "Reduce heart rate"
   ],
   "answer": "Increase AV conduction",
   "explanation": "Isoproterenol’s β1 action enhances AV nodal conduction and heart rate in block."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00198",
   "question": "Which irreversible nonselective α-blocker is used preoperatively in pheochromocytoma?",
   "options": [
      "Phenoxybenzamine",
      "Prazosin",
      "Yohimbine",
      "Phentolamine"
   ],
   "answer": "Phenoxybenzamine",
   "explanation": "Phenoxybenzamine forms a covalent bond with α₁ and α₂ receptors, irreversibly blocking them and preventing catecholamine‐induced vasoconstriction during pheochromocytoma surgery."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00199",
   "question": "Which selective α₁-blocker is particularly used to improve urinary flow in benign prostatic hyperplasia?",
   "options": [
      "Tamsulosin",
      "Prazosin",
      "Phenoxybenzamine",
      "Yohimbine"
   ],
   "answer": "Tamsulosin",
   "explanation": "Tamsulosin selectively antagonizes α₁A receptors in the prostate and bladder neck, reducing smooth muscle tone and improving urine flow with minimal blood pressure effects."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00200",
   "question": "Which adverse effect is characteristic of first-dose administration of prazosin?",
   "options": [
      "Orthostatic hypotension",
      "Bradycardia",
      "Reflex tachycardia",
      "Dry mouth"
   ],
   "answer": "Orthostatic hypotension",
   "explanation": "The “first-dose phenomenon” of prazosin can cause marked postural hypotension due to abrupt α₁ blockade of vascular smooth muscle."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00201",
   "question": "Which α₂-blocker is used experimentally to increase sympathetic tone and treat erectile dysfunction?",
   "options": [
      "Yohimbine",
      "Phenoxybenzamine",
      "Prazosin",
      "Phentolamine"
   ],
   "answer": "Yohimbine",
   "explanation": "Yohimbine selectively blocks presynaptic α₂ receptors, increasing NE release and sympathetic outflow; it has been used off-label for erectile dysfunction."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00202",
   "question": "Nonselective β-blockers block which receptors?",
   "options": [
      "β₁ and β₂",
      "α₁ and α₂",
      "β₁ only",
      "β₂ only"
   ],
   "answer": "β₁ and β₂",
   "explanation": "Nonselective β-blockers such as propranolol antagonize both β₁ (cardiac) and β₂ (bronchial/vascular) receptors."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00203",
   "question": "Which β₁-selective blocker is preferred in patients with asthma?",
   "options": [
      "Metoprolol",
      "Propranolol",
      "Nadolol",
      "Carvedilol"
   ],
   "answer": "Metoprolol",
   "explanation": "Metoprolol selectively antagonizes β₁ receptors in the heart at therapeutic doses, minimizing β₂-mediated bronchoconstriction."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00204",
   "question": "Which β-blocker has intrinsic sympathomimetic activity (ISA)?",
   "options": [
      "Pindolol",
      "Propranolol",
      "Atenolol",
      "Metoprolol"
   ],
   "answer": "Pindolol",
   "explanation": "Pindolol is a partial agonist at β receptors, providing some agonist activity at low catecholamine levels, reducing resting bradycardia."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00205",
   "question": "Which combined α/β-blocker is used in hypertensive emergencies and heart failure?",
   "options": [
      "Labetalol",
      "Propranolol",
      "Phentolamine",
      "Pindolol"
   ],
   "answer": "Labetalol",
   "explanation": "Labetalol antagonizes α₁, β₁, and β₂ receptors, reducing blood pressure by vasodilation and decreasing cardiac output without reflex tachycardia."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00206",
   "question": "Which nonselective β-blocker is highly lipophilic and crosses the blood-brain barrier readily?",
   "options": [
      "Propranolol",
      "Nadolol",
      "Atenolol",
      "Metoprolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol is lipid-soluble, enters the CNS easily, and can be used for migraine prophylaxis and essential tremor."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00207",
   "question": "Which β-blocker is excreted unchanged by the kidneys and requires dose adjustment in renal failure?",
   "options": [
      "Nadolol",
      "Propranolol",
      "Metoprolol",
      "Timolol"
   ],
   "answer": "Nadolol",
   "explanation": "Nadolol is hydrophilic and renally excreted; impaired renal function prolongs its half-life, necessitating dose reduction."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00208",
   "question": "Which β-blocker has partial α₁-blocking activity, reducing peripheral vascular resistance?",
   "options": [
      "Carvedilol",
      "Propranolol",
      "Atenolol",
      "Metoprolol"
   ],
   "answer": "Carvedilol",
   "explanation": "Carvedilol blocks β₁, β₂, and α₁ receptors, providing both negative inotropy and vasodilation beneficial in heart failure."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00209",
   "question": "Which adverse effect is most associated with nonselective β-blockers?",
   "options": [
      "Bronchoconstriction",
      "Dry mouth",
      "Constipation",
      "Urinary retention"
   ],
   "answer": "Bronchoconstriction",
   "explanation": "Blocking β₂ receptors in bronchial smooth muscle can precipitate or worsen asthma and COPD."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00210",
   "question": "Rebound hypertension on abrupt withdrawal is most likely with:",
   "options": [
      "Propranolol",
      "Pindolol",
      "Phentolamine",
      "Prazosin"
   ],
   "answer": "Propranolol",
   "explanation": "Chronic β-blockade increases receptor density; sudden cessation can lead to catecholamine‐induced hypertension and tachycardia."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00211",
   "question": "Which α₁-blocker is preferred to treat hypertension in patients with PTSD nightmares?",
   "options": [
      "Prazosin",
      "Phenoxybenzamine",
      "Tamsulosin",
      "Phentolamine"
   ],
   "answer": "Prazosin",
   "explanation": "Prazosin crosses the blood-brain barrier and antagonizes central α₁ receptors, reducing PTSD-related nightmares."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00212",
   "question": "Which α-blocker can cause reflex tachycardia due to unopposed β activity?",
   "options": [
      "Phentolamine",
      "Prazosin",
      "Tamsulosin",
      "Yohimbine"
   ],
   "answer": "Phentolamine",
   "explanation": "Nonselective α₁/α₂ blockade leads to vasodilation and reflex sympathetic activation of β₁ receptors, increasing heart rate."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00213",
   "question": "Which β-blocker is indicated for migraine prophylaxis and essential tremor?",
   "options": [
      "Propranolol",
      "Atenolol",
      "Esmolol",
      "Metoprolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol’s CNS penetration and β₁/β₂ blockade reduce tremor amplitude and migraine frequency."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00214",
   "question": "Which β-blocker is ultra short-acting and used in acute tachyarrhythmias?",
   "options": [
      "Esmolol",
      "Propranolol",
      "Metoprolol",
      "Atenolol"
   ],
   "answer": "Esmolol",
   "explanation": "Esmolol has a half-life of ~9 minutes, is metabolized by red blood cell esterases, and is ideal for IV use in emergencies."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00215",
   "question": "Which β-blocker improves survival post-myocardial infarction by reducing remodeling?",
   "options": [
      "Metoprolol",
      "Propranolol",
      "Pindolol",
      "Esmolol"
   ],
   "answer": "Metoprolol",
   "explanation": "Metoprolol’s β₁ blockade reduces heart rate and myocardial oxygen demand, improving outcomes after MI."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00216",
   "question": "Which α₁-blocker can cause nasal congestion as a side effect?",
   "options": [
      "Prazosin",
      "Phenoxybenzamine",
      "Tamsulosin",
      "Yohimbine"
   ],
   "answer": "Prazosin",
   "explanation": "α₁ blockade in nasal mucosa causes vasodilation and congestion."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00217",
   "question": "Which α-blocker can improve insulin sensitivity by increasing blood flow to skeletal muscle?",
   "options": [
      "Doxazosin",
      "Phenoxybenzamine",
      "Phentolamine",
      "Yohimbine"
   ],
   "answer": "Doxazosin",
   "explanation": "By antagonizing vascular α₁ receptors, doxazosin enhances peripheral perfusion, improving glucose uptake."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00218",
   "question": "Which β-blocker is contraindicated in patients with Wolff–Parkinson–White syndrome and atrial fibrillation?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Esmolol",
      "Timolol"
   ],
   "answer": "Propranolol",
   "explanation": "Blocking AV nodal conduction without addressing the accessory pathway can worsen tachycardia in WPW."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00219",
   "question": "Which α₁-blocker is associated with minimal orthostatic hypotension due to uroselectivity?",
   "options": [
      "Tamsulosin",
      "Prazosin",
      "Doxazosin",
      "Terazosin"
   ],
   "answer": "Tamsulosin",
   "explanation": "Tamsulosin’s selectivity for prostatic α₁A receptors reduces vascular effects and orthostasis."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00220",
   "question": "Which β-blocker reduces aqueous humor production to treat glaucoma?",
   "options": [
      "Timolol",
      "Propranolol",
      "Metoprolol",
      "Atenolol"
   ],
   "answer": "Timolol",
   "explanation": "Timolol’s β₁/β₂ blockade decreases cAMP in ciliary epithelium, reducing aqueous secretion."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00221",
   "question": "Which β-blocker is also a potassium channel opener and used in pulmonary hypertension?",
   "options": [
      "Carvedilol",
      "Propranolol",
      "Pindolol",
      "Atenolol"
   ],
   "answer": "Carvedilol",
   "explanation": "Carvedilol opens K⁺ channels in pulmonary vasculature, contributing to its benefit in pulmonary hypertension."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00222",
   "question": "Which β-blocker has NO vasodilatory activity?",
   "options": [
      "Metoprolol",
      "Carvedilol",
      "Labetalol",
      "Nebivolol"
   ],
   "answer": "Metoprolol",
   "explanation": "Metoprolol is cardioselective with no direct vasodilatory properties."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00223",
   "question": "Which β-blocker stimulates nitric oxide release, causing vasodilation?",
   "options": [
      "Nebivolol",
      "Propranolol",
      "Metoprolol",
      "Esmolol"
   ],
   "answer": "Nebivolol",
   "explanation": "Nebivolol increases endothelial NO production, providing vasodilatory and antihypertensive effects."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00224",
   "question": "Which β-blocker is safe in diabetic patients because it does not mask hypoglycemia symptoms as much?",
   "options": [
      "Atenolol",
      "Propranolol",
      "Pindolol",
      "Carvedilol"
   ],
   "answer": "Atenolol",
   "explanation": "Atenolol is β₁-selective, sparing β₂-mediated gluconeogenesis and tremor, partially preserving hypoglycemia warning signs."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00225",
   "question": "Which α₂-blocking agent can precipitate tachycardia and hypertension?",
   "options": [
      "Yohimbine",
      "Prazosin",
      "Phentolamine",
      "Phenoxybenzamine"
   ],
   "answer": "Yohimbine",
   "explanation": "Blocking inhibitory α₂ autoreceptors increases NE release, causing sympathetic overactivity."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00226",
   "question": "Which α₁-blocker is used to treat frostbite by improving perfusion?",
   "options": [
      "Prazosin",
      "Phenoxybenzamine",
      "Tamsulosin",
      "Yohimbine"
   ],
   "answer": "Prazosin",
   "explanation": "Prazosin’s vasodilatory effect improves blood flow in cold-induced vasospasm."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00227",
   "question": "Which β-blocker is preferred in heart failure for its additional antioxidant properties?",
   "options": [
      "Carvedilol",
      "Propranolol",
      "Metoprolol",
      "Atenolol"
   ],
   "answer": "Carvedilol",
   "explanation": "Carvedilol’s α₁ blockade and antioxidant activity reduce afterload and oxidative stress in heart failure."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00228",
   "question": "Which β-blocker is contraindicated in vasospastic angina because it may worsen coronary vasoconstriction?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Nadolol"
   ],
   "answer": "Propranolol",
   "explanation": "Nonselective β₂ blockade removes β₂-mediated coronary vasodilation, exacerbating vasospasm."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00229",
   "question": "Which α-blocker requires dietary restriction of tyramine to avoid hypertensive crisis?",
   "options": [
      "Phenoxybenzamine",
      "Prazosin",
      "Phentolamine",
      "Yohimbine"
   ],
   "answer": "None",
   "explanation": "Unlike MAO inhibitors, α-blockers do not impair tyramine metabolism and therefore do not require dietary restrictions."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00230",
   "question": "Which β-blocker is most likely to cause lipid profile changes (↑ triglycerides, ↓ HDL)?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Esmolol"
   ],
   "answer": "Propranolol",
   "explanation": "Nonselective β-blockers impair β₂-mediated lipolysis, leading to unfavorable lipid alterations."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00231",
   "question": "Which β-blocker can worsen peripheral arterial disease by further reducing peripheral perfusion?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Nebivolol"
   ],
   "answer": "Propranolol",
   "explanation": "Nonselective β₂ blockade decreases vasodilation in skeletal muscle vessels, aggravating claudication."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00232",
   "question": "Which α-blocker is reversible and competitive?",
   "options": [
      "Phentolamine",
      "Phenoxybenzamine",
      "Prazosin",
      "Yohimbine"
   ],
   "answer": "Phentolamine",
   "explanation": "Phentolamine reversibly and competitively antagonizes α₁ and α₂ receptors, whereas phenoxybenzamine is irreversible."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00233",
   "question": "Which β-blocker can improve survival in cirrhotic patients by reducing portal hypertension?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Carvedilol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol reduces cardiac output and splanchnic blood flow, lowering portal pressure and bleeding risk."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00234",
   "question": "Which β-blocker should be avoided in Prinzmetal angina?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Esmolol"
   ],
   "answer": "Propranolol",
   "explanation": "Nonselective β-blockade may worsen vasospasm by blocking β₂-mediated vasodilation in coronary vessels."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00235",
   "question": "Which β-blocker has no intrinsic sympathomimetic activity and high β₁ selectivity?",
   "options": [
      "Atenolol",
      "Pindolol",
      "Carteolol",
      "Labetalol"
   ],
   "answer": "Atenolol",
   "explanation": "Atenolol is β₁-selective with no partial agonist activity, providing pure antagonism at β₁ receptors."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00236",
   "question": "Which β-blocker is used topically for glaucoma?",
   "options": [
      "Timolol",
      "Propranolol",
      "Metoprolol",
      "Atenolol"
   ],
   "answer": "Timolol",
   "explanation": "Timolol eye drops reduce aqueous humor formation via β blockade of ciliary epithelium."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00237",
   "question": "Which α/β-blocker reduces heart rate less than pure β-blockers due to α₁ antagonism?",
   "options": [
      "Carvedilol",
      "Propranolol",
      "Metoprolol",
      "Atenolol"
   ],
   "answer": "Carvedilol",
   "explanation": "Carvedilol’s α₁ blockade causes vasodilation, requiring less reflex sympathetic activation and less heart rate change."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00238",
   "question": "Which β-blocker can cross the blood–brain barrier and is used for performance anxiety?",
   "options": [
      "Propranolol",
      "Atenolol",
      "Nadolol",
      "Esmolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol’s lipid solubility permits CNS penetration, reducing central adrenergic symptoms of anxiety."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00239",
   "question": "Which block of β₂ receptors impairs glycogenolysis, potentially worsening hypoglycemia?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Nebivolol"
   ],
   "answer": "Propranolol",
   "explanation": "Nonselective β-blockade inhibits hepatic β₂-mediated glycogen breakdown, blunting counterregulatory responses."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00240",
   "question": "Which β-blocker has lipophilic properties and a high first-pass metabolism?",
   "options": [
      "Propranolol",
      "Nadolol",
      "Atenolol",
      "Esmolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol is highly lipophilic and extensively metabolized by the liver, with variable oral bioavailability."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00241",
   "question": "Which α-blocker can be reversed by increasing epinephrine concentration (surmountable)?",
   "options": [
      "Phentolamine",
      "Phenoxybenzamine",
      "Prazosin",
      "Yohimbine"
   ],
   "answer": "Phentolamine",
   "explanation": "Phentolamine is a competitive antagonist whose effects can be overcome by higher agonist levels; phenoxybenzamine is irreversible."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00242",
   "question": "Which β-blocker is used in portal hypertension to prevent variceal bleeding?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Carvedilol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol decreases portal pressure via reduced cardiac output and splanchnic vasoconstriction."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00243",
   "question": "Which β-blocker has a very short half-life and is metabolized by plasma esterases?",
   "options": [
      "Esmolol",
      "Propranolol",
      "Nadolol",
      "Atenolol"
   ],
   "answer": "Esmolol",
   "explanation": "Esmolol is hydrolyzed by red blood cell esterases, leading to a half-life of ~9 minutes."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00244",
   "question": "Which α-blocker is most likely to cause reflex tachycardia?",
   "options": [
      "Phentolamine",
      "Prazosin",
      "Tamsulosin",
      "Phenoxybenzamine"
   ],
   "answer": "Phentolamine",
   "explanation": "Reversible nonselective α blockade causes vasodilation and reflex sympathetic activation of the heart."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00245",
   "question": "Which β-blocker is indicated for hypertrophic obstructive cardiomyopathy?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Esmolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol reduces heart rate and contractility, improving outflow tract obstruction and symptoms."
},
 {
   "chapter_id": 7,
   "chapter": "Adrenergic Antagonists",
   "question_id": "00007-00246",
   "question": "Which β-blocker is commonly used to treat performance anxiety (stage fright)?",
   "options": [
      "Propranolol",
      "Metoprolol",
      "Atenolol",
      "Nadolol"
   ],
   "answer": "Propranolol",
   "explanation": "Propranolol blunts sympathetic symptoms (tachycardia, tremor) of acute anxiety without sedation."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00247",
   "question": "Thiazide diuretics lower blood pressure primarily by inhibiting which transporter?",
   "options": [
      "Na⁺-Cl⁻ symporter in distal convoluted tubule",
      "Na⁺-K⁺-2Cl⁻ cotransporter in loop of Henle",
      "ENaC in collecting duct",
      "Na⁺-H⁺ exchanger in proximal tubule"
   ],
   "answer": "Na⁺-Cl⁻ symporter in distal convoluted tubule",
   "explanation": "Thiazides block the NCC transporter in the distal convoluted tubule, increasing Na⁺ and water excretion and lowering blood volume."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00248",
   "question": "Which metabolic disturbances are commonly seen with thiazide diuretics?",
   "options": [
      "Hyperglycemia, hyperlipidemia, hyperuricemia",
      "Hypoglycemia, hyponatremia, hypouricemia",
      "Hyperkalemia, metabolic acidosis, hypercalciuria",
      "Hypolipidemia, hypoglycemia, hypokalemia"
   ],
   "answer": "Hyperglycemia, hyperlipidemia, hyperuricemia",
   "explanation": "Thiazides can impair glucose tolerance, raise LDL/triglycerides, and decrease uric acid excretion, precipitating gout."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00249",
   "question": "Loop diuretics lower blood pressure by inhibiting which transporter?",
   "options": [
      "Na⁺-K⁺-2Cl⁻ cotransporter in thick ascending limb",
      "Na⁺-Cl⁻ symporter in DCT",
      "ENaC in collecting duct",
      "Na⁺-H⁺ exchanger in proximal tubule"
   ],
   "answer": "Na⁺-K⁺-2Cl⁻ cotransporter in thick ascending limb",
   "explanation": "Loop diuretics block NKCC2, causing profound natriuresis and diuresis, which can reduce blood pressure."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00250",
   "question": "Which adverse effect is characteristic of high-dose loop diuretics?",
   "options": [
      "Ototoxicity",
      "Hyperglycemia",
      "Gynecomastia",
      "Cough"
   ],
   "answer": "Ototoxicity",
   "explanation": "Loop diuretics can cause reversible or irreversible hearing loss by affecting electrolyte handling in the inner ear."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00251",
   "question": "Spironolactone lowers blood pressure by antagonizing which receptor?",
   "options": [
      "Aldosterone receptor in collecting duct",
      "β₁ receptor in heart",
      "α₁ receptor in vessels",
      "L-type Ca²⁺ channel in smooth muscle"
   ],
   "answer": "Aldosterone receptor in collecting duct",
   "explanation": "Spironolactone blocks mineralocorticoid receptors in the distal nephron, promoting Na⁺ excretion while sparing K⁺."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00252",
   "question": "Which endocrine side effect is most associated with spironolactone?",
   "options": [
      "Gynecomastia",
      "Hyperglycemia",
      "Hypothyroidism",
      "Cushingoid features"
   ],
   "answer": "Gynecomastia",
   "explanation": "Spironolactone’s steroid structure allows it to antagonize androgen receptors, leading to gynecomastia in men."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00253",
   "question": "Eplerenone differs from spironolactone by:",
   "options": [
      "Greater selectivity for aldosterone receptor",
      "Longer half-life",
      "Greater androgen receptor antagonism",
      "Irreversible binding"
   ],
   "answer": "Greater selectivity for aldosterone receptor",
   "explanation": "Eplerenone selectively blocks mineralocorticoid receptors with less affinity for sex steroid receptors, reducing endocrine side effects."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00254",
   "question": "ACE inhibitors lower blood pressure by preventing formation of:",
   "options": [
      "Angiotensin II",
      "Bradykinin",
      "Aldosterone",
      "Renin"
   ],
   "answer": "Angiotensin II",
   "explanation": "ACE inhibitors block conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone release while increasing bradykinin."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00255",
   "question": "Which side effect of ACE inhibitors is due to increased bradykinin levels?",
   "options": [
      "Dry cough",
      "Hyperglycemia",
      "Photosensitivity",
      "Constipation"
   ],
   "answer": "Dry cough",
   "explanation": "Bradykinin accumulation in the respiratory tract stimulates cough reflex in susceptible patients."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00256",
   "question": "ACE inhibitors can cause hyperkalemia primarily by:",
   "options": [
      "Decreasing aldosterone secretion",
      "Increasing renin release",
      "Blocking Na⁺ reabsorption in loop",
      "Stimulating bradykinin"
   ],
   "answer": "Decreasing aldosterone secretion",
   "explanation": "Reduced angiotensin II lowers aldosterone, decreasing K⁺ excretion and risking hyperkalemia."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00257",
   "question": "Angiotensin II receptor blockers (ARBs) differ from ACE inhibitors because they:",
   "options": [
      "Do not increase bradykinin",
      "Increase bradykinin more",
      "Block renin directly",
      "Activate AT2 receptors"
   ],
   "answer": "Do not increase bradykinin",
   "explanation": "ARBs selectively block AT1 receptors without inhibiting bradykinin breakdown, reducing cough risk."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00258",
   "question": "Aliskiren lowers blood pressure by:",
   "options": [
      "Inhibiting renin",
      "Blocking AT1 receptor",
      "Inhibiting ACE",
      "Stimulating bradykinin"
   ],
   "answer": "Inhibiting renin",
   "explanation": "Aliskiren binds renin’s active site, reducing conversion of angiotensinogen to angiotensin I."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00259",
   "question": "β₁-selective blockers reduce blood pressure in part by:",
   "options": [
      "Decreasing renin release",
      "Increasing heart rate",
      "Vasodilation",
      "Increasing contractility"
   ],
   "answer": "Decreasing renin release",
   "explanation": "β₁ blockade in juxtaglomerular cells lowers renin secretion, diminishing RAAS activation."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00260",
   "question": "Nonselective β-blockers may worsen asthma because they:",
   "options": [
      "Block β₂-mediated bronchodilation",
      "Increase bronchial secretions",
      "Activate muscarinic receptors",
      "Stimulate histamine release"
   ],
   "answer": "Block β₂-mediated bronchodilation",
   "explanation": "β₂ blockade in bronchial smooth muscle leads to constriction and reduced airflow."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00261",
   "question": "α₁-blockers improve urinary symptoms of BPH by:",
   "options": [
      "Relaxing smooth muscle in prostate and bladder neck",
      "Inhibiting 5α-reductase",
      "Increasing detrusor contraction",
      "Antagonizing muscarinic receptors"
   ],
   "answer": "Relaxing smooth muscle in prostate and bladder neck",
   "explanation": "α₁ antagonism reduces tone in prostatic stroma and bladder outlet, easing urine flow."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00262",
   "question": "Labetalol lowers blood pressure by:",
   "options": [
      "Blocking α₁ and β receptors",
      "Stimulating α₂ receptors",
      "Inhibiting renin",
      "Opening K⁺ channels"
   ],
   "answer": "Blocking α₁ and β receptors",
   "explanation": "Labetalol’s combined α₁ and β blockade decreases peripheral resistance and heart rate without reflex tachycardia."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00263",
   "question": "Hydralazine reduces blood pressure by:",
   "options": [
      "Direct arteriolar vasodilation via NO release",
      "β-blockade in heart",
      "ACE inhibition",
      "Diuresis"
   ],
   "answer": "Direct arteriolar vasodilation via NO release",
   "explanation": "Hydralazine relaxes vascular smooth muscle through endothelial NO, lowering systemic resistance."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00264",
   "question": "Hydralazine’s long-term side effect includes:",
   "options": [
      "Lupus-like syndrome",
      "Pulmonary fibrosis",
      "Hyperuricemia",
      "Ototoxicity"
   ],
   "answer": "Lupus-like syndrome",
   "explanation": "Prolonged hydralazine use can induce a reversible SLE-like condition with arthralgias and rash."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00265",
   "question": "Minoxidil lowers blood pressure by:",
   "options": [
      "Opening vascular K⁺ channels",
      "ACE inhibition",
      "β₁-blockade",
      "Ca²⁺ channel blockade"
   ],
   "answer": "Opening vascular K⁺ channels",
   "explanation": "Minoxidil hyperpolarizes smooth muscle cells via K_ATP channel opening, causing potent arteriolar dilation."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00266",
   "question": "A prominent side effect of minoxidil is:",
   "options": [
      "Hypertrichosis",
      "Cough",
      "Bradycardia",
      "Hyperglycemia"
   ],
   "answer": "Hypertrichosis",
   "explanation": "Minoxidil stimulates hair follicles, leading to unwanted hair growth on face and body."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00267",
   "question": "Nitroprusside lowers blood pressure in emergencies by:",
   "options": [
      "Releasing NO to dilate arteries and veins",
      "Blocking β receptors",
      "Inhibiting RAAS",
      "Opening K⁺ channels exclusively"
   ],
   "answer": "Releasing NO to dilate arteries and veins",
   "explanation": "Nitroprusside releases nitric oxide, causing rapid balanced vasodilation; monitored for cyanide toxicity."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00268",
   "question": "Use of nitroprusside is limited by risk of:",
   "options": [
      "Cyanide toxicity",
      "Lupus-like syndrome",
      "Gout",
      "Ototoxicity"
   ],
   "answer": "Cyanide toxicity",
   "explanation": "Nitroprusside metabolism liberates cyanide, which must be detoxified or can accumulate dangerously."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00269",
   "question": "Fenoldopam lowers blood pressure by:",
   "options": [
      "Agonizing D1 receptors",
      "Blocking α₁ receptors",
      "Inhibiting ACE",
      "β₁ blockade"
   ],
   "answer": "Agonizing D1 receptors",
   "explanation": "Fenoldopam activates D1 receptors in renal and peripheral vessels, causing vasodilation and natriuresis."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00270",
   "question": "A common side effect of fenoldopam is:",
   "options": [
      "Reflex tachycardia",
      "Cough",
      "Bradycardia",
      "Hyperuricemia"
   ],
   "answer": "Reflex tachycardia",
   "explanation": "Peripheral vasodilation triggers sympathetic reflex, increasing heart rate."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00271",
   "question": "Clonidine lowers blood pressure by:",
   "options": [
      "Stimulating central α₂ receptors",
      "Blocking β₁ receptors",
      "Inhibiting ACE",
      "Opening K⁺ channels"
   ],
   "answer": "Stimulating central α₂ receptors",
   "explanation": "Clonidine activates α₂ receptors in the brainstem, decreasing sympathetic outflow to the periphery."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00272",
   "question": "Which side effect is notable with clonidine?",
   "options": [
      "Sedation and dry mouth",
      "Hyperglycemia",
      "Peripheral edema",
      "Ototoxicity"
   ],
   "answer": "Sedation and dry mouth",
   "explanation": "Central α₂ activation causes CNS depression and reduced salivary secretion."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00273",
   "question": "Abrupt withdrawal of clonidine may cause:",
   "options": [
      "Rebound hypertension",
      "Orthostatic hypotension",
      "Hyperkalemia",
      "Dry cough"
   ],
   "answer": "Rebound hypertension",
   "explanation": "Discontinuing central sympatholytics rapidly leads to excessive sympathetic activation and severe hypertension."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00274",
   "question": "Methyldopa is preferred in pregnancy because it:",
   "options": [
      "Is a central α₂ agonist safe for the fetus",
      "Blocks β receptors",
      "Inhibits ACE",
      "Opens K⁺ channels"
   ],
   "answer": "Is a central α₂ agonist safe for the fetus",
   "explanation": "Methyldopa’s long history and minimal teratogenicity make it the antihypertensive of choice in pregnancy."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00275",
   "question": "A notable adverse effect of methyldopa is:",
   "options": [
      "Hemolytic anemia with positive Coombs test",
      "Dry cough",
      "Hypertrichosis",
      "Ototoxicity"
   ],
   "answer": "Hemolytic anemia with positive Coombs test",
   "explanation": "Methyldopa can induce autoimmune hemolysis, detectable by a positive Coombs assay."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00276",
   "question": "Dihydropyridine calcium channel blockers differ from non-dihydropyridines by primarily affecting:",
   "options": [
      "Vascular smooth muscle more than cardiac conduction",
      "Heart rate more than vessels",
      "Renin release",
      "Aldosterone secretion"
   ],
   "answer": "Vascular smooth muscle more than cardiac conduction",
   "explanation": "Dihydropyridines (e.g., amlodipine) preferentially block L-type Ca²⁺ channels in vessels, causing vasodilation."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00277",
   "question": "A common side effect of dihydropyridine CCBs is:",
   "options": [
      "Peripheral edema",
      "Bradycardia",
      "Dry cough",
      "Hyperuricemia"
   ],
   "answer": "Peripheral edema",
   "explanation": "Arteriolar dilation increases capillary hydrostatic pressure, leading to fluid extravasation in dependent tissues."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00278",
   "question": "Non-dihydropyridine CCBs (verapamil, diltiazem) can cause:",
   "options": [
      "Constipation",
      "Hyperglycemia",
      "Ototoxicity",
      "Gout"
   ],
   "answer": "Constipation",
   "explanation": "Verapamil slows GI smooth muscle contraction by blocking Ca²⁺ channels, leading to constipation."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00279",
   "question": "ACE inhibitors reduce diabetic nephropathy progression by:",
   "options": [
      "Dilating efferent arterioles",
      "Blocking renin release",
      "Increasing GFR",
      "Stimulating bradykinin"
   ],
   "answer": "Dilating efferent arterioles",
   "explanation": "Reduced angiotensin II lowers efferent arteriole tone, decreasing intraglomerular pressure and proteinuria."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00280",
   "question": "According to guidelines, first-line therapy for uncomplicated hypertension often includes:",
   "options": [
      "Thiazide diuretics",
      "Loop diuretics",
      "Alpha-blockers",
      "Central agonists"
   ],
   "answer": "Thiazide diuretics",
   "explanation": "Thiazides are recommended first-line due to efficacy, safety, and long-term outcome benefits."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00281",
   "question": "A hypertensive emergency is defined by:",
   "options": [
      "BP >180/120 mmHg with acute end-organ damage",
      "BP >160/100 mmHg without symptoms",
      "Any BP ≥140/90 mmHg",
      "BP <90/60 mmHg with symptoms"
   ],
   "answer": "BP >180/120 mmHg with acute end-organ damage",
   "explanation": "Emergencies require immediate IV therapy to prevent or limit organ injury."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00282",
   "question": "Hypertensive urgency differs from emergency by:",
   "options": [
      "Absence of acute end-organ damage",
      "Higher BP threshold",
      "Presence of chest pain",
      "Need for IV nitroprusside"
   ],
   "answer": "Absence of acute end-organ damage",
   "explanation": "Urgencies involve severely elevated BP without signs of target-organ injury and can often be managed with oral agents."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00283",
   "question": "Which antihypertensive is considered safest in pregnancy?",
   "options": [
      "Methyldopa",
      "Lisinopril",
      "Losartan",
      "Hydrochlorothiazide"
   ],
   "answer": "Methyldopa",
   "explanation": "Methyldopa’s extensive safety data support its use in gestational hypertension."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00284",
   "question": "Which antihypertensive class is contraindicated in pregnancy due to fetal renal malformations?",
   "options": [
      "ACE inhibitors",
      "Beta-blockers",
      "Calcium channel blockers",
      "Alpha-blockers"
   ],
   "answer": "ACE inhibitors",
   "explanation": "ACE inhibitors and ARBs can cause fetal renal dysplasia and oligohydramnios and must be avoided."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00285",
   "question": "Thiazide diuretics can benefit bone density by:",
   "options": [
      "Increasing renal calcium reabsorption",
      "Blocking PTH",
      "Direct osteoblast activation",
      "Inhibiting vitamin D synthesis"
   ],
   "answer": "Increasing renal calcium reabsorption",
   "explanation": "By reducing urinary Ca²⁺ loss, thiazides may help preserve bone mineral density."
},
 {
   "chapter_id": 8,
   "chapter": "Antihypertensives",
   "question_id": "00008-00286",
   "question": "ACE inhibitors improve left ventricular hypertrophy by:",
   "options": [
      "Reducing afterload and remodeling",
      "Blocking natriuresis",
      "Increasing preload",
      "Stimulating sympathetic tone"
   ],
   "answer": "Reducing afterload and remodeling",
   "explanation": "Decreased angiotensin II and improved hemodynamics lessen wall stress and pathological remodeling."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00287",
   "question": "Carbonic anhydrase inhibitors like acetazolamide act primarily at which part of the nephron?",
   "options": [
      "Proximal convoluted tubule",
      "Thick ascending limb",
      "Distal convoluted tubule",
      "Collecting duct"
   ],
   "answer": "Proximal convoluted tubule",
   "explanation": "Carbonic anhydrase inhibitors reduce bicarbonate reabsorption in the PCT by inhibiting CA, leading to diuresis and alkaline urine."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00288",
   "question": "Acetazolamide is used to treat all of the following EXCEPT:",
   "options": [
      "Altitude sickness",
      "Metabolic alkalosis",
      "Open-angle glaucoma",
      "Pulmonary edema"
   ],
   "answer": "Pulmonary edema",
   "explanation": "Acetazolamide treats altitude sickness, metabolic alkalosis, and glaucoma but is not used to treat pulmonary edema."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00289",
   "question": "Which adverse effect is most characteristic of carbonic anhydrase inhibitors?",
   "options": [
      "Metabolic acidosis",
      "Hypokalemia",
      "Hyperglycemia",
      "Hyperuricemia"
   ],
   "answer": "Metabolic acidosis",
   "explanation": "By promoting bicarbonate loss, CA inhibitors can cause a normal anion gap metabolic acidosis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00290",
   "question": "Loop diuretics inhibit which transporter in the thick ascending limb?",
   "options": [
      "Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2)",
      "Na⁺-Cl⁻ symporter (NCC)",
      "Epithelial Na⁺ channel (ENaC)",
      "Na⁺-H⁺ exchanger"
   ],
   "answer": "Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2)",
   "explanation": "Loop diuretics block NKCC2 in TAL, preventing reabsorption of sodium, potassium, and chloride."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00291",
   "question": "Loop diuretics are effective in treating edema associated with all EXCEPT:",
   "options": [
      "Heart failure",
      "Cirrhosis",
      "Nephrotic syndrome",
      "Hyponatremia"
   ],
   "answer": "Hyponatremia",
   "explanation": "Loop diuretics worsen hyponatremia by increasing free water loss; they treat edema in heart failure, cirrhosis, and nephrotic syndrome."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00292",
   "question": "Which loop diuretic is non-sulfonamide and used in sulfa-allergic patients?",
   "options": [
      "Ethacrynic acid",
      "Furosemide",
      "Bumetanide",
      "Torsemide"
   ],
   "answer": "Ethacrynic acid",
   "explanation": "Ethacrynic acid lacks a sulfonamide group, making it suitable for patients with sulfa allergies."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00293",
   "question": "Loop diuretics can cause ototoxicity by:",
   "options": [
      "Altering endolymph electrolyte composition",
      "Inhibiting acetylcholinesterase in the ear",
      "Blocking cochlear NMDA receptors",
      "Causing cochlear inflammation"
   ],
   "answer": "Altering endolymph electrolyte composition",
   "explanation": "Loop diuretics disrupt transport in the inner ear, altering endolymph and causing ototoxicity."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00294",
   "question": "Thiazide diuretics lower blood pressure by inhibiting which transporter?",
   "options": [
      "Na⁺-Cl⁻ symporter in distal convoluted tubule",
      "NKCC2 in TAL",
      "ENaC in collecting duct",
      "Na⁺-H⁺ exchanger"
   ],
   "answer": "Na⁺-Cl⁻ symporter in distal convoluted tubule",
   "explanation": "Thiazides inhibit NCC in DCT, promoting sodium and water excretion and lowering blood volume."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00295",
   "question": "Which diuretic is associated with hyperglycemia, hyperlipidemia, and hyperuricemia?",
   "options": [
      "Hydrochlorothiazide",
      "Furosemide",
      "Acetazolamide",
      "Spironolactone"
   ],
   "answer": "Hydrochlorothiazide",
   "explanation": "Thiazide diuretics can impair glucose tolerance, increase lipid levels, and promote hyperuricemia."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00296",
   "question": "Thiazides decrease calcium excretion, making them useful for preventing:",
   "options": [
      "Kidney stones",
      "Ototoxicity",
      "Diabetic nephropathy",
      "Gout"
   ],
   "answer": "Kidney stones",
   "explanation": "By enhancing Ca²⁺ reabsorption in DCT, thiazides reduce urinary calcium excretion and risk of kidney stones."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00297",
   "question": "Which diuretic is used to treat nephrogenic diabetes insipidus?",
   "options": [
      "Hydrochlorothiazide",
      "Furosemide",
      "Acetazolamide",
      "Mannitol"
   ],
   "answer": "Hydrochlorothiazide",
   "explanation": "Thiazides reduce polyuria in nephrogenic DI by causing mild volume depletion and increased proximal water reabsorption."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00298",
   "question": "Which potassium-sparing diuretic acts by blocking epithelial sodium channels (ENaC)?",
   "options": [
      "Amiloride",
      "Spironolactone",
      "Furosemide",
      "Hydrochlorothiazide"
   ],
   "answer": "Amiloride",
   "explanation": "Amiloride directly inhibits ENaC in the collecting duct, reducing sodium reabsorption and potassium secretion."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00299",
   "question": "Spironolactone antagonizes:",
   "options": [
      "Aldosterone receptor in collecting duct",
      "NKCC2 in TAL",
      "ENaC in DCT",
      "V2 vasopressin receptor"
   ],
   "answer": "Aldosterone receptor in collecting duct",
   "explanation": "Spironolactone blocks mineralocorticoid receptors, reducing Na⁺ reabsorption and K⁺ excretion."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00300",
   "question": "Aldosterone antagonists like spironolactone can cause all EXCEPT:",
   "options": [
      "Gynecomastia",
      "Hyperkalemia",
      "Metabolic acidosis",
      "Hypocalcemia"
   ],
   "answer": "Hypocalcemia",
   "explanation": "Spironolactone causes gynecomastia, hyperkalemia, metabolic acidosis, but not hypocalcemia."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00301",
   "question": "Which diuretic is most effective at increasing free water excretion without altering electrolyte balance?",
   "options": [
      "Mannitol",
      "Furosemide",
      "Acetazolamide",
      "Hydrochlorothiazide"
   ],
   "answer": "Mannitol",
   "explanation": "Mannitol is an osmotic diuretic that draws water into the lumen without significant solute excretion."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00302",
   "question": "Mannitol is contraindicated in patients with:",
   "options": [
      "Pulmonary edema",
      "Hyponatremia",
      "Glaucoma",
      "Renal failure"
   ],
   "answer": "Pulmonary edema",
   "explanation": "Mannitol can expand extracellular volume and worsen pulmonary edema due to osmotic fluid shift."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00303",
   "question": "Which diuretic class produces the greatest diuresis?",
   "options": [
      "Loop diuretics",
      "Thiazides",
      "Carbonic anhydrase inhibitors",
      "Potassium-sparing diuretics"
   ],
   "answer": "Loop diuretics",
   "explanation": "Loop diuretics inhibit a large fraction of sodium reabsorption in TAL, yielding potent diuresis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00304",
   "question": "Loop diuretics are preferred over thiazides in patients with:",
   "options": [
      "Reduced renal function (low GFR)",
      "Hypertension only",
      "Kidney stones only",
      "Nephrogenic DI"
   ],
   "answer": "Reduced renal function (low GFR)",
   "explanation": "Loops remain effective even at low GFR, whereas thiazides lose efficacy when GFR <30 mL/min."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00305",
   "question": "Carbonic anhydrase inhibitors can induce metabolic acidosis by promoting retention of:",
   "options": [
      "H⁺ and HCO₃⁻ excretion",
      "K⁺ and Na⁺ reabsorption",
      "Ca²⁺ excretion",
      "Mg²⁺ retention"
   ],
   "answer": "H⁺ and HCO₃⁻ excretion",
   "explanation": "CA inhibition reduces H⁺ secretion and HCO₃⁻ reabsorption, causing systemic acidosis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00306",
   "question": "Thiazide diuretics can worsen gout by:",
   "options": [
      "Decreasing uric acid excretion",
      "Increasing urinary calcium",
      "Blocking aldosterone",
      "Inhibiting carbonic anhydrase"
   ],
   "answer": "Decreasing uric acid excretion",
   "explanation": "Thiazides compete for urate transporters, reducing uric acid clearance and precipitating gout."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00307",
   "question": "Osmotic diuretics like mannitol increase urine osmolarity by:",
   "options": [
      "Non-reabsorbable solute effect",
      "Direct NKCC2 stimulation",
      "Carbonic anhydrase activation",
      "Aldosterone antagonism"
   ],
   "answer": "Non-reabsorbable solute effect",
   "explanation": "Osmotic agents remain in tubule lumen, drawing water into urine."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00308",
   "question": "Acetazolamide is contraindicated in patients with:",
   "options": [
      "Metabolic acidosis",
      "Sulfa allergy",
      "Open-angle glaucoma",
      "Mountain sickness"
   ],
   "answer": "Metabolic acidosis",
   "explanation": "Acetazolamide induces acidosis and is counterproductive in existing metabolic acidosis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00309",
   "question": "Which transporter mutation causes Liddle syndrome, treatable with amiloride?",
   "options": [
      "ENaC gain-of-function",
      "NKCC2 loss-of-function",
      "NCC loss-of-function",
      "CA II deficiency"
   ],
   "answer": "ENaC gain-of-function",
   "explanation": "Enhanced ENaC activity in collecting duct mimics hyperaldosteronism and responds to ENaC blockers."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00310",
   "question": "Which diuretic combination is used to overcome diuretic resistance in heart failure?",
   "options": [
      "Loop + thiazide",
      "Loop + K-sparing",
      "Thiazide + CA inhibitor",
      "Osmotic + loop"
   ],
   "answer": "Loop + thiazide",
   "explanation": "Sequential nephron blockade with loop and thiazide prevents distal sodium reabsorption escape."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00311",
   "question": "Which diuretic causes paresthesias and photosensitivity as side effects?",
   "options": [
      "Carbonic anhydrase inhibitors",
      "Thiazides",
      "Loops",
      "Amiloride"
   ],
   "answer": "Carbonic anhydrase inhibitors",
   "explanation": "Carbonic anhydrase inhibitors can produce paresthesias and photosensitivity rashes."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00312",
   "question": "Eplerenone differs from spironolactone by having:",
   "options": [
      "Less antiandrogenic effects",
      "Greater gynecomastia risk",
      "More K⁺ loss",
      "Irreversible aldosterone blockade"
   ],
   "answer": "Less antiandrogenic effects",
   "explanation": "Eplerenone has greater selectivity for mineralocorticoid receptors, reducing endocrine side effects."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00313",
   "question": "Which diuretic can be used to treat idiopathic intracranial hypertension?",
   "options": [
      "Acetazolamide",
      "Furosemide",
      "Mannitol",
      "Spironolactone"
   ],
   "answer": "Acetazolamide",
   "explanation": "CA inhibitors reduce CSF production, lowering intracranial pressure."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00314",
   "question": "Which diuretic increases calcium reabsorption, potentially benefiting osteoporosis?",
   "options": [
      "Thiazides",
      "Loops",
      "Carbonic anhydrase inhibitors",
      "Osmotics"
   ],
   "answer": "Thiazides",
   "explanation": "Thiazides enhance distal calcium reabsorption and reduce urinary calcium excretion."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00315",
   "question": "Which diuretic acts on the V2 receptor, causing aquaresis without electrolyte loss?",
   "options": [
      "Tolvaptan",
      "Furosemide",
      "Hydrochlorothiazide",
      "Spironolactone"
   ],
   "answer": "Tolvaptan",
   "explanation": "Vaptans antagonize vasopressin V2 receptors in the collecting duct, increasing free water clearance."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00316",
   "question": "Which diuretic is effective in reducing intracranial pressure but must be used cautiously in heart failure?",
   "options": [
      "Mannitol",
      "Acetazolamide",
      "Furosemide",
      "Hydrochlorothiazide"
   ],
   "answer": "Mannitol",
   "explanation": "Osmotic expansion of plasma volume may exacerbate heart failure."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00317",
   "question": "Combining potassium-sparing diuretics with ACE inhibitors can increase risk of:",
   "options": [
      "Hyperkalemia",
      "Metabolic alkalosis",
      "Hypocalcemia",
      "Hyponatremia"
   ],
   "answer": "Hyperkalemia",
   "explanation": "Both reduce aldosterone and K⁺ excretion, leading to elevated serum potassium."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00318",
   "question": "Which diuretic can cause metabolic alkalosis due to contraction and increased bicarbonate reabsorption?",
   "options": [
      "Loop diuretics",
      "Carbonic anhydrase inhibitors",
      "Osmotic diuretics",
      "Potassium-sparing diuretics"
   ],
   "answer": "Loop diuretics",
   "explanation": "Volume contraction enhances RAAS, increasing bicarbonate reabsorption and metabolic alkalosis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00319",
   "question": "Loop diuretics worsen calcium stone risk by:",
   "options": [
      "Increasing urinary calcium",
      "Decreasing PTH secretion",
      "Increasing urinary oxalate",
      "Increasing urinary citrate"
   ],
   "answer": "Increasing urinary calcium",
   "explanation": "Loop diuretics inhibit calcium reabsorption in TAL, causing hypercalciuria and stones."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00320",
   "question": "Thiazide diuretics can decrease the risk of kidney stones by:",
   "options": [
      "Reducing urinary calcium excretion",
      "Increasing urinary calcium excretion",
      "Increasing PTH secretion",
      "Blocking oxalate absorption"
   ],
   "answer": "Reducing urinary calcium excretion",
   "explanation": "Thiazides enhance DCT calcium reabsorption, lowering urinary calcium and stone risk."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00321",
   "question": "In Liddle syndrome, treatment with amiloride corrects hypertension by:",
   "options": [
      "Blocking ENaC",
      "Inhibiting NKCC2",
      "Inhibiting CA",
      "Blocking NCC"
   ],
   "answer": "Blocking ENaC",
   "explanation": "Amiloride directly inhibits overactive ENaC, reducing sodium reabsorption and hypertension."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00322",
   "question": "Which diuretic class is contraindicated in patients with sulfa allergy?",
   "options": [
      "Thiazides and loops",
      "Potassium-sparing diuretics",
      "Mannitol",
      "Spironolactone"
   ],
   "answer": "Thiazides and loops",
   "explanation": "Most loops and thiazides contain sulfonamide moieties and may cause allergic reactions."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00323",
   "question": "Which diuretic is used in acute glaucoma to rapidly lower intraocular pressure?",
   "options": [
      "Mannitol",
      "Acetazolamide",
      "Furosemide",
      "Hydrochlorothiazide"
   ],
   "answer": "Mannitol",
   "explanation": "Mannitol reduces ocular volume by osmotic gradient, rapidly decreasing IOP."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00324",
   "question": "Osmotic diuretics can increase excretion of:",
   "options": [
      "Sodium and water",
      "Potassium only",
      "Calcium only",
      "Magnesium only"
   ],
   "answer": "Sodium and water",
   "explanation": "Osmotics cause nonselective natriuresis and diuresis of water and electrolytes."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00325",
   "question": "Which potassium-sparing diuretic is contraindicated in Addison’s disease due to risk of hyperkalemia?",
   "options": [
      "Spironolactone",
      "Hydrochlorothiazide",
      "Furosemide",
      "Acetazolamide"
   ],
   "answer": "Spironolactone",
   "explanation": "Spironolactone antagonizes aldosterone; in primary adrenal insufficiency, it exacerbates hyperkalemia."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00326",
   "question": "Which diuretic class can lead to contraction alkalosis when overused?",
   "options": [
      "Loop diuretics",
      "Carbonic anhydrase inhibitors",
      "Potassium-sparing diuretics",
      "Osmotic diuretics"
   ],
   "answer": "Loop diuretics",
   "explanation": "Excess loop diuretic use leads to volume contraction, RAAS activation, and bicarbonate retention causing metabolic alkalosis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00327",
   "question": "Which diuretic is preferred in patients with both hypertension and osteoporosis?",
   "options": [
      "Thiazides",
      "Loops",
      "CA inhibitors",
      "Mannitol"
   ],
   "answer": "Thiazides",
   "explanation": "Thiazides lower blood pressure and reduce urinary calcium excretion, benefiting bone mineral density."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00328",
   "question": "Which of the following is a V2 receptor antagonist?",
   "options": [
      "Tolvaptan",
      "Furosemide",
      "Spironolactone",
      "Acetazolamide"
   ],
   "answer": "Tolvaptan",
   "explanation": "Tolvaptan blocks vasopressin V2 receptors in the collecting duct, promoting aquaresis."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00329",
   "question": "Which diuretic combination is most likely to cause severe hypokalemia?",
   "options": [
      "Loop + thiazide",
      "Loop + potassium-sparing",
      "Thiazide + potassium-sparing",
      "Loop + CA inhibitor"
   ],
   "answer": "Loop + thiazide",
   "explanation": "Combining loop and thiazide diuretics enhances sodium delivery distally, increasing K⁺ loss."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00330",
   "question": "Which diuretic increases renin release by reducing renal perfusion?",
   "options": [
      "Loop diuretics",
      "CA inhibitors",
      "Potassium-sparing",
      "Osmotics"
   ],
   "answer": "Loop diuretics",
   "explanation": "By reducing volume and NaCl delivery, loops enhance renin secretion via macula densa feedback."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00331",
   "question": "Which diuretic can be used to treat altitude sickness?",
   "options": [
      "Acetazolamide",
      "Furosemide",
      "Thiazide",
      "Spironolactone"
   ],
   "answer": "Acetazolamide",
   "explanation": "CA inhibition induces metabolic acidosis, stimulating ventilation to prevent altitude-related hypoxia."
},
 {
   "chapter_id": 9,
   "chapter": "Diuretics",
   "question_id": "00009-00332",
   "question": "Which diuretic is used to protect against hypercalcemia in acute settings?",
   "options": [
      "Loop diuretics",
      "Thiazide diuretics",
      "CA inhibitors",
      "Potassium-sparing"
   ],
   "answer": "Loop diuretics",
   "explanation": "Loops increase urinary calcium excretion, lowering serum calcium in hypercalcemic emergencies."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00333",
   "question": "Digoxin exerts its positive inotropic effect by inhibiting which enzyme?",
   "options": [
      "Na⁺/K⁺-ATPase",
      "Phosphodiesterase-3",
      "ACE",
      "Renin"
   ],
   "answer": "Na⁺/K⁺-ATPase",
   "explanation": "Digoxin blocks the cardiac Na⁺/K⁺-ATPase, increasing intracellular Na⁺ and indirectly raising Ca²⁺ via the Na⁺/Ca²⁺ exchanger."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00334",
   "question": "Which ECG change is characteristic of digoxin effect?",
   "options": [
      "Scooped ST segments",
      "Peaked T waves",
      "Prolonged QT interval",
      "Delta waves"
   ],
   "answer": "Scooped ST segments",
   "explanation": "Digoxin produces a down-sloping ('scooped') ST depression, often called the 'digitalis effect.'"
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00335",
   "question": "Hypokalemia enhances digoxin toxicity because:",
   "options": [
      "Less K⁺ competes at Na⁺/K⁺-ATPase",
      "It increases digoxin clearance",
      "It blocks digoxin uptake",
      "It raises renal elimination"
   ],
   "answer": "Less K⁺ competes at Na⁺/K⁺-ATPase",
   "explanation": "Low serum K⁺ increases digoxin binding to Na⁺/K⁺-ATPase, potentiating its effects and toxicity."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00336",
   "question": "The antidote for severe digoxin toxicity is:",
   "options": [
      "Digoxin immune Fab",
      "Atropine",
      "Calcium gluconate",
      "Propanolol"
   ],
   "answer": "Digoxin immune Fab",
   "explanation": "Digoxin-specific antibody fragments bind free drug, preventing it from inhibiting Na⁺/K⁺-ATPase."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00337",
   "question": "Which class of drugs is first-line for chronic HFrEF to reduce mortality?",
   "options": [
      "ACE inhibitors",
      "Loop diuretics",
      "Hydralazine",
      "Digoxin"
   ],
   "answer": "ACE inhibitors",
   "explanation": "ACE inhibitors decrease afterload and remodeling and have been proven to reduce mortality in HFrEF."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00338",
   "question": "An angiotensin receptor blocker (ARB) is used in HF patients intolerant of ACE inhibitors to avoid:",
   "options": [
      "Cough",
      "Hypokalemia",
      "Bradycardia",
      "Diuresis"
   ],
   "answer": "Cough",
   "explanation": "ARBs block AT1 receptors without increasing bradykinin, reducing the risk of ACE inhibitor–induced cough."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00339",
   "question": "Which β-blocker has been shown to improve survival in HF by reducing remodeling?",
   "options": [
      "Carvedilol",
      "Propranolol",
      "Atenolol",
      "Esmolol"
   ],
   "answer": "Carvedilol",
   "explanation": "Carvedilol’s β₁/β₂ and α₁ blockade reduces heart rate, contractility, and afterload, improving survival and remodeling."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00340",
   "question": "Which aldosterone antagonist reduces mortality in severe HFrEF?",
   "options": [
      "Spironolactone",
      "Hydrochlorothiazide",
      "Furosemide",
      "Amiloride"
   ],
   "answer": "Spironolactone",
   "explanation": "Spironolactone blocks aldosterone’s deleterious effects on myocardial fibrosis and fluid retention, improving survival."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00341",
   "question": "Hydralazine combined with isosorbide dinitrate is especially indicated in:",
   "options": [
      "Black patients with HFrEF",
      "Diabetic nephropathy",
      "Acute decompensated HF",
      "HFpEF only"
   ],
   "answer": "Black patients with HFrEF",
   "explanation": "This combination improves outcomes in black patients with HFrEF who remain symptomatic on standard therapy."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00342",
   "question": "Sacubitril/valsartan (ARNI) combines an ARB with:",
   "options": [
      "Neprilysin inhibitor",
      "ACE inhibitor",
      "Renin inhibitor",
      "Beta-blocker"
   ],
   "answer": "Neprilysin inhibitor",
   "explanation": "Sacubitril inhibits neprilysin to enhance natriuretic peptides; valsartan blocks AT1 receptors, synergizing to reduce HF morbidity."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00343",
   "question": "In acute decompensated HF with low perfusion, which inotrope is often used?",
   "options": [
      "Dobutamine",
      "Digoxin",
      "Hydralazine",
      "Metoprolol"
   ],
   "answer": "Dobutamine",
   "explanation": "Dobutamine’s β₁ agonism increases contractility and cardiac output with modest vasodilation via β₂."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00344",
   "question": "Milrinone improves cardiac output by inhibiting:",
   "options": [
      "Phosphodiesterase-3",
      "Na⁺/K⁺-ATPase",
      "ACE",
      "Renin"
   ],
   "answer": "Phosphodiesterase-3",
   "explanation": "Milrinone increases cAMP in cardiomyocytes and vascular smooth muscle, enhancing inotropy and vasodilation."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00345",
   "question": "Nesiritide, recombinant BNP, works by stimulating:",
   "options": [
      "Guanylate cyclase",
      "Adenylate cyclase",
      "Na⁺/K⁺-ATPase",
      "ACE"
   ],
   "answer": "Guanylate cyclase",
   "explanation": "Nesiritide increases cGMP, causing vasodilation and natriuresis in acute decompensated HF."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00346",
   "question": "Ivabradine reduces hospitalization in HFrEF by:",
   "options": [
      "Inhibiting If current in SA node",
      "Blocking β₁ receptors",
      "Inhibiting ACE",
      "Stimulating BNP"
   ],
   "answer": "Inhibiting If current in SA node",
   "explanation": "Ivabradine selectively slows heart rate by inhibiting the funny current without affecting contractility."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00347",
   "question": "Which diuretic class is preferred to relieve congestion in HF?",
   "options": [
      "Loop diuretics",
      "Thiazides",
      "Carbonic anhydrase inhibitors",
      "Potassium-sparing"
   ],
   "answer": "Loop diuretics",
   "explanation": "Loops (e.g., furosemide) produce potent diuresis even at low GFR, reducing preload and congestion."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00348",
   "question": "Which loop diuretic adverse effect may limit high-dose use?",
   "options": [
      "Ototoxicity",
      "Gynecomastia",
      "Dry cough",
      "Bradycardia"
   ],
   "answer": "Ototoxicity",
   "explanation": "High doses of loop diuretics can alter inner ear electrolyte composition and cause hearing loss."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00349",
   "question": "Which medication requires serum creatinine and potassium monitoring due to hyperkalemia risk in HF?",
   "options": [
      "ACE inhibitors",
      "Digoxin",
      "Hydralazine",
      "Ivabradine"
   ],
   "answer": "ACE inhibitors",
   "explanation": "ACE inhibitors reduce aldosterone, causing potassium retention; renal function must be monitored."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00350",
   "question": "ARNI therapy must be initiated after a washout period when switching from an ACE inhibitor to avoid:",
   "options": [
      "Angioedema",
      "Hyperglycemia",
      "Hypotension",
      "Renal failure"
   ],
   "answer": "Angioedema",
   "explanation": "Bradykinin accumulation from overlapping ACE inhibition and neprilysin blockade increases angioedema risk."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00351",
   "question": "Which drug increases cardiac contractility without significantly increasing heart rate?",
   "options": [
      "Digoxin",
      "Dobutamine",
      "Milrinone",
      "Epinephrine"
   ],
   "answer": "Digoxin",
   "explanation": "Digoxin’s vagotonic effect slows AV conduction, so contractility rises while heart rate often decreases."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00352",
   "question": "Which HF drug class reduces mortality by reversing remodeling in chronic HFrEF?",
   "options": [
      "β-blockers",
      "Loop diuretics",
      "Nesiritide",
      "Hydralazine"
   ],
   "answer": "β-blockers",
   "explanation": "Chronic β1 blockade reduces sympathetic overdrive and attenuates pathologic remodeling in HFrEF."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00353",
   "question": "Which agent is contraindicated in acute decompensated HF due to negative inotropy?",
   "options": [
      "Metoprolol",
      "Milrinone",
      "Dobutamine",
      "Nesiritide"
   ],
   "answer": "Metoprolol",
   "explanation": "β-blockers acutely reduce contractility and may worsen decompensation, so they are held in acute settings."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00354",
   "question": "Which medication reduces preload by venous dilation in acute HF?",
   "options": [
      "Nitroglycerin",
      "Hydralazine",
      "Carvedilol",
      "Enalapril"
   ],
   "answer": "Nitroglycerin",
   "explanation": "Nitroglycerin primarily dilates veins, reducing venous return and preload in acute decompensation."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00355",
   "question": "Which agent reduces afterload by arteriolar dilation in HF?",
   "options": [
      "Hydralazine",
      "Nitroglycerin",
      "Digoxin",
      "Spironolactone"
   ],
   "answer": "Hydralazine",
   "explanation": "Hydralazine selectively dilates arterioles, lowering systemic vascular resistance and afterload."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00356",
   "question": "Which drug combination improves survival when added to standard HF therapy in black patients?",
   "options": [
      "Hydralazine + isosorbide dinitrate",
      "Hydralazine + digoxin",
      "ACE inhibitor + loop",
      "Beta-blocker + loop"
   ],
   "answer": "Hydralazine + isosorbide dinitrate",
   "explanation": "This combination showed additional mortality benefit in black patients with HFrEF on ACE inhibitors and β-blockers."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00357",
   "question": "Which drug is a selective cardiac Na⁺ channel blocker that may worsen HF?",
   "options": [
      "Flecainide",
      "Digoxin",
      "Milrinone",
      "Spironolactone"
   ],
   "answer": "Flecainide",
   "explanation": "Flecainide depresses conduction and contractility and is contraindicated in structural heart disease including HF."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00358",
   "question": "Which medication class is used to prevent sudden cardiac death in HF survivors?",
   "options": [
      "ACE inhibitors",
      "Antiarrhythmics",
      "Statins",
      "Calcium channel blockers"
   ],
   "answer": "Antiarrhythmics",
   "explanation": "AICDs rather than antiarrhythmic drugs prevent sudden death; however, β-blockers also reduce arrhythmic mortality."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00359",
   "question": "Which HF therapy should be initiated first in most patients with HFrEF?",
   "options": [
      "ACE inhibitor",
      "Digoxin",
      "Hydralazine",
      "Ivabradine"
   ],
   "answer": "ACE inhibitor",
   "explanation": "ACE inhibitors are first-line for symptom relief, mortality reduction, and remodeling attenuation in HFrEF."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00360",
   "question": "Which inotrope is most appropriate for bridging to transplant in end-stage HF?",
   "options": [
      "Milrinone",
      "Digoxin",
      "Enalapril",
      "Hydralazine"
   ],
   "answer": "Milrinone",
   "explanation": "Milrinone improves hemodynamics without tachyphylaxis, making it suitable for short-term IV inotropic support."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00361",
   "question": "Which drug’s benefit in HF is attributed to diuretic and RAAS‐modulating effects?",
   "options": [
      "Spironolactone",
      "Hydrochlorothiazide",
      "Acetazolamide",
      "Mannitol"
   ],
   "answer": "Spironolactone",
   "explanation": "Spironolactone’s diuretic effect and aldosterone blockade reduce fibrosis, remodeling, and fluid retention."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00362",
   "question": "Which measure should be monitored in patients on ARNI therapy?",
   "options": [
      "Blood pressure and renal function",
      "Serum digoxin level",
      "QT interval",
      "Serum calcium"
   ],
   "answer": "Blood pressure and renal function",
   "explanation": "ARNIs can cause hypotension and renal impairment; monitoring these parameters ensures safety."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00363",
   "question": "In addition to β-blockers and ACE inhibitors, which drug class is recommended for symptomatic relief in NYHA class II–IV HF?",
   "options": [
      "Loop diuretics",
      "Thiazide diuretics",
      "Calcium channel blockers",
      "Nitrates"
   ],
   "answer": "Loop diuretics",
   "explanation": "Loops relieve congestion and dyspnea by reducing fluid overload; they do not improve mortality but improve symptoms."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00364",
   "question": "Which electrolyte disturbance increases risk of digitalis toxicity?",
   "options": [
      "Hypokalemia",
      "Hypernatremia",
      "Hypercalcemia",
      "Hypomagnesemia"
   ],
   "answer": "Hypokalemia",
   "explanation": "Low K⁺ enhances digoxin binding to Na⁺/K⁺-ATPase; magnesium also modulates toxicity risk but hypokalemia is primary."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00365",
   "question": "Which drug reduces heart rate without affecting myocardial contractility and is used in HFrEF with resting HR ≥70 bpm?",
   "options": [
      "Ivabradine",
      "Metoprolol",
      "Digoxin",
      "Milrinone"
   ],
   "answer": "Ivabradine",
   "explanation": "Ivabradine selectively inhibits the If current in the SA node, lowering heart rate without negative inotropy."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00366",
   "question": "Which agent is contraindicated in decompensated HF due to risk of myocardial depression?",
   "options": [
      "Verapamil",
      "Milrinone",
      "Dobutamine",
      "Hydralazine"
   ],
   "answer": "Verapamil",
   "explanation": "Non-dihydropyridine CCBs reduce contractility, worsening HF; they are contraindicated in systolic dysfunction."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00367",
   "question": "Which hormone analog reduces pulmonary capillary wedge pressure in acute HF?",
   "options": [
      "Nesiritide",
      "Epinephrine",
      "Vasopressin",
      "Aldosterone"
   ],
   "answer": "Nesiritide",
   "explanation": "Nesiritide’s natriuretic and vasodilatory effects lower preload and pulmonary pressures in acute decompensation."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00368",
   "question": "Which parameter improves with chronic ACE inhibitor therapy in HF?",
   "options": [
      "Left ventricular ejection fraction",
      "Serum K⁺",
      "Heart rate",
      "Proteinuria only"
   ],
   "answer": "Left ventricular ejection fraction",
   "explanation": "ACE inhibitors reverse remodeling and improve LVEF over time in HFrEF patients."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00369",
   "question": "Which medication reduces hospitalization but not mortality in mild-moderate HF?",
   "options": [
      "Ivabradine",
      "ACE inhibitors",
      "Beta-blockers",
      "Spironolactone"
   ],
   "answer": "Ivabradine",
   "explanation": "Ivabradine decreased HF hospitalizations in trials but did not demonstrate a significant mortality benefit."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00370",
   "question": "Which therapy requires an initial 36-hour washout when transitioning from an ACE inhibitor?",
   "options": [
      "Sacubitril/valsartan",
      "Spironolactone",
      "Metoprolol",
      "Milrinone"
   ],
   "answer": "Sacubitril/valsartan",
   "explanation": "To avoid angioedema, ARNIs require a 36-hour interval after stopping ACE inhibitors before initiation."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00371",
   "question": "Which inotrope also has vasodilatory properties and is useful in right HF?",
   "options": [
      "Milrinone",
      "Digoxin",
      "Epinephrine",
      "Spironolactone"
   ],
   "answer": "Milrinone",
   "explanation": "Milrinone’s combined inotropy and vasodilation reduce both preload and afterload, improving right ventricular output."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00372",
   "question": "Which antifailure drug is a renin inhibitor preventing Ang I formation?",
   "options": [
      "Aliskiren",
      "Losartan",
      "Enalapril",
      "Sacubitril"
   ],
   "answer": "Aliskiren",
   "explanation": "Aliskiren directly inhibits renin, blocking the conversion of angiotensinogen to Ang I."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00373",
   "question": "Which drug must be held before contrast imaging due to increased risk of renal injury?",
   "options": [
      "ACE inhibitors",
      "Digoxin",
      "Hydralazine",
      "Milrinone"
   ],
   "answer": "ACE inhibitors",
   "explanation": "ACE inhibitors can exacerbate contrast-induced renal vasoconstriction, increasing risk of acute kidney injury."
},
 {
   "chapter_id": 10,
   "chapter": "Drugs for Heart Failure",
   "question_id": "00010-00374",
   "question": "Which agent’s benefit in HF is largely due to afterload reduction via selective arterial dilation?",
   "options": [
      "Hydralazine",
      "Nitroglycerin",
      "Digoxin",
      "Milrinone"
   ],
   "answer": "Hydralazine",
   "explanation": "Hydralazine primarily dilates arterioles, reducing systemic vascular resistance and afterload in HF."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00375",
   "question": "Procainamide prolongs which ECG interval?",
   "options": [
      "QT interval",
      "PR interval",
      "QRS duration",
      "ST segment"
   ],
   "answer": "QT interval",
   "explanation": "Procainamide (Class IA) blocks Na⁺ channels and K⁺ channels, prolonging action potential duration and the QT interval."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00376",
   "question": "Which side effect is most characteristic of quinidine?",
   "options": [
      "Cinchonism",
      "Torsades de pointes",
      "Pulmonary fibrosis",
      "Constipation"
   ],
   "answer": "Cinchonism",
   "explanation": "Quinidine can cause cinchonism (headache, tinnitus, blurred vision) due to its cinchona alkaloid structure."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00377",
   "question": "Disopyramide’s major anticholinergic side effect is:",
   "options": [
      "Urinary retention",
      "Bronchospasm",
      "Hyperglycemia",
      "Hypotension"
   ],
   "answer": "Urinary retention",
   "explanation": "Disopyramide has strong anticholinergic effects (M3 blockade), causing urinary retention, dry mouth, and blurred vision."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00378",
   "question": "Lidocaine is preferred for ventricular arrhythmias because it:",
   "options": [
      "Targets ischemic tissue",
      "Prolongs QT",
      "Blocks β receptors",
      "Causes vasodilation"
   ],
   "answer": "Targets ischemic tissue",
   "explanation": "Class IB agents like lidocaine preferentially bind inactivated Na⁺ channels in ischemic myocardium and shorten action potentials."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00379",
   "question": "Mexiletine differs from lidocaine by being:",
   "options": [
      "Orally active",
      "IV only",
      "Selective β-blocker",
      "K⁺ channel blocker"
   ],
   "answer": "Orally active",
   "explanation": "Mexiletine is an oral analogue of lidocaine (Class IB) used for ventricular arrhythmias when oral therapy is needed."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00380",
   "question": "Flecainide is contraindicated in:",
   "options": [
      "Structural heart disease",
      "SVT without heart disease",
      "Isolated PVCs",
      "Vagal-induced bradycardia"
   ],
   "answer": "Structural heart disease",
   "explanation": "Class IC agents like flecainide markedly slow conduction and can be proarrhythmic in structural heart disease (CAST trial)."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00381",
   "question": "Propafenone has additional activity as a:",
   "options": [
      "β-blocker",
      "K⁺ channel opener",
      "ACE inhibitor",
      "Ca²⁺ channel blocker"
   ],
   "answer": "β-blocker",
   "explanation": "Propafenone (Class IC) also exhibits mild β-adrenergic blockade, slowing heart rate and AV conduction."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00382",
   "question": "Amiodarone causes thyroid dysfunction due to its:",
   "options": [
      "High iodine content",
      "Sulfa moiety",
      "Calcium channel block",
      "β-blocking action"
   ],
   "answer": "High iodine content",
   "explanation": "Amiodarone is ~37% iodine by weight, which can cause hypo- or hyperthyroidism."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00383",
   "question": "Sotalol’s Class III effect is:",
   "options": [
      "K⁺ channel blockade",
      "Na⁺ channel blockade",
      "Ca²⁺ channel blockade",
      "β₂ agonism"
   ],
   "answer": "K⁺ channel blockade",
   "explanation": "Sotalol nonselectively blocks β₁/β₂ receptors (Class II) and delays repolarization via K⁺ channel blockade (Class III)."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00384",
   "question": "Dofetilide requires monitoring of:",
   "options": [
      "QT interval",
      "PR interval",
      "QRS duration",
      "ST elevation"
   ],
   "answer": "QT interval",
   "explanation": "Dofetilide (Class III) prolongs the QT interval and has a risk of torsades de pointes, requiring inpatient ECG monitoring."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00385",
   "question": "Ibutilide is used for acute conversion of:",
   "options": [
      "Atrial fibrillation",
      "Ventricular tachycardia",
      "Atrial flutter",
      "Wolf-Parkinson-White"
   ],
   "answer": "Atrial fibrillation",
   "explanation": "Ibutilide (Class III) is administered IV to convert atrial fibrillation or flutter to sinus rhythm by prolonging repolarization."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00386",
   "question": "Metoprolol reduces arrhythmias by:",
   "options": [
      "Decreasing AV nodal conduction",
      "Blocking Na⁺ channels",
      "Prolonging QT",
      "Increasing vagal tone"
   ],
   "answer": "Decreasing AV nodal conduction",
   "explanation": "Class II β₁-selective blockers slow AV nodal conduction and reduce automaticity in pacemaker cells."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00387",
   "question": "Esmolol is characterized by:",
   "options": [
      "Ultra-short half-life",
      "Strong alpha blockade",
      "Oral dosing",
      "K⁺ channel blockade"
   ],
   "answer": "Ultra-short half-life",
   "explanation": "Esmolol (Class II) is metabolized by red blood cell esterases and has a half-life of ~9 minutes, ideal for acute control."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00388",
   "question": "Verapamil’s antiarrhythmic action is primarily in:",
   "options": [
      "AV node",
      "Ventricular muscle",
      "Purkinje fibers",
      "SA node only"
   ],
   "answer": "AV node",
   "explanation": "Class IV Ca²⁺ channel blockers slow phase 0 in nodal tissue, prolonging AV nodal conduction and refractory period."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00389",
   "question": "Diltiazem differs from verapamil by:",
   "options": [
      "Less negative inotropy",
      "Pure β-blockade",
      "K⁺ channel opening",
      "Iodine content"
   ],
   "answer": "Less negative inotropy",
   "explanation": "Diltiazem (Class IV) has less effect on myocardial contractility than verapamil, making it better tolerated in HF."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00390",
   "question": "Adenosine terminates SVT by:",
   "options": [
      "Hyperpolarizing AV node",
      "Blocking β receptors",
      "Opening K⁺ channels in atrium",
      "Inhibiting Na⁺ channels"
   ],
   "answer": "Hyperpolarizing AV node",
   "explanation": "Adenosine (Class V) activates A1 receptors, increasing K⁺ efflux and transiently blocking AV nodal conduction to break reentry."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00391",
   "question": "Digoxin’s antiarrhythmic effect is mediated by:",
   "options": [
      "Increased vagal tone",
      "K⁺ channel blockade",
      "β-blockade",
      "Block of L-type Ca²⁺"
   ],
   "answer": "Increased vagal tone",
   "explanation": "Digoxin enhances vagal (parasympathetic) activity, slowing AV nodal conduction and increasing refractory period."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00392",
   "question": "Magnesium sulfate is the treatment of choice for:",
   "options": [
      "Torsades de pointes",
      "Ventricular fibrillation",
      "Atrial flutter",
      "Sinus tachycardia"
   ],
   "answer": "Torsades de pointes",
   "explanation": "Magnesium stabilizes cardiomyocyte membranes and corrects early afterdepolarizations in torsades."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00393",
   "question": "Class IA agents affect action potential duration how?",
   "options": [
      "Increase",
      "Decrease",
      "No change",
      "Transient decrease"
   ],
   "answer": "Increase",
   "explanation": "Class IA drugs block K⁺ channels in addition to Na⁺ channels, prolonging repolarization and action potential duration."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00394",
   "question": "Class IB agents change AP duration by:",
   "options": [
      "Decrease",
      "Increase",
      "No change",
      "Biphasic change"
   ],
   "answer": "Decrease",
   "explanation": "Class IB drugs shorten action potential duration, especially in ischemic or depolarized tissue."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00395",
   "question": "Class IC agents affect action potential duration:",
   "options": [
      "No significant change",
      "Increase",
      "Decrease",
      "Biphasic change"
   ],
   "answer": "No significant change",
   "explanation": "Class IC drugs strongly slow conduction (phase 0) but have minimal effect on repolarization duration."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00396",
   "question": "Which drug interaction increases risk of torsades when used with Class IA or III agents?",
   "options": [
      "Macrolide antibiotics",
      "Aminoglycosides",
      "Beta-agonists",
      "Digoxin"
   ],
   "answer": "Macrolide antibiotics",
   "explanation": "Macrolides (e.g., erythromycin) can prolong QT and, when combined with IA/III drugs, heighten torsades risk."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00397",
   "question": "Which antiarrhythmic is contraindicated in atrial fibrillation with WPW syndrome?",
   "options": [
      "Verapamil",
      "Procainamide",
      "Ibutilide",
      "Amiodarone"
   ],
   "answer": "Verapamil",
   "explanation": "AV nodal blockers like verapamil can accelerate conduction through accessory pathways in WPW, worsening rate control."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00398",
   "question": "Which Class III agent has the lowest risk of pulmonary fibrosis?",
   "options": [
      "Sotalol",
      "Amiodarone",
      "Dofetilide",
      "Ibutilide"
   ],
   "answer": "Sotalol",
   "explanation": "Amiodarone carries the highest pulmonary toxicity risk; sotalol does not accumulate in lung tissue."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00399",
   "question": "Amiodarone’s metabolism is inhibited by:",
   "options": [
      "CYP3A4 inhibitors",
      "P-glycoprotein inducers",
      "ACE inhibitors",
      "Loop diuretics"
   ],
   "answer": "CYP3A4 inhibitors",
   "explanation": "Amiodarone is metabolized by CYP3A4; inhibitors (e.g., ketoconazole) raise its levels and toxicity risk."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00400",
   "question": "Which Class II agent also prolongs action potential via K⁺ channel blockade?",
   "options": [
      "Sotalol",
      "Metoprolol",
      "Esmolol",
      "Propranolol"
   ],
   "answer": "Sotalol",
   "explanation": "Sotalol is both a nonselective β-blocker (Class II) and a K⁺ channel blocker (Class III)."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00401",
   "question": "Which antiarrhythmic is a pure Class III agent?",
   "options": [
      "Dofetilide",
      "Amiodarone",
      "Sotalol",
      "Quinidine"
   ],
   "answer": "Dofetilide",
   "explanation": "Dofetilide selectively blocks K⁺ channels without significant β, Na⁺, or Ca²⁺ channel effects."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00402",
   "question": "Class IV agents prolong which interval on ECG?",
   "options": [
      "PR interval",
      "QT interval",
      "QRS duration",
      "ST segment"
   ],
   "answer": "PR interval",
   "explanation": "Ca²⁺ channel blockers slow AV nodal conduction, manifesting as PR prolongation."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00403",
   "question": "Which agent is used to diagnose SVT by temporarily blocking AV nodal conduction?",
   "options": [
      "Adenosine",
      "Digoxin",
      "Lidocaine",
      "Propranolol"
   ],
   "answer": "Adenosine",
   "explanation": "Adenosine transiently blocks AV nodal conduction, terminating reentrant SVT or revealing underlying atrial activity."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00404",
   "question": "Which antiarrhythmic can exacerbate digitalis toxicity by displacing it from tissues?",
   "options": [
      "Quinidine",
      "Amiodarone",
      "Procainamide",
      "Sotalol"
   ],
   "answer": "Quinidine",
   "explanation": "Quinidine displaces digoxin from tissue binding sites, increasing its free plasma concentration and toxicity."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00405",
   "question": "Which Class IA drug is associated with drug-induced lupus?",
   "options": [
      "Procainamide",
      "Quinidine",
      "Disopyramide",
      "Lidocaine"
   ],
   "answer": "Procainamide",
   "explanation": "Procainamide can induce a lupus-like syndrome after prolonged use due to its N-acetylation profile."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00406",
   "question": "Which antiarrhythmic requires dose adjustment in renal failure due to prolonged half-life?",
   "options": [
      "Dofetilide",
      "Amiodarone",
      "Quinidine",
      "Lidocaine"
   ],
   "answer": "Dofetilide",
   "explanation": "Dofetilide is renally excreted and accumulates in renal impairment, increasing torsades risk."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00407",
   "question": "Which agent shortens the action potential in Purkinje fibers and is used in digitalis-induced arrhythmias?",
   "options": [
      "Lidocaine",
      "Procainamide",
      "Amiodarone",
      "Verapamil"
   ],
   "answer": "Lidocaine",
   "explanation": "Lidocaine (Class IB) preferentially shortens action potentials in Purkinje and ventricular tissue, treating digitalis toxicity arrhythmias."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00408",
   "question": "Which antiarrhythmic is contraindicated in Wolff-Parkinson-White syndrome with atrial fibrillation?",
   "options": [
      "Digoxin",
      "Procainamide",
      "Amiodarone",
      "Ibutilide"
   ],
   "answer": "Digoxin",
   "explanation": "Digoxin can preferentially block AV node and accelerate conduction through the accessory pathway, worsening WPW."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00409",
   "question": "Which antiarrhythmic’s major toxicity is pulmonary fibrosis?",
   "options": [
      "Amiodarone",
      "Sotalol",
      "Procainamide",
      "Lidocaine"
   ],
   "answer": "Amiodarone",
   "explanation": "Amiodarone can cause interstitial pneumonitis and pulmonary fibrosis due to accumulation in lung tissue."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00410",
   "question": "Which agent increases PR interval without affecting QRS or QT significantly?",
   "options": [
      "Digoxin",
      "Amiodarone",
      "Procainamide",
      "Sotalol"
   ],
   "answer": "Digoxin",
   "explanation": "Digoxin slows AV nodal conduction (increasing PR) via vagal tone but has minimal direct effect on QRS/QT."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00411",
   "question": "Which drug is most likely to cause constipation by blocking smooth muscle Ca²⁺ channels in the gut?",
   "options": [
      "Verapamil",
      "Diltiazem",
      "Lidocaine",
      "Procainamide"
   ],
   "answer": "Verapamil",
   "explanation": "Verapamil’s Ca²⁺ channel blockade slows GI motility and can cause constipation."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00412",
   "question": "Which antiarrhythmic is safe in heart failure and does not depress contractility?",
   "options": [
      "Amiodarone",
      "Flecainide",
      "Verapamil",
      "Propranolol"
   ],
   "answer": "Amiodarone",
   "explanation": "Amiodarone has minimal negative inotropic effect and can be used in patients with reduced ejection fraction."
},
 {
   "chapter_id": 11,
   "chapter": "Antiarrhythmics",
   "question_id": "00011-00413",
   "question": "Which antiarrhythmic is most proarrhythmic in patients with structural heart disease?",
   "options": [
      "Flecainide",
      "Procainamide",
      "Amiodarone",
      "Lidocaine"
   ],
   "answer": "Flecainide",
   "explanation": "Class IC agents can precipitate life-threatening arrhythmias in structural heart disease (CAST study)."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00414",
   "question": "Which mechanism explains how sublingual nitroglycerin relieves angina?",
   "options": [
      "Increases cGMP in vascular smooth muscle",
      "Blocks L-type Ca²⁺ channels",
      "Inhibits β₁ receptors",
      "Opens K_ATP channels"
   ],
   "answer": "Increases cGMP in vascular smooth muscle",
   "explanation": "Nitroglycerin is converted to NO which activates guanylate cyclase, raising cGMP and causing vasodilation that reduces preload and myocardial oxygen demand."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00415",
   "question": "Which nitrate is most appropriate for preventing exercise-induced angina when taken 1–2 hours before activity?",
   "options": [
      "Isosorbide mononitrate",
      "Nitroprusside",
      "Amyl nitrite",
      "Sodium nitrite"
   ],
   "answer": "Isosorbide mononitrate",
   "explanation": "Isosorbide mononitrate has a long half-life and high oral bioavailability without significant first-pass metabolism, making it suitable for prophylaxis."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00416",
   "question": "Nitrate tolerance can be minimized by:",
   "options": [
      "Daily nitrate-free interval",
      "Increasing dose every day",
      "Concurrent ACE inhibitor",
      "Weekend dosing only"
   ],
   "answer": "Daily nitrate-free interval",
   "explanation": "Interrupting nitrate exposure for 8–10 hours daily (usually overnight) prevents tachyphylaxis and maintains efficacy."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00417",
   "question": "Which adverse effect is most characteristic of nitrates?",
   "options": [
      "Headache",
      "Constipation",
      "Bradycardia",
      "Hyperglycemia"
   ],
   "answer": "Headache",
   "explanation": "Vasodilation of cerebral vessels causes increased intracranial pressure and throbbing headaches, a common side effect of nitrates."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00418",
   "question": "Combining nitrates with sildenafil is contraindicated because it causes:",
   "options": [
      "Severe hypotension",
      "Torsades de pointes",
      "Hyperkalemia",
      "Bronchospasm"
   ],
   "answer": "Severe hypotension",
   "explanation": "Both agents increase cGMP; their synergistic vasodilatory effect can lead to life-threatening drops in blood pressure."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00419",
   "question": "Which β-blocker is considered first-line for chronic stable angina?",
   "options": [
      "Metoprolol",
      "Propranolol",
      "Nadolol",
      "Atenolol"
   ],
   "answer": "Metoprolol",
   "explanation": "Metoprolol is β₁-selective, reducing heart rate and contractility to decrease myocardial oxygen demand without significant bronchoconstriction."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00420",
   "question": "Beta-blockers relieve angina primarily by:",
   "options": [
      "Decreasing heart rate and contractility",
      "Dilating coronary arteries",
      "Increasing preload",
      "Blocking Na⁺ channels"
   ],
   "answer": "Decreasing heart rate and contractility",
   "explanation": "By reducing heart rate (chronotropy) and contractile force (inotropy), β-blockers lower myocardial oxygen demand and prolong diastole for better perfusion."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00421",
   "question": "Which patient population should use β-blockers with caution for angina therapy?",
   "options": [
      "Asthmatics",
      "Diabetics",
      "Elderly",
      "Smokers"
   ],
   "answer": "Asthmatics",
   "explanation": "Nonselective β-blockers can precipitate bronchoconstriction via β₂ blockade; even β₁-selective agents may lose selectivity at high doses."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00422",
   "question": "Which CCB is preferred for variant (Prinzmetal) angina?",
   "options": [
      "Diltiazem",
      "Propranolol",
      "Metoprolol",
      "Nitroglycerin"
   ],
   "answer": "Diltiazem",
   "explanation": "Diltiazem, a nondihydropyridine CCB, prevents coronary artery spasm by relaxing vascular smooth muscle without provoking reflex tachycardia."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00423",
   "question": "Dihydropyridine CCBs (e.g., amlodipine) relieve angina by:",
   "options": [
      "Primarily dilating arterioles",
      "Blocking β receptors",
      "Inhibiting Na⁺/K⁺-ATPase",
      "Increasing contractility"
   ],
   "answer": "Primarily dilating arterioles",
   "explanation": "Amlodipine lowers afterload and reduces myocardial oxygen demand by relaxing vascular smooth muscle via L-type Ca²⁺ channel blockade."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00424",
   "question": "Which antianginal drug reduces intracellular sodium and calcium overload in ischemic myocytes?",
   "options": [
      "Ranolazine",
      "Verapamil",
      "Nitroglycerin",
      "Propranolol"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine inhibits the late sodium current, reducing intracellular Na⁺ and thus Ca²⁺ accumulation, improving diastolic relaxation."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00425",
   "question": "Ranolazine’s major adverse effect is:",
   "options": [
      "QT prolongation",
      "Bradycardia",
      "Hypotension",
      "Constipation"
   ],
   "answer": "QT prolongation",
   "explanation": "By affecting repolarizing potassium currents, ranolazine can prolong the QT interval, increasing torsades risk."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00426",
   "question": "Ivabradine relieves angina by:",
   "options": [
      "Selective inhibition of the funny If current",
      "β₂-agonism",
      "Nitrate-like vasodilation",
      "ACE inhibition"
   ],
   "answer": "Selective inhibition of the funny If current",
   "explanation": "Ivabradine slows SA nodal pacemaker activity without affecting contractility, lowering heart rate and oxygen demand."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00427",
   "question": "Which medication is contraindicated in variant angina?",
   "options": [
      "Propranolol",
      "Diltiazem",
      "Nitroglycerin",
      "Amlodipine"
   ],
   "answer": "Propranolol",
   "explanation": "β-blockers may worsen coronary spasm in variant angina by leaving α-mediated vasoconstriction unopposed."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00428",
   "question": "Which combination is recommended for refractory angina not controlled by monotherapy?",
   "options": [
      "β-blocker + CCB + nitrate",
      "β-blocker + ACE inhibitor",
      "CCB + ARB",
      "Nitrate + hydralazine"
   ],
   "answer": "β-blocker + CCB + nitrate",
   "explanation": "Combining drugs with complementary mechanisms optimally reduces heart rate, preload, and afterload to relieve symptoms."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00429",
   "question": "Which agent reduces myocardial wall stress by venodilation?",
   "options": [
      "Nitroglycerin",
      "Amlodipine",
      "Metoprolol",
      "Ranolazine"
   ],
   "answer": "Nitroglycerin",
   "explanation": "Venodilation decreases venous return and preload, lowering end-diastolic volume and wall stress."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00430",
   "question": "Tachyphylaxis to nitrates is due to:",
   "options": [
      "Depletion of sulfhydryl groups",
      "Calcium channel upregulation",
      "β-receptor downregulation",
      "Thiol oxidation"
   ],
   "answer": "Depletion of sulfhydryl groups",
   "explanation": "Continuous nitrate use oxidizes sulfhydryl moieties required for NO bioactivation, diminishing efficacy."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00431",
   "question": "Which CCB can cause significant constipation as an adverse effect?",
   "options": [
      "Verapamil",
      "Amlodipine",
      "Nifedipine",
      "Diltiazem"
   ],
   "answer": "Verapamil",
   "explanation": "Verapamil’s strong GI smooth muscle blockade slows gut motility, leading to constipation."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00432",
   "question": "Which antianginal increases coronary blood flow by dilating both epicardial and subendocardial vessels?",
   "options": [
      "Nitrates",
      "Verapamil",
      "Propranolol",
      "Ranolazine"
   ],
   "answer": "Nitrates",
   "explanation": "Nitrates preferentially dilate large epicardial and small subendocardial vessels, improving perfusion of ischemic regions."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00433",
   "question": "Which antianginal drug’s efficacy does NOT depend on heart rate reduction?",
   "options": [
      "Ranolazine",
      "Metoprolol",
      "Ivabradine",
      "Verapamil"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine acts on ion channels to improve diastolic function without affecting heart rate or blood pressure."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00434",
   "question": "Which antianginal drug requires monitoring for CYP3A4 interactions?",
   "options": [
      "Ranolazine",
      "Amlodipine",
      "Nitroglycerin",
      "Propranolol"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine is metabolized by CYP3A4; inhibitors or inducers can significantly alter its plasma levels."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00435",
   "question": "Which antianginal is administered via transdermal patch?",
   "options": [
      "Nitroglycerin",
      "Amlodipine",
      "Propranolol",
      "Ranolazine"
   ],
   "answer": "Nitroglycerin",
   "explanation": "Transdermal nitroglycerin patches provide sustained low-level nitrate delivery for chronic prophylaxis."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00436",
   "question": "Which antianginal class reduces myocardial oxygen demand by decreasing afterload?",
   "options": [
      "Dihydropyridine CCBs",
      "β-blockers",
      "Nitrates",
      "Late Na⁺ current inhibitors"
   ],
   "answer": "Dihydropyridine CCBs",
   "explanation": "By dilating arterioles, dihydropyridine CCBs reduce systemic vascular resistance and myocardial wall tension."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00437",
   "question": "Which drug is preferred for acute relief of chest pain during an anginal attack?",
   "options": [
      "Sublingual nitroglycerin",
      "Oral amlodipine",
      "IV ranolazine",
      "Oral propranolol"
   ],
   "answer": "Sublingual nitroglycerin",
   "explanation": "Sublingual nitroglycerin has rapid onset (2–3 minutes) due to fast absorption and bypass of first-pass metabolism."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00438",
   "question": "Which antianginal should be avoided in patients with severe hypotension?",
   "options": [
      "Nitroprusside",
      "Nitroglycerin",
      "Propranolol",
      "Ranolazine"
   ],
   "answer": "Nitroglycerin",
   "explanation": "Nitrates can cause significant vasodilation and worsening hypotension in susceptible patients."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00439",
   "question": "Which agent increases diastolic perfusion time most effectively?",
   "options": [
      "β-blockers",
      "Nitrates",
      "Amlodipine",
      "Ranolazine"
   ],
   "answer": "β-blockers",
   "explanation": "By lowering heart rate, β-blockers extend diastolic duration, enhancing coronary blood flow."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00440",
   "question": "Which antianginal drug can worsen heart failure due to negative inotropy?",
   "options": [
      "Verapamil",
      "Nitroglycerin",
      "Ranolazine",
      "Isosorbide mononitrate"
   ],
   "answer": "Verapamil",
   "explanation": "Verapamil’s negative inotropic effect can depress myocardial contractility and exacerbate heart failure."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00441",
   "question": "Which antianginal reduces myocardial oxygen consumption without affecting blood pressure?",
   "options": [
      "Ranolazine",
      "Amlodipine",
      "Nitroglycerin",
      "Metoprolol"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine improves diastolic relaxation and perfusion without significant hemodynamic changes."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00442",
   "question": "Which antianginal drug is most likely to cause reflex tachycardia?",
   "options": [
      "Dihydropyridine CCBs",
      "β-blockers",
      "Ranolazine",
      "Ivabradine"
   ],
   "answer": "Dihydropyridine CCBs",
   "explanation": "Rapid arteriolar dilation by dihydropyridines triggers baroreceptor-mediated sympathetic activation and tachycardia."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00443",
   "question": "Which antianginal combination is beneficial in systolic dysfunction and coronary disease?",
   "options": [
      "β-blocker + ACE inhibitor",
      "CCB + nitrate",
      "Ranolazine + ivabradine",
      "Nitrate + hydralazine"
   ],
   "answer": "β-blocker + ACE inhibitor",
   "explanation": "ACE inhibitors reduce remodeling and afterload, while β-blockers decrease oxygen demand, improving outcomes in HFrEF with angina."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00444",
   "question": "Which antianginal agent has no effect on heart rate or blood pressure?",
   "options": [
      "Ranolazine",
      "Nitroglycerin",
      "Propranolol",
      "Amlodipine"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine’s mechanism targets ion channels without significant vasodilation or chronotropic effects."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00445",
   "question": "Which treatment is preferred for microvascular angina (syndrome X)?",
   "options": [
      "Ranolazine",
      "Nitroglycerin",
      "Metoprolol",
      "Amlodipine"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine improves microvascular perfusion and reduces chest pain in patients with normal coronaries but microvascular dysfunction."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00446",
   "question": "Which antianginal should be avoided in severe hepatic impairment?",
   "options": [
      "Ranolazine",
      "Nitroglycerin",
      "Metoprolol",
      "Diltiazem"
   ],
   "answer": "Ranolazine",
   "explanation": "Ranolazine is extensively metabolized by the liver (CYP3A4); hepatic dysfunction can lead to accumulation and toxicity."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00447",
   "question": "Which antianginal is not affected by first-pass metabolism?",
   "options": [
      "Sublingual nitroglycerin",
      "Oral isosorbide dinitrate",
      "Oral amlodipine",
      "Ranolazine"
   ],
   "answer": "Sublingual nitroglycerin",
   "explanation": "Sublingual administration bypasses the liver, providing rapid bioavailability without first-pass degradation."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00448",
   "question": "Which drug improves exercise tolerance by reducing late systolic myocardial wall stress?",
   "options": [
      "Ranolazine",
      "Propranolol",
      "Amlodipine",
      "Nitroglycerin"
   ],
   "answer": "Ranolazine",
   "explanation": "By decreasing intracellular calcium overload, ranolazine lowers diastolic tension and wall stress, improving function."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00449",
   "question": "Which antianginal is categorized as a class V agent?",
   "options": [
      "Ranolazine",
      "Verapamil",
      "Nitroglycerin",
      "Propranolol"
   ],
   "answer": "Ranolazine",
   "explanation": "Class V antiarrhythmic classification is not applicable, but ranolazine is often referred to as a ‘novel’ antianginal with unique mechanism."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00450",
   "question": "Which antianginal drug requires dose adjustment in renal impairment?",
   "options": [
      "Ivabradine",
      "Amlodipine",
      "Nitroglycerin",
      "Propranolol"
   ],
   "answer": "Ivabradine",
   "explanation": "Ivabradine and its metabolites are renally excreted; reduced clearance in renal dysfunction necessitates dose reduction."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00451",
   "question": "Which antianginal therapy is indicated for nocturnal angina when nitrates cause tolerance?",
   "options": [
      "Late-night ranolazine dosing",
      "Increased nitrate dose",
      "Caffeine ingestion",
      "Ivabradine only"
   ],
   "answer": "Late-night ranolazine dosing",
   "explanation": "Ranolazine provides antianginal benefit without tolerance, ideal for nocturnal symptoms when nitrates are less effective."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00452",
   "question": "Which antianginal drug has the longest onset of action when taken orally?",
   "options": [
      "Amlodipine",
      "Sublingual nitroglycerin",
      "Verapamil",
      "Metoprolol"
   ],
   "answer": "Amlodipine",
   "explanation": "Amlodipine has a slow absorption and long half-life, with onset over several hours compared to rapid-acting sublingual agents."
},
 {
   "chapter_id": 12,
   "chapter": "Antianginal Drugs",
   "question_id": "00012-00453",
   "question": "Which antianginal is most likely to cause reflex fluid retention?",
   "options": [
      "Amlodipine",
      "Nitroglycerin",
      "Metoprolol",
      "Ranolazine"
   ],
   "answer": "Amlodipine",
   "explanation": "Peripheral arteriolar dilation can activate RAAS and baroreflexes, leading to fluid retention and edema."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00454",
   "question": "A clot that remains attached to a vessel wall is called a:",
   "options": [
      "Thrombus",
      "Embolus",
      "Hematoma",
      "Aneurysm"
   ],
   "answer": "Thrombus",
   "explanation": "A thrombus is a blood clot that forms in situ and remains attached to the vessel wall, whereas an embolus is a fragment that detaches and travels."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00455",
   "question": "An embolus lodging in a distal vessel typically originates from:",
   "options": [
      "A thrombus",
      "An aneurysm",
      "A hematoma",
      "A varicosity"
   ],
   "answer": "A thrombus",
   "explanation": "An embolus is most often a fragment of a thrombus that breaks free and travels until it lodges in a smaller vessel."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00456",
   "question": "Arterial thrombi are characteristically rich in:",
   "options": [
      "Platelets",
      "Red blood cells",
      "Fibrin only",
      "Leukocytes"
   ],
   "answer": "Platelets",
   "explanation": "Arterial clots form under high shear and are platelet-rich, whereas venous clots form more slowly and contain more fibrin and red cells."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00457",
   "question": "Venous thrombosis is most effectively prevented by drugs targeting:",
   "options": [
      "Fibrin formation",
      "Platelet aggregation",
      "Leukocyte adhesion",
      "Endothelial nitric oxide"
   ],
   "answer": "Fibrin formation",
   "explanation": "Venous clots depend heavily on fibrin for stability, so anticoagulants that inhibit thrombin or factor Xa are most effective."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00458",
   "question": "The intrinsic and extrinsic coagulation pathways both converge on activation of:",
   "options": [
      "Factor X",
      "Factor VII",
      "Factor II",
      "Factor XII"
   ],
   "answer": "Factor X",
   "explanation": "Both pathways generate factor Xa, which is the key enzyme that converts prothrombin to thrombin."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00459",
   "question": "Antithrombin III inactivates clotting factors by forming complexes with:",
   "options": [
      "Thrombin and factor Xa",
      "Fibrin and fibrinogen",
      "Platelet GP IIb/IIIa",
      "Vitamin K epoxide"
   ],
   "answer": "Thrombin and factor Xa",
   "explanation": "Antithrombin III binds and inactivates thrombin (IIa) and factor Xa, and heparin greatly accelerates this process."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00460",
   "question": "Heparin exerts its anticoagulant effect by:",
   "options": [
      "Binding antithrombin III",
      "Inhibiting vitamin K epoxide reductase",
      "Blocking P2Y12 receptors",
      "Activating plasmin"
   ],
   "answer": "Binding antithrombin III",
   "explanation": "Heparin binds to antithrombin III, inducing a conformational change that accelerates inactivation of thrombin and factor Xa."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00461",
   "question": "Low-molecular-weight heparins differ from unfractionated heparin in that they:",
   "options": [
      "Preferentially inhibit factor Xa",
      "Bind more strongly to thrombin",
      "Require aPTT monitoring",
      "Are fully reversible by protamine"
   ],
   "answer": "Preferentially inhibit factor Xa",
   "explanation": "LMWHs have shorter chains and inhibit factor Xa more than thrombin; they have more predictable kinetics and less need for aPTT monitoring."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00462",
   "question": "The reversal agent for heparin is:",
   "options": [
      "Protamine sulfate",
      "Vitamin K1",
      "Idarucizumab",
      "Andexanet alfa"
   ],
   "answer": "Protamine sulfate",
   "explanation": "Protamine sulfate is a positively charged protein that binds and neutralizes heparin in a 1:1 ratio."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00463",
   "question": "Heparin-induced thrombocytopenia is caused by:",
   "options": [
      "Antibodies to heparin-PF4 complex",
      "Excess fibrinolytic activity",
      "Vitamin K deficiency",
      "Excess plasmin generation"
   ],
   "answer": "Antibodies to heparin-PF4 complex",
   "explanation": "In HIT, the immune system forms antibodies against platelet factor 4–heparin complexes, causing platelet activation and paradoxical thrombosis."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00464",
   "question": "A direct thrombin inhibitor used in HIT is:",
   "options": [
      "Argatroban",
      "Fondaparinux",
      "Warfarin",
      "Dabigatran"
   ],
   "answer": "Argatroban",
   "explanation": "Argatroban is a small-molecule direct thrombin inhibitor indicated for prophylaxis and treatment of thrombosis in HIT."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00465",
   "question": "Bivalirudin differs from argatroban in that it:",
   "options": [
      "Reversibly inhibits both free and clot-bound thrombin",
      "Requires antithrombin III for activity",
      "Is a vitamin K antagonist",
      "Activates plasmin"
   ],
   "answer": "Reversibly inhibits both free and clot-bound thrombin",
   "explanation": "Bivalirudin is a hirudin analog that directly and reversibly binds to thrombin, including that bound to fibrin."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00466",
   "question": "Fondaparinux is a synthetic pentasaccharide that:",
   "options": [
      "Enhances antithrombin III activity against factor Xa",
      "Directly inhibits thrombin",
      "Blocks vitamin K recycling",
      "Inhibits plasminogen"
   ],
   "answer": "Enhances antithrombin III activity against factor Xa",
   "explanation": "Fondaparinux binds antithrombin III and selectively accelerates inhibition of factor Xa without significant anti-thrombin activity."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00467",
   "question": "Warfarin exerts its effect by inhibiting:",
   "options": [
      "Vitamin K epoxide reductase",
      "Antithrombin III",
      "Plasmin activity",
      "Platelet aggregation"
   ],
   "answer": "Vitamin K epoxide reductase",
   "explanation": "Warfarin blocks vitamin K regeneration, preventing γ-carboxylation of clotting factors II, VII, IX, and X."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00468",
   "question": "Therapeutic monitoring of warfarin uses the:",
   "options": [
      "INR",
      "aPTT",
      "Platelet count",
      "Bleeding time"
   ],
   "answer": "INR",
   "explanation": "The international normalized ratio (INR) standardizes prothrombin time to account for reagent variability in warfarin monitoring."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00469",
   "question": "Warfarin’s anticoagulant effect is delayed initially because:",
   "options": [
      "Preexisting clotting factors must be cleared",
      "It requires antithrombin III",
      "It acts immediately on platelets",
      "It must be activated by liver enzymes"
   ],
   "answer": "Preexisting clotting factors must be cleared",
   "explanation": "Existing vitamin K–dependent factors have half-lives of 6–60 hours, so full anticoagulant effect develops over days."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00470",
   "question": "To prevent transient hypercoagulability when starting warfarin, one uses:",
   "options": [
      "Heparin bridging",
      "High-dose vitamin K",
      "Fibrinolytics",
      "Platelet inhibitors"
   ],
   "answer": "Heparin bridging",
   "explanation": "Heparin is continued until factors C and S—natural anticoagulants—are no longer deficient relative to procoagulant factors."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00471",
   "question": "The antidote for life-threatening warfarin bleeding is:",
   "options": [
      "Vitamin K1 and PCC",
      "Protamine sulfate",
      "Idarucizumab",
      "Andexanet alfa"
   ],
   "answer": "Vitamin K1 and PCC",
   "explanation": "Vitamin K1 restores clotting factor synthesis, and prothrombin complex concentrate (PCC) provides immediate factors II, VII, IX, X."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00472",
   "question": "Dabigatran is an oral anticoagulant that:",
   "options": [
      "Directly inhibits thrombin",
      "Inhibits factor Xa",
      "Blocks vitamin K epoxide reductase",
      "Activates antithrombin"
   ],
   "answer": "Directly inhibits thrombin",
   "explanation": "Dabigatran etexilate is converted to active dabigatran, a reversible direct inhibitor of thrombin (factor IIa)."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00473",
   "question": "The specific reversal agent for dabigatran is:",
   "options": [
      "Idarucizumab",
      "Protamine sulfate",
      "Vitamin K1",
      "Andexanet alfa"
   ],
   "answer": "Idarucizumab",
   "explanation": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity, neutralizing its effect."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00474",
   "question": "Apixaban and rivaroxaban act by:",
   "options": [
      "Directly inhibiting factor Xa",
      "Directly inhibiting thrombin",
      "Blocking vitamin K",
      "Activating plasmin"
   ],
   "answer": "Directly inhibiting factor Xa",
   "explanation": "These direct oral anticoagulants (DOACs) selectively and reversibly inhibit factor Xa, preventing thrombin generation."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00475",
   "question": "Andexanet alfa is used to reverse bleeding from:",
   "options": [
      "Factor Xa inhibitors",
      "Thrombin inhibitors",
      "Vitamin K antagonists",
      "GP IIb/IIIa inhibitors"
   ],
   "answer": "Factor Xa inhibitors",
   "explanation": "Andexanet alfa is a decoy recombinant factor Xa that binds and sequesters Xa inhibitors."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00476",
   "question": "Alteplase is classified as a:",
   "options": [
      "Thrombolytic",
      "Heparin",
      "Vitamin K antagonist",
      "P2Y₁₂ inhibitor"
   ],
   "answer": "Thrombolytic",
   "explanation": "Alteplase is tissue plasminogen activator (tPA) that converts plasminogen to plasmin, lysing fibrin clots."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00477",
   "question": "The major risk of thrombolytic therapy is:",
   "options": [
      "Bleeding",
      "Thrombocytopenia",
      "Hyperkalemia",
      "Renal failure"
   ],
   "answer": "Bleeding",
   "explanation": "Systemic activation of plasmin increases bleeding risk, including intracranial hemorrhage."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00478",
   "question": "Aspirin inhibits platelet aggregation by irreversibly acetylating:",
   "options": [
      "COX-1",
      "P2Y₁₂ receptor",
      "GP IIb/IIIa",
      "Thrombin"
   ],
   "answer": "COX-1",
   "explanation": "Aspirin blocks cyclooxygenase-1 in platelets, preventing thromboxane A₂ synthesis for the life of the platelet."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00479",
   "question": "The antiplatelet effect of a single dose of aspirin lasts:",
   "options": [
      "7–10 days",
      "24 hours",
      "12 hours",
      "2 hours"
   ],
   "answer": "7–10 days",
   "explanation": "Platelets are anucleate and cannot resynthesize COX-1, so aspirin’s effect persists for the platelet lifespan."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00480",
   "question": "Clopidogrel exerts its antiplatelet effect by irreversibly blocking:",
   "options": [
      "P2Y₁₂ ADP receptor",
      "COX-1",
      "GP IIb/IIIa",
      "Thromboxane synthase"
   ],
   "answer": "P2Y₁₂ ADP receptor",
   "explanation": "Clopidogrel prevents ADP-mediated activation of the GPIIb/IIIa complex, reducing platelet aggregation."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00481",
   "question": "Concurrent use of omeprazole with clopidogrel may reduce clopidogrel’s efficacy by:",
   "options": [
      "Inhibiting CYP2C19-mediated activation",
      "Blocking P2Y₁₂ receptors",
      "Enhancing aspirin’s effect",
      "Increasing platelet count"
   ],
   "answer": "Inhibiting CYP2C19-mediated activation",
   "explanation": "Omeprazole inhibits CYP2C19, the enzyme needed to convert clopidogrel to its active metabolite."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00482",
   "question": "Prasugrel differs from clopidogrel in that it:",
   "options": [
      "Has more consistent P2Y₁₂ inhibition",
      "Blocks COX-1",
      "Reverses warfarin",
      "Inhibits plasmin"
   ],
   "answer": "Has more consistent P2Y₁₂ inhibition",
   "explanation": "Prasugrel is more efficiently metabolized to its active form, yielding more potent and predictable platelet inhibition."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00483",
   "question": "Ticagrelor is unique among P2Y₁₂ inhibitors because it is:",
   "options": [
      "Reversible and direct-acting",
      "An irreversible prodrug",
      "A vitamin K antagonist",
      "A GP IIb/IIIa blocker"
   ],
   "answer": "Reversible and direct-acting",
   "explanation": "Ticagrelor binds directly to the P2Y₁₂ receptor without metabolic activation and dissociates over time."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00484",
   "question": "GP IIb/IIIa inhibitors prevent platelet aggregation by blocking:",
   "options": [
      "Fibrinogen binding",
      "COX-1",
      "ADP receptor",
      "Thrombin binding"
   ],
   "answer": "Fibrinogen binding",
   "explanation": "Blocking the GP IIb/IIIa receptor prevents fibrinogen from cross-linking platelets at sites of arterial injury."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00485",
   "question": "Dipyridamole enhances antiplatelet activity by:",
   "options": [
      "Inhibiting phosphodiesterase and adenosine uptake",
      "Blocking COX-1",
      "Reversing warfarin",
      "Inhibiting factor Xa"
   ],
   "answer": "Inhibiting phosphodiesterase and adenosine uptake",
   "explanation": "Dipyridamole raises cAMP in platelets by preventing its breakdown and allowing extracellular adenosine to accumulate."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00486",
   "question": "Dipyridamole can worsen myocardial ischemia via the:",
   "options": [
      "Coronary steal phenomenon",
      "Increase in afterload",
      "Platelet activation",
      "Thrombin generation"
   ],
   "answer": "Coronary steal phenomenon",
   "explanation": "By vasodilating healthy vessels, dipyridamole may shunt blood away from ischemic areas, reducing perfusion to those regions."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00487",
   "question": "Cilostazol, used for intermittent claudication, acts by:",
   "options": [
      "Inhibiting phosphodiesterase III",
      "Blocking P2Y₁₂",
      "Activating antithrombin",
      "Enhancing vitamin K"
   ],
   "answer": "Inhibiting phosphodiesterase III",
   "explanation": "PDE III inhibition increases cAMP in platelets and vascular smooth muscle, leading to antiplatelet effects and vasodilation."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00488",
   "question": "Vorapaxar’s antiplatelet effect is mediated by antagonism of:",
   "options": [
      "Thrombin receptor PAR-1",
      "ADP receptor P2Y₁₂",
      "COX-1",
      "GP IIb/IIIa"
   ],
   "answer": "Thrombin receptor PAR-1",
   "explanation": "Vorapaxar blocks protease-activated receptor-1 on platelets, preventing thrombin-induced platelet aggregation."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00489",
   "question": "Platelet adhesion to injured endothelium is mediated primarily by:",
   "options": [
      "vWF binding to GP Ib",
      "Fibrinogen binding to GP IIb/IIIa",
      "ADP binding to P2Y₁₂",
      "Thrombin binding to PAR-1"
   ],
   "answer": "vWF binding to GP Ib",
   "explanation": "von Willebrand factor bridges exposed collagen and platelet GP Ib receptors, initiating adhesion under high shear."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00490",
   "question": "Bernard-Soulier syndrome results from a defect in:",
   "options": [
      "GP Ib",
      "GP IIb/IIIa",
      "P2Y₁₂ receptor",
      "COX-1 enzyme"
   ],
   "answer": "GP Ib",
   "explanation": "A deficiency of GP Ib prevents vWF-mediated platelet adhesion, leading to bleeding diathesis."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00491",
   "question": "Glanzmann thrombasthenia is caused by defective:",
   "options": [
      "GP IIb/IIIa",
      "GP Ib",
      "P2Y₁₂ receptor",
      "Fibrinogen synthesis"
   ],
   "answer": "GP IIb/IIIa",
   "explanation": "Mutations in GP IIb/IIIa impair fibrinogen binding and platelet aggregation, resulting in mucocutaneous bleeding."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00492",
   "question": "Aspirin resistance may occur due to increased platelet turnover or:",
   "options": [
      "NSAID competition at COX-1",
      "Excess thrombin",
      "Vitamin K excess",
      "P2Y₁₂ overexpression"
   ],
   "answer": "NSAID competition at COX-1",
   "explanation": "Nonselective NSAIDs can reversibly occupy COX-1 active sites, preventing aspirin from acetylating the enzyme."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00493",
   "question": "Which antiplatelet agent is avoided in current stroke guidelines due to coronary steal?",
   "options": [
      "Dipyridamole",
      "Clopidogrel",
      "Aspirin",
      "Ticagrelor"
   ],
   "answer": "Dipyridamole",
   "explanation": "Because of the risk of coronary steal, dipyridamole is no longer recommended alone for secondary stroke prevention."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00494",
   "question": "Reversal of ticagrelor’s antiplatelet effect requires:",
   "options": [
      "Platelet transfusion",
      "Vitamin K",
      "Protamine sulfate",
      "Idarucizumab"
   ],
   "answer": "Platelet transfusion",
   "explanation": "Because ticagrelor binds reversibly and has no specific antidote, replenishing functional platelets restores aggregation."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00495",
   "question": "Heparin must be used with caution in patients with:",
   "options": [
      "Severe thrombocytopenia",
      "Active GI bleeding",
      "Aspirin allergy",
      "Warfarin therapy"
   ],
   "answer": "Active GI bleeding",
   "explanation": "Any anticoagulant increases bleeding risk; active bleeding is a contraindication to use."
},
 {
   "chapter_id": 13,
   "chapter": "Anticoagulants and Antiplatelet Agents",
   "question_id": "00013-00496",
   "question": "Which drug combination increases bleeding risk synergistically?",
   "options": [
      "Warfarin + aspirin",
      "Heparin + protamine",
      "Clopidogrel + dipyridamole",
      "Rivaroxaban + andexanet alfa"
   ],
   "answer": "Warfarin + aspirin",
   "explanation": "Combining an anticoagulant with an antiplatelet multiplies bleeding risk and requires careful justification."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00497",
   "question": "Which enzyme is competitively inhibited by statins to reduce cholesterol synthesis?",
   "options": [
      "HMG CoA reductase",
      "Lipoprotein lipase",
      "Cholesterol ester transfer protein",
      "ATP-citrate lyase"
   ],
   "answer": "HMG CoA reductase",
   "explanation": "Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, decreasing intracellular cholesterol and upregulating LDL receptors :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00498",
   "question": "Which of the following statins is hydrophilic and least likely to penetrate extrahepatic tissues?",
   "options": [
      "Pravastatin",
      "Atorvastatin",
      "Simvastatin",
      "Lovastatin"
   ],
   "answer": "Pravastatin",
   "explanation": "Pravastatin is more hydrophilic compared to other statins, resulting in reduced nonhepatic tissue uptake and potentially fewer muscle side effects :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00499",
   "question": "A major adverse effect of statins is:",
   "options": [
      "Myopathy and rhabdomyolysis",
      "Gallstones",
      "Hyperuricemia",
      "Pancreatitis"
   ],
   "answer": "Myopathy and rhabdomyolysis",
   "explanation": "Statins can cause dose-dependent muscle toxicity ranging from mild myalgias to rhabdomyolysis, especially in renal insufficiency :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00500",
   "question": "Ezetimibe reduces LDL-C by inhibiting:",
   "options": [
      "NPC1L1 transporter in the intestine",
      "HMG CoA reductase",
      "Bile acid reabsorption",
      "PCSK9"
   ],
   "answer": "NPC1L1 transporter in the intestine",
   "explanation": "Ezetimibe blocks the Niemann–Pick C1-like 1 (NPC1L1) transporter on enterocytes, decreasing cholesterol absorption and lowering LDL-C :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00501",
   "question": "Bile acid sequestrants lower LDL-C by:",
   "options": [
      "Interrupting enterohepatic circulation of bile acids",
      "Inhibiting cholesterol synthesis",
      "Increasing lipoprotein lipase activity",
      "Blocking NPC1L1"
   ],
   "answer": "Interrupting enterohepatic circulation of bile acids",
   "explanation": "Sequestrants like cholestyramine bind bile acids in the gut, preventing reabsorption, depleting hepatic bile acid pool and upregulating LDL receptors :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00502",
   "question": "Which side effect is characteristic of bile acid sequestrants?",
   "options": [
      "Constipation and fat-soluble vitamin malabsorption",
      "Myopathy",
      "Hyperglycemia",
      "Pancreatitis"
   ],
   "answer": "Constipation and fat-soluble vitamin malabsorption",
   "explanation": "By binding bile acids, these agents can cause gastrointestinal discomfort, constipation, and reduced absorption of vitamins A, D, E, and K."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00503",
   "question": "PCSK9 inhibitors lower LDL-C by:",
   "options": [
      "Preventing LDL receptor degradation",
      "Inhibiting HMG CoA reductase",
      "Blocking cholesterol absorption",
      "Sequestering bile acids"
   ],
   "answer": "Preventing LDL receptor degradation",
   "explanation": "Monoclonal antibodies against PCSK9 reduce its binding to LDL receptors, increasing receptor recycling and LDL clearance."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00504",
   "question": "Bempedoic acid exerts its lipid-lowering effect by inhibiting:",
   "options": [
      "ATP-citrate lyase",
      "HMG CoA reductase",
      "Lipoprotein lipase",
      "PCSK9"
   ],
   "answer": "ATP-citrate lyase",
   "explanation": "Bempedoic acid inhibits ATP-citrate lyase in the cholesterol synthesis pathway upstream of HMG CoA reductase :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00505",
   "question": "Lomitapide is indicated for:",
   "options": [
      "Homozygous familial hypercholesterolemia",
      "Type I hyperlipidemia",
      "Hypertriglyceridemia",
      "Dysbetalipoproteinemia"
   ],
   "answer": "Homozygous familial hypercholesterolemia",
   "explanation": "Lomitapide inhibits microsomal triglyceride transfer protein, reducing VLDL assembly and LDL in HoFH patients :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00506",
   "question": "Which of the following targets triglyceride reduction rather than LDL-C?",
   "options": [
      "Fenofibrate",
      "Rosuvastatin",
      "Ezetimibe",
      "PCSK9 inhibitor"
   ],
   "answer": "Fenofibrate",
   "explanation": "Fibrates activate PPARα, increasing lipoprotein lipase activity and lowering TG-rich lipoproteins :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00507",
   "question": "Niacin lowers triglycerides by:",
   "options": [
      "Inhibiting hormone-sensitive lipase in adipose tissue",
      "Blocking cholesterol absorption",
      "Inhibiting HMG CoA reductase",
      "Sequestering bile acids"
   ],
   "answer": "Inhibiting hormone-sensitive lipase in adipose tissue",
   "explanation": "Niacin reduces lipolysis in adipose tissue, decreasing FFA flux to the liver and VLDL synthesis."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00508",
   "question": "An adverse effect of niacin is:",
   "options": [
      "Flushing mediated by prostaglandins",
      "Rhabdomyolysis",
      "Constipation",
      "Pancreatitis"
   ],
   "answer": "Flushing mediated by prostaglandins",
   "explanation": "Niacin causes dose-dependent flushing due to prostaglandin release; aspirin can mitigate this."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00509",
   "question": "Omega-3 fatty acids lower triglycerides by:",
   "options": [
      "Reducing hepatic VLDL synthesis",
      "Inhibiting HMG CoA reductase",
      "Blocking cholesterol absorption",
      "Sequestering bile acids"
   ],
   "answer": "Reducing hepatic VLDL synthesis",
   "explanation": "EPA/DHA decrease TG synthesis and increase TG clearance; high-dose formulations reduce TG significantly."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00510",
   "question": "Icosapent ethyl is approved to reduce:",
   "options": [
      "Cardiovascular events in high-risk patients",
      "LDL-C in HoFH",
      "HDL-C in low-risk patients",
      "Cholesterol absorption"
   ],
   "answer": "Cardiovascular events in high-risk patients",
   "explanation": "Icosapent ethyl (pure EPA) added to statin therapy lowers residual ASCVD risk by reducing TG and inflammation."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00511",
   "question": "Which combination has evidence to further reduce ASCVD events beyond statin monotherapy?",
   "options": [
      "Statin + PCSK9 inhibitor",
      "Statin + bile acid sequestrant",
      "Statin + niacin",
      "Statin + fibrate"
   ],
   "answer": "Statin + PCSK9 inhibitor",
   "explanation": "PCSK9 inhibitors on top of maximally tolerated statins further lower LDL-C and reduce ASCVD events :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00512",
   "question": "Statin therapy should be continued indefinitely unless:",
   "options": [
      "Serious adverse effects occur",
      "LDL-C is normal",
      "HDL-C is high",
      "Triglycerides are low"
   ],
   "answer": "Serious adverse effects occur",
   "explanation": "Statins are taken long-term to maintain ASCVD risk reduction unless intolerable toxicity arises :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00513",
   "question": "Treatment goals for hyperlipidemia focus on lowering:",
   "options": [
      "LDL-C",
      "VLDL directly",
      "HDL-C",
      "Total protein"
   ],
   "answer": "LDL-C",
   "explanation": "Elevated LDL-C correlates strongly with CHD risk; lowering LDL-C is primary goal, with secondary TG and HDL targets :contentReference[oaicite:22]{index=22}."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00514",
   "question": "High-intensity statin therapy typically reduces LDL-C by:",
   "options": [
      "≥50%",
      "20–30%",
      "10–15%",
      "30–40%"
   ],
   "answer": "≥50%",
   "explanation": "High-intensity statins (e.g., atorvastatin ≥40 mg, rosuvastatin ≥20 mg) lower LDL-C by at least 50%."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00515",
   "question": "Which statin is eliminated primarily by CYP3A4 and prone to drug interactions?",
   "options": [
      "Simvastatin",
      "Pravastatin",
      "Rosuvastatin",
      "Pitavastatin"
   ],
   "answer": "Simvastatin",
   "explanation": "Simvastatin is metabolized by CYP3A4; inhibitors like grapefruit juice increase risk of myopathy."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00516",
   "question": "Statin-associated autoimmune myopathy is characterized by:",
   "options": [
      "Anti-HMGCR antibodies",
      "Anti-dsDNA antibodies",
      "ANA positivity",
      "RF positivity"
   ],
   "answer": "Anti-HMGCR antibodies",
   "explanation": "Rare necrotizing myopathy involves autoantibodies against HMG CoA reductase, persisting despite statin withdrawal."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00517",
   "question": "Which agent requires monitoring of liver enzymes due to hepatotoxicity risk?",
   "options": [
      "Statins",
      "Bile acid sequestrants",
      "PCSK9 inhibitors",
      "Omega-3 FAs"
   ],
   "answer": "Statins",
   "explanation": "Statin therapy is associated with asymptomatic transaminase elevations; routine LFT monitoring is recommended."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00518",
   "question": "Brief interruption of statin before major surgery may be considered if:",
   "options": [
      "Risk of rhabdomyolysis is high",
      "LDL-C is too low",
      "HDL-C is high",
      "TG are normal"
   ],
   "answer": "Risk of rhabdomyolysis is high",
   "explanation": "In perioperative settings with CK elevation risk, temporary statin pause may reduce muscle injury."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00519",
   "question": "Which drug is indicated for patients with primary hypertriglyceridemia to prevent pancreatitis?",
   "options": [
      "Fenofibrate",
      "Statins",
      "Ezetimibe",
      "PCSK9 inhibitor"
   ],
   "answer": "Fenofibrate",
   "explanation": "Fibrates lower TGs substantially, reducing risk of TG-induced pancreatitis in severe hypertriglyceridemia."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00520",
   "question": "Niacin’s lipid effects include:",
   "options": [
      "↓TG, ↓LDL-C, ↑HDL-C",
      "↑TG, ↓LDL-C, ↓HDL-C",
      "↓TG only",
      "↑HDL-C only"
   ],
   "answer": "↓TG, ↓LDL-C, ↑HDL-C",
   "explanation": "Niacin reduces VLDL secretion and LDL, while robustly raising HDL by decreasing HDL catabolism."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00521",
   "question": "What is the mechanism of action of mipomersen?",
   "options": [
      "Antisense oligonucleotide against apoB-100 mRNA",
      "PCSK9 inhibition",
      "HMG CoA reductase inhibition",
      "Cholesterol absorption blockade"
   ],
   "answer": "Antisense oligonucleotide against apoB-100 mRNA",
   "explanation": "Mipomersen binds apoB-100 mRNA, reducing synthesis of apoB-containing lipoproteins; used in severe FH."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00522",
   "question": "Which agent is restricted to homozygous FH due to hepatosteatosis risk?",
   "options": [
      "Lomitapide",
      "Ezetimibe",
      "Fenofibrate",
      "Niacin"
   ],
   "answer": "Lomitapide",
   "explanation": "Lomitapide’s MTP inhibition causes hepatic fat accumulation; reserved for HoFH under REMS program."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00523",
   "question": "A patient with statin intolerance might benefit from:",
   "options": [
      "PCSK9 inhibitor",
      "Higher-dose statin",
      "Niacin monotherapy",
      "Bile acid sequestrant only"
   ],
   "answer": "PCSK9 inhibitor",
   "explanation": "PCSK9 inhibitors effectively lower LDL-C independent of statin use and are options for statin-intolerant patients."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00524",
   "question": "Which lipid-lowering drug is safe in pregnancy when hyperlipidemia is severe?",
   "options": [
      "Bile acid sequestrants",
      "Statins",
      "Niacin",
      "Fenofibrate"
   ],
   "answer": "Bile acid sequestrants",
   "explanation": "Sequestrants are not systemically absorbed and are considered safest for pregnant women requiring LDL-C lowering."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00525",
   "question": "Which drug lowers LDL-C by increasing LDL receptor recycling?",
   "options": [
      "Evolocumab",
      "Ezetimibe",
      "Niacin",
      "Fenofibrate"
   ],
   "answer": "Evolocumab",
   "explanation": "Evolocumab is a PCSK9 monoclonal antibody that prevents LDLR degradation, enhancing receptor availability."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00526",
   "question": "Which class of drugs may worsen triglycerides?",
   "options": [
      "Bile acid sequestrants",
      "Statins",
      "PCSK9 inhibitors",
      "Omega-3 fatty acids"
   ],
   "answer": "Bile acid sequestrants",
   "explanation": "By interrupting bile acid reabsorption, these agents can increase hepatic TG synthesis and raise TG levels."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00527",
   "question": "Which therapy is recommended for patients with LDL ≥190 mg/dL regardless of ASCVD risk?",
   "options": [
      "High-intensity statin",
      "Low-intensity statin",
      "Ezetimibe alone",
      "Niacin"
   ],
   "answer": "High-intensity statin",
   "explanation": "Very high LDL-C levels (≥190 mg/dL) warrant first-line high-intensity statin therapy to aggressively lower LDL."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00528",
   "question": "Which agent is contraindicated in active gallbladder disease?",
   "options": [
      "Fenofibrate",
      "Statins",
      "Ezetimibe",
      "PCSK9 inhibitors"
   ],
   "answer": "Fenofibrate",
   "explanation": "Fibrates can increase gallstone risk and are avoided in active gallbladder disease."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00529",
   "question": "Which drug requires monitoring of CK if combined with high-dose statin?",
   "options": [
      "Gemfibrozil",
      "Ezetimibe",
      "Niacin",
      "Evolocumab"
   ],
   "answer": "Gemfibrozil",
   "explanation": "Gemfibrozil inhibits statin glucuronidation, significantly raising myopathy risk when used together."
},
 {
   "chapter_id": 14,
   "chapter": "Drugs for Hyperlipidemia",
   "question_id": "00014-00530",
   "question": "Which medication improves HDL function rather than simply raising HDL-C levels?",
   "options": [
      "PCSK9 inhibitors",
      "Niacin",
      "Statins",
      "Bile acid sequestrants"
   ],
   "answer": "PCSK9 inhibitors",
   "explanation": "PCSK9 inhibitors not only lower LDL but also enhance HDL-mediated reverse cholesterol transport and endothelial function."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00531",
   "question": "Which of the following best describes the primary pathology underlying Parkinson disease?",
   "options": [
      "Autoimmune demyelination of central neurons",
      "Destruction of dopaminergic neurons in the substantia nigra",
      "Accumulation of β-amyloid plaques in the cortex",
      "Loss of cholinergic neurons in the basal forebrain"
   ],
   "answer": "Destruction of dopaminergic neurons in the substantia nigra",
   "explanation": "Parkinson disease is correlated with destruction of dopaminergic neurons in the substantia nigra, leading to reduced central dopamine levels and characteristic motor symptoms."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00532",
   "question": "Levodopa is administered in Parkinson disease primarily because it:",
   "options": [
      "Inhibits cholinergic receptors in the striatum",
      "Acts as a direct dopamine receptor agonist",
      "Crosses the blood–brain barrier and is converted to dopamine",
      "Prevents dopamine breakdown by monoamine oxidase B"
   ],
   "answer": "Crosses the blood–brain barrier and is converted to dopamine",
   "explanation": "Levodopa is a precursor of dopamine that crosses the blood–brain barrier and is decarboxylated to dopamine in the CNS, restoring depleted levels."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00533",
   "question": "Carbidopa is coadministered with levodopa to:",
   "options": [
      "Enhance levodopa’s penetration of the blood–brain barrier",
      "Reduce peripheral decarboxylation of levodopa",
      "Block levodopa’s metabolism by COMT",
      "Inhibit MAO-B in the CNS"
   ],
   "answer": "Reduce peripheral decarboxylation of levodopa",
   "explanation": "Carbidopa inhibits peripheral aromatic L-amino acid decarboxylase, preventing levodopa’s conversion to dopamine outside the CNS and increasing its availability to the brain."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00534",
   "question": "Which nonergot dopamine agonist is administered as a once-daily transdermal patch?",
   "options": [
      "Pramipexole",
      "Apomorphine",
      "Ropinirole",
      "Rotigotine"
   ],
   "answer": "Rotigotine",
   "explanation": "Rotigotine is provided as a once-daily transdermal patch, delivering continuous dopaminergic stimulation."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00535",
   "question": "Selegiline exerts its antiparkinsonian effect by:",
   "options": [
      "Inhibiting catechol-O-methyltransferase",
      "Reversibly blocking NMDA receptors",
      "Selectively inhibiting MAO-B and increasing brain dopamine",
      "Stimulating dopamine release from vesicles"
   ],
   "answer": "Selectively inhibiting MAO-B and increasing brain dopamine",
   "explanation": "Selegiline selectively inhibits MAO-B, the enzyme that metabolizes dopamine, thereby increasing dopamine levels in the brain."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00536",
   "question": "A patient on levodopa/carbidopa experiences wearing-off due to fluctuating dopamine levels. Which class of drugs can extend levodopa’s duration by reducing peripheral 3-O-methyldopa formation?",
   "options": [
      "MAO-B inhibitors",
      "COMT inhibitors",
      "Antimuscarinics",
      "NMDA antagonists"
   ],
   "answer": "COMT inhibitors",
   "explanation": "COMT inhibitors (entacapone, tolcapone, opicapone) decrease peripheral conversion of levodopa to 3-O-methyldopa, increasing its CNS uptake and reducing wearing-off."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00537",
   "question": "Which COMT inhibitor has been associated with fulminant hepatic necrosis and requires liver function monitoring?",
   "options": [
      "Entacapone",
      "Opicapone",
      "Tolcapone",
      "Rasagiline"
   ],
   "answer": "Tolcapone",
   "explanation": "Tolcapone carries a risk of severe hepatic necrosis and mandates regular monitoring of liver enzymes during therapy."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00538",
   "question": "The antiviral drug amantadine benefits Parkinson disease patients by:",
   "options": [
      "Inhibiting dopamine reuptake",
      "Blocking COMT",
      "Increasing dopamine release and antagonizing NMDA receptors",
      "Inhibiting peripheral decarboxylase"
   ],
   "answer": "Increasing dopamine release and antagonizing NMDA receptors",
   "explanation": "Amantadine increases dopamine release, blocks cholinergic receptors, and inhibits NMDA-type glutamate receptors, contributing to its antiparkinsonian effects."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00539",
   "question": "Which antimuscarinic agent is used to reduce tremor in Parkinson disease?",
   "options": [
      "Trihexyphenidyl",
      "Memantine",
      "Istradefylline",
      "Safinamide"
   ],
   "answer": "Trihexyphenidyl",
   "explanation": "Trihexyphenidyl reduces central cholinergic activity and is effective in improving tremor-predominant Parkinson disease."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00540",
   "question": "Istradefylline, used as an adjunct in Parkinson disease, acts by:",
   "options": [
      "Inhibiting MAO-B",
      "Blocking adenosine A₂A receptors",
      "Stimulating dopamine D₂ receptors",
      "Inhibiting COMT"
   ],
   "answer": "Blocking adenosine A₂A receptors",
   "explanation": "Istradefylline is a selective adenosine A₂A receptor antagonist that reduces off episodes when added to levodopa therapy."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00541",
   "question": "Which vitamin supplement increases peripheral breakdown of levodopa and diminishes its effectiveness?",
   "options": [
      "Vitamin B₁",
      "Vitamin B₆",
      "Vitamin B₁₂",
      "Vitamin D"
   ],
   "answer": "Vitamin B₆",
   "explanation": "Pyridoxine (vitamin B₆) enhances peripheral decarboxylation of levodopa, reducing the amount available to cross into the CNS."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00542",
   "question": "Which agent is approved for the management of psychosis in Parkinson disease due to its 5-HT₂A inverse agonism?",
   "options": [
      "Quetiapine",
      "Clozapine",
      "Pimavanserin",
      "Haloperidol"
   ],
   "answer": "Pimavanserin",
   "explanation": "Pimavanserin is a selective 5-HT₂A inverse agonist approved for Parkinson disease–related psychosis, with minimal risk of worsening motor symptoms."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00543",
   "question": "Which acetylcholinesterase inhibitor is available as a transdermal patch and indicated for both Alzheimer disease and Parkinson disease–associated dementia?",
   "options": [
      "Donepezil",
      "Galantamine",
      "Rivastigmine",
      "Memantine"
   ],
   "answer": "Rivastigmine",
   "explanation": "Rivastigmine patch provides continuous drug delivery and is approved for mild to moderate Alzheimer disease and Parkinson disease dementia."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00544",
   "question": "Which acetylcholinesterase inhibitor also allosterically modulates nicotinic receptors, potentially enhancing therapeutic effects?",
   "options": [
      "Donepezil",
      "Galantamine",
      "Rivastigmine",
      "Tacrine"
   ],
   "answer": "Galantamine",
   "explanation": "Galantamine not only inhibits acetylcholinesterase but also potentiates nicotinic receptors, augmenting cholinergic neurotransmission."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00545",
   "question": "Memantine, used in moderate to severe Alzheimer disease, acts by:",
   "options": [
      "Inhibiting acetylcholinesterase",
      "Blocking NMDA glutamate receptors",
      "Antagonizing dopamine D₂ receptors",
      "Stimulating GABA_A receptors"
   ],
   "answer": "Blocking NMDA glutamate receptors",
   "explanation": "Memantine is an NMDA receptor antagonist that reduces excitotoxic glutamate signaling and is often combined with an AChE inhibitor."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00546",
   "question": "Which agent is recommended for acute exacerbations of multiple sclerosis?",
   "options": [
      "Siponimod",
      "High-dose IV methylprednisolone",
      "Cladribine",
      "Ofatumumab"
   ],
   "answer": "High-dose IV methylprednisolone",
   "explanation": "High-dose IV corticosteroids such as methylprednisolone for 3–5 days are the standard of care for acute MS relapses."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00547",
   "question": "Glatiramer acetate exerts its immunomodulatory effect by:",
   "options": [
      "Blocking sphingosine 1-phosphate receptors",
      "Mimicking myelin basic protein as a T cell decoy",
      "Inhibiting pyrimidine synthesis",
      "Activating Nrf2 antioxidant pathways"
   ],
   "answer": "Mimicking myelin basic protein as a T cell decoy",
   "explanation": "Glatiramer acetate is a synthetic polypeptide that resembles myelin protein and diverts T cell–mediated attack from native myelin."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00548",
   "question": "Fingolimod, an oral multiple sclerosis therapy, acts by:",
   "options": [
      "Inhibiting pyrimidine synthesis",
      "Modulating sphingosine 1-phosphate receptors to sequester lymphocytes",
      "Mimicking myelin basic protein",
      "Activating Nrf2 antioxidant pathways"
   ],
   "answer": "Modulating sphingosine 1-phosphate receptors to sequester lymphocytes",
   "explanation": "Fingolimod binds S1P receptors, preventing lymphocyte egress from lymph nodes and reducing CNS infiltration."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00549",
   "question": "Teriflunomide’s mechanism in multiple sclerosis involves:",
   "options": [
      "Blocking sphingosine 1-phosphate receptors",
      "Inhibiting pyrimidine synthesis to reduce active lymphocytes",
      "Mimicking myelin basic protein",
      "Activating Nrf2 antioxidant pathways"
   ],
   "answer": "Inhibiting pyrimidine synthesis to reduce active lymphocytes",
   "explanation": "Teriflunomide inhibits dihydroorotate dehydrogenase, decreasing pyrimidine synthesis and reducing proliferating lymphocytes."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00550",
   "question": "Siponimod therapy requires genetic testing for:",
   "options": [
      "HLA-B*5701",
      "CYP2C9 polymorphisms",
      "G6PD deficiency",
      "HLA-DR4"
   ],
   "answer": "CYP2C9 polymorphisms",
   "explanation": "Siponimod is metabolized by CYP2C9; individuals with CYP2C9*3/*3 genotype are at risk of elevated drug levels and contraindicated."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00551",
   "question": "Dimethyl fumarate, used in multiple sclerosis, activates:",
   "options": [
      "MAO-B",
      "Pyrimidine synthesis",
      "Nrf2 antioxidant response pathway",
      "Sphingosine 1-phosphate receptors"
   ],
   "answer": "Nrf2 antioxidant response pathway",
   "explanation": "Dimethyl fumarate activates the Nrf2 pathway, upregulating antioxidant defenses and reducing inflammatory damage."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00552",
   "question": "Which drug indicated for ALS acts by inhibiting glutamate release and blocking sodium channels?",
   "options": [
      "Riluzole",
      "Edaravone",
      "Interferon beta-1a",
      "Glatiramer acetate"
   ],
   "answer": "Riluzole",
   "explanation": "Riluzole modulates glutamate neurotransmission and blocks sodium channels, which may slow ALS progression."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00553",
   "question": "Edaravone, used in ALS, exerts its effect as a:",
   "options": [
      "Glutamate release inhibitor",
      "Free radical scavenger and antioxidant",
      "S1P receptor modulator",
      "Pyrimidine synthesis inhibitor"
   ],
   "answer": "Free radical scavenger and antioxidant",
   "explanation": "Edaravone acts as a free radical scavenger and antioxidant, which may mitigate oxidative neuronal damage in ALS."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00554",
   "question": "Aducanumab, an Alzheimer disease therapy, functions by:",
   "options": [
      "Inhibiting acetylcholinesterase",
      "Blocking NMDA receptors",
      "Reducing amyloid β plaques via monoclonal antibody",
      "Modulating nicotinic receptors"
   ],
   "answer": "Reducing amyloid β plaques via monoclonal antibody",
   "explanation": "Aducanumab is a monoclonal antibody that binds amyloid β, promoting its clearance from the brain."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00555",
   "question": "Which of the following adverse effects is associated with aducanumab therapy?",
   "options": [
      "Hepatic necrosis",
      "Amyloid-related imaging abnormalities (ARIA)",
      "First-dose bradycardia",
      "Serotonin syndrome"
   ],
   "answer": "Amyloid-related imaging abnormalities (ARIA)",
   "explanation": "Aducanumab can cause ARIA, including brain edema and microhemorrhages visible on MRI."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00556",
   "question": "Safinamide, used as adjunct to levodopa–carbidopa, is classified as a:",
   "options": [
      "COMT inhibitor",
      "Reversible MAO-B inhibitor",
      "Antimuscarinic agent",
      "Dopamine agonist"
   ],
   "answer": "Reversible MAO-B inhibitor",
   "explanation": "Safinamide selectively and reversibly inhibits MAO-B, enhancing dopamine levels when added to levodopa therapy."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00557",
   "question": "Fingolimod therapy in MS carries a risk of which ocular adverse effect?",
   "options": [
      "Cataracts",
      "Keratitis",
      "Macular edema",
      "Glaucoma"
   ],
   "answer": "Macular edema",
   "explanation": "Fingolimod and other S1P modulators can cause macular edema; ophthalmologic monitoring is recommended."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00558",
   "question": "Use of sphingosine 1-phosphate receptor modulators in MS is associated with an increased risk of:",
   "options": [
      "Osteonecrosis",
      "Progressive multifocal leukoencephalopathy",
      "Hypertensive crisis",
      "Serotonin syndrome"
   ],
   "answer": "Progressive multifocal leukoencephalopathy",
   "explanation": "S1P receptor modulators carry a risk of PML, a rare but serious demyelinating infection."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00559",
   "question": "Which oral MS agent commonly causes flushing, abdominal pain, diarrhea, and nausea?",
   "options": [
      "Teriflunomide",
      "Dimethyl fumarate",
      "Siponimod",
      "Interferon beta-1a"
   ],
   "answer": "Dimethyl fumarate",
   "explanation": "Dimethyl fumarate often causes GI side effects including flushing, abdominal pain, diarrhea, and nausea."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00560",
   "question": "Which injectable MS therapy may cause flu-like symptoms, depression, and elevated hepatic enzymes?",
   "options": [
      "Interferon beta-1a",
      "Glatiramer acetate",
      "Fingolimod",
      "Dimethyl fumarate"
   ],
   "answer": "Interferon beta-1a",
   "explanation": "Injectable interferon beta-1a can cause flu-like symptoms, depression, injection site reactions, and elevated liver enzymes."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00561",
   "question": "Which MAO-B inhibitor should be avoided with SSRIs due to risk of serotonin syndrome?",
   "options": [
      "Selegiline",
      "Entacapone",
      "Ropinirole",
      "Amantadine"
   ],
   "answer": "Selegiline",
   "explanation": "Selegiline may precipitate serotonin syndrome when combined with SSRIs and should be avoided in such combinations."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00562",
   "question": "Rasagiline differs from selegiline in that it:",
   "options": [
      "Is a reversible MAO-B inhibitor",
      "Has five times the potency and is not metabolized to amphetamines",
      "Inhibits COMT instead of MAO",
      "Requires liver function monitoring"
   ],
   "answer": "Has five times the potency and is not metabolized to amphetamines",
   "explanation": "Rasagiline is an irreversible MAO-B inhibitor that is more potent than selegiline and does not produce amphetamine-like metabolites."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00563",
   "question": "Which dopamine agonist used in Parkinson disease may cause vasospasm and is contraindicated in peripheral vascular disease?",
   "options": [
      "Pramipexole",
      "Bromocriptine",
      "Rotigotine",
      "Apomorphine"
   ],
   "answer": "Bromocriptine",
   "explanation": "Bromocriptine, an ergot-derived agonist, can cause vasospasm and is contraindicated in patients with peripheral vascular disease."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00564",
   "question": "Which nonselective MAOI is contraindicated with levodopa due to risk of hypertensive crisis?",
   "options": [
      "Safinamide",
      "Phenelzine",
      "Entacapone",
      "Trihexyphenidyl"
   ],
   "answer": "Phenelzine",
   "explanation": "Phenelzine and other nonselective MAOIs can precipitate hypertensive crises when combined with levodopa."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00565",
   "question": "Which combination of drugs is appropriate to reduce wearing-off and peripheral side effects in Parkinson disease?",
   "options": [
      "Amantadine, carbidopa, and entacapone",
      "Levodopa, carbidopa, and entacapone",
      "Pramipexole, carbidopa, and entacapone",
      "Ropinirole, carbidopa, and selegiline"
   ],
   "answer": "Levodopa, carbidopa, and entacapone",
   "explanation": "Adding entacapone to levodopa/carbidopa reduces peripheral metabolism of levodopa to 3-O-methyldopa, increasing its CNS uptake and reducing wearing-off."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00566",
   "question": "Which MAO-B inhibitor is reversible and indicated as adjunct therapy in Parkinson disease?",
   "options": [
      "Selegiline",
      "Rasagiline",
      "Safinamide",
      "Tolcapone"
   ],
   "answer": "Safinamide",
   "explanation": "Safinamide is a selective, reversible MAO-B inhibitor used as adjunctive therapy with levodopa/carbidopa."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00567",
   "question": "Which COMT inhibitor is administered once daily at bedtime?",
   "options": [
      "Entacapone",
      "Tolcapone",
      "Opicapone",
      "Rasagiline"
   ],
   "answer": "Opicapone",
   "explanation": "Opicapone is a once-daily bedtime COMT inhibitor, unlike entacapone and tolcapone which require multiple daily doses."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00568",
   "question": "Which MS therapy has the lowest risk for PML (progressive multifocal leukoencephalopathy)?",
   "options": [
      "Fingolimod",
      "Ocrelizumab",
      "Natalizumab",
      "Interferon beta-1a"
   ],
   "answer": "Interferon beta-1a",
   "explanation": "Interferons have not been associated with increased PML risk, whereas many newer immunomodulators carry higher risk."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00569",
   "question": "Riluzole therapy in amyotrophic lateral sclerosis may cause which laboratory abnormality?",
   "options": [
      "Hyperglycemia",
      "Elevated liver enzymes",
      "Leukopenia",
      "Renal failure"
   ],
   "answer": "Elevated liver enzymes",
   "explanation": "Riluzole can elevate transaminases; patients should have liver enzymes monitored during treatment."
},
 {
   "chapter_id": 15,
   "chapter": "Drugs for Neurodegenerative Diseases",
   "question_id": "00015-00570",
   "question": "Edaravone, in addition to being a radical scavenger, may cause which adverse effect?",
   "options": [
      "Arrhythmias",
      "Abnormal gait",
      "Renal impairment",
      "Severe hypertension"
   ],
   "answer": "Abnormal gait",
   "explanation": "Edaravone may cause gait disturbances, bruising, and headache during IV administration."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00571",
   "question": "How do benzodiazepines modulate the GABAA receptor?",
   "options": [
      "They directly open the chloride channel",
      "They increase the duration of channel opening",
      "They increase the frequency of channel opening",
      "They decrease GABA affinity for its receptor"
   ],
   "answer": "They increase the frequency of channel opening",
   "explanation": "Benzodiazepines bind to a modulatory site at the α–γ subunit interface of GABAA receptors and increase the frequency of chloride channel openings produced by GABA :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00572",
   "question": "At which subunit interface do benzodiazepines bind on the GABAA receptor?",
   "options": [
      "α–β interface",
      "β–γ interface",
      "α–γ interface",
      "Within the chloride channel pore"
   ],
   "answer": "α–γ interface",
   "explanation": "Benzodiazepines bind to a high-affinity site located at the interface of the α and γ subunits on the GABAA receptor :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00573",
   "question": "Which GABAA receptor subunit mediates the sedative and hypnotic effects of benzodiazepines?",
   "options": [
      "α1 subunit",
      "α2 subunit",
      "β2 subunit",
      "γ2 subunit"
   ],
   "answer": "α1 subunit",
   "explanation": "The sedative/hypnotic effects of benzodiazepines are mediated via the α1-containing GABAA receptors :contentReference[oaicite:48]{index=48}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00574",
   "question": "Which GABAA receptor subunit is chiefly responsible for the anxiolytic actions of benzodiazepines?",
   "options": [
      "α1 subunit",
      "α2 subunit",
      "β1 subunit",
      "γ1 subunit"
   ],
   "answer": "α2 subunit",
   "explanation": "Benzodiazepines reduce anxiety by selectively enhancing GABAergic transmission in neurons expressing the α2 subunit of GABAA receptors :contentReference[oaicite:49]{index=49}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00575",
   "question": "Which benzodiazepine is preferred in patients with hepatic or renal dysfunction due to its metabolism via glucuronidation?",
   "options": [
      "Diazepam",
      "Lorazepam",
      "Flurazepam",
      "Alprazolam"
   ],
   "answer": "Lorazepam",
   "explanation": "Lorazepam (along with oxazepam and temazepam) is glucuronidated to inactive metabolites without phase I metabolism, making it safer in hepatic or renal impairment :contentReference[oaicite:50]{index=50}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00576",
   "question": "Which benzodiazepine is classified as a short-acting hypnotic?",
   "options": [
      "Flurazepam",
      "Diazepam",
      "Chlordiazepoxide",
      "Triazolam"
   ],
   "answer": "Triazolam",
   "explanation": "Triazolam has the shortest half-life among the listed benzodiazepines and is best used for insomnia with minimal daytime sedation :contentReference[oaicite:51]{index=51}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00577",
   "question": "Which benzodiazepine is more suitable for patients who have difficulty staying asleep due to its intermediate duration of action?",
   "options": [
      "Triazolam",
      "Temazepam",
      "Alprazolam",
      "Flurazepam"
   ],
   "answer": "Temazepam",
   "explanation": "Intermediate-acting agents such as temazepam are useful for patients who experience frequent awakenings or have difficulty staying asleep :contentReference[oaicite:52]{index=52}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00578",
   "question": "Which benzodiazepine is commonly used for both short- and long-term treatment of panic disorders?",
   "options": [
      "Diazepam",
      "Clonazepam",
      "Alprazolam",
      "Lorazepam"
   ],
   "answer": "Alprazolam",
   "explanation": "Alprazolam is effective for acute and long-term management of panic disorder, although it carries a risk of withdrawal reactions in about 30% of patients :contentReference[oaicite:53]{index=53}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00579",
   "question": "Discontinuation of which benzodiazepine is most likely to cause rebound insomnia?",
   "options": [
      "Temazepam",
      "Triazolam",
      "Flurazepam",
      "Diazepam"
   ],
   "answer": "Triazolam",
   "explanation": "Short-acting agents like triazolam induce more frequent rebound insomnia upon withdrawal compared to longer-acting drugs :contentReference[oaicite:54]{index=54}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00580",
   "question": "What is the primary clinical use of flumazenil?",
   "options": [
      "To treat insomnia",
      "To reverse benzodiazepine overdose",
      "To manage chronic anxiety",
      "To induce anesthesia"
   ],
   "answer": "To reverse benzodiazepine overdose",
   "explanation": "Flumazenil is a benzodiazepine receptor antagonist used intravenously to rapidly reverse benzodiazepine effects in overdose :contentReference[oaicite:55]{index=55}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00581",
   "question": "Buspirone’s anxiolytic actions are primarily mediated through which receptor?",
   "options": [
      "GABAA receptor",
      "5-HT1A receptor",
      "D2 dopamine receptor",
      "NMDA receptor"
   ],
   "answer": "5-HT1A receptor",
   "explanation": "Buspirone’s therapeutic effects are mediated by partial agonism at the 5-HT1A serotonin receptors :contentReference[oaicite:56]{index=56}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00582",
   "question": "Which adverse effect is least likely with buspirone?",
   "options": [
      "Headache",
      "Dizziness",
      "Dependence",
      "Nausea"
   ],
   "answer": "Dependence",
   "explanation": "Buspirone has minimal risk of dependence and does not potentiate the CNS depression of alcohol :contentReference[oaicite:57]{index=57}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00583",
   "question": "Which of the following non-benzodiazepine hypnotics is a melatonin receptor agonist?",
   "options": [
      "Suvorexant",
      "Zolpidem",
      "Ramelteon",
      "Zaleplon"
   ],
   "answer": "Ramelteon",
   "explanation": "Ramelteon and tasimelteon are melatonin receptor agonists acting at MT1 and MT2 receptors, with minimal risk of dependency :contentReference[oaicite:58]{index=58}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00584",
   "question": "Suvorexant produces its hypnotic effects by antagonizing which system?",
   "options": [
      "GABAergic system",
      "Orexin system",
      "Melatonin system",
      "Histaminergic system"
   ],
   "answer": "Orexin system",
   "explanation": "Suvorexant antagonizes orexin receptors OX1R and OX2R, suppressing the wake drive :contentReference[oaicite:59]{index=59}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00585",
   "question": "Which of the following adverse events is most associated with suvorexant?",
   "options": [
      "Memory impairment",
      "Cataplexy",
      "Ataxia",
      "Seizures"
   ],
   "answer": "Cataplexy",
   "explanation": "Orexin antagonism by suvorexant may precipitate narcolepsy-like effects, including cataplexy and sleep paralysis :contentReference[oaicite:60]{index=60}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00586",
   "question": "Which hypnotic has the shortest half-life among the non-benzodiazepines?",
   "options": [
      "Zolpidem",
      "Zaleplon",
      "Eszopiclone",
      "Suvorexant"
   ],
   "answer": "Zaleplon",
   "explanation": "Zaleplon has the shortest half-life and duration of action in this class, making it ideal for difficulty falling asleep without daytime sedation :contentReference[oaicite:61]{index=61}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00587",
   "question": "Which hypnotic agent is associated with the lowest risk of cognitive impairment?",
   "options": [
      "Diphenhydramine",
      "Zolpidem",
      "Lemborexant",
      "Ramelteon"
   ],
   "answer": "Ramelteon",
   "explanation": "Ramelteon, a melatonin receptor agonist, is non-controlled and has a lower risk of cognitive impairment compared to other hypnotics :contentReference[oaicite:62]{index=62}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00588",
   "question": "Which benzodiazepine is most commonly used for procedural sedation due to its ultra-short action and amnestic effect?",
   "options": [
      "Clonazepam",
      "Midazolam",
      "Ramelteon",
      "Lemborexant"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam’s rapid onset, short duration, IV formulation, and amnestic properties make it ideal for pre-anesthetic and procedural sedation :contentReference[oaicite:63]{index=63}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00589",
   "question": "Which class of drugs is considered first-line for long-term management of generalized anxiety disorder?",
   "options": [
      "Benzodiazepines",
      "SSRIs/SNRIs",
      "Barbiturates",
      "Antihistamines"
   ],
   "answer": "SSRIs/SNRIs",
   "explanation": "SSRIs or SNRIs are preferred for chronic anxiety due to low dependence risk; benzodiazepines may be added only during the first week of SSRI/SNRI therapy :contentReference[oaicite:64]{index=64}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00590",
   "question": "Which benzodiazepine does not require CYP450 metabolism and is thus preferred in polypharmacy?",
   "options": [
      "Diazepam",
      "Lorazepam",
      "Chlordiazepoxide",
      "Flurazepam"
   ],
   "answer": "Lorazepam",
   "explanation": "Lorazepam undergoes direct glucuronidation without CYP450 involvement, minimizing drug–drug interactions :contentReference[oaicite:65]{index=65}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00591",
   "question": "Which over-the-counter agent is a sedating antihistamine used for situational insomnia?",
   "options": [
      "Diphenhydramine",
      "Zolpidem",
      "Eszopiclone",
      "Zaleplon"
   ],
   "answer": "Diphenhydramine",
   "explanation": "Sedating antihistamines like diphenhydramine are commonly used OTC for mild insomnia but have anticholinergic side effects :contentReference[oaicite:66]{index=66}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00592",
   "question": "Which barbiturate is classified as ultra-short-acting and used for anesthesia induction?",
   "options": [
      "Phenobarbital",
      "Pentobarbital",
      "Secobarbital",
      "Thiopental"
   ],
   "answer": "Thiopental",
   "explanation": "Ultra-short-acting barbiturates like thiopental are used for induction of anesthesia due to rapid onset and brief duration :contentReference[oaicite:67]{index=67}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00593",
   "question": "Barbiturates exert their sedative–hypnotic action primarily by which mechanism?",
   "options": [
      "Increasing frequency of channel opening",
      "Directly opening chloride channels",
      "Prolonging duration of chloride channel opening",
      "Blocking GABA release"
   ],
   "answer": "Prolonging duration of chloride channel opening",
   "explanation": "Barbiturates enhance GABAergic transmission by prolonging the duration of GABAA receptor chloride channel openings :contentReference[oaicite:68]{index=68}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00594",
   "question": "Why are benzodiazepines considered safer than barbiturates?",
   "options": [
      "They have a wider therapeutic index due to requiring GABA for activity",
      "They directly open chloride channels",
      "They do not cause tolerance",
      "They have intrinsic analgesic properties"
   ],
   "answer": "They have a wider therapeutic index due to requiring GABA for activity",
   "explanation": "Benzodiazepines require endogenous GABA to open chloride channels, reducing overdose lethality compared to barbiturates :contentReference[oaicite:69]{index=69}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00595",
   "question": "Which non-benzodiazepine hypnotic acts at the benzodiazepine receptor but is a controlled substance?",
   "options": [
      "Zolpidem",
      "Ramelteon",
      "Diphenhydramine",
      "Buspirone"
   ],
   "answer": "Zolpidem",
   "explanation": "Zolpidem binds the benzodiazepine receptor to enhance GABA activity but remains a controlled substance with risks of dependence :contentReference[oaicite:70]{index=70}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00596",
   "question": "Which antagonist can reverse the effects of both benzodiazepines and many non-benzodiazepine hypnotics?",
   "options": [
      "Naloxone",
      "Flumazenil",
      "Bupropion",
      "Buspirone"
   ],
   "answer": "Flumazenil",
   "explanation": "Flumazenil antagonizes the benzodiazepine receptor and can reverse effects of zolpidem and eszopiclone :contentReference[oaicite:71]{index=71}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00597",
   "question": "Which benzodiazepine is most strongly associated with anterograde amnesia during premedication?",
   "options": [
      "Diazepam",
      "Triazolam",
      "Clonazepam",
      "Midazolam"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam produces conscious sedation with anterograde amnesia, facilitating patient cooperation during procedures :contentReference[oaicite:72]{index=72}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00598",
   "question": "Chronic insomnia often requires evaluation for underlying conditions such as:",
   "options": [
      "Iron deficiency anemia",
      "Sleep apnea",
      "Migraine",
      "Hypertension"
   ],
   "answer": "Sleep apnea",
   "explanation": "Chronic insomnia frequently reflects underlying pathologies like sleep apnea, which should be addressed for optimal management :contentReference[oaicite:73]{index=73}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00599",
   "question": "Which tricyclic antidepressant with strong antihistamine properties is FDA-approved at low doses for insomnia?",
   "options": [
      "Trazodone",
      "Mirtazapine",
      "Doxepin",
      "Amitriptyline"
   ],
   "answer": "Doxepin",
   "explanation": "Doxepin is approved at low doses for insomnia due to its strong antihistaminergic action :contentReference[oaicite:74]{index=74}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00600",
   "question": "Which adverse effect has been reported with both suvorexant and lemborexant?",
   "options": [
      "Weight gain",
      "Sleep paralysis",
      "Urinary retention",
      "Hypertension"
   ],
   "answer": "Sleep paralysis",
   "explanation": "Orexin receptor antagonists can produce narcolepsy-like adverse events such as sleep paralysis and hallucinations :contentReference[oaicite:75]{index=75}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00601",
   "question": "Which benzodiazepine should be avoided in combination with alcohol due to additive CNS depression?",
   "options": [
      "Buspirone",
      "Lorazepam",
      "Ramelteon",
      "Zaleplon"
   ],
   "answer": "Lorazepam",
   "explanation": "Lorazepam’s CNS depressant effects are potentiated by alcohol, increasing risk of sedation and respiratory depression :contentReference[oaicite:76]{index=76}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00602",
   "question": "Which anxiolytic does not potentiate CNS depression of alcohol?",
   "options": [
      "Clonazepam",
      "Diazepam",
      "Triazolam",
      "Buspirone"
   ],
   "answer": "Buspirone",
   "explanation": "Buspirone lacks additive CNS depressant effects with alcohol and has minimal sedation risk :contentReference[oaicite:77]{index=77}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00603",
   "question": "Short-acting benzodiazepines with rapid elimination half-lives, such as triazolam, are associated with:",
   "options": [
      "Minimal withdrawal symptoms",
      "Abrupt and severe withdrawal reactions",
      "Lower risk of rebound insomnia",
      "Lack of dependence"
   ],
   "answer": "Abrupt and severe withdrawal reactions",
   "explanation": "Short-acting benzodiazepines like triazolam induce more abrupt and severe withdrawal reactions compared to longer-acting agents :contentReference[oaicite:78]{index=78}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00604",
   "question": "Which benzodiazepine is first-line for rapid relief of acute anxiety symptoms?",
   "options": [
      "Buspirone",
      "Venlafaxine",
      "Alprazolam",
      "Sertraline"
   ],
   "answer": "Alprazolam",
   "explanation": "Benzodiazepines like alprazolam have rapid onset with same-day efficacy for acute anxiety, unlike antidepressants that require weeks :contentReference[oaicite:79]{index=79}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00605",
   "question": "Which benzodiazepine is preferred for long-term use in a patient with alcohol use disorder?",
   "options": [
      "Clonazepam",
      "Chlordiazepoxide",
      "Alprazolam",
      "Venlafaxine"
   ],
   "answer": "Venlafaxine",
   "explanation": "In patients with a history of alcohol use disorder, SSRIs or SNRIs such as venlafaxine are preferred to avoid abuse potential of benzodiazepines :contentReference[oaicite:80]{index=80}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00606",
   "question": "Which antihistamine is effective for mild situational insomnia but carries undesirable anticholinergic effects?",
   "options": [
      "Diphenhydramine",
      "Hydroxyzine",
      "Doxylamine",
      "All of the above"
   ],
   "answer": "All of the above",
   "explanation": "Sedating antihistamines like diphenhydramine, hydroxyzine, and doxylamine are used OTC for situational insomnia but have anticholinergic side effects :contentReference[oaicite:81]{index=81}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00607",
   "question": "Which benzodiazepine has predominant anticonvulsant and muscle-relaxant effects mediated in part via the α2 subunit?",
   "options": [
      "Diazepam",
      "Alprazolam",
      "Clonazepam",
      "Buspirone"
   ],
   "answer": "Diazepam",
   "explanation": "Diazepam exhibits anticonvulsant and muscle-relaxant actions, partly via α1 and α2 subunits respectively, of the GABAA receptor :contentReference[oaicite:82]{index=82}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00608",
   "question": "Which benzodiazepine-receptor antagonist may precipitate seizures in benzodiazepine-dependent patients?",
   "options": [
      "Naloxone",
      "Flumazenil",
      "Naltrexone",
      "Buspirone"
   ],
   "answer": "Flumazenil",
   "explanation": "Flumazenil can precipitate withdrawal and seizures in benzodiazepine-dependent patients or mixed overdoses :contentReference[oaicite:83]{index=83}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00609",
   "question": "For chronic insomnia without controlled substances, which agent class is preferred?",
   "options": [
      "Benzodiazepines",
      "Noncontrolled antihistamines",
      "Barbiturates",
      "Orexin antagonists"
   ],
   "answer": "Noncontrolled antihistamines",
   "explanation": "Noncontrolled agents such as low-dose doxepin reduce dependency risk and are preferred for chronic insomnia management :contentReference[oaicite:84]{index=84}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00610",
   "question": "Which hypnotic acts by antagonizing orexin receptors but carries risks similar to benzodiazepines?",
   "options": [
      "Zolpidem",
      "Ramelteon",
      "Suvorexant",
      "Buspirone"
   ],
   "answer": "Suvorexant",
   "explanation": "Although suvorexant targets the orexin system, it shares risks of anterograde amnesia and dependency akin to benzodiazepines :contentReference[oaicite:85]{index=85}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00611",
   "question": "Which antidepressant is FDA-approved at low doses specifically for insomnia due to its antihistamine properties?",
   "options": [
      "Trazodone",
      "Doxepin",
      "Mirtazapine",
      "Nortriptyline"
   ],
   "answer": "Doxepin",
   "explanation": "Low-dose doxepin is approved for insomnia, exploiting its potent H1 antagonism without typical antidepressant dosing :contentReference[oaicite:86]{index=86}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00612",
   "question": "Which benzodiazepine is known for causing significant anterograde amnesia and is often used preoperatively?",
   "options": [
      "Lorazepam",
      "Triazolam",
      "Midazolam",
      "Clonazepam"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam’s potent anterograde amnesia makes it a standard choice for preoperative sedation :contentReference[oaicite:87]{index=87}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00613",
   "question": "Which benzodiazepine’s active metabolites accumulate and prolong sedation, especially in the elderly?",
   "options": [
      "Diazepam",
      "Lorazepam",
      "Oxazepam",
      "Temazepam"
   ],
   "answer": "Diazepam",
   "explanation": "Diazepam is metabolized to active compounds that can accumulate, increasing hangover effects in older patients :contentReference[oaicite:88]{index=88}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00614",
   "question": "Which hypnotic is most likely to decrease REM and slow-wave sleep?",
   "options": [
      "Triazolam",
      "Ramelteon",
      "Buspirone",
      "Suvorexant"
   ],
   "answer": "Triazolam",
   "explanation": "Benzodiazepine hypnotics reduce REM and slow-wave sleep while increasing stage II NREM, with triazolam being prototypical :contentReference[oaicite:89]{index=89}."
},
 {
   "chapter_id": 16,
   "chapter": "Anxiolytic and Hypnotic Drugs",
   "question_id": "00016-00615",
   "question": "Which agent is effective for acute management of anxiety within hours to days?",
   "options": [
      "SSRIs",
      "SNRIs",
      "Benzodiazepines",
      "Buspirone"
   ],
   "answer": "Benzodiazepines",
   "explanation": "Benzodiazepines provide rapid clinical improvement in anxiety within hours to days, unlike antidepressants that require weeks :contentReference[oaicite:90]{index=90}."
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00616",
   "question": "Which neurotransmitter’s reuptake is specifically inhibited by SSRIs?",
   "options": [
      "Norepinephrine",
      "Dopamine",
      "Serotonin",
      "GABA"
   ],
   "answer": "Serotonin",
   "explanation": "SSRIs block the reuptake of serotonin at the serotonin transporter, increasing synaptic 5-HT levels and leaving norepinephrine and dopamine uptake largely unaffected. :contentReference[oaicite:41]{index=41}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00617",
   "question": "Which drug is the pure S-enantiomer of citalopram?",
   "options": [
      "Fluoxetine",
      "Paroxetine",
      "Escitalopram",
      "Sertraline"
   ],
   "answer": "Escitalopram",
   "explanation": "Escitalopram is the pure S-enantiomer of the racemic SSRI citalopram, and it has greater selectivity for the serotonin transporter than its R-enantiomer. :contentReference[oaicite:42]{index=42}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00618",
   "question": "Why have SSRIs replaced TCAs and MAOIs as first-line agents in depression?",
   "options": [
      "They are more effective",
      "They have fewer receptor-mediated adverse effects and are safer in overdose",
      "They are less expensive",
      "They act faster"
   ],
   "answer": "They have fewer receptor-mediated adverse effects and are safer in overdose",
   "explanation": "SSRIs have minimal blocking activity at muscarinic, α-adrenergic, and histamine H₁ receptors, resulting in a more benign adverse-effect profile and lower overdose toxicity compared with TCAs and MAOIs. :contentReference[oaicite:43]{index=43}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00619",
   "question": "Which SSRI is most likely to cause QT prolongation?",
   "options": [
      "Paroxetine",
      "Sertraline",
      "Citalopram",
      "Fluoxetine"
   ],
   "answer": "Citalopram",
   "explanation": "Among SSRIs, citalopram has the highest risk of QT interval prolongation, necessitating ECG monitoring in high-risk patients. :contentReference[oaicite:44]{index=44}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00620",
   "question": "Which adverse effect is most commonly associated with SSRI therapy?",
   "options": [
      "Agranulocytosis",
      "Sexual dysfunction",
      "Hyperglycemia",
      "Extrapyramidal symptoms"
   ],
   "answer": "Sexual dysfunction",
   "explanation": "Loss of libido, delayed ejaculation, and anorgasmia are frequent with SSRIs and often lead to nonadherence. :contentReference[oaicite:45]{index=45}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00621",
   "question": "Which SSRI has the lowest risk of causing a discontinuation syndrome?",
   "options": [
      "Fluoxetine",
      "Paroxetine",
      "Sertraline",
      "Fluvoxamine"
   ],
   "answer": "Fluoxetine",
   "explanation": "Fluoxetine’s long half-life and active metabolite (norfluoxetine) result in a lower incidence of discontinuation symptoms compared to other SSRIs. :contentReference[oaicite:46]{index=46}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00622",
   "question": "At high doses, venlafaxine also inhibits the reuptake of which neurotransmitter?",
   "options": [
      "Dopamine",
      "GABA",
      "Norepinephrine",
      "Acetylcholine"
   ],
   "answer": "Norepinephrine",
   "explanation": "Venlafaxine is primarily an SSRI at low to medium doses but adds norepinephrine reuptake inhibition at higher doses. :contentReference[oaicite:47]{index=47}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00623",
   "question": "Which SNRI should be avoided in patients with significant hepatic dysfunction?",
   "options": [
      "Venlafaxine",
      "Desvenlafaxine",
      "Duloxetine",
      "Levomilnacipran"
   ],
   "answer": "Duloxetine",
   "explanation": "Duloxetine undergoes extensive hepatic metabolism to inactive metabolites and is contraindicated in patients with liver impairment. :contentReference[oaicite:48]{index=48}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00624",
   "question": "Levomilnacipran is an enantiomer of which drug and is used notably for fibromyalgia?",
   "options": [
      "Milnacipran",
      "Venlafaxine",
      "Desvenlafaxine",
      "Duloxetine"
   ],
   "answer": "Milnacipran",
   "explanation": "Levomilnacipran is the active enantiomer of milnacipran and shares its indications, including fibromyalgia management in the U.S. :contentReference[oaicite:49]{index=49}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00625",
   "question": "Brexanolone exerts its antidepressant effects primarily through modulation of which receptor?",
   "options": [
      "Serotonin transporter",
      "GABAA",
      "NMDA",
      "Dopamine D2"
   ],
   "answer": "GABAA",
   "explanation": "Brexanolone is a positive allosteric modulator of GABAA receptors and is approved for postpartum depression. :contentReference[oaicite:50]{index=50}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00626",
   "question": "Which atypical antidepressant is associated with a dose-dependent risk of seizures?",
   "options": [
      "Bupropion",
      "Mirtazapine",
      "Esketamine",
      "Trazodone"
   ],
   "answer": "Bupropion",
   "explanation": "Bupropion, a weak dopamine/NE reuptake inhibitor, carries a dose-related seizure risk, particularly at higher doses. :contentReference[oaicite:51]{index=51}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00627",
   "question": "Esketamine, used in treatment-resistant depression, is administered via which route?",
   "options": [
      "Intravenous",
      "Intranasal",
      "Oral",
      "Subcutaneous"
   ],
   "answer": "Intranasal",
   "explanation": "Esketamine (the S-enantiomer of ketamine) is delivered intranasally under supervision for treatment-resistant depression. :contentReference[oaicite:52]{index=52}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00628",
   "question": "Mirtazapine enhances monoaminergic transmission by antagonizing which receptor?",
   "options": [
      "Central presynaptic α₂",
      "Serotonin transporter",
      "Dopamine D₃",
      "NMDA"
   ],
   "answer": "Central presynaptic α₂",
   "explanation": "Mirtazapine blocks central presynaptic α₂-adrenergic receptors, increasing NE and 5-HT release. :contentReference[oaicite:53]{index=53}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00629",
   "question": "Vortioxetine’s multimodal mechanism includes serotonin reuptake inhibition and antagonism of which receptor subtype?",
   "options": [
      "5-HT1A",
      "5-HT2A",
      "5-HT3",
      "5-HT4"
   ],
   "answer": "5-HT3",
   "explanation": "Vortioxetine combines serotonin reuptake inhibition with 5-HT1A agonism and 5-HT3 (and 5-HT7) antagonism. :contentReference[oaicite:54]{index=54}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00630",
   "question": "Tricyclic antidepressants inhibit the reuptake of which two neurotransmitters?",
   "options": [
      "Serotonin and dopamine",
      "Serotonin and norepinephrine",
      "Norepinephrine and GABA",
      "Dopamine and acetylcholine"
   ],
   "answer": "Serotonin and norepinephrine",
   "explanation": "TCAs block both serotonin and norepinephrine transporters, increasing synaptic levels of these monoamines. :contentReference[oaicite:55]{index=55}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00631",
   "question": "The anticholinergic adverse effects of TCAs are primarily due to blockade of which receptors?",
   "options": [
      "Histamine H₁",
      "Muscarinic",
      "α₁-Adrenergic",
      "Dopamine D₂"
   ],
   "answer": "Muscarinic",
   "explanation": "TCAs’ blockade of muscarinic acetylcholine receptors leads to dry mouth, blurred vision, urinary retention, and constipation. :contentReference[oaicite:56]{index=56}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00632",
   "question": "Which drug is considered the prototype of the tricyclic antidepressant class?",
   "options": [
      "Amitriptyline",
      "Imipramine",
      "Nortriptyline",
      "Doxepin"
   ],
   "answer": "Imipramine",
   "explanation": "Imipramine is the prototypical TCA, from which other tricyclic agents were developed. :contentReference[oaicite:57]{index=57}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00633",
   "question": "Monoamine oxidase inhibitors are generally reserved as last-line therapy because of what concern?",
   "options": [
      "High cost",
      "Multiple drug–food and drug–drug interactions",
      "Low efficacy",
      "Rapid tolerance"
   ],
   "answer": "Multiple drug–food and drug–drug interactions",
   "explanation": "MAOIs carry serious interactions with tyramine-rich foods and many medications, limiting their use. :contentReference[oaicite:58]{index=58}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00634",
   "question": "Which mood stabilizer does not require hepatic metabolism and may be preferred in hepatic impairment?",
   "options": [
      "Lithium",
      "Valproate",
      "Carbamazepine",
      "Lamotrigine"
   ],
   "answer": "Lithium",
   "explanation": "Lithium is eliminated renally and does not undergo hepatic metabolism, making it safer in liver disease. :contentReference[oaicite:59]{index=59}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00635",
   "question": "Which clinical sign is a hallmark of lithium toxicity?",
   "options": [
      "Hyperreflexia",
      "Ataxia and coarse tremors",
      "Bradycardia",
      "Hyperthermia"
   ],
   "answer": "Ataxia and coarse tremors",
   "explanation": "High lithium levels produce neurological toxicity manifesting as ataxia, slurred speech, coarse tremors, and confusion. :contentReference[oaicite:60]{index=60}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00636",
   "question": "Lithium requires careful monitoring of which organ system due to its elimination pathway?",
   "options": [
      "Hepatic",
      "Renal",
      "Pulmonary",
      "Endocrine"
   ],
   "answer": "Renal",
   "explanation": "Because lithium is renally eliminated, dosing must be adjusted and renal function monitored to avoid toxicity. :contentReference[oaicite:61]{index=61}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00637",
   "question": "Which of the following is NOT used as a mood stabilizer for bipolar disorder?",
   "options": [
      "Carbamazepine",
      "Divalproex sodium",
      "Lamotrigine",
      "Phenytoin"
   ],
   "answer": "Phenytoin",
   "explanation": "Carbamazepine, divalproex (valproic acid), and lamotrigine are approved for bipolar mood stabilization; phenytoin is not. :contentReference[oaicite:62]{index=62}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00638",
   "question": "Which atypical antipsychotic is approved as an adjunct to antidepressants for treatment-resistant depression?",
   "options": [
      "Risperidone",
      "Quetiapine",
      "Aripiprazole",
      "Haloperidol"
   ],
   "answer": "Aripiprazole",
   "explanation": "Aripiprazole (along with brexpiprazole and quetiapine) is FDA-approved as adjunctive therapy in treatment-resistant major depressive disorder. :contentReference[oaicite:63]{index=63}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00639",
   "question": "The combination of olanzapine and fluoxetine is approved for which indication?",
   "options": [
      "Bipolar depression",
      "Obsessive–compulsive disorder",
      "Postpartum depression",
      "Generalized anxiety disorder"
   ],
   "answer": "Bipolar depression",
   "explanation": "Olanzapine/fluoxetine combination is indicated for bipolar depression and treatment-resistant depression. :contentReference[oaicite:64]{index=64}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00640",
   "question": "The biogenic amine theory of depression proposes a deficiency of which biogenic amines?",
   "options": [
      "Acetylcholine and GABA",
      "Dopamine only",
      "Norepinephrine and serotonin",
      "Glutamate and glycine"
   ],
   "answer": "Norepinephrine and serotonin",
   "explanation": "The biogenic amine hypothesis states that depression stems from reduced levels of monoamines, primarily norepinephrine and serotonin, in the brain. :contentReference[oaicite:65]{index=65}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00641",
   "question": "The therapeutic effects of most antidepressants typically take how long to manifest?",
   "options": [
      "A few hours",
      "1–2 days",
      "Several weeks to months",
      "Over a year"
   ],
   "answer": "Several weeks to months",
   "explanation": "Although pharmacodynamic actions occur quickly, clinical improvement usually appears after at least 2–4 weeks, with full benefit in up to 12 weeks. :contentReference[oaicite:66]{index=66}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00642",
   "question": "Which antidepressant is least likely to cause sexual dysfunction?",
   "options": [
      "Sertraline",
      "Paroxetine",
      "Bupropion",
      "Citalopram"
   ],
   "answer": "Bupropion",
   "explanation": "Bupropion has a very low incidence of sexual side effects compared to SSRIs and SNRIs. :contentReference[oaicite:67]{index=67}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00643",
   "question": "Which TCA’s strong histamine-blocking activity contributes to its sedative effect?",
   "options": [
      "Imipramine",
      "Nortriptyline",
      "Maprotiline",
      "Doxepin"
   ],
   "answer": "Doxepin",
   "explanation": "Doxepin’s potent H₁ antagonism makes it highly sedating and useful at low doses for insomnia. :contentReference[oaicite:68]{index=68}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00644",
   "question": "The risk of serotonin syndrome is particularly increased when an SSRI is combined with what class of drugs?",
   "options": [
      "MAOIs",
      "TCAs",
      "Antipsychotics",
      "Mood stabilizers"
   ],
   "answer": "MAOIs",
   "explanation": "Co-administration of SSRIs with MAOIs dramatically raises synaptic serotonin levels, risking serotonin syndrome. :contentReference[oaicite:69]{index=69}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00645",
   "question": "Which antidepressant has been associated with priapism?",
   "options": [
      "Sertraline",
      "Bupropion",
      "Trazodone",
      "Vilazodone"
   ],
   "answer": "Trazodone",
   "explanation": "Trazodone carries a rare risk of priapism due to its α₁ antagonism. :contentReference[oaicite:70]{index=70}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00646",
   "question": "Which drug is specifically approved for postpartum depression?",
   "options": [
      "Esketamine",
      "Brexanolone",
      "Sertraline",
      "Venlafaxine"
   ],
   "answer": "Brexanolone",
   "explanation": "Brexanolone, a GABAA modulator, is the only FDA-approved therapy for postpartum depression. :contentReference[oaicite:71]{index=71}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00647",
   "question": "Nefazodone is limited in use primarily because of what serious adverse effect?",
   "options": [
      "Cardiotoxicity",
      "Hepatotoxicity",
      "Nephrotoxicity",
      "QT prolongation"
   ],
   "answer": "Hepatotoxicity",
   "explanation": "Nefazodone carries a risk of severe liver injury, which restricts its clinical use. :contentReference[oaicite:72]{index=72}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00648",
   "question": "Vilazodone is unique among SSRIs because it also has what additional action?",
   "options": [
      "Dopamine reuptake inhibition",
      "5-HT1A receptor partial agonism",
      "Monoamine oxidase inhibition",
      "NMDA receptor antagonism"
   ],
   "answer": "5-HT1A receptor partial agonism",
   "explanation": "Vilazodone combines serotonin reuptake inhibition with partial agonism at 5-HT1A receptors. :contentReference[oaicite:73]{index=73}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00649",
   "question": "Which SNRI is a moderate inhibitor of CYP2D6 and may increase concentrations of co-administered CYP2D6 substrates?",
   "options": [
      "Venlafaxine",
      "Desvenlafaxine",
      "Duloxetine",
      "Levomilnacipran"
   ],
   "answer": "Duloxetine",
   "explanation": "Duloxetine moderately inhibits CYP2D6, potentially elevating levels of drugs metabolized by this enzyme. :contentReference[oaicite:74]{index=74}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00650",
   "question": "Duloxetine is indicated for major depression and which other condition?",
   "options": [
      "Migraine prophylaxis",
      "Diabetic peripheral neuropathy",
      "Epilepsy",
      "Osteoporosis"
   ],
   "answer": "Diabetic peripheral neuropathy",
   "explanation": "With dual inhibition of 5-HT and NE reuptake, duloxetine is FDA-approved for depression and diabetic peripheral neuropathy. :contentReference[oaicite:75]{index=75}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00651",
   "question": "SSRIs have minimal blockade of which receptor type, contributing to their tolerability?",
   "options": [
      "Muscarinic",
      "Dopaminergic",
      "NMDA",
      "Nicotinic"
   ],
   "answer": "Muscarinic",
   "explanation": "SSRIs lack significant muscarinic receptor blockade, reducing anticholinergic side effects seen with TCAs. :contentReference[oaicite:76]{index=76}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00652",
   "question": "Lithium therapy may decrease the function of which gland, requiring monitoring?",
   "options": [
      "Adrenal",
      "Thyroid",
      "Pituitary",
      "Pancreas"
   ],
   "answer": "Thyroid",
   "explanation": "Long-term lithium use can cause hypothyroidism; thyroid function tests should be regularly monitored. :contentReference[oaicite:77]{index=77}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00653",
   "question": "Divalproex sodium is a prodrug that becomes which active drug after ingestion?",
   "options": [
      "Valproic acid",
      "Carbamazepine",
      "Lamotrigine",
      "Lithium"
   ],
   "answer": "Valproic acid",
   "explanation": "Divalproex is converted to valproic acid in the gut, serving as a mood stabilizer in bipolar disorder. :contentReference[oaicite:78]{index=78}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00654",
   "question": "Which antidepressant is NOT approved for treatment of major depression in adolescents?",
   "options": [
      "Fluoxetine",
      "Escitalopram",
      "Sertraline",
      "Vilazodone"
   ],
   "answer": "Vilazodone",
   "explanation": "Fluoxetine and escitalopram (and some TCAs) are approved for use in adolescents; vilazodone is not. :contentReference[oaicite:79]{index=79}"
},
 {
   "chapter_id": 17,
   "chapter": "Antidepressants",
   "question_id": "00017-00655",
   "question": "Which adjunctive intranasal therapy is approved for treatment-resistant depression?",
   "options": [
      "Brexanolone",
      "Esketamine",
      "Aripiprazole",
      "Risperidone"
   ],
   "answer": "Esketamine",
   "explanation": "Esketamine nasal spray is approved as an adjunct to oral antidepressants for treatment-resistant depression. :contentReference[oaicite:80]{index=80}"
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00656",
   "question": "Antipsychotic drugs are used primarily to treat which of the following conditions?",
   "options": [
      "Major depressive disorder",
      "Schizophrenia",
      "Generalized anxiety disorder",
      "Bipolar depression"
   ],
   "answer": "Schizophrenia",
   "explanation": "Antipsychotic drugs are used primarily to treat schizophrenia by decreasing the intensity of hallucinations and delusions and permitting patients to function in a supportive environment :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00657",
   "question": "The antipsychotic effects of first-generation antipsychotics (FGAs) reflect competitive blockade of which receptor?",
   "options": [
      "Dopamine D1",
      "Dopamine D2",
      "Serotonin 5-HT1A",
      "GABA_A"
   ],
   "answer": "Dopamine D2",
   "explanation": "First-generation antipsychotics exert their antipsychotic effects primarily through competitive blockade of dopamine D2 receptors :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00658",
   "question": "Which of the following is considered a high-potency first-generation antipsychotic?",
   "options": [
      "Chlorpromazine",
      "Thioridazine",
      "Haloperidol",
      "Clozapine"
   ],
   "answer": "Haloperidol",
   "explanation": "Haloperidol binds tightly to D2 receptors and is classified as a high-potency FGA, whereas chlorpromazine and thioridazine are low-potency agents :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00659",
   "question": "Which first-generation antipsychotic is classified as low potency?",
   "options": [
      "Haloperidol",
      "Chlorpromazine",
      "Fluphenazine",
      "Perphenazine"
   ],
   "answer": "Chlorpromazine",
   "explanation": "Chlorpromazine has lower affinity for D2 receptors compared to high-potency agents and is therefore classified as a low-potency FGA :contentReference[oaicite:42]{index=42}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00660",
   "question": "Second-generation antipsychotics (SGAs) are distinguished by blockade of which receptors?",
   "options": [
      "Dopamine D1 only",
      "Dopamine D2 only",
      "Serotonin 5-HT2 and dopamine D2",
      "GABA_B and NMDA"
   ],
   "answer": "Serotonin 5-HT2 and dopamine D2",
   "explanation": "SGAs owe their unique activity to blockade of both serotonin 5-HT2 and dopamine D2 receptors, reducing EPS risk but increasing metabolic effects :contentReference[oaicite:43]{index=43}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00661",
   "question": "Which of the following antipsychotics is a D2 partial agonist and 5-HT1A agonist?",
   "options": [
      "Cariprazine",
      "Clozapine",
      "Perphenazine",
      "Risperidone"
   ],
   "answer": "Cariprazine",
   "explanation": "Cariprazine, along with aripiprazole and brexpiprazole, is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors :contentReference[oaicite:44]{index=44}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00662",
   "question": "Pimavanserin, indicated for Parkinson disease psychosis, exerts its effect by acting on which receptor?",
   "options": [
      "Dopamine D2",
      "Serotonin 5-HT2A as inverse agonist",
      "GABA_A",
      "Histamine H1"
   ],
   "answer": "Serotonin 5-HT2A as inverse agonist",
   "explanation": "Pimavanserin is an inverse agonist and antagonist at 5-HT2A (and 5-HT2C) receptors with no appreciable affinity for dopamine receptors :contentReference[oaicite:45]{index=45}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00663",
   "question": "Which statement best characterizes the effect of FGAs on schizophrenia symptoms?",
   "options": [
      "They improve negative but not positive symptoms",
      "They improve positive but not negative symptoms",
      "They improve both positive and negative equally",
      "They worsen both symptom types"
   ],
   "answer": "They improve positive but not negative symptoms",
   "explanation": "FGAs primarily alleviate positive symptoms (hallucinations, delusions) but have limited efficacy on negative symptoms such as avolition and blunted affect :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00664",
   "question": "Hyperactivity of which dopaminergic tract is believed to underlie the positive symptoms of schizophrenia?",
   "options": [
      "Mesocortical",
      "Mesolimbic",
      "Nigrostriatal",
      "Tuberoinfundibular"
   ],
   "answer": "Mesolimbic",
   "explanation": "Positive symptoms are related to hyperdopaminergic dysfunction of the mesolimbic tract :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00665",
   "question": "Hypodopaminergic dysfunction in which tract may contribute to the negative symptoms of schizophrenia?",
   "options": [
      "Mesolimbic",
      "Mesocortical",
      "Nigrostriatal",
      "Tuberoinfundibular"
   ],
   "answer": "Mesocortical",
   "explanation": "Negative symptoms and cognitive dysfunction may be related to hypodopaminergic activity in the mesocortical tract :contentReference[oaicite:48]{index=48}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00666",
   "question": "Blockade of dopamine receptors in which tract leads to extrapyramidal symptoms?",
   "options": [
      "Mesolimbic",
      "Mesocortical",
      "Nigrostriatal",
      "Tuberoinfundibular"
   ],
   "answer": "Nigrostriatal",
   "explanation": "Dopamine blockade in the nigrostriatal tract disrupts the balance between dopaminergic and cholinergic influence, causing EPS :contentReference[oaicite:49]{index=49}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00667",
   "question": "Blockade in which dopaminergic pathway leads to increased prolactin release?",
   "options": [
      "Mesolimbic",
      "Mesocortical",
      "Nigrostriatal",
      "Tuberoinfundibular"
   ],
   "answer": "Tuberoinfundibular",
   "explanation": "Dopamine blockade in the tuberoinfundibular pathway causes disinhibition of prolactin release, leading to hyperprolactinemia :contentReference[oaicite:50]{index=50}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00668",
   "question": "The antiemetic effects of certain antipsychotics are mediated by blockade of D2 receptors in which region?",
   "options": [
      "Mesolimbic system",
      "Chemoreceptor trigger zone",
      "Nigrostriatal pathway",
      "Mesocortical system"
   ],
   "answer": "Chemoreceptor trigger zone",
   "explanation": "Antiemetic effects are mediated by blocking D2 receptors in the chemoreceptor trigger zone of the medulla :contentReference[oaicite:51]{index=51}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00669",
   "question": "Which antipsychotic has long been used to treat intractable hiccups?",
   "options": [
      "Haloperidol",
      "Chlorpromazine",
      "Risperidone",
      "Olanzapine"
   ],
   "answer": "Chlorpromazine",
   "explanation": "Chlorpromazine has been used for intractable hiccups, though baclofen and gabapentin are now preferred :contentReference[oaicite:52]{index=52}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00670",
   "question": "Which second-generation antipsychotic is approved for bipolar depression?",
   "options": [
      "Risperidone",
      "Haloperidol",
      "Lurasidone",
      "Thioridazine"
   ],
   "answer": "Lurasidone",
   "explanation": "Lurasidone, along with cariprazine and quetiapine, is indicated for treatment of bipolar depression :contentReference[oaicite:53]{index=53}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00671",
   "question": "Which antipsychotic is approved for irritability associated with autism spectrum disorder?",
   "options": [
      "Pimozide",
      "Lumateperone",
      "Olanzapine",
      "Aripiprazole"
   ],
   "answer": "Aripiprazole",
   "explanation": "Aripiprazole (and risperidone) is approved for managing irritability and disruptive behavior in autism spectrum disorder :contentReference[oaicite:54]{index=54}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00672",
   "question": "Which long-acting injectable antipsychotic is approved for maintenance of bipolar disorder?",
   "options": [
      "Quetiapine",
      "Risperidone",
      "Chlorpromazine",
      "Lurasidone"
   ],
   "answer": "Risperidone",
   "explanation": "Risperidone is available as extended-release microspheres in an LAI formulation for maintenance and relapse reduction in bipolar disorder :contentReference[oaicite:55]{index=55}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00673",
   "question": "Which antipsychotic carries a boxed warning for severe agranulocytosis requiring regular WBC monitoring?",
   "options": [
      "Risperidone",
      "Olanzapine",
      "Lithium",
      "Clozapine"
   ],
   "answer": "Clozapine",
   "explanation": "Clozapine has the highest risk of agranulocytosis (~1% incidence) and is only available through a special prescribing program :contentReference[oaicite:56]{index=56}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00674",
   "question": "Tardive dyskinesia, an involuntary movement disorder, may be managed with which agent?",
   "options": [
      "Propranolol",
      "Valbenazine",
      "Haloperidol",
      "Benztropine"
   ],
   "answer": "Valbenazine",
   "explanation": "Valbenazine is a vesicular monoamine transporter inhibitor indicated for tardive dyskinesia by depleting dopamine stores :contentReference[oaicite:57]{index=57}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00675",
   "question": "Neuroleptic malignant syndrome is treated acutely with discontinuation of the antipsychotic and administration of:",
   "options": [
      "Dantrolene",
      "Benztropine",
      "Propranolol",
      "Serotonin"
   ],
   "answer": "Dantrolene",
   "explanation": "Treatment of NMS includes discontinuation of the antipsychotic and supportive care, with dantrolene or bromocriptine being helpful :contentReference[oaicite:58]{index=58}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00676",
   "question": "Which drug is used to treat acute dystonic reactions secondary to antipsychotics?",
   "options": [
      "Benztropine",
      "Bromocriptine",
      "Prochlorperazine",
      "Risperidone"
   ],
   "answer": "Benztropine",
   "explanation": "Acute dystonias are treated with anticholinergic agents such as benztropine to restore cholinergic–dopaminergic balance in the striatum :contentReference[oaicite:59]{index=59}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00677",
   "question": "Which intervention is more effective for antipsychotic-induced akathisia?",
   "options": [
      "Benztropine",
      "Propranolol",
      "Bromocriptine",
      "Lorazepam"
   ],
   "answer": "Propranolol",
   "explanation": "Akathisia often responds better to β-blockers (e.g., propranolol) or benzodiazepines, rather than anticholinergics :contentReference[oaicite:60]{index=60}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00678",
   "question": "Tardive dyskinesia typically appears after how long of antipsychotic therapy?",
   "options": [
      "Hours",
      "Days",
      "Weeks",
      "Months to years"
   ],
   "answer": "Months to years",
   "explanation": "Tardive dyskinesia arises after months or years of treatment and may be irreversible, reflecting up-regulation of dopamine receptors :contentReference[oaicite:61]{index=61}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00679",
   "question": "Sedation from antipsychotics is most closely associated with blockade of which receptor?",
   "options": [
      "D2 dopamine",
      "H1 histamine",
      "5-HT2A serotonin",
      "α₁-adrenergic"
   ],
   "answer": "H1 histamine",
   "explanation": "Potent H1-histamine receptor antagonism (e.g., chlorpromazine, quetiapine) causes sedation during initial weeks of treatment :contentReference[oaicite:62]{index=62}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00680",
   "question": "Orthostatic hypotension with antipsychotics is primarily due to blockade of:",
   "options": [
      "D2 receptors",
      "α₁-adrenergic receptors",
      "Muscarinic receptors",
      "Serotonin receptors"
   ],
   "answer": "α₁-adrenergic receptors",
   "explanation": "Blockade of α₁-adrenergic receptors (e.g., chlorpromazine, clozapine) leads to orthostatic hypotension and light-headedness :contentReference[oaicite:63]{index=63}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00681",
   "question": "Which antipsychotic uniquely increases salivation despite anticholinergic effects?",
   "options": [
      "Chlorpromazine",
      "Clozapine",
      "Olanzapine",
      "Haloperidol"
   ],
   "answer": "Clozapine",
   "explanation": "Clozapine paradoxically increases salivation, whereas other antipsychotics produce dry mouth via muscarinic blockade :contentReference[oaicite:64]{index=64}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00682",
   "question": "Significant weight gain with SGAs often necessitates monitoring of:",
   "options": [
      "Renal function",
      "Liver enzymes",
      "Glucose and lipid profiles",
      "Thyroid function"
   ],
   "answer": "Glucose and lipid profiles",
   "explanation": "SGAs may increase glucose and lipid parameters, exacerbating diabetes or hyperlipidemia, so monitoring is required :contentReference[oaicite:65]{index=65}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00683",
   "question": "Which antipsychotic has the highest risk of QT prolongation?",
   "options": [
      "Risperidone",
      "Ziprasidone",
      "Thioridazine",
      "Clozapine"
   ],
   "answer": "Thioridazine",
   "explanation": "Thioridazine carries the highest QT prolongation risk among antipsychotics, with ziprasidone and iloperidone also posing cautions :contentReference[oaicite:66]{index=66}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00684",
   "question": "Which antipsychotic is least likely to prolong the QT interval?",
   "options": [
      "Thioridazine",
      "Ziprasidone",
      "Iloperidone",
      "Risperidone"
   ],
   "answer": "Risperidone",
   "explanation": "While thioridazine, ziprasidone, and iloperidone have notable QT risks, risperidone’s risk is relatively low :contentReference[oaicite:67]{index=67}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00685",
   "question": "Use of antipsychotics in elderly patients with dementia-related psychosis carries a boxed warning for:",
   "options": [
      "Increased risk of mortality",
      "Seizure threshold elevation",
      "Weight loss",
      "Hypoglycemia"
   ],
   "answer": "Increased risk of mortality",
   "explanation": "Antipsychotics carry a warning for increased mortality risk in elderly patients with dementia-related behavioral disturbances :contentReference[oaicite:68]{index=68}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00686",
   "question": "A combination of olanzapine with samidorphan was developed to mitigate which adverse effect?",
   "options": [
      "Orthostatic hypotension",
      "Weight gain",
      "Extrapyramidal symptoms",
      "Agranulocytosis"
   ],
   "answer": "Weight gain",
   "explanation": "Olanzapine–samidorphan was developed to lessen olanzapine-associated weight gain but is contraindicated in patients receiving opioids :contentReference[oaicite:69]{index=69}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00687",
   "question": "After two or more psychotic episodes, maintenance antipsychotic therapy is recommended for at least:",
   "options": [
      "6 months",
      "1 year",
      "5 years",
      "Lifetime only"
   ],
   "answer": "5 years",
   "explanation": "Patients with ≥2 psychotic episodes should receive maintenance therapy for at least 5 years; some experts recommend indefinite treatment :contentReference[oaicite:70]{index=70}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00688",
   "question": "Compared to oral agents, long-acting injectable formulations may result in:",
   "options": [
      "Higher relapse rates",
      "Lower relapse rates",
      "More weight gain",
      "Increased QT prolongation"
   ],
   "answer": "Lower relapse rates",
   "explanation": "LAIs are associated with lower relapse rates in schizophrenia maintenance compared to oral agents :contentReference[oaicite:71]{index=71}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00689",
   "question": "Which class of antipsychotics is generally preferred as first-line therapy to minimize EPS?",
   "options": [
      "First-generation antipsychotics",
      "Second-generation antipsychotics",
      "Tricyclic antidepressants",
      "Lithium salts"
   ],
   "answer": "Second-generation antipsychotics",
   "explanation": "SGAs are used as first-line therapy to minimize debilitating EPS associated with FGAs :contentReference[oaicite:72]{index=72}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00690",
   "question": "Which antipsychotic is reserved for refractory schizophrenia due to risk of agranulocytosis and seizures?",
   "options": [
      "Risperidone",
      "Olanzapine",
      "Clozapine",
      "Haloperidol"
   ],
   "answer": "Clozapine",
   "explanation": "Clozapine is effective in refractory patients but limited by risk of severe agranulocytosis, seizures, and orthostatic hypotension :contentReference[oaicite:73]{index=73}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00691",
   "question": "Which newer SGA demonstrates very low incidence of EPS due to higher potency at blocking serotonin than dopamine?",
   "options": [
      "Lumateperone",
      "Haloperidol",
      "Chlorpromazine",
      "Fluphenazine"
   ],
   "answer": "Lumateperone",
   "explanation": "Lumateperone has a low EPS risk likely because it blocks serotonin receptors more potently than dopamine receptors :contentReference[oaicite:74]{index=74}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00692",
   "question": "Which second-generation antipsychotic binds relatively weakly to D2 and has low EPS risk due to short receptor residence time?",
   "options": [
      "Risperidone",
      "Quetiapine",
      "Clozapine",
      "Pimavanserin"
   ],
   "answer": "Quetiapine",
   "explanation": "Quetiapine’s low EPS risk may relate to its relatively weak and transient binding to D2 receptors :contentReference[oaicite:75]{index=75}."
},
 {
   "chapter_id": 18,
   "chapter": "Antipsychotic Drugs",
   "question_id": "00018-00693",
   "question": "Which antipsychotic is most strongly associated with hyperprolactinemia?",
   "options": [
      "Clozapine",
      "Quetiapine",
      "Aripiprazole",
      "Risperidone"
   ],
   "answer": "Risperidone",
   "explanation": "Risperidone blocks D2 receptors in the tuberoinfundibular pathway, increasing prolactin release and causing galactorrhea, amenorrhea, and gynecomastia :contentReference[oaicite:76]{index=76}."
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00694",
   "question": "Which of the following is NOT an objective of sedation in anesthesia?",
   "options": [
      "Sedation and reduced anxiety",
      "Lack of awareness and amnesia",
      "Skeletal muscle relaxation",
      "Insulin release"
   ],
   "answer": "Insulin release",
   "explanation": "Sedation objectives include anxiety reduction, amnesia, muscle relaxation, reflex suppression, and analgesia—but not insulin release. :contentReference[oaicite:41]{index=41}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00695",
   "question": "Regarding levels of sedation, which indicates having some response to stimuli, but respirations may be inadequate?",
   "options": [
      "Anxiolysis",
      "General anesthesia",
      "Moderate sedation",
      "Deep sedation"
   ],
   "answer": "Deep sedation",
   "explanation": "Deep sedation is characterized by some response to stimuli but potentially inadequate respirations. :contentReference[oaicite:42]{index=42}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00696",
   "question": "Which level of sedation maintains mentation with adequate airway and respiratory competency?",
   "options": [
      "Anxiolysis",
      "General anesthesia",
      "Moderate sedation",
      "Deep sedation"
   ],
   "answer": "Moderate sedation",
   "explanation": "Moderate sedation maintains conscious mentation and preserves airway and breathing. :contentReference[oaicite:43]{index=43}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00697",
   "question": "Which state is defined by a total loss of perception and sensation to stimuli?",
   "options": [
      "Anxiolysis",
      "General anesthesia",
      "Moderate sedation",
      "Deep sedation"
   ],
   "answer": "General anesthesia",
   "explanation": "General anesthesia causes complete loss of perception and response to stimuli. :contentReference[oaicite:44]{index=44}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00698",
   "question": "Which factor primarily determines the speed of recovery from an IV induction anesthetic?",
   "options": [
      "Liver metabolism of the drug",
      "Redistribution from the CNS",
      "Ionization of the drug",
      "Protein binding of the drug"
   ],
   "answer": "Redistribution from the CNS",
   "explanation": "Recovery speed is governed by redistribution of the drug out of the CNS, not by metabolism. :contentReference[oaicite:45]{index=45}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00699",
   "question": "Which of the following decreases the minimum alveolar concentration (MAC) of inhaled anesthetics?",
   "options": [
      "Hyperthermia",
      "Cocaine intoxication",
      "Chronic ethanol abuse",
      "Acute ethanol intoxication"
   ],
   "answer": "Acute ethanol intoxication",
   "explanation": "Acute ethanol intoxication lowers MAC, whereas other factors tend to increase it. :contentReference[oaicite:46]{index=46}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00700",
   "question": "The MAC of an inhaled anesthetic is defined as the end-tidal concentration needed to:",
   "options": [
      "Prevent awareness in 50% of patients",
      "Eliminate movement in 50% of patients",
      "Produce amnesia in 50% of patients",
      "Suppress coughing in 50% of patients"
   ],
   "answer": "Eliminate movement in 50% of patients",
   "explanation": "MAC is the concentration required to prevent movement in response to a noxious stimulus in 50% of subjects. :contentReference[oaicite:47]{index=47}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00701",
   "question": "Which characteristic describes modern inhalational anesthetics?",
   "options": [
      "Flammable and explosive",
      "Nonflammable and nonexplosive",
      "Only nitrous oxide is flammable",
      "All are halogen-free"
   ],
   "answer": "Nonflammable and nonexplosive",
   "explanation": "Modern inhaled agents (e.g., nitrous oxide, isoflurane, sevoflurane, desflurane) are nonflammable and nonexplosive. :contentReference[oaicite:48]{index=48}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00702",
   "question": "Except for nitrous oxide, inhaled anesthetics are which type of compounds?",
   "options": [
      "Volatile hydrocarbons",
      "Ketone derivatives",
      "Ether derivatives",
      "Alcohols"
   ],
   "answer": "Volatile hydrocarbons",
   "explanation": "Except for N₂O, modern inhalational anesthetics are volatile, halogenated hydrocarbons. :contentReference[oaicite:49]{index=49}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00703",
   "question": "Malignant hyperthermia can be treated acutely with which agent?",
   "options": [
      "Dantrolene",
      "Bromocriptine",
      "Benztropine",
      "Cholinesterase inhibitors"
   ],
   "answer": "Dantrolene",
   "explanation": "Dantrolene is the specific treatment for malignant hyperthermia by reducing calcium release in muscle. :contentReference[oaicite:50]{index=50}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00704",
   "question": "Which IV anesthetic decreases intracranial pressure by reducing cerebral blood flow?",
   "options": [
      "Thiopental",
      "Propofol",
      "Ketamine",
      "Etomidate"
   ],
   "answer": "Thiopental",
   "explanation": "Thiopental lowers intracranial pressure via reduction of cerebral blood flow and oxygen consumption. :contentReference[oaicite:51]{index=51}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00705",
   "question": "Which ultra–short-acting barbiturate is no longer available in many countries including the U.S.?",
   "options": [
      "Thiopental",
      "Methohexital",
      "Phenobarbital",
      "Pentobarbital"
   ],
   "answer": "Thiopental",
   "explanation": "Thiopental has been withdrawn in many countries despite its rapid onset due to redistribution. :contentReference[oaicite:52]{index=52}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00706",
   "question": "Which barbiturate is preferred for electroconvulsive therapy because it lowers the seizure threshold?",
   "options": [
      "Methohexital",
      "Thiopental",
      "Phenobarbital",
      "Pentobarbital"
   ],
   "answer": "Methohexital",
   "explanation": "Methohexital uniquely lowers seizure threshold, making it ideal for ECT. :contentReference[oaicite:53]{index=53}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00707",
   "question": "Which benzodiazepine is most commonly used intraoperatively for sedation and amnesia?",
   "options": [
      "Midazolam",
      "Diazepam",
      "Lorazepam",
      "Alprazolam"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam is the preferred benzodiazepine for procedural sedation due to rapid onset and amnestic effects. :contentReference[oaicite:54]{index=54}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00708",
   "question": "For inhalational induction in a child without IV access, the best choice is:",
   "options": [
      "Isoflurane",
      "Desflurane",
      "Sevoflurane",
      "Propofol"
   ],
   "answer": "Sevoflurane",
   "explanation": "Sevoflurane’s low pungency and minimal airway irritation make it ideal for pediatric mask inductions. :contentReference[oaicite:55]{index=55}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00709",
   "question": "Which inhaled agent is preferred in pediatrics because of low respiratory irritation?",
   "options": [
      "Isoflurane",
      "Sevoflurane",
      "Desflurane",
      "Nitrous oxide"
   ],
   "answer": "Sevoflurane",
   "explanation": "Sevoflurane’s low pungency reduces airway irritation compared to isoflurane or desflurane. :contentReference[oaicite:56]{index=56}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00710",
   "question": "Which agent should be avoided in patients susceptible to malignant hyperthermia?",
   "options": [
      "Isoflurane",
      "Propofol",
      "Midazolam",
      "Fentanyl"
   ],
   "answer": "Isoflurane",
   "explanation": "All halogenated hydrocarbons, including isoflurane, trigger malignant hyperthermia and must be avoided. :contentReference[oaicite:57]{index=57}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00711",
   "question": "Which local anesthetic’s metabolite can cause methemoglobinemia?",
   "options": [
      "Prilocaine",
      "Lidocaine",
      "Bupivacaine",
      "Chloroprocaine"
   ],
   "answer": "Prilocaine",
   "explanation": "Prilocaine is metabolized in plasma and kidney to an oxidizing agent that can induce methemoglobinemia. :contentReference[oaicite:58]{index=58}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00712",
   "question": "Local anesthetics generally cause vasodilation except for which one?",
   "options": [
      "Lidocaine",
      "Bupivacaine",
      "Cocaine",
      "Ropivacaine"
   ],
   "answer": "Cocaine",
   "explanation": "Cocaine uniquely causes vasoconstriction, whereas other local anesthetics dilate blood vessels. :contentReference[oaicite:59]{index=59}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00713",
   "question": "Structurally, local anesthetics consist of a lipophilic group, an intermediate linkage, and a:",
   "options": [
      "Hydrophilic group",
      "Steroid nucleus",
      "Peptide chain",
      "Carboxylic acid"
   ],
   "answer": "Hydrophilic group",
   "explanation": "They have a lipophilic moiety joined via an ester or amide linkage to a hydrophilic amine. :contentReference[oaicite:60]{index=60}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00714",
   "question": "Which agent reverses rocuronium- or vecuronium-induced neuromuscular blockade?",
   "options": [
      "Neostigmine",
      "Edrophonium",
      "Sugammadex",
      "Pyridostigmine"
   ],
   "answer": "Sugammadex",
   "explanation": "Sugammadex encapsulates steroidal neuromuscular blockers, rapidly reversing blockade. :contentReference[oaicite:61]{index=61}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00715",
   "question": "Sugammadex terminates neuromuscular blockade by:",
   "options": [
      "Inhibiting acetylcholinesterase",
      "Trapping blocker molecules in a complex",
      "Blocking nicotinic receptors",
      "Increasing acetylcholine release"
   ],
   "answer": "Trapping blocker molecules in a complex",
   "explanation": "Its cyclodextrin structure forms a 1:1 complex with rocuronium or vecuronium, making them inactive. :contentReference[oaicite:62]{index=62}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00716",
   "question": "Which adjunct is a glucocorticoid used to prevent postoperative nausea and vomiting?",
   "options": [
      "Ondansetron",
      "Metoclopramide",
      "Dexamethasone",
      "Scopolamine"
   ],
   "answer": "Dexamethasone",
   "explanation": "Dexamethasone given at induction reduces PONV, although its mechanism is unclear. :contentReference[oaicite:63]{index=63}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00717",
   "question": "Which preoperative adjunct is used as a prokinetic to reduce aspiration risk?",
   "options": [
      "Famotidine",
      "Omeprazole",
      "Metoclopramide",
      "Scopolamine"
   ],
   "answer": "Metoclopramide",
   "explanation": "Metoclopramide enhances gastric emptying and increases LES tone, lowering aspiration risk. :contentReference[oaicite:64]{index=64}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00718",
   "question": "To reduce gastric acidity preoperatively, which agent is commonly used?",
   "options": [
      "Famotidine",
      "Ondansetron",
      "Dexmedetomidine",
      "Diphenhydramine"
   ],
   "answer": "Famotidine",
   "explanation": "H2-blockers like famotidine decrease gastric acid and are used in patients at aspiration risk. :contentReference[oaicite:65]{index=65}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00719",
   "question": "Which α₂-agonist is used for sedation without significant respiratory depression?",
   "options": [
      "Clonidine",
      "Dexmedetomidine",
      "Midazolam",
      "Diazepam"
   ],
   "answer": "Dexmedetomidine",
   "explanation": "Dexmedetomidine provides sedation, analgesia, and sympatholysis with minimal respiratory compromise. :contentReference[oaicite:66]{index=66}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00720",
   "question": "Extended etomidate infusions should be avoided because they inhibit:",
   "options": [
      "11-β hydroxylase, lowering cortisol/aldosterone",
      "GABA transaminase",
      "Acetylcholinesterase",
      "NMDA receptors"
   ],
   "answer": "11-β hydroxylase, lowering cortisol/aldosterone",
   "explanation": "Prolonged etomidate suppresses adrenal steroid synthesis via 11-β hydroxylase inhibition. :contentReference[oaicite:67]{index=67}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00721",
   "question": "Which benzodiazepine’s duration is prolonged by CYP3A4 inhibitors?",
   "options": [
      "Midazolam",
      "Diazepam",
      "Lorazepam",
      "Clonazepam"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam is metabolized by CYP3A4, so inhibitors of this enzyme extend its effect. :contentReference[oaicite:68]{index=68}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00722",
   "question": "Which IV anesthetic is an NMDA receptor antagonist that provides both anesthesia and analgesia?",
   "options": [
      "Propofol",
      "Methohexital",
      "Ketamine",
      "Etomidate"
   ],
   "answer": "Ketamine",
   "explanation": "Ketamine blocks NMDA receptors, yielding potent analgesic and anesthetic effects. :contentReference[oaicite:69]{index=69}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00723",
   "question": "Which adjunct enhances GABAergic inhibition to produce anterograde amnesia?",
   "options": [
      "Midazolam",
      "Clonidine",
      "Diphenhydramine",
      "Dexmedetomidine"
   ],
   "answer": "Midazolam",
   "explanation": "Midazolam’s GABAergic potentiation causes anterograde amnesia, preventing new memory formation. :contentReference[oaicite:70]{index=70}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00724",
   "question": "For maintenance of general anesthesia after IV induction, which route is used?",
   "options": [
      "Intravenous infusion",
      "Inhaled gases",
      "Oral agents",
      "Rectal suppositories"
   ],
   "answer": "Inhaled gases",
   "explanation": "Inhalational agents are predominantly used to maintain anesthesia following IV induction. :contentReference[oaicite:71]{index=71}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00725",
   "question": "General anesthesia can be divided into which three stages?",
   "options": [
      "Induction, maintenance, emergence",
      "Analgesia, excitement, paralysis",
      "Preoperative, intraoperative, postoperative",
      "Sedation, analgesia, recovery"
   ],
   "answer": "Induction, maintenance, emergence",
   "explanation": "The stages of general anesthesia are induction (onset), maintenance (sustained), and emergence (recovery). :contentReference[oaicite:72]{index=72}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00726",
   "question": "Which factor does NOT influence onset of local anesthetics?",
   "options": [
      "Tissue pH",
      "Nerve fiber diameter",
      "Drug pKa",
      "Patient age"
   ],
   "answer": "Patient age",
   "explanation": "Onset depends on pH, fiber morphology, concentration, pKa, and lipid solubility—not patient age. :contentReference[oaicite:73]{index=73}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00727",
   "question": "Treatment for local anesthetic systemic toxicity (LAST) includes:",
   "options": [
      "Calcium gluconate",
      "Lipid emulsion infusion",
      "Flumazenil",
      "Naloxone"
   ],
   "answer": "Lipid emulsion infusion",
   "explanation": "Lipid ‘rescue’ therapy is key for LAST to sequester lipophilic anesthetic agents. :contentReference[oaicite:74]{index=74}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00728",
   "question": "Which class of local anesthetics is metabolized by plasma cholinesterase?",
   "options": [
      "Esters",
      "Amides",
      "Ketones",
      "Alcohols"
   ],
   "answer": "Esters",
   "explanation": "Ester-linked local anesthetics are hydrolyzed by plasma cholinesterase; amides are hepatic. :contentReference[oaicite:75]{index=75}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00729",
   "question": "Active infection at the injection site can delay onset of local anesthesia due to:",
   "options": [
      "Lower tissue pH",
      "Increased lipid solubility",
      "Higher temperature",
      "Increased protein binding"
   ],
   "answer": "Lower tissue pH",
   "explanation": "Acidosis at infected sites reduces unionized drug fraction, slowing membrane penetration. :contentReference[oaicite:76]{index=76}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00730",
   "question": "Which IV agent has minimal effect on CNS-evoked potentials, making it useful for neuromonitoring?",
   "options": [
      "Propofol",
      "Isoflurane",
      "Sevoflurane",
      "Ketamine"
   ],
   "answer": "Propofol",
   "explanation": "Propofol preserves evoked potentials better than volatile agents, ideal for spinal cord monitoring. :contentReference[oaicite:77]{index=77}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00731",
   "question": "Which of the following is a modern inhalational anesthetic agent?",
   "options": [
      "Nitrous oxide",
      "Propofol",
      "Midazolam",
      "Ketamine"
   ],
   "answer": "Nitrous oxide",
   "explanation": "Nitrous oxide is a nonflammable, nonexplosive inhalational anesthetic used for maintenance. :contentReference[oaicite:78]{index=78}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00732",
   "question": "Which adjunct for anxiety is an H₁-receptor antagonist?",
   "options": [
      "Diphenhydramine",
      "Midazolam",
      "Clonidine",
      "Ondansetron"
   ],
   "answer": "Diphenhydramine",
   "explanation": "Diphenhydramine’s H₁ antagonism provides sedation and anxiolysis as an anesthetic adjunct. :contentReference[oaicite:79]{index=79}"
},
 {
   "chapter_id": 20,
   "chapter": "Anesthetics",
   "question_id": "00020-00733",
   "question": "Which nonparticulate antacid is used preoperatively to raise gastric pH and reduce aspiration risk?",
   "options": [
      "Sodium citrate",
      "Famotidine",
      "Metoclopramide",
      "Ondansetron"
   ],
   "answer": "Sodium citrate",
   "explanation": "Nonparticulate antacids like sodium citrate rapidly increase stomach pH before surgery. :contentReference[oaicite:80]{index=80}"
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00734",
   "question": "Which receptor primarily mediates the analgesic properties of opioids?",
   "options": [
      "μ receptor",
      "κ receptor",
      "δ receptor",
      "NOP receptor"
   ],
   "answer": "μ receptor",
   "explanation": "The analgesic effects of opioids are primarily mediated by μ receptors, which modulate nociceptive signaling in the CNS; κ and δ also contribute to analgesia to a lesser extent :contentReference[oaicite:36]{index=36}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00735",
   "question": "Which organization defines pain as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage”?",
   "options": [
      "World Health Organization",
      "International Association for the Study of Pain",
      "American Pain Society",
      "National Institutes of Health"
   ],
   "answer": "International Association for the Study of Pain",
   "explanation": "The IASP’s definition emphasizes both sensory and emotional aspects of pain, guiding clinical assessment and management :contentReference[oaicite:37]{index=37}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00736",
   "question": "Natural opioids, such as morphine and codeine, are classified based on:",
   "options": [
      "Being fully synthetic",
      "Derivation from opium poppy",
      "Lack of active metabolites",
      "Synthetic modification"
   ],
   "answer": "Derivation from opium poppy",
   "explanation": "Natural opioids are directly derived from opium (Papaver somniferum) and include morphine and codeine :contentReference[oaicite:38]{index=38}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00737",
   "question": "The nociceptin receptor, also known as ORL1, differs from classical opioid receptors because it:",
   "options": [
      "Binds enkephalins selectively",
      "Does not bind classical opioids",
      "Activates adenylyl cyclase",
      "Is a ligand-gated ion channel"
   ],
   "answer": "Does not bind classical opioids",
   "explanation": "NOP/ORL1 is activated by nociceptin and buprenorphine but does not bind endogenous endorphins or morphine-like ligands :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00738",
   "question": "Opioid receptor activation leads to which ion channel effect?",
   "options": [
      "Increased postsynaptic Na⁺ influx",
      "Increased postsynaptic K⁺ efflux",
      "Increased presynaptic Cl⁻ influx",
      "Decreased presynaptic K⁺ efflux"
   ],
   "answer": "Increased postsynaptic K⁺ efflux",
   "explanation": "Opioid GPCRs open K⁺ channels causing hyperpolarization and reduce Ca²⁺ influx presynaptically, inhibiting neurotransmitter release :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00739",
   "question": "Morphine is metabolized to two glucuronide metabolites. Which one is a potent analgesic?",
   "options": [
      "Morphine-3-glucuronide",
      "Morphine-6-glucuronide",
      "Normeperidine",
      "Codeine"
   ],
   "answer": "Morphine-6-glucuronide",
   "explanation": "M6G is an active metabolite with potent analgesic activity, whereas M3G lacks analgesic properties :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00740",
   "question": "Which biased μ-opioid agonist preferentially activates G protein pathways over β-arrestin recruitment?",
   "options": [
      "Morphine",
      "Methadone",
      "Buprenorphine",
      "Oliceridine"
   ],
   "answer": "Oliceridine",
   "explanation": "Oliceridine is G protein–biased, reducing β-arrestin–mediated respiratory and GI effects compared to morphine :contentReference[oaicite:42]{index=42}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00741",
   "question": "Codeine’s analgesic effect depends on its conversion to morphine by which enzyme?",
   "options": [
      "CYP2C9",
      "CYP2D6",
      "CYP3A4",
      "UGT2B7"
   ],
   "answer": "CYP2D6",
   "explanation": "Codeine is a prodrug whose analgesia derives from CYP2D6-mediated O-demethylation to morphine :contentReference[oaicite:43]{index=43}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00742",
   "question": "Buprenorphine is preferred in patients at high risk of respiratory depression because it is a:",
   "options": [
      "Full μ agonist",
      "κ receptor agonist",
      "Partial μ agonist",
      "NMDA antagonist"
   ],
   "answer": "Partial μ agonist",
   "explanation": "As a partial μ agonist, buprenorphine provides analgesia with a ceiling on respiratory depression :contentReference[oaicite:44]{index=44}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00743",
   "question": "Methadone’s prolonged half-life (up to 150 hours) is due to its:",
   "options": [
      "High renal clearance",
      "Lipophilicity and slow redistribution",
      "Rapid hepatic metabolism",
      "Extensive protein binding"
   ],
   "answer": "Lipophilicity and slow redistribution",
   "explanation": "Methadone’s lipophilicity allows wide distribution and slow release, resulting in a prolonged half-life :contentReference[oaicite:45]{index=45}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00744",
   "question": "Which opioid is preferred in patients with renal dysfunction due to minimal active metabolite accumulation?",
   "options": [
      "Morphine",
      "Hydromorphone",
      "Codeine",
      "Meperidine"
   ],
   "answer": "Hydromorphone",
   "explanation": "Hydromorphone has fewer active metabolites and is safer than morphine in renal impairment :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00745",
   "question": "Which cough suppressant has minimal analgesic activity and low abuse potential at antitussive doses?",
   "options": [
      "Morphine",
      "Dextromethorphan",
      "Fentanyl",
      "Meperidine"
   ],
   "answer": "Dextromethorphan",
   "explanation": "Dextromethorphan suppresses cough via NMDA antagonism without significant analgesia or abuse risk :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00746",
   "question": "Tapentadol should be avoided in patients on MAO inhibitors because of the risk of:",
   "options": [
      "QT prolongation",
      "Serotonin syndrome",
      "Renal toxicity",
      "Hypotension"
   ],
   "answer": "Serotonin syndrome",
   "explanation": "Tapentadol’s norepinephrine/serotonin reuptake inhibition can precipitate serotonin syndrome with MAOIs :contentReference[oaicite:48]{index=48}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00747",
   "question": "Which peripherally acting μ-opioid antagonist is indicated for laxative-refractory opioid-induced constipation?",
   "options": [
      "Naloxone",
      "Methylnaltrexone",
      "Diphenoxylate",
      "Lactulose"
   ],
   "answer": "Methylnaltrexone",
   "explanation": "Methylnaltrexone selectively blocks peripheral μ receptors to relieve opioid-induced constipation without affecting analgesia :contentReference[oaicite:49]{index=49}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00748",
   "question": "Buprenorphine overdose is only partially reversed by naloxone because buprenorphine:",
   "options": [
      "Is lipophilic",
      "Has low μ affinity",
      "Is a full agonist",
      "Has high μ receptor affinity"
   ],
   "answer": "Has high μ receptor affinity",
   "explanation": "Buprenorphine binds μ receptors tightly, requiring higher or continuous naloxone doses for reversal :contentReference[oaicite:50]{index=50}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00749",
   "question": "Compared to naltrexone, naloxone is characterized by a:",
   "options": [
      "Longer half-life",
      "Shorter half-life",
      "Once-daily oral dose",
      "Monthly injection"
   ],
   "answer": "Shorter half-life",
   "explanation": "Naloxone’s half-life is 30–90 minutes, much shorter than naltrexone’s oral 24-hour or IM 30-day duration :contentReference[oaicite:51]{index=51}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00750",
   "question": "Morphine-induced pinpoint pupils result from stimulation of which receptors?",
   "options": [
      "μ and κ receptors",
      "δ receptors only",
      "NOP receptor",
      "γ receptors"
   ],
   "answer": "μ and κ receptors",
   "explanation": "Miosis from morphine is mediated by μ and κ receptor activation, with little tolerance to this effect :contentReference[oaicite:52]{index=52}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00751",
   "question": "Urticaria, hypotension, and bronchoconstriction caused by morphine are due to:",
   "options": [
      "Dopamine release",
      "Histamine release",
      "Serotonin blockade",
      "Bradykinin activation"
   ],
   "answer": "Histamine release",
   "explanation": "Morphine triggers mast cell histamine release, leading to vasodilation, urticaria, and bronchospasm :contentReference[oaicite:53]{index=53}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00752",
   "question": "Fentanyl is preferred in anesthesia because it:",
   "options": [
      "Is the least potent opioid",
      "Causes minimal respiratory depression",
      "Onset and offset faster than morphine",
      "Is administered orally"
   ],
   "answer": "Onset and offset faster than morphine",
   "explanation": "Fentanyl and its congeners induce analgesia more rapidly and redistribute faster than morphine :contentReference[oaicite:54]{index=54}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00753",
   "question": "Which endogenous peptides selectively interact with δ opioid receptors in the periphery?",
   "options": [
      "Endorphins",
      "Enkephalins",
      "Dynorphins",
      "Nociceptin"
   ],
   "answer": "Enkephalins",
   "explanation": "Enkephalins have higher affinity for δ receptors, modulating peripheral nociception :contentReference[oaicite:55]{index=55}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00754",
   "question": "Which agent is available in an intranasal autoinjector for community distribution to reverse opioid overdose?",
   "options": [
      "Naltrexone",
      "Naloxone",
      "Methylnaltrexone",
      "Naloxegol"
   ],
   "answer": "Naloxone",
   "explanation": "Naloxone’s intranasal and autoinjector formulations enable community use to promptly reverse overdose :contentReference[oaicite:56]{index=56}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00755",
   "question": "Tramadol’s unique adverse effect profile includes a higher risk of seizures when reversed with:",
   "options": [
      "Naloxone",
      "Naltrexone",
      "Methylnaltrexone",
      "Naloxegol"
   ],
   "answer": "Naloxone",
   "explanation": "Naloxone reversal of tramadol toxicity can precipitate seizures due to increased serotonin and monoamine levels :contentReference[oaicite:57]{index=57}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00756",
   "question": "What is the most common cause of death in acute opioid overdose?",
   "options": [
      "Cardiac arrest",
      "Seizures",
      "Respiratory depression",
      "Liver failure"
   ],
   "answer": "Respiratory depression",
   "explanation": "Opioids depress medullary respiratory centers, and respiratory failure is the leading cause of fatality :contentReference[oaicite:58]{index=58}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00757",
   "question": "Meperidine differs from morphine in that its active metabolite is not fully reversible by naloxone because meperidine is a:",
   "options": [
      "Phenanthrene",
      "Phenylpiperidine",
      "Aniline",
      "Carboxylic acid"
   ],
   "answer": "Phenylpiperidine",
   "explanation": "Meperidine is a phenylpiperidine whose metabolite normeperidine is not reversed by naloxone :contentReference[oaicite:59]{index=59}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00758",
   "question": "Which oral opioid antagonist is approved for management of both opioid and alcohol use disorders?",
   "options": [
      "Naloxone",
      "Naltrexone",
      "Methylnaltrexone",
      "Naloxegol"
   ],
   "answer": "Naltrexone",
   "explanation": "Naltrexone’s longer duration and oral formulation make it suitable for OUD and AUD treatment :contentReference[oaicite:60]{index=60}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00759",
   "question": "Opioid-induced androgen deficiency is caused by suppression of which axis?",
   "options": [
      "Hypothalamic–pituitary–thyroid",
      "Hypothalamic–pituitary–adrenal",
      "Hypothalamic–pituitary–gonadal",
      "Renin–angiotensin"
   ],
   "answer": "Hypothalamic–pituitary–gonadal",
   "explanation": "Chronic morphine use suppresses the HPG axis, reducing sex hormone production and causing OPIAD :contentReference[oaicite:61]{index=61}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00760",
   "question": "Which opioid can prolong the second stage of labor by decreasing uterine contraction frequency and strength?",
   "options": [
      "Morphine",
      "Fentanyl",
      "Meperidine",
      "Buprenorphine"
   ],
   "answer": "Morphine",
   "explanation": "Morphine transiently reduces uterine contractility, prolonging labor’s second stage :contentReference[oaicite:62]{index=62}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00761",
   "question": "Which statement about morphine’s CNS penetration is correct?",
   "options": [
      "It is the most lipophilic opioid",
      "It rapidly crosses the BBB",
      "It has the least lipophilicity among common opioids",
      "It is not affected by first-pass metabolism"
   ],
   "answer": "It has the least lipophilicity among common opioids",
   "explanation": "Morphine is less lipophilic than fentanyl or methadone, limiting BBB penetration :contentReference[oaicite:63]{index=63}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00762",
   "question": "Which opioid undergoes extensive first-pass glucuronidation, making subcutaneous or IV routes more reliable?",
   "options": [
      "Morphine",
      "Codeine",
      "Tapentadol",
      "Buprenorphine"
   ],
   "answer": "Morphine",
   "explanation": "Oral morphine has erratic absorption and high first-pass metabolism; parenteral routes yield consistent plasma levels :contentReference[oaicite:64]{index=64}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00763",
   "question": "Which opioid agonist is effective for both nociceptive and neuropathic pain but has complex kinetics and interactions?",
   "options": [
      "Morphine",
      "Methadone",
      "Codeine",
      "Oxycodone"
   ],
   "answer": "Methadone",
   "explanation": "Methadone’s mixed mechanisms and long, variable half-life require cautious dosing for diverse pain types :contentReference[oaicite:65]{index=65}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00764",
   "question": "Abrupt administration of opioid antagonists in a dependent patient precipitates withdrawal by:",
   "options": [
      "Partial receptor activation",
      "Competitive displacement of agonist",
      "Enhanced β-arrestin signaling",
      "Histamine release"
   ],
   "answer": "Competitive displacement of agonist",
   "explanation": "Antagonists bind with high affinity and displace agonists, abruptly terminating receptor activation and causing withdrawal :contentReference[oaicite:66]{index=66}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00765",
   "question": "Which adverse effect of opioids shows minimal tolerance development?",
   "options": [
      "Analgesia",
      "Euphoria",
      "Constipation",
      "Respiratory depression"
   ],
   "answer": "Constipation",
   "explanation": "Tolerance develops to analgesic and respiratory effects but not to constipation or miosis :contentReference[oaicite:67]{index=67}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00766",
   "question": "Which drug interaction carries a boxed warning when co-prescribed with opioids?",
   "options": [
      "Statins",
      "Benzodiazepines",
      "Antibiotics",
      "NSAIDs"
   ],
   "answer": "Benzodiazepines",
   "explanation": "Concurrent use of opioids and benzodiazepines increases risk of respiratory depression and has a boxed warning :contentReference[oaicite:68]{index=68}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00767",
   "question": "Ketamine’s analgesic properties are mediated through antagonism of which receptor?",
   "options": [
      "μ receptor",
      "κ receptor",
      "NMDA receptor",
      "GABA_A receptor"
   ],
   "answer": "NMDA receptor",
   "explanation": "Ketamine blocks NMDA receptors, producing dissociative anesthesia and analgesia while stimulating sympathetic outflow :contentReference[oaicite:69]{index=69}."
},
 {
   "chapter_id": 21,
   "chapter": "Opioids",
   "question_id": "00021-00768",
   "question": "Which opioid antagonist requires monitoring of hepatic function due to potential liver enzyme elevations?",
   "options": [
      "Naloxone",
      "Naltrexone",
      "Methylnaltrexone",
      "Naloxegol"
   ],
   "answer": "Naltrexone",
   "explanation": "Naltrexone can elevate liver enzymes, so hepatic monitoring is recommended during therapy :contentReference[oaicite:70]{index=70}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00769",
   "question": "CNS stimulants are indicated for all of the following EXCEPT:",
   "options": [
      "Attention-deficit/hyperactivity disorder",
      "Narcolepsy",
      "Obesity",
      "Schizophrenia"
   ],
   "answer": "Schizophrenia",
   "explanation": "CNS stimulants are effective treatments for ADHD, narcolepsy, obesity, and binge eating disorder—but not schizophrenia :contentReference[oaicite:38]{index=38}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00770",
   "question": "The principal mechanism of action common to most CNS stimulants is:",
   "options": [
      "Enhancement of GABA release",
      "Blockade of NMDA receptors",
      "Inhibition of presynaptic dopamine or norepinephrine reuptake",
      "Agonism at serotonin 5-HT2A receptors"
   ],
   "answer": "Inhibition of presynaptic dopamine or norepinephrine reuptake",
   "explanation": "Most CNS stimulants act by inhibiting presynaptic dopamine or norepinephrine reuptake, increasing catecholamine levels in synaptic clefts :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00771",
   "question": "Which of the following statements about CNS stimulants is TRUE?",
   "options": [
      "They have a low potential for abuse",
      "They are metabolized exclusively by the kidneys",
      "They carry a high risk for abuse and dependence",
      "They are first-line in treatment of anxiety disorders"
   ],
   "answer": "They carry a high risk for abuse and dependence",
   "explanation": "CNS stimulants have a high risk for abuse and dependence; many commonly abused drugs (nicotine, caffeine, cocaine) are CNS stimulants :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00772",
   "question": "Before initiating prescription CNS stimulants, patients should be evaluated for:",
   "options": [
      "Diabetes mellitus",
      "Hypertension and heart disease",
      "Hypothyroidism",
      "Renal insufficiency"
   ],
   "answer": "Hypertension and heart disease",
   "explanation": "Prescription CNS stimulants can worsen hypertension and heart disease, so patients require medical evaluation prior to therapy :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00773",
   "question": "Recent ADHD treatments have focused on which of the following innovations?",
   "options": [
      "Intravenous bolus dosing",
      "Extended-release and transdermal formulations",
      "Sublingual tablets",
      "Rectal suppositories"
   ],
   "answer": "Extended-release and transdermal formulations",
   "explanation": "New ADHD treatments emphasize innovative delivery such as extended-release oral agents and transdermal patches :contentReference[oaicite:42]{index=42}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00774",
   "question": "First-line stimulant agents for ADHD include all EXCEPT:",
   "options": [
      "Amphetamine",
      "Dextroamphetamine",
      "Methylphenidate",
      "Lithium"
   ],
   "answer": "Lithium",
   "explanation": "First-line stimulants for ADHD are amphetamine, dextroamphetamine, methylphenidate, and dexmethylphenidate—not lithium :contentReference[oaicite:43]{index=43}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00775",
   "question": "First-line pharmacotherapy for narcolepsy consists of:",
   "options": [
      "Amphetamines",
      "Methylphenidate",
      "Modafinil or armodafinil",
      "Bupropion"
   ],
   "answer": "Modafinil or armodafinil",
   "explanation": "Modafinil and armodafinil are considered first-line therapy for narcolepsy, with amphetamines reserved for severe cases :contentReference[oaicite:44]{index=44}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00776",
   "question": "Which of the following methylxanthines is found in tea?",
   "options": [
      "Caffeine",
      "Theophylline",
      "Theobromine",
      "Pentoxifylline"
   ],
   "answer": "Theophylline",
   "explanation": "Theophylline, a methylxanthine, is found naturally in tea leaves :contentReference[oaicite:45]{index=45}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00777",
   "question": "Which methylxanthine is present in cocoa products?",
   "options": [
      "Caffeine",
      "Theophylline",
      "Theobromine",
      "Pentoxifylline"
   ],
   "answer": "Theobromine",
   "explanation": "Theobromine, another methylxanthine, is found in cocoa and chocolate :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00778",
   "question": "The most widely consumed methylxanthine stimulant worldwide is:",
   "options": [
      "Caffeine",
      "Theophylline",
      "Theobromine",
      "Pentoxifylline"
   ],
   "answer": "Caffeine",
   "explanation": "Caffeine is the most widely consumed stimulant, present in coffee, tea, cola drinks, and chocolate :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00779",
   "question": "Amphetamines exert their CNS stimulant effects primarily by:",
   "options": [
      "Activating GABA_A receptors",
      "Releasing intracellular catecholamines and inhibiting reuptake",
      "Blocking NMDA receptors",
      "Stimulating adenosine receptors"
   ],
   "answer": "Releasing intracellular catecholamines and inhibiting reuptake",
   "explanation": "Amphetamines release stored catecholamines and inhibit their reuptake, increasing synaptic levels :contentReference[oaicite:48]{index=48}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00780",
   "question": "In addition to releasing catecholamines, amphetamines also:",
   "options": [
      "Activate monoamine oxidase",
      "Inhibit monoamine oxidase",
      "Potentiate GABA reuptake",
      "Block histamine receptors"
   ],
   "answer": "Inhibit monoamine oxidase",
   "explanation": "Amphetamines weakly inhibit monoamine oxidase, further elevating catecholamine levels :contentReference[oaicite:49]{index=49}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00781",
   "question": "Common CNS adverse effects of amphetamines include all EXCEPT:",
   "options": [
      "Insomnia",
      "Irritability",
      "Dizziness",
      "Bradycardia"
   ],
   "answer": "Bradycardia",
   "explanation": "Amphetamines cause insomnia, irritability, dizziness, tremor, and hyperreflexia—but not bradycardia :contentReference[oaicite:50]{index=50}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00782",
   "question": "Long-term amphetamine use may lead to:",
   "options": [
      "Psychological dependence and amphetamine psychosis",
      "Permanent insomnia without tolerance",
      "Decreased tolerance to effects",
      "Neurodegenerative disease"
   ],
   "answer": "Psychological dependence and amphetamine psychosis",
   "explanation": "Chronic amphetamine use produces psychological dependence and can induce an amphetamine psychosis resembling schizophrenia :contentReference[oaicite:51]{index=51}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00783",
   "question": "Cardiovascular effects of amphetamines include:",
   "options": [
      "Bradycardia and hypotension",
      "Palpitations, arrhythmias, and hypertension",
      "Vasodilation and flushing",
      "Decreased cardiac output"
   ],
   "answer": "Palpitations, arrhythmias, and hypertension",
   "explanation": "Amphetamines may cause palpitations, cardiac arrhythmias, hypertension, anginal pain, and circulatory collapse :contentReference[oaicite:52]{index=52}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00784",
   "question": "Amphetamines are contraindicated in patients with all EXCEPT:",
   "options": [
      "Hypertension",
      "Hyperthyroidism",
      "Glaucoma",
      "Depression"
   ],
   "answer": "Depression",
   "explanation": "Contraindications include hypertension, cardiovascular disease, hyperthyroidism, glaucoma, and MAO inhibitor use—but not depression :contentReference[oaicite:53]{index=53}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00785",
   "question": "Methylphenidate’s principal mechanism involves:",
   "options": [
      "Enhancing GABA release",
      "Blocking dopamine and norepinephrine transporters",
      "Inhibiting acetylcholinesterase",
      "Antagonizing serotonin receptors"
   ],
   "answer": "Blocking dopamine and norepinephrine transporters",
   "explanation": "Methylphenidate inhibits dopamine and norepinephrine reuptake, increasing synaptic catecholamines :contentReference[oaicite:54]{index=54}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00786",
   "question": "Which methylphenidate derivative is a prodrug converted to dexmethylphenidate?",
   "options": [
      "Lisdexamfetamine",
      "Serdexmethylphenidate",
      "Methamphetamine",
      "Atomoxetine"
   ],
   "answer": "Serdexmethylphenidate",
   "explanation": "Serdexmethylphenidate is a prodrug that converts to dexmethylphenidate after ingestion :contentReference[oaicite:55]{index=55}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00787",
   "question": "Which formulation of methylphenidate allows once-daily administration via the skin?",
   "options": [
      "Extended-release oral tablet",
      "Immediate-release capsule",
      "Transdermal patch",
      "Intravenous solution"
   ],
   "answer": "Transdermal patch",
   "explanation": "Methylphenidate is available as a transdermal patch for once-daily delivery, as well as extended-release oral forms :contentReference[oaicite:56]{index=56}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00788",
   "question": "A notable adverse effect of methylphenidate is:",
   "options": [
      "Weight gain",
      "Hypotension",
      "Gastrointestinal upset and insomnia",
      "Bradycardia"
   ],
   "answer": "Gastrointestinal upset and insomnia",
   "explanation": "Methylphenidate commonly causes abdominal pain, nausea, anorexia, insomnia, nervousness, and may increase seizure frequency :contentReference[oaicite:57]{index=57}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00789",
   "question": "Modafinil’s mechanism of action likely involves:",
   "options": [
      "Selective GABA_A agonism",
      "Adrenergic and dopaminergic pathways",
      "Opioid receptor antagonism",
      "Serotonin reuptake inhibition"
   ],
   "answer": "Adrenergic and dopaminergic pathways",
   "explanation": "Modafinil’s exact mechanism is unclear but may involve modulation of adrenergic and dopaminergic systems :contentReference[oaicite:58]{index=58}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00790",
   "question": "Which adverse effects are common with modafinil/armodafinil?",
   "options": [
      "Sedation and weight gain",
      "Headache, nausea, and nervousness",
      "Bradycardia and hypotension",
      "Dry mouth and urinary retention"
   ],
   "answer": "Headache, nausea, and nervousness",
   "explanation": "Modafinil and armodafinil can cause headache, nausea, and nervousness and have some abuse potential :contentReference[oaicite:59]{index=59}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00791",
   "question": "Nonstimulant drugs approved for narcolepsy or excessive daytime sleepiness include:",
   "options": [
      "Atomoxetine and clonidine",
      "Solriamfetol and pitolisant",
      "Amphetamine salts",
      "Methylphenidate"
   ],
   "answer": "Solriamfetol and pitolisant",
   "explanation": "Solriamfetol (DAT/NET inhibitor) and pitolisant (H₃ antagonist) are nonstimulant options for narcolepsy and sleepiness :contentReference[oaicite:60]{index=60}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00792",
   "question": "Which of the following is a sympathomimetic anorexiant used in obesity management?",
   "options": [
      "Orlistat",
      "Phentermine",
      "Semaglutide",
      "Liraglutide"
   ],
   "answer": "Phentermine",
   "explanation": "Phentermine is a sympathomimetic amine used as an appetite suppressant for obesity :contentReference[oaicite:61]{index=61}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00793",
   "question": "Phentermine’s anorectic effect is due to its structural similarity to:",
   "options": [
      "Cocaine",
      "Amphetamine",
      "Barbiturates",
      "Opioids"
   ],
   "answer": "Amphetamine",
   "explanation": "Phentermine is structurally related to amphetamine and exerts sympathomimetic appetite suppression :contentReference[oaicite:62]{index=62}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00794",
   "question": "Phentermine should be avoided in patients with:",
   "options": [
      "Controlled hypertension",
      "Uncontrolled hypertension",
      "Diabetes mellitus",
      "Asthma"
   ],
   "answer": "Uncontrolled hypertension",
   "explanation": "Use of phentermine is contraindicated in patients with uncontrolled hypertension due to risk of increased blood pressure and heart rate :contentReference[oaicite:63]{index=63}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00795",
   "question": "Which obesity pharmacotherapy acts by inhibiting gastrointestinal lipases?",
   "options": [
      "Phentermine",
      "Diethylpropion",
      "Orlistat",
      "Bupropion"
   ],
   "answer": "Orlistat",
   "explanation": "Orlistat inhibits pancreatic and gastric lipases, reducing dietary fat absorption and aiding weight loss :contentReference[oaicite:64]{index=64}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00796",
   "question": "A common gastrointestinal adverse effect of orlistat is:",
   "options": [
      "Constipation",
      "Oily spotting and fecal urgency",
      "Upper abdominal pain",
      "Acid reflux"
   ],
   "answer": "Oily spotting and fecal urgency",
   "explanation": "Orlistat often causes oily spotting, flatulence, and fecal urgency due to unabsorbed fats :contentReference[oaicite:65]{index=65}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00797",
   "question": "Liraglutide promotes weight loss by:",
   "options": [
      "Blocking cannabinoid receptors",
      "Agonism at GLP-1 receptors",
      "Inhibiting serotonin uptake",
      "Stimulating GABA release"
   ],
   "answer": "Agonism at GLP-1 receptors",
   "explanation": "Liraglutide is a GLP-1 receptor agonist that reduces hunger and caloric intake for chronic weight management :contentReference[oaicite:66]{index=66}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00798",
   "question": "Which GLP-1 agonist is administered once weekly for obesity?",
   "options": [
      "Liraglutide",
      "Semaglutide",
      "Exenatide",
      "Dulaglutide"
   ],
   "answer": "Semaglutide",
   "explanation": "Semaglutide has a once-weekly dosing schedule, whereas liraglutide is dosed daily :contentReference[oaicite:67]{index=67}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00799",
   "question": "The combination of phentermine and topiramate is used because:",
   "options": [
      "Phentermine reduces topiramate’s weight loss",
      "Topiramate counteracts phentermine’s stimulation",
      "Topiramate counters sedation from phentermine",
      "Phentermine enhances topiramate’s anticonvulsant effect"
   ],
   "answer": "Topiramate counteracts phentermine’s stimulation",
   "explanation": "Topiramate adds weight loss but is sedating, so phentermine is combined to offset sedation and enhance appetite suppression :contentReference[oaicite:68]{index=68}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00800",
   "question": "Abrupt discontinuation of phentermine/topiramate may precipitate:",
   "options": [
      "Seizures",
      "Hypertension",
      "Hyperglycemia",
      "Asthma exacerbation"
   ],
   "answer": "Seizures",
   "explanation": "Stopping phentermine/topiramate abruptly can precipitate seizures due to topiramate withdrawal :contentReference[oaicite:69]{index=69}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00801",
   "question": "Topiramate use in women of childbearing potential is limited by risk of:",
   "options": [
      "Neural tube defects",
      "Cleft palate",
      "Cardiac malformations",
      "Limb deformities"
   ],
   "answer": "Cleft palate",
   "explanation": "Topiramate is associated with birth defects such as cleft palate, so combinations containing it are contraindicated in pregnancy :contentReference[oaicite:70]{index=70}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00802",
   "question": "Bupropion/naltrexone aids weight loss by targeting:",
   "options": [
      "Pancreatic lipase",
      "Mesolimbic reward pathways",
      "GLP-1 receptors",
      "Melanocortin receptors"
   ],
   "answer": "Mesolimbic reward pathways",
   "explanation": "Bupropion/naltrexone combination works through the mesolimbic reward system to reduce appetite :contentReference[oaicite:71]{index=71}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00803",
   "question": "Bupropion/naltrexone is contraindicated in patients with:",
   "options": [
      "Controlled diabetes",
      "Uncontrolled hypertension",
      "Hypothyroidism",
      "Asthma"
   ],
   "answer": "Uncontrolled hypertension",
   "explanation": "The combination is contraindicated in uncontrolled hypertension due to risk of elevated blood pressure :contentReference[oaicite:72]{index=72}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00804",
   "question": "Lisdexamfetamine is approved for which eating disorder?",
   "options": [
      "Anorexia nervosa",
      "Bulimia nervosa",
      "Binge eating disorder",
      "Pica"
   ],
   "answer": "Binge eating disorder",
   "explanation": "Lisdexamfetamine is approved for the treatment of binge eating disorder :contentReference[oaicite:73]{index=73}."
},
 {
   "chapter_id": 22,
   "chapter": "CNS Stimulants",
   "question_id": "00022-00805",
   "question": "Which nonstimulant ADHD medication is a centrally acting α₂-adrenoceptor agonist?",
   "options": [
      "Atomoxetine",
      "Guanfacine",
      "Methylphenidate",
      "Dextroamphetamine"
   ],
   "answer": "Guanfacine",
   "explanation": "Guanfacine (and clonidine) is a centrally acting α₂-adrenoceptor agonist used for ADHD :contentReference[oaicite:74]{index=74}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00806",
   "question": "What is the primary mechanism of action of fluoroquinolones?",
   "options": [
      "They inhibit bacterial folate synthesis",
      "They bind DNA gyrase and topoisomerase IV, interfering with DNA ligation",
      "They block peptidoglycan cross-linking",
      "They disrupt bacterial cell membranes"
   ],
   "answer": "They bind DNA gyrase and topoisomerase IV, interfering with DNA ligation",
   "explanation": "Fluoroquinolones bind and inhibit bacterial type II topoisomerases—DNA gyrase in gram-negative organisms and topoisomerase IV in gram-positive organisms—interfering with DNA ligation and causing chromosomal breaks leading to cell death :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00807",
   "question": "Why do fluoroquinolones have different primary targets in gram-negative versus gram-positive bacteria?",
   "options": [
      "Gram-negative bacteria lack topoisomerase IV",
      "Modifications in the quinolone nucleus alter target preference",
      "DNA gyrase is the main target in gram-negative, while topoisomerase IV is preferred in gram-positive",
      "Efflux pumps determine the enzyme targeted"
   ],
   "answer": "DNA gyrase is the main target in gram-negative, while topoisomerase IV is preferred in gram-positive",
   "explanation": "Fluoroquinolones preferentially inhibit DNA gyrase in gram-negative bacteria and topoisomerase IV in gram-positive organisms, reflecting differences in enzyme vulnerability and leading to rapid cell death :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00808",
   "question": "Which describes the spectrum of first-generation quinolones such as nalidixic acid?",
   "options": [
      "Broad spectrum against gram-positive and atypicals",
      "Narrow spectrum against aerobic gram-negative bacilli",
      "Enhanced activity against Pseudomonas and anaerobes",
      "Activity against MRSA"
   ],
   "answer": "Narrow spectrum against aerobic gram-negative bacilli",
   "explanation": "First-generation compounds like nalidixic acid are narrow-spectrum agents active primarily against aerobic gram-negative bacilli such as Enterobacteriaceae :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00809",
   "question": "What additional coverage do second-generation fluoroquinolones (e.g., ciprofloxacin) provide compared to first-generation agents?",
   "options": [
      "Improved gram-positive anaerobic coverage",
      "Enhanced activity against Chlamydia, Legionella, H. influenzae, Pseudomonas aeruginosa",
      "Activity against Mycobacterium tuberculosis",
      "MRSA coverage"
   ],
   "answer": "Enhanced activity against Chlamydia, Legionella, H. influenzae, Pseudomonas aeruginosa",
   "explanation": "Second-generation fluoroquinolones like ciprofloxacin broaden coverage to include Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria spp., Chlamydia spp., and Legionella spp. with improved intracellular penetration :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00810",
   "question": "Which enhancement characterizes third-generation fluoroquinolones such as levofloxacin?",
   "options": [
      "Improved anaerobic coverage only",
      "Better activity against Streptococcus pneumoniae and Staphylococcus aureus",
      "Exclusive Pseudomonas coverage",
      "Addition of antiprotozoal effects"
   ],
   "answer": "Better activity against Streptococcus pneumoniae and Staphylococcus aureus",
   "explanation": "Third-generation agents like levofloxacin maintain second-generation coverage and add improved activity against Streptococcus spp., including S. pneumoniae, as well as methicillin-susceptible Staphylococcus aureus and some Mycobacterium spp. :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00811",
   "question": "What distinguishes fourth-generation fluoroquinolones (e.g., moxifloxacin, delafloxacin)?",
   "options": [
      "They have no gram-negative activity",
      "Enhanced gram-positive and anaerobic coverage, including MRSA by delafloxacin",
      "Only active against atypicals",
      "They are only available topically"
   ],
   "answer": "Enhanced gram-positive and anaerobic coverage, including MRSA by delafloxacin",
   "explanation": "Fourth-generation agents have improved gram-positive activity, anaerobic coverage (e.g., Bacteroides fragilis), and delafloxacin uniquely covers MRSA and Enterococcus faecalis while maintaining atypical coverage :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00812",
   "question": "Which fluoroquinolone uniquely retains activity against Pseudomonas aeruginosa among fourth-generation agents?",
   "options": [
      "Moxifloxacin",
      "Gemifloxacin",
      "Delafloxacin",
      "Levofloxacin"
   ],
   "answer": "Delafloxacin",
   "explanation": "Of the fourth-generation fluoroquinolones, only delafloxacin has reliable activity against Pseudomonas aeruginosa :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00813",
   "question": "A mutation in which bacterial genes primarily mediates high-level fluoroquinolone resistance?",
   "options": [
      "pbpA or pbpB",
      "gyrA or parC",
      "rpoB or katG",
      "mexA or mexB"
   ],
   "answer": "gyrA or parC",
   "explanation": "High-level resistance is driven by chromosomal mutations in genes encoding DNA gyrase (gyrA) or topoisomerase IV (parC), reducing drug binding efficiency :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00814",
   "question": "Which mechanism contributes to reduced intracellular fluoroquinolone concentration?",
   "options": [
      "Increased porin expression",
      "Efflux pump activity and decreased membrane permeability",
      "Enhanced drug binding to ribosomes",
      "Inhibition of DNA gyrase"
   ],
   "answer": "Efflux pump activity and decreased membrane permeability",
   "explanation": "Reduced intracellular levels occur via decreased membrane permeability (porin loss) and active efflux pumps that remove fluoroquinolones from the cell :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00815",
   "question": "An aminoglycoside acetyltransferase variant can confer resistance to fluoroquinolones by what mechanism?",
   "options": [
      "Target site mutation",
      "Enhanced efflux",
      "Direct enzymatic acetylation of the drug",
      "Reduced drug uptake"
   ],
   "answer": "Direct enzymatic acetylation of the drug",
   "explanation": "An aminoglycoside acetyltransferase variant can acetylate fluoroquinolones, inactivating them enzymatically :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00816",
   "question": "What factor most commonly reduces oral absorption of fluoroquinolones?",
   "options": [
      "High-fat meal",
      "Co-administration with divalent or trivalent cations (e.g., antacids, iron supplements)",
      "Renal impairment",
      "CYP3A4 inhibitors"
   ],
   "answer": "Co-administration with divalent or trivalent cations (e.g., antacids, iron supplements)",
   "explanation": "Fluoroquinolone absorption is reduced by sucralfate, aluminum- or magnesium-containing antacids, and iron or zinc supplements due to chelation with divalent/trivalent cations :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00817",
   "question": "Which best describes fluoroquinolone distribution?",
   "options": [
      "Limited to blood plasma",
      "Extensive, with high levels in bone, urine, lung, prostatic tissue, CSF, and phagocytes",
      "Only in extracellular fluid",
      "Restricted to tissues with pH < 7"
   ],
   "answer": "Extensive, with high levels in bone, urine, lung, prostatic tissue, CSF, and phagocytes",
   "explanation": "Fluoroquinolones distribute widely into tissues and fluids—bone, urine (except moxifloxacin), kidney, prostatic tissue, lungs, CSF—and accumulate in macrophages and neutrophils :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00818",
   "question": "Which adverse effects carry a boxed warning for fluoroquinolones?",
   "options": [
      "Hepatotoxicity only",
      "Tendinitis, tendon rupture, peripheral neuropathy, CNS effects, phototoxicity, QT prolongation",
      "Nephrotoxicity and ototoxicity",
      "Bone marrow suppression"
   ],
   "answer": "Tendinitis, tendon rupture, peripheral neuropathy, CNS effects, phototoxicity, QT prolongation",
   "explanation": "Fluoroquinolones carry boxed warnings for tendinitis and tendon rupture, peripheral neuropathy, CNS effects (hallucinations, seizures), phototoxicity, and QTc prolongation; arthropathy may occur in children :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00819",
   "question": "How does ciprofloxacin interact with other drugs?",
   "options": [
      "It induces CYP3A4",
      "It inhibits CYP1A2 and CYP3A4, increasing levels of drugs like warfarin and tizanidine",
      "It is a P-glycoprotein inducer",
      "It has no significant interactions"
   ],
   "answer": "It inhibits CYP1A2 and CYP3A4, increasing levels of drugs like warfarin and tizanidine",
   "explanation": "Ciprofloxacin inhibits CYP1A2 and CYP3A4, raising serum concentrations of substrates such as alprazolam, tizanidine, warfarin, and others :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00820",
   "question": "Which is a common clinical use of ciprofloxacin?",
   "options": [
      "First-line for MRSA skin infections",
      "Traveler’s diarrhea, typhoid fever, anthrax prophylaxis, Pseudomonas infections (high-dose)",
      "Prophylaxis of fungal infections",
      "Treatment of viral pneumonia"
   ],
   "answer": "Traveler’s diarrhea, typhoid fever, anthrax prophylaxis, Pseudomonas infections (high-dose)",
   "explanation": "Ciprofloxacin is used for traveler’s diarrhea, typhoid fever, anthrax, and as second-line therapy for intra-abdominal, lung, skin, or urinary infections; high-dose regimens treat Pseudomonas aeruginosa :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00821",
   "question": "Levofloxacin is often considered first-line therapy for which condition?",
   "options": [
      "Community-acquired pneumonia",
      "Uncomplicated cystitis",
      "MRSA bacteremia",
      "Toxoplasmosis"
   ],
   "answer": "Community-acquired pneumonia",
   "explanation": "Levofloxacin has enhanced Streptococcus pneumoniae coverage and is first-line for community-acquired pneumonia; it otherwise mirrors ciprofloxacin’s gram-negative activity :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00822",
   "question": "Moxifloxacin should be avoided in hospital-acquired pneumonia due to poor coverage of which organism?",
   "options": [
      "Streptococcus pneumoniae",
      "Pseudomonas aeruginosa",
      "Haemophilus influenzae",
      "Enterococcus faecalis"
   ],
   "answer": "Pseudomonas aeruginosa",
   "explanation": "Moxifloxacin lacks reliable Pseudomonas coverage, limiting its use in hospital-acquired and ventilator-associated pneumonia :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00823",
   "question": "For which indication is delafloxacin uniquely approved among fluoroquinolones?",
   "options": [
      "Skin and soft tissue infections including MRSA",
      "Acute bacterial sinusitis",
      "First-line TB therapy",
      "Prophylaxis of anthrax"
   ],
   "answer": "Skin and soft tissue infections including MRSA",
   "explanation": "Delafloxacin has improved gram-positive activity, including MRSA and Enterococcus spp., and is indicated for acute bacterial skin and skin structure infections with both IV and oral formulations :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00824",
   "question": "Sulfonamides inhibit which bacterial enzyme?",
   "options": [
      "Dihydropteroate synthetase",
      "Dihydrofolate reductase",
      "DNA gyrase",
      "Peptidoglycan transpeptidase"
   ],
   "answer": "Dihydropteroate synthetase",
   "explanation": "Sulfonamides are PABA analogs that competitively inhibit dihydropteroate synthetase, blocking dihydrofolic acid synthesis :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00825",
   "question": "What is the antibacterial spectrum of sulfonamides?",
   "options": [
      "Only gram-positive cocci",
      "Broad gram-negative and gram-positive activity including Enterobacteriaceae, H. influenzae, Streptococcus, Staphylococcus, Nocardia",
      "Only anaerobes",
      "Only atypical organisms"
   ],
   "answer": "Broad gram-negative and gram-positive activity including Enterobacteriaceae, H. influenzae, Streptococcus, Staphylococcus, Nocardia",
   "explanation": "Sulfonamides cover both gram-negative and gram-positive bacteria—Enterobacteriaceae, H. influenzae, Streptococcus spp., Staphylococcus spp., and Nocardia. Sulfadiazine plus pyrimethamine is used for toxoplasmosis :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00826",
   "question": "Acquired bacterial resistance to sulfonamides may involve:",
   "options": [
      "Efflux pumps only",
      "Altered dihydropteroate synthetase, decreased permeability, or enhanced PABA production",
      "Target site overexpression only",
      "Mutation in DNA gyrase"
   ],
   "answer": "Altered dihydropteroate synthetase, decreased permeability, or enhanced PABA production",
   "explanation": "Resistance arises via altered enzyme, reduced drug entry (porin changes), or increased PABA synthesis, rendering sulfa ineffective :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00827",
   "question": "Which describes sulfonamide pharmacokinetics?",
   "options": [
      "Poor oral absorption and biliary excretion",
      "Good oral absorption (except sulfasalazine), hepatic acetylation, renal excretion of unchanged drug and metabolites",
      "Extensive phase I metabolism only",
      "No renal adjustment needed"
   ],
   "answer": "Good oral absorption (except sulfasalazine), hepatic acetylation, renal excretion of unchanged drug and metabolites",
   "explanation": "Most sulfonamides are well absorbed except sulfasalazine, are acetylated and conjugated in the liver, and excreted unchanged via glomerular filtration and secretion :contentReference[oaicite:21]{index=21} and :contentReference[oaicite:22]{index=22}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00828",
   "question": "Which adverse reaction is characteristic of sulfonamides due to crystalluria?",
   "options": [
      "Hepatic necrosis",
      "Nephrotoxicity from stone formation",
      "Neurotoxicity",
      "Ototoxicity"
   ],
   "answer": "Nephrotoxicity from stone formation",
   "explanation": "Sulfonamide crystalluria can precipitate in renal tubules, causing nephrotoxicity and stone formation unless urine is well hydrated and alkalinized :contentReference[oaicite:23]{index=23}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00829",
   "question": "Sulfonamide hypersensitivity reactions may include:",
   "options": [
      "Stevens–Johnson syndrome and photosensitivity",
      "Tendon rupture and neuropathy",
      "Serotonin syndrome",
      "Nystagmus"
   ],
   "answer": "Stevens–Johnson syndrome and photosensitivity",
   "explanation": "Sulfonamides can cause hypersensitivity—rash, angioedema, Stevens–Johnson syndrome—and photosensitivity :contentReference[oaicite:24]{index=24}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00830",
   "question": "Trimethoprim inhibits which bacterial enzyme?",
   "options": [
      "Dihydropteroate synthetase",
      "DNA gyrase",
      "Dihydrofolate reductase",
      "Peptidyl transferase"
   ],
   "answer": "Dihydrofolate reductase",
   "explanation": "Trimethoprim potently inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolic acid formation and sparing human enzyme :contentReference[oaicite:25]{index=25}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00831",
   "question": "Compared to sulfonamides, trimethoprim is:",
   "options": [
      "Less potent and used only topically",
      "20–50 fold more potent, and may be used alone for UTIs and prostatitis",
      "Active against anaerobes only",
      "Primarily excreted hepatically"
   ],
   "answer": "20–50 fold more potent, and may be used alone for UTIs and prostatitis",
   "explanation": "Trimethoprim is 20–50 fold more potent than sulfonamides and can be used alone to treat UTIs and bacterial prostatitis :contentReference[oaicite:26]{index=26}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00832",
   "question": "Resistance to trimethoprim arises primarily through:",
   "options": [
      "Altered dihydrofolate reductase with lower drug affinity",
      "Enhanced drug efflux only",
      "Mutations in topoisomerases",
      "Increased folate uptake from diet"
   ],
   "answer": "Altered dihydrofolate reductase with lower drug affinity",
   "explanation": "Resistance is due to altered dihydrofolate reductase enzymes with reduced trimethoprim binding, as well as efflux and permeability changes :contentReference[oaicite:27]{index=27}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00833",
   "question": "Which pharmacokinetic property of trimethoprim contributes to its use in prostatitis?",
   "options": [
      "Acidic pH inactivates it",
      "High concentrations in acidic prostatic and vaginal fluids",
      "Extensive protein binding prevents tissue entry",
      "No renal excretion"
   ],
   "answer": "High concentrations in acidic prostatic and vaginal fluids",
   "explanation": "Trimethoprim is a weak base achieving higher levels in acidic prostatic and vaginal fluids; it is widely distributed and partly renally excreted unchanged :contentReference[oaicite:28]{index=28}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00834",
   "question": "Trimethoprim adverse effects include:",
   "options": [
      "Tendon rupture",
      "Megaloblastic anemia, leukopenia, granulocytopenia, and hyperkalemia",
      "Nephrotoxicity and ototoxicity",
      "Serotonin syndrome"
   ],
   "answer": "Megaloblastic anemia, leukopenia, granulocytopenia, and hyperkalemia",
   "explanation": "Trimethoprim can cause folate deficiency–type blood disorders (reversible with folinic acid) and a potassium-sparing effect leading to hyperkalemia :contentReference[oaicite:29]{index=29}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00835",
   "question": "The synergistic mechanism of TMP/SMX is due to:",
   "options": [
      "Sequential inhibition of dihydropteroate synthetase and dihydrofolate reductase",
      "Binding to ribosomal subunits",
      "DNA gyrase inhibition only",
      "Cell membrane disruption"
   ],
   "answer": "Sequential inhibition of dihydropteroate synthetase and dihydrofolate reductase",
   "explanation": "TMP/SMX combines sulfonamide inhibition of dihydropteroate synthetase with trimethoprim inhibition of dihydrofolate reductase for synergistic blockade of folate synthesis :contentReference[oaicite:30]{index=30}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00836",
   "question": "TMP/SMX has enhanced spectrum over sulfonamides alone, including activity against:",
   "options": [
      "Only Enterobacteriaceae",
      "UTIs, respiratory infections, Pneumocystis jirovecii, toxoplasmosis, Listeria, Salmonella, MRSA, Nocardia, S. maltophilia",
      "Only anaerobes",
      "Only gram-positive cocci"
   ],
   "answer": "UTIs, respiratory infections, Pneumocystis jirovecii, toxoplasmosis, Listeria, Salmonella, MRSA, Nocardia, S. maltophilia",
   "explanation": "TMP/SMX treats UTIs, respiratory infections, Pneumocystis jirovecii, toxoplasmosis, Listeria, Salmonella, MRSA, Nocardia, and S. maltophilia due to combined bacteriostatic effects :contentReference[oaicite:31]{index=31}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00837",
   "question": "Why is resistance to the TMP/SMX combination less common than to either drug alone?",
   "options": [
      "Because bacteria cannot alter folate pathways",
      "It requires simultaneous resistance mechanisms to both drugs",
      "Because TMP/SMX inhibits efflux pumps",
      "Because of high protein binding"
   ],
   "answer": "It requires simultaneous resistance mechanisms to both drugs",
   "explanation": "Dual resistance is rare because bacteria must acquire mechanisms against both sulfamethoxazole and trimethoprim simultaneously :contentReference[oaicite:32]{index=32}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00838",
   "question": "TMP/SMX pharmacokinetics include:",
   "options": [
      "Poor tissue penetration and no renal excretion",
      "Oral and IV routes, TMP concentrates in acidic prostatic fluids, crosses BBB, both drugs excreted in urine",
      "Extensive hepatic metabolism only",
      "No CNS penetration"
   ],
   "answer": "Oral and IV routes, TMP concentrates in acidic prostatic fluids, crosses BBB, both drugs excreted in urine",
   "explanation": "TMP/SMX is given orally or IV; TMP concentrates in acidic prostatic fluids and both agents cross the BBB and are excreted in urine :contentReference[oaicite:33]{index=33}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00839",
   "question": "Common adverse effects of TMP/SMX include:",
   "options": [
      "Tendon rupture and neuropathy",
      "Nausea, vomiting, skin rash, hematologic toxicity, hyperkalemia",
      "Nephrotoxicity only",
      "Hepatic failure"
   ],
   "answer": "Nausea, vomiting, skin rash, hematologic toxicity, hyperkalemia",
   "explanation": "TMP/SMX commonly causes nausea, vomiting, rash, hematologic toxicity, and hyperkalemia :contentReference[oaicite:34]{index=34}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00840",
   "question": "Methenamine’s bactericidal action relies on:",
   "options": [
      "Inhibition of DNA gyrase",
      "Conversion to formaldehyde in acidic urine, denaturing proteins and nucleic acids",
      "Blockade of dihydropteroate synthetase",
      "Binding to ribosomal 30S subunit"
   ],
   "answer": "Conversion to formaldehyde in acidic urine, denaturing proteins and nucleic acids",
   "explanation": "Methenamine salts hydrolyze in urine (pH ≤ 5.5) to ammonia and formaldehyde, which denatures bacterial proteins and nucleic acids :contentReference[oaicite:35]{index=35}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00841",
   "question": "At what urinary pH does methenamine reliably generate formaldehyde?",
   "options": [
      "pH ≥ 7.5",
      "pH ≤ 5.5",
      "pH ≈ 6.8",
      "Any pH"
   ],
   "answer": "pH ≤ 5.5",
   "explanation": "Methenamine requires acidic urine (pH ≤ 5.5) to produce formaldehyde and exert bactericidal effects :contentReference[oaicite:36]{index=36}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00842",
   "question": "Which organisms are commonly susceptible to nitrofurantoin?",
   "options": [
      "Only Pseudomonas aeruginosa",
      "Enterobacteriaceae (e.g., E. coli, Klebsiella), Enterococcus, Staphylococcus",
      "Mycobacterium tuberculosis",
      "Anaerobes only"
   ],
   "answer": "Enterobacteriaceae (e.g., E. coli, Klebsiella), Enterococcus, Staphylococcus",
   "explanation": "Nitrofurantoin is bactericidal against common urinary pathogens—Enterobacteriaceae, Enterococcus spp., and Staphylococcus spp. :contentReference[oaicite:37]{index=37}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00843",
   "question": "What distinguishes nitrofurantoin macrocrystals from the monohydrate formulation?",
   "options": [
      "Macrocrystals dissolve faster and require once-daily dosing",
      "Combination of macrocrystals and monohydrate forms a gel matrix for twice-daily dosing",
      "Only monohydrate is absorbed",
      "Neither is excreted in urine"
   ],
   "answer": "Combination of macrocrystals and monohydrate forms a gel matrix for twice-daily dosing",
   "explanation": "The macrocrystal/monohydrate combo forms a gel-like matrix for gradual release, allowing twice-daily dosing; macrocrystals alone dissolve more slowly and require more frequent dosing :contentReference[oaicite:38]{index=38}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00844",
   "question": "Which adverse effect limits nitrofurantoin use in patients with renal impairment?",
   "options": [
      "Increased risk of pulmonary fibrosis and neuropathy due to reduced clearance",
      "Enhanced CNS toxicity",
      "Increased QT prolongation",
      "Hyperkalemia"
   ],
   "answer": "Increased risk of pulmonary fibrosis and neuropathy due to reduced clearance",
   "explanation": "In renal impairment, nitrofurantoin levels rise, increasing risk of pulmonary fibrosis, neuropathy, and autoimmune hepatitis; it is contraindicated when kidney function is poor :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00845",
   "question": "Fosfomycin exerts its bactericidal effect by inhibiting:",
   "options": [
      "DNA gyrase",
      "Enolpyruvyl transferase in peptidoglycan synthesis",
      "Dihydrofolate reductase",
      "Protein synthesis at the 30S subunit"
   ],
   "answer": "Enolpyruvyl transferase in peptidoglycan synthesis",
   "explanation": "Fosfomycin blocks enolpyruvyl transferase, a key enzyme in the initial step of peptidoglycan synthesis, and reduces bacterial adherence to the urinary epithelium :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 31,
   "chapter": "Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics",
   "question_id": "00031-00846",
   "question": "For which indication is fosfomycin considered first-line therapy?",
   "options": [
      "Pyelonephritis requiring prolonged therapy",
      "Acute uncomplicated cystitis as a single oral dose",
      "MRSA skin infections",
      "Bacterial prostatitis"
   ],
   "answer": "Acute uncomplicated cystitis as a single oral dose",
   "explanation": "Fosfomycin is a one-time oral dose and is first-line therapy for acute uncomplicated cystitis :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00847",
   "question": "Which structural component is targeted by echinocandins?",
   "options": [
      "Fungal cell membrane ergosterol",
      "Fungal cell wall β-(1,3)-D-glucan",
      "Fungal DNA synthesis",
      "Fungal protein synthesis"
   ],
   "answer": "Fungal cell wall β-(1,3)-D-glucan",
   "explanation": "Echinocandins inhibit β-(1,3)-D-glucan synthase, disrupting fungal cell wall integrity :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00848",
   "question": "What is the mechanism of action of amphotericin B?",
   "options": [
      "Inhibits β-glucan synthase",
      "Binds ergosterol forming membrane pores",
      "Inhibits ergosterol synthesis",
      "Inhibits DNA synthesis"
   ],
   "answer": "Binds ergosterol forming membrane pores",
   "explanation": "Amphotericin B binds to ergosterol in fungal membranes, forming pores that allow ion leakage and cell death :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00849",
   "question": "What is the major dose-limiting toxicity of amphotericin B?",
   "options": [
      "Nephrotoxicity",
      "Hepatotoxicity",
      "Cardiotoxicity",
      "Ototoxicity"
   ],
   "answer": "Nephrotoxicity",
   "explanation": "Amphotericin B frequently causes dose-dependent renal impairment :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00850",
   "question": "Which advantage do liposomal formulations of amphotericin B have over the conventional form?",
   "options": [
      "Lower cost",
      "Higher CNS penetration",
      "Reduced renal toxicity",
      "Longer half-life"
   ],
   "answer": "Reduced renal toxicity",
   "explanation": "Liposomal amphotericin B significantly lowers renal and infusion-related toxicities compared to conventional formulation :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00851",
   "question": "How does flucytosine exert its antifungal effect?",
   "options": [
      "Inhibits ergosterol synthesis",
      "Converted to 5-fluorouracil inhibiting DNA synthesis",
      "Binds β-glucan",
      "Inhibits protein synthesis"
   ],
   "answer": "Converted to 5-fluorouracil inhibiting DNA synthesis",
   "explanation": "Flucytosine is deaminated in fungal cells to 5-FU and its metabolites, which disrupt nucleic acid synthesis :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00852",
   "question": "Which organisms are principally susceptible to flucytosine?",
   "options": [
      "Dermatophytes",
      "Molds",
      "Candida and Cryptococcus",
      "Aspergillus only"
   ],
   "answer": "Candida and Cryptococcus",
   "explanation": "Flucytosine demonstrates activity against Candida species and Cryptococcus neoformans :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00853",
   "question": "What is a notable adverse effect of flucytosine monotherapy?",
   "options": [
      "Bone marrow suppression",
      "Nephrotoxicity",
      "Visual disturbances",
      "Hepatic failure"
   ],
   "answer": "Bone marrow suppression",
   "explanation": "Flucytosine causes dose-related bone marrow toxicity, including neutropenia and thrombocytopenia :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00854",
   "question": "What is the primary mechanism of action of azole antifungals?",
   "options": [
      "Bind ergosterol",
      "Inhibit lanosterol demethylase",
      "Inhibit β-glucan synthase",
      "Inhibit DNA gyrase"
   ],
   "answer": "Inhibit lanosterol demethylase",
   "explanation": "Azoles reversibly inhibit fungal 14-α-demethylase, blocking ergosterol synthesis :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00855",
   "question": "Which drug interaction is characteristic of systemic azoles?",
   "options": [
      "Induce CYP3A4",
      "Inhibit CYP3A4",
      "No effect",
      "Induce P-glycoprotein"
   ],
   "answer": "Inhibit CYP3A4",
   "explanation": "Azoles inhibit CYP3A4, leading to elevated levels of co-administered substrates :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00856",
   "question": "Which azole uniquely shortens the QT interval?",
   "options": [
      "Fluconazole",
      "Voriconazole",
      "Isavuconazole",
      "Posaconazole"
   ],
   "answer": "Isavuconazole",
   "explanation": "Isavuconazole is the only azole that shortens rather than prolongs the QT interval :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00857",
   "question": "For which condition is oral terbinafine the drug of choice?",
   "options": [
      "Systemic candidiasis",
      "Onychomycosis",
      "Cryptococcal meningitis",
      "Mucormycosis"
   ],
   "answer": "Onychomycosis",
   "explanation": "Terbinafine, an allylamine, is first-line oral therapy for dermatophyte nail infections :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00858",
   "question": "Allylamines inhibit which fungal enzyme?",
   "options": [
      "β-glucan synthase",
      "Lanosterol demethylase",
      "Squalene epoxidase",
      "DNA polymerase"
   ],
   "answer": "Squalene epoxidase",
   "explanation": "Allylamines such as terbinafine block squalene epoxidase, reducing ergosterol synthesis :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00859",
   "question": "What is the mechanism of action of tavaborole?",
   "options": [
      "Inhibits tRNA synthetase",
      "Inhibits lanosterol demethylase",
      "Inhibits β-glucan synthase",
      "Binds ergosterol"
   ],
   "answer": "Inhibits tRNA synthetase",
   "explanation": "Tavaborole inhibits fungal leucyl-tRNA synthetase, blocking protein synthesis :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00860",
   "question": "Which topical agent acts by chelating metal ions to interfere with nucleic acid synthesis?",
   "options": [
      "Efinaconazole",
      "Ciclopirox",
      "Tolnaftate",
      "Terbinafine"
   ],
   "answer": "Ciclopirox",
   "explanation": "Ciclopirox chelates trivalent cations, disrupting DNA, RNA, and protein synthesis :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00861",
   "question": "Which topical triazole is approved for toenail onychomycosis?",
   "options": [
      "Fluconazole",
      "Miconazole",
      "Efinaconazole",
      "Ketoconazole"
   ],
   "answer": "Efinaconazole",
   "explanation": "Efinaconazole is a topical triazole indicated for toenail onychomycosis requiring extended therapy :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00862",
   "question": "Resistance to amphotericin B is most often due to which change?",
   "options": [
      "Efflux pumps",
      "Decreased ergosterol content",
      "β-glucan overproduction",
      "Lanosterol demethylase mutation"
   ],
   "answer": "Decreased ergosterol content",
   "explanation": "Rare amphotericin B resistance arises from reduced ergosterol in fungal membranes :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00863",
   "question": "Which combination is preferred for cryptococcal meningitis induction therapy?",
   "options": [
      "Amphotericin B plus flucytosine",
      "Fluconazole plus terbinafine",
      "Voriconazole plus caspofungin",
      "Itraconazole plus amphotericin B"
   ],
   "answer": "Amphotericin B plus flucytosine",
   "explanation": "Induction therapy combines amphotericin B and flucytosine for synergistic fungal killing in cryptococcal meningitis :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00864",
   "question": "Which echinocandin does NOT require CYP450 metabolism and has minimal drug interactions?",
   "options": [
      "Caspofungin",
      "Micafungin",
      "Anidulafungin",
      "Both Micafungin and Anidulafungin"
   ],
   "answer": "Both Micafungin and Anidulafungin",
   "explanation": "Micafungin and anidulafungin are not CYP450 substrates, resulting in few interactions :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00865",
   "question": "Which topical agent distorts hyphae and stunts mycelial growth by a thiocarbamate mechanism?",
   "options": [
      "Tolnaftate",
      "Ciclopirox",
      "Terbinafine",
      "Clotrimazole"
   ],
   "answer": "Tolnaftate",
   "explanation": "Tolnaftate distorts fungal hyphae, inhibiting mycelial growth; effective for dermatophyte infections :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00866",
   "question": "Which systemic azole requires dose adjustment in renal impairment?",
   "options": [
      "Fluconazole",
      "Itraconazole",
      "Voriconazole",
      "Posaconazole"
   ],
   "answer": "Fluconazole",
   "explanation": "Fluconazole is excreted unchanged in urine and must be dose-adjusted in renal dysfunction :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00867",
   "question": "Which antifungal class is teratogenic and generally avoided in pregnancy?",
   "options": [
      "Polyenes",
      "Echinocandins",
      "Azoles",
      "Allylamines"
   ],
   "answer": "Azoles",
   "explanation": "Systemic azoles are teratogenic and should be avoided unless benefits outweigh risks :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00868",
   "question": "Which antifungal is the preferred initial therapy for aspergillosis?",
   "options": [
      "Itraconazole",
      "Voriconazole",
      "Amphotericin B",
      "Flucytosine"
   ],
   "answer": "Voriconazole",
   "explanation": "Voriconazole is first-line treatment for invasive aspergillosis :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 33,
   "chapter": "Antifungal Drugs",
   "question_id": "00033-00869",
   "question": "Which topical agent is the drug of choice for seborrheic dermatitis?",
   "options": [
      "Terbinafine cream",
      "Ciclopirox shampoo",
      "Tolnaftate powder",
      "Efinaconazole solution"
   ],
   "answer": "Ciclopirox shampoo",
   "explanation": "Ciclopirox shampoo is indicated for seborrheic dermatitis due to its broad cutaneous activity :contentReference[oaicite:22]{index=22}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00870",
   "question": "Which class of antivirals inhibits viral DNA polymerase by chain termination after incorporation?",
   "options": [
      "Nucleoside reverse transcriptase inhibitors",
      "Nucleoside analog DNA polymerase inhibitors",
      "Protease inhibitors",
      "Neuraminidase inhibitors"
   ],
   "answer": "Nucleoside analog DNA polymerase inhibitors",
   "explanation": "Nucleoside analogs are phosphorylated by viral kinases, incorporated into DNA, and cause chain termination :contentReference[oaicite:23]{index=23}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00871",
   "question": "Which drug requires activation by the HSV thymidine kinase?",
   "options": [
      "Cidofovir",
      "Acyclovir",
      "Foscarnet",
      "Ganciclovir"
   ],
   "answer": "Acyclovir",
   "explanation": "Acyclovir is monophosphorylated by viral thymidine kinase before further phosphorylation by host enzymes :contentReference[oaicite:24]{index=24}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00872",
   "question": "What is the main toxicity of ganciclovir therapy?",
   "options": [
      "Nephrotoxicity",
      "Bone marrow suppression",
      "Cardiotoxicity",
      "Neurotoxicity"
   ],
   "answer": "Bone marrow suppression",
   "explanation": "Ganciclovir causes dose-related neutropenia and thrombocytopenia through bone marrow toxicity :contentReference[oaicite:25]{index=25}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00873",
   "question": "Which antiviral is effective against CMV and does NOT require initial phosphorylation by viral kinase?",
   "options": [
      "Foscarnet",
      "Ganciclovir",
      "Cidofovir",
      "Acyclovir"
   ],
   "answer": "Foscarnet",
   "explanation": "Foscarnet directly inhibits viral polymerases without needing activation by viral kinases :contentReference[oaicite:26]{index=26}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00874",
   "question": "Which drug class blocks HIV protease, preventing maturation of viral particles?",
   "options": [
      "NRTIs",
      "NNRTIs",
      "Protease inhibitors",
      "Integrase inhibitors"
   ],
   "answer": "Protease inhibitors",
   "explanation": "Protease inhibitors bind the active site of HIV protease, blocking cleavage of gag-pol polyproteins :contentReference[oaicite:27]{index=27}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00875",
   "question": "Which integrase inhibitor is used in initial HIV therapy?",
   "options": [
      "Raltegravir",
      "Zidovudine",
      "Efavirenz",
      "Ritonavir"
   ],
   "answer": "Raltegravir",
   "explanation": "Raltegravir inhibits viral integrase, preventing proviral DNA insertion into host genome :contentReference[oaicite:28]{index=28}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00876",
   "question": "Which drug combination is recommended for HIV post-exposure prophylaxis?",
   "options": [
      "Two NRTIs plus a protease inhibitor",
      "Two NNRTIs alone",
      "Integrase inhibitor monotherapy",
      "Acyclovir and ganciclovir"
   ],
   "answer": "Two NRTIs plus a protease inhibitor",
   "explanation": "PEP typically includes two NRTIs plus a boosted protease inhibitor for 28 days :contentReference[oaicite:29]{index=29}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00877",
   "question": "Which neuraminidase inhibitor is active against both influenza A and B?",
   "options": [
      "Oseltamivir",
      "Amantadine",
      "Rimantadine",
      "Acyclovir"
   ],
   "answer": "Oseltamivir",
   "explanation": "Oseltamivir blocks viral neuraminidase, preventing release of progeny virions in both A and B strains :contentReference[oaicite:30]{index=30}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00878",
   "question": "Which antiviral is approved for hepatitis C as an NS5A inhibitor?",
   "options": [
      "Sofosbuvir",
      "Ledipasvir",
      "Ribavirin",
      "Interferon alfa"
   ],
   "answer": "Ledipasvir",
   "explanation": "Ledipasvir inhibits HCV NS5A protein, blocking viral replication complex formation :contentReference[oaicite:31]{index=31}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00879",
   "question": "Which drug requires monitoring of hemolytic anemia risk when used for RSV prophylaxis?",
   "options": [
      "Palivizumab",
      "Ribavirin",
      "Oseltamivir",
      "Zanamivir"
   ],
   "answer": "Ribavirin",
   "explanation": "Ribavirin can cause dose-related hemolytic anemia; monitor CBC during therapy :contentReference[oaicite:32]{index=32}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00880",
   "question": "Which hepatitis B drug is a nucleotide analog that can lead to mitochondrial toxicity?",
   "options": [
      "Lamivudine",
      "Adefovir",
      "Entecavir",
      "Tenofovir"
   ],
   "answer": "Adefovir",
   "explanation": "Adefovir dipivoxil may cause mitochondrial DNA polymerase γ inhibition, leading to toxicity :contentReference[oaicite:33]{index=33}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00881",
   "question": "What is the mechanism of action of entecavir?",
   "options": [
      "Neuraminidase inhibition",
      "Reverse transcriptase inhibition",
      "Protease inhibition",
      "Integrase inhibition"
   ],
   "answer": "Reverse transcriptase inhibition",
   "explanation": "Entecavir inhibits HBV polymerase with reverse transcriptase activity :contentReference[oaicite:34]{index=34}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00882",
   "question": "Which antiviral requires testing for HLA-B*5701 due to hypersensitivity risk?",
   "options": [
      "Abacavir",
      "Efavirenz",
      "Ritonavir",
      "Zidovudine"
   ],
   "answer": "Abacavir",
   "explanation": "HLA-B*5701 testing is mandatory before abacavir to prevent severe hypersensitivity :contentReference[oaicite:35]{index=35}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00883",
   "question": "Which drug is a CCR5 antagonist used in HIV therapy?",
   "options": [
      "Maraviroc",
      "Dolutegravir",
      "Zidovudine",
      "Lamivudine"
   ],
   "answer": "Maraviroc",
   "explanation": "Maraviroc blocks CCR5 co-receptor on host cells, preventing HIV entry :contentReference[oaicite:36]{index=36}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00884",
   "question": "Which combination therapy is preferred for hepatitis C genotype 1 infection?",
   "options": [
      "Sofosbuvir plus ledipasvir",
      "Ribavirin plus interferon",
      "Tenofovir plus lamivudine",
      "Entecavir monotherapy"
   ],
   "answer": "Sofosbuvir plus ledipasvir",
   "explanation": "Sofosbuvir/ledipasvir is once-daily, interferon-free regimen with high SVR in genotype 1 :contentReference[oaicite:37]{index=37}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00885",
   "question": "Which influenza drug is administered via inhalation?",
   "options": [
      "Oseltamivir",
      "Zanamivir",
      "Amantadine",
      "Ribavirin"
   ],
   "answer": "Zanamivir",
   "explanation": "Zanamivir is inhaled dry powder neuraminidase inhibitor active against influenza A and B :contentReference[oaicite:38]{index=38}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00886",
   "question": "Which antiviral is contraindicated in pregnancy due to teratogenicity?",
   "options": [
      "Valganciclovir",
      "Acyclovir",
      "Zanamivir",
      "Oseltamivir"
   ],
   "answer": "Valganciclovir",
   "explanation": "Valganciclovir is teratogenic in animal studies; avoid in pregnancy :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00887",
   "question": "Which drug is an sialidase inhibitor used to treat influenza A in children?",
   "options": [
      "Peramivir",
      "Ribavirin",
      "Oseltamivir",
      "Ganciclovir"
   ],
   "answer": "Oseltamivir",
   "explanation": "Oseltamivir is approved for pediatric influenza treatment by inhibiting viral neuraminidase :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 34,
   "chapter": "Antiviral Drugs",
   "question_id": "00034-00888",
   "question": "Which HIV drug class causes fat redistribution and metabolic syndrome?",
   "options": [
      "Integrase inhibitors",
      "Protease inhibitors",
      "NNRTIs",
      "NRTIs"
   ],
   "answer": "Protease inhibitors",
   "explanation": "Long-term protease inhibitor use can induce lipodystrophy and insulin resistance :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00889",
   "question": "Which agent is the first-line treatment for Plasmodium falciparum malaria in most regions?",
   "options": [
      "Chloroquine",
      "Artemether–lumefantrine",
      "Mefloquine",
      "Quinine"
   ],
   "answer": "Artemether–lumefantrine",
   "explanation": "Artemisinin combination therapies are WHO-recommended first-line for P. falciparum :contentReference[oaicite:42]{index=42}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00890",
   "question": "Which drug targets Plasmodium liver hypnozoites of P. vivax?",
   "options": [
      "Primaquine",
      "Chloroquine",
      "Artemether",
      "Mefloquine"
   ],
   "answer": "Primaquine",
   "explanation": "Primaquine eradicates dormant hypnozoites in the liver, preventing P. vivax relapses :contentReference[oaicite:43]{index=43}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00891",
   "question": "Which drug combination is preferred for acute babesiosis?",
   "options": [
      "Atovaquone plus azithromycin",
      "Clindamycin alone",
      "Quinine alone",
      "Metronidazole plus paromomycin"
   ],
   "answer": "Atovaquone plus azithromycin",
   "explanation": "Atovaquone-azithromycin is first-line for babesiosis; clindamycin requires quinine co-administration :contentReference[oaicite:44]{index=44}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00892",
   "question": "Which agent is indicated for late-stage T. brucei rhodesiense infection?",
   "options": [
      "Pentamidine",
      "Melarsoprol",
      "Suramin",
      "Eflornithine"
   ],
   "answer": "Melarsoprol",
   "explanation": "Melarsoprol remains the only drug for late CNS-involved T. b. rhodesiense despite toxicity :contentReference[oaicite:45]{index=45}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00893",
   "question": "What is the treatment of choice for Chagas disease in children?",
   "options": [
      "Benznidazole",
      "Pentamidine",
      "Suramin",
      "Sodium stibogluconate"
   ],
   "answer": "Benznidazole",
   "explanation": "Benznidazole is indicated for acute T. cruzi infection (Chagas) in pediatric patients :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00894",
   "question": "Which oral agent is FDA-approved for visceral leishmaniasis?",
   "options": [
      "Artemether–lumefantrine",
      "Miltefosine",
      "Nitazoxanide",
      "Tinidazole"
   ],
   "answer": "Miltefosine",
   "explanation": "Miltefosine is the only oral drug approved for visceral leishmaniasis treatment :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00895",
   "question": "For Giardia lamblia infection, which single-dose agent is preferred?",
   "options": [
      "Metronidazole",
      "Tinidazole",
      "Paromomycin",
      "Chloroquine"
   ],
   "answer": "Tinidazole",
   "explanation": "Tinidazole is preferred for giardiasis and amebiasis due to single-dose efficacy :contentReference[oaicite:48]{index=48}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00896",
   "question": "Which drug is indicated for visceral leishmaniasis via oral route?",
   "options": [
      "Pentamidine",
      "Miltefosine",
      "Suramin",
      "Benznidazole"
   ],
   "answer": "Miltefosine",
   "explanation": "Miltefosine is uniquely available orally for visceral leishmaniasis :contentReference[oaicite:49]{index=49}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00897",
   "question": "Which therapy is recommended for American trypanosomiasis (Chagas)?",
   "options": [
      "Suramin",
      "Nifurtimox",
      "Pentamidine",
      "Miltefosine"
   ],
   "answer": "Nifurtimox",
   "explanation": "Nifurtimox and benznidazole are used for T. cruzi; nifurtimox also treats some Trypanosoma species :contentReference[oaicite:50]{index=50}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00898",
   "question": "Which drug combination is used for amebic dysentery with systemic symptoms?",
   "options": [
      "Paromomycin plus metronidazole",
      "Tinidazole plus albendazole",
      "Chloroquine plus quinine",
      "Pentamidine plus suramin"
   ],
   "answer": "Paromomycin plus metronidazole",
   "explanation": "Paromomycin/metronidazole treats systemic amebic dysentery, addressing luminal and tissue forms :contentReference[oaicite:51]{index=51}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00899",
   "question": "Which agent is preferred for P. vivax relapse prevention?",
   "options": [
      "Primaquine",
      "Chloroquine",
      "Quinine",
      "Atovaquone"
   ],
   "answer": "Primaquine",
   "explanation": "Primaquine targets hypnozoites in the liver, preventing P. vivax relapse :contentReference[oaicite:52]{index=52}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00900",
   "question": "Which agent treats babesiosis in combination therapy?",
   "options": [
      "Clindamycin and quinine",
      "Atovaquone plus azithromycin",
      "Tinidazole plus chloroquine",
      "Miltefosine plus paromomycin"
   ],
   "answer": "Atovaquone plus azithromycin",
   "explanation": "Atovaquone/azithromycin is preferred; clindamycin requires quinine adjunct :contentReference[oaicite:53]{index=53}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00901",
   "question": "What is first-line for African trypanosomiasis early phase?",
   "options": [
      "Pentamidine",
      "Melarsoprol",
      "Suramin",
      "Eflornithine"
   ],
   "answer": "Suramin",
   "explanation": "Suramin is used for early-stage West African trypanosomiasis (T. brucei gambiense) :contentReference[oaicite:54]{index=54}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00902",
   "question": "Which drug combination is used for toxoplasmosis treatment?",
   "options": [
      "Sulfadiazine and pyrimethamine",
      "Clindamycin and streptomycin",
      "Metronidazole and tinidazole",
      "Chloroquine and primaquine"
   ],
   "answer": "Sulfadiazine and pyrimethamine",
   "explanation": "Sulfadiazine/pyrimethamine plus leucovorin covers Toxoplasma cysts and prevents folate depletion :contentReference[oaicite:55]{index=55}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00903",
   "question": "Which agent is preferred for giardiasis treatment?",
   "options": [
      "Tinidazole",
      "Paromomycin",
      "Chloroquine",
      "Suramin"
   ],
   "answer": "Tinidazole",
   "explanation": "Tinidazole offers single-dose therapy for Giardia lamblia with high cure rates :contentReference[oaicite:56]{index=56}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00904",
   "question": "Which drug is indicated for visceral leishmaniasis and is oral?",
   "options": [
      "Miltefosine",
      "Benznidazole",
      "Suramin",
      "Pentamidine"
   ],
   "answer": "Miltefosine",
   "explanation": "Miltefosine is the only oral option for visceral leishmaniasis :contentReference[oaicite:57]{index=57}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00905",
   "question": "Which combination treats amebic dysentery with systemic involvement?",
   "options": [
      "Paromomycin plus metronidazole",
      "Tinidazole alone",
      "Chloroquine plus quinine",
      "Suramin alone"
   ],
   "answer": "Paromomycin plus metronidazole",
   "explanation": "Paromomycin addresses luminal cysts; metronidazole treats tissue infection :contentReference[oaicite:58]{index=58}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00906",
   "question": "Which agent is used for American trypanosomiasis and also African trypanosomiasis early phase?",
   "options": [
      "Benznidazole",
      "Nifurtimox",
      "Suramin",
      "Pentamidine"
   ],
   "answer": "Pentamidine",
   "explanation": "Pentamidine treats early-stage T. brucei gambiense and certain protozoal infections :contentReference[oaicite:59]{index=59}."
},
 {
   "chapter_id": 35,
   "chapter": "Antiprotozoal Drugs",
   "question_id": "00035-00907",
   "question": "Which agent is used for hyperinfection syndrome in strongyloidiasis?",
   "options": [
      "Albendazole",
      "Ivermectin",
      "Mebendazole",
      "Pyrantel pamoate"
   ],
   "answer": "Ivermectin",
   "explanation": "Hyperinfection and disseminated strongyloidiasis require daily ivermectin until negative stool for 2 weeks :contentReference[oaicite:60]{index=60}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00908",
   "question": "Which benzimidazole binds parasite β-tubulin and inhibits microtubule polymerization?",
   "options": [
      "Mebendazole",
      "Pyrantel pamoate",
      "Ivermectin",
      "Niclosamide"
   ],
   "answer": "Mebendazole",
   "explanation": "Mebendazole and related benzimidazoles bind β-tubulin, blocking microtubule assembly in nematodes :contentReference[oaicite:61]{index=61}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00909",
   "question": "Which adverse effect is associated with high-dose mebendazole in infants?",
   "options": [
      "Convulsions and Stevens–Johnson syndrome",
      "Nephrotoxicity",
      "Ototoxicity",
      "Cardiotoxicity"
   ],
   "answer": "Convulsions and Stevens–Johnson syndrome",
   "explanation": "Rare mebendazole toxicity includes seizures in <1 year olds and SJS/TEN when combined with metronidazole :contentReference[oaicite:62]{index=62}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00910",
   "question": "How does pyrantel pamoate eradicate pinworms and hookworms?",
   "options": [
      "Depolarizing neuromuscular blockade",
      "Microtubule inhibition",
      "Mitochondrial phosphorylation inhibition",
      "Ergosterol binding"
   ],
   "answer": "Depolarizing neuromuscular blockade",
   "explanation": "Pyrantel pamoate depolarizes worm muscle via ACh release and cholinesterase inhibition, causing paralysis :contentReference[oaicite:63]{index=63}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00911",
   "question": "Which drug is the treatment of choice for cutaneous larva migrans and strongyloidiasis?",
   "options": [
      "Ivermectin",
      "Albendazole",
      "Mebendazole",
      "Pyrantel pamoate"
   ],
   "answer": "Ivermectin",
   "explanation": "Ivermectin is preferred for cutaneous larva migrans, strongyloidiasis, and onchocerciasis :contentReference[oaicite:64]{index=64}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00912",
   "question": "What is a Mazzotti reaction and which drug can precipitate it?",
   "options": [
      "Inflammatory reaction to dying microfilariae; Ivermectin",
      "Severe rash; Mebendazole",
      "Liver failure; Albendazole",
      "Renal failure; Praziquantel"
   ],
   "answer": "Inflammatory reaction to dying microfilariae; Ivermectin",
   "explanation": "Ivermectin kills microfilariae in onchocerciasis, causing Mazzotti reaction; steroids may mitigate symptoms :contentReference[oaicite:65]{index=65}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00913",
   "question": "Which alternative to ivermectin lacks activity against adult worms but treats river blindness?",
   "options": [
      "Moxidectin",
      "Albendazole",
      "Praziquantel",
      "Triclabendazole"
   ],
   "answer": "Moxidectin",
   "explanation": "Moxidectin, like ivermectin, targets microfilariae in onchocerciasis but not adult worms :contentReference[oaicite:66]{index=66}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00914",
   "question": "Which drug is first-line for filariasis caused by Wuchereria bancrofti?",
   "options": [
      "Diethylcarbamazine",
      "Albendazole",
      "Ivermectin",
      "Mebendazole"
   ],
   "answer": "Diethylcarbamazine",
   "explanation": "Diethylcarbamazine is preferred for Wuchereria and Brugia infections; it kills microfilariae and adults :contentReference[oaicite:67]{index=67}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00915",
   "question": "Which agent is contraindicated in pregnancy unless in mass prevention programs?",
   "options": [
      "Mebendazole",
      "Pyrantel pamoate",
      "Ivermectin",
      "Albendazole"
   ],
   "answer": "Mebendazole",
   "explanation": "Mebendazole should be avoided in pregnancy, though occasionally used in 2nd/3rd trimester in mass campaigns :contentReference[oaicite:68]{index=68}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00916",
   "question": "Which drug inhibits trematode cell membranes by increasing calcium permeability?",
   "options": [
      "Praziquantel",
      "Triclabendazole",
      "Niclosamide",
      "Diethylcarbamazine"
   ],
   "answer": "Praziquantel",
   "explanation": "Praziquantel increases calcium influx in trematodes and cestodes, causing paralysis :contentReference[oaicite:69]{index=69}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00917",
   "question": "Which strong CYP3A4 inducers reduce praziquantel efficacy?",
   "options": [
      "Phenytoin, rifampin, carbamazepine",
      "Itraconazole, ketoconazole",
      "Ritonavir, saquinavir",
      "Ciprofloxacin, clarithromycin"
   ],
   "answer": "Phenytoin, rifampin, carbamazepine",
   "explanation": "These inducers accelerate praziquantel metabolism, decreasing its parasiticidal effect :contentReference[oaicite:70]{index=70}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00918",
   "question": "Which benzimidazole is indicated for fascioliasis caused by Fasciola species?",
   "options": [
      "Triclabendazole",
      "Mebendazole",
      "Albendazole",
      "Praziquantel"
   ],
   "answer": "Triclabendazole",
   "explanation": "Triclabendazole is the drug of choice for liver fluke infections by Fasciola spp. :contentReference[oaicite:71]{index=71}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00919",
   "question": "Which drug inhibits cestode mitochondrial phosphorylation of ADP?",
   "options": [
      "Niclosamide",
      "Praziquantel",
      "Albendazole",
      "Triclabendazole"
   ],
   "answer": "Niclosamide",
   "explanation": "Niclosamide uncouples oxidative phosphorylation in tapeworms, killing the scolex and segments :contentReference[oaicite:72]{index=72}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00920",
   "question": "Which agent is preferred for cestodal hydatid disease but requires monitoring of LFTs?",
   "options": [
      "Albendazole",
      "Praziquantel",
      "Diethylcarbamazine",
      "Ivermectin"
   ],
   "answer": "Albendazole",
   "explanation": "Albendazole, used for cysticercosis and hydatid disease, risks hepatotoxicity and cytopenias; monitor LFTs and blood counts :contentReference[oaicite:73]{index=73}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00921",
   "question": "Which agent is used for neurocysticercosis treatment?",
   "options": [
      "Albendazole",
      "Ivermectin",
      "Praziquantel",
      "Pyrantel pamoate"
   ],
   "answer": "Albendazole",
   "explanation": "Albendazole is the drug of choice for neurocysticercosis; other agents lack larval activity :contentReference[oaicite:74]{index=74}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00922",
   "question": "Which drug should not be co-administered with mebendazole due to SJS risk?",
   "options": [
      "Metronidazole",
      "Rifampin",
      "Dexamethasone",
      "Niclosamide"
   ],
   "answer": "Metronidazole",
   "explanation": "Metronidazole plus mebendazole greatly increases Stevens–Johnson syndrome risk :contentReference[oaicite:75]{index=75}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00923",
   "question": "Which regimen is used annually for filariasis endemic regions as preventive chemotherapy?",
   "options": [
      "Ivermectin alone",
      "Diethylcarbamazine plus albendazole",
      "Mebendazole plus praziquantel",
      "Niclosamide plus pyrantel"
   ],
   "answer": "Diethylcarbamazine plus albendazole",
   "explanation": "Combined annual DEC and albendazole is used in mass preventive chemotherapy for filariasis :contentReference[oaicite:76]{index=76}."
},
 {
   "chapter_id": 36,
   "chapter": "Anthelmintic Drugs",
   "question_id": "00036-00924",
   "question": "Which drug is poorly absorbed, acting only in the intestinal lumen against pinworms?",
   "options": [
      "Pyrantel pamoate",
      "Albendazole",
      "Ivermectin",
      "Diethylcarbamazine"
   ],
   "answer": "Pyrantel pamoate",
   "explanation": "Pyrantel pamoate is minimally absorbed and acts locally in the gut against intestinal nematodes :contentReference[oaicite:77]{index=77}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00925",
   "question": "Which term describes chemotherapy given after surgery to eradicate micrometastases?",
   "options": [
      "Adjuvant",
      "Neoadjuvant",
      "Palliative",
      "Maintenance"
   ],
   "answer": "Adjuvant",
   "explanation": "Adjuvant chemotherapy is given after surgery to attack residual micrometastases and improve cure rates :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00926",
   "question": "What is the ultimate goal of cancer chemotherapy when cure is unattainable?",
   "options": [
      "Control disease and improve quality of life",
      "Eliminate every neoplastic cell",
      "Cause complete tumor regression",
      "Induce irreversible cytotoxicity"
   ],
   "answer": "Control disease and improve quality of life",
   "explanation": "When cure is not attainable, the goal becomes control of tumor growth to extend survival and maintain quality of life :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00927",
   "question": "Which of the following is NOT a main class of traditional anticancer drugs?",
   "options": [
      "Antimetabolites",
      "Microtubule inhibitors",
      "Beta-lactams",
      "Topoisomerase inhibitors"
   ],
   "answer": "Beta-lactams",
   "explanation": "Main classes include antimetabolites, antitumor antibiotics, alkylating agents, microtubule inhibitors, monoclonal antibodies, kinase inhibitors, checkpoint inhibitors, and topoisomerase inhibitors :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00928",
   "question": "Which drug is most likely to inhibit cancer cells during S phase?",
   "options": [
      "Pemetrexed",
      "Docetaxel",
      "Dacarbazine",
      "Epirubicin"
   ],
   "answer": "Pemetrexed",
   "explanation": "Pemetrexed is an antimetabolite with maximal cytotoxic effect in S phase :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00929",
   "question": "Which agent carries a risk of irreversible, dose-dependent cardiotoxicity?",
   "options": [
      "Doxorubicin",
      "Cyclophosphamide",
      "Bleomycin",
      "Cisplatin"
   ],
   "answer": "Doxorubicin",
   "explanation": "Doxorubicin causes irreversible, dose-dependent cardiotoxicity that increases with cumulative dose :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00930",
   "question": "Which chemoprotectant is given to prevent hemorrhagic cystitis from ifosfamide?",
   "options": [
      "Mesna",
      "Leucovorin",
      "Amifostine",
      "Dexrazoxane"
   ],
   "answer": "Mesna",
   "explanation": "Mesna binds the toxic metabolite of ifosfamide, reducing the risk of hemorrhagic cystitis :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00931",
   "question": "Resistance to many anticancer drugs is mediated by overexpression of which protein?",
   "options": [
      "P-glycoprotein",
      "Topoisomerase II",
      "CD20",
      "HER2"
   ],
   "answer": "P-glycoprotein",
   "explanation": "Amplification of the gene encoding P-glycoprotein leads to ATP-dependent efflux of drugs and multidrug resistance :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00932",
   "question": "Which class of anticancer drugs is cell-cycle nonspecific?",
   "options": [
      "Alkylating agents",
      "Antimetabolites",
      "Microtubule inhibitors",
      "Topoisomerase inhibitors"
   ],
   "answer": "Alkylating agents",
   "explanation": "Alkylating agents and other classes like antitumor antibiotics are cell-cycle nonspecific :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00933",
   "question": "Which agent’s dose-limiting toxicity is pulmonary fibrosis?",
   "options": [
      "Bleomycin",
      "Cyclophosphamide",
      "Doxorubicin",
      "Cisplatin"
   ],
   "answer": "Bleomycin",
   "explanation": "Bleomycin’s dose-limiting toxicity is pulmonary toxicity, including fibrosis :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00934",
   "question": "Which drug commonly causes ototoxicity with nephrotoxicity and severe nausea/vomiting?",
   "options": [
      "Cisplatin",
      "Cyclophosphamide",
      "Bleomycin",
      "Doxorubicin"
   ],
   "answer": "Cisplatin",
   "explanation": "Cisplatin is notable for ototoxicity, nephrotoxicity, and severe nausea/vomiting :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00935",
   "question": "Nitrosoureas exert cytotoxicity primarily by what mechanism?",
   "options": [
      "DNA alkylation inhibiting replication",
      "Microtubule stabilization",
      "Proteasome inhibition",
      "Immune checkpoint blockade"
   ],
   "answer": "DNA alkylation inhibiting replication",
   "explanation": "Nitrosoureas alkylate DNA to inhibit replication, RNA, and protein synthesis :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00936",
   "question": "Which nitrosourea readily penetrates the CNS due to lipophilicity?",
   "options": [
      "Lomustine",
      "Melphalan",
      "Cisplatin",
      "Busulfan"
   ],
   "answer": "Lomustine",
   "explanation": "Lomustine is lipophilic, distributes widely, and penetrates the CNS :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00937",
   "question": "Which agent does NOT require CYP450 for conversion to its active metabolite?",
   "options": [
      "Temozolomide",
      "Dacarbazine",
      "Cyclophosphamide",
      "Carmustine"
   ],
   "answer": "Temozolomide",
   "explanation": "Temozolomide undergoes spontaneous conversion at physiological pH without CYP450 involvement :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00938",
   "question": "Which platinum compound was first developed but limited by toxicity?",
   "options": [
      "Cisplatin",
      "Carboplatin",
      "Oxaliplatin",
      "Dacarbazine"
   ],
   "answer": "Cisplatin",
   "explanation": "Cisplatin was the first platinum coordination complex, later followed by carboplatin to reduce toxicity :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00939",
   "question": "Which platinum analog is preferred when patients cannot tolerate vigorous hydration?",
   "options": [
      "Carboplatin",
      "Cisplatin",
      "Oxaliplatin",
      "Cyclophosphamide"
   ],
   "answer": "Carboplatin",
   "explanation": "Carboplatin is used when hydration risks prohibit cisplatin use, such as in renal dysfunction :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00940",
   "question": "Which platinum agent is commonly used in colorectal cancer regimens?",
   "options": [
      "Oxaliplatin",
      "Cisplatin",
      "Carboplatin",
      "Bleomycin"
   ],
   "answer": "Oxaliplatin",
   "explanation": "Oxaliplatin is widely used for colorectal cancer :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00941",
   "question": "What is the primary route of elimination for platinum coordination complexes?",
   "options": [
      "Renal excretion",
      "Biliary excretion",
      "Pulmonary exhalation",
      "Sweat"
   ],
   "answer": "Renal excretion",
   "explanation": "Renal excretion is the major elimination route for platinum agents :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00942",
   "question": "Which vinca alkaloid is derived from the periwinkle plant and used in pediatric leukemia?",
   "options": [
      "Vincristine",
      "Vinblastine",
      "Paclitaxel",
      "Docetaxel"
   ],
   "answer": "Vincristine",
   "explanation": "Vincristine is used in acute lymphoblastic leukemia and other pediatric neoplasms :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00943",
   "question": "Which antitumor antibiotic works primarily in G2 phase of the cell cycle?",
   "options": [
      "Bleomycin",
      "Doxorubicin",
      "Daunorubicin",
      "Mitoxantrone"
   ],
   "answer": "Bleomycin",
   "explanation": "Bleomycin primarily exerts its cytotoxic effect in G2 phase :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00944",
   "question": "How do anthracyclines like doxorubicin kill cancer cells?",
   "options": [
      "DNA intercalation, topoisomerase II inhibition, and free radical damage",
      "Microtubule stabilization",
      "Proteasome inhibition",
      "Immune checkpoint activation"
   ],
   "answer": "DNA intercalation, topoisomerase II inhibition, and free radical damage",
   "explanation": "Anthracyclines intercalate DNA, inhibit topoisomerase II, and generate free radicals :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00945",
   "question": "Which antimetabolite requires intrathecal administration for meningeal leukemia?",
   "options": [
      "Cytarabine",
      "Methotrexate",
      "Fluorouracil",
      "Mercaptopurine"
   ],
   "answer": "Cytarabine",
   "explanation": "Cytarabine is inactivated orally and may be given intrathecally for meningeal leukemia :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00946",
   "question": "Which nucleoside analog is used primarily for pancreatic and non–small cell lung cancer?",
   "options": [
      "Gemcitabine",
      "Azacitidine",
      "Cytarabine",
      "Fludarabine"
   ],
   "answer": "Gemcitabine",
   "explanation": "Gemcitabine is a deoxycytidine analog used in pancreatic and non–small cell lung cancer :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00947",
   "question": "Azacitidine is indicated for which hematologic disorders?",
   "options": [
      "Myelodysplastic syndromes and acute myeloid leukemia",
      "Chronic lymphocytic leukemia",
      "Multiple myeloma",
      "Non–Hodgkin lymphoma"
   ],
   "answer": "Myelodysplastic syndromes and acute myeloid leukemia",
   "explanation": "Azacitidine treats myelodysplastic syndromes and AML by incorporation into DNA/RNA :contentReference[oaicite:22]{index=22}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00948",
   "question": "Proteasome inhibitors like bortezomib exert anticancer effects by:",
   "options": [
      "Preventing degradation of proapoptotic factors",
      "Cross-linking DNA strands",
      "Inhibiting microtubule disassembly",
      "Intercalating into DNA"
   ],
   "answer": "Preventing degradation of proapoptotic factors",
   "explanation": "Proteasome inhibitors block proteasome function, leading to accumulation of proapoptotic proteins :contentReference[oaicite:23]{index=23}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00949",
   "question": "Which proteasome inhibitor is administered subcutaneously to reduce neuropathy?",
   "options": [
      "Bortezomib",
      "Ixazomib",
      "Carfilzomib",
      "Lenalidomide"
   ],
   "answer": "Bortezomib",
   "explanation": "Subcutaneous administration of bortezomib is preferred to lower neuropathy risk :contentReference[oaicite:24]{index=24}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00950",
   "question": "Lenalidomide and pomalidomide are contraindicated in pregnancy because they structurally resemble:",
   "options": [
      "Thalidomide",
      "Methotrexate",
      "Cyclophosphamide",
      "Bleomycin"
   ],
   "answer": "Thalidomide",
   "explanation": "Structural similarity to thalidomide led to teratogenic birth defects, so analogs are contraindicated in pregnancy :contentReference[oaicite:25]{index=25}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00951",
   "question": "The primary cytotoxic goal of chemotherapy is to:",
   "options": [
      "Induce apoptosis or lethal cytotoxic events in cancer cells",
      "Activate the patient’s immune system nonspecifically",
      "Promote blood vessel growth in tumors",
      "Enhance DNA repair mechanisms"
   ],
   "answer": "Induce apoptosis or lethal cytotoxic events in cancer cells",
   "explanation": "Chemotherapy aims to trigger apoptosis or lethal cytotoxicity in cancer cells to arrest tumor growth :contentReference[oaicite:26]{index=26}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00952",
   "question": "Newer targeted therapies may act by blocking:",
   "options": [
      "Cell-cycle checkpoints",
      "Microtubule polymerization",
      "DNA gyrase",
      "Thymidylate synthase"
   ],
   "answer": "Cell-cycle checkpoints",
   "explanation": "Targeted agents block checkpoints, allowing immune-mediated tumor cell death :contentReference[oaicite:27]{index=27}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00953",
   "question": "Adverse effects of checkpoint inhibitors often manifest as:",
   "options": [
      "Autoimmune toxicity",
      "Myelosuppression",
      "Alopecia",
      "Pulmonary fibrosis"
   ],
   "answer": "Autoimmune toxicity",
   "explanation": "Immune checkpoint inhibitors can cause autoimmune toxicities, contrasting traditional myelosuppressive effects :contentReference[oaicite:28]{index=28}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00954",
   "question": "Microtubule inhibitors like vincristine disrupt cancer cells by:",
   "options": [
      "Altering equilibrium between polymerized and depolymerized tubulin",
      "Cross-linking DNA",
      "Inhibiting topoisomerase II",
      "Blocking proteasomes"
   ],
   "answer": "Altering equilibrium between polymerized and depolymerized tubulin",
   "explanation": "Microtubule inhibitors disrupt tubulin dynamics, causing mitotic arrest and cytotoxicity :contentReference[oaicite:29]{index=29}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00955",
   "question": "Which supportive therapy reduces risk of neutropenic fever after chemotherapy?",
   "options": [
      "Granulocyte colony-stimulating factor",
      "Erythropoietin",
      "Platelet transfusion",
      "Antiemetic"
   ],
   "answer": "Granulocyte colony-stimulating factor",
   "explanation": "G-CSF increases neutrophil production to prevent neutropenic infections :contentReference[oaicite:30]{index=30}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00956",
   "question": "Tumor lysis syndrome most characteristically causes:",
   "options": [
      "Hyperuricemia",
      "Hyponatremia",
      "Hypoglycemia",
      "Hypercalcemia"
   ],
   "answer": "Hyperuricemia",
   "explanation": "Massive tumor cell lysis leads to hyperuricemia and other metabolic disturbances :contentReference[oaicite:31]{index=31}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00957",
   "question": "Long-term use of certain chemotherapeutics may lead to:",
   "options": [
      "Secondary malignancies",
      "Permanent alopecia",
      "Chronic fatigue syndrome",
      "Hypertension"
   ],
   "answer": "Secondary malignancies",
   "explanation": "Some agents are mutagenic and can cause secondary leukemias years after therapy :contentReference[oaicite:32]{index=32}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00958",
   "question": "Which rescue agent mitigates methotrexate-induced megaloblastic anemia?",
   "options": [
      "Leucovorin",
      "Mesna",
      "Amifostine",
      "Dexrazoxane"
   ],
   "answer": "Leucovorin",
   "explanation": "Leucovorin rescues normal cells from methotrexate’s folate antagonism :contentReference[oaicite:33]{index=33}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00959",
   "question": "Which drug most commonly causes hemorrhagic cystitis?",
   "options": [
      "Cyclophosphamide",
      "Bleomycin",
      "Doxorubicin",
      "Cisplatin"
   ],
   "answer": "Cyclophosphamide",
   "explanation": "Cyclophosphamide (and ifosfamide) can cause hemorrhagic cystitis as a dose-limiting toxicity :contentReference[oaicite:34]{index=34}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00960",
   "question": "Peripheral neuropathy is a common toxicity of:",
   "options": [
      "Vinca alkaloids and taxanes",
      "Anthracyclines",
      "Nitrosoureas",
      "Proteasome inhibitors"
   ],
   "answer": "Vinca alkaloids and taxanes",
   "explanation": "Vinca alkaloids, taxanes, and oxaliplatin commonly cause peripheral neuropathies :contentReference[oaicite:35]{index=35}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00961",
   "question": "Cells are most vulnerable to platinum agents during which phases?",
   "options": [
      "G1 and S",
      "G0",
      "G2 and M",
      "M only"
   ],
   "answer": "G1 and S",
   "explanation": "While cytotoxic at any stage, platinum complexes show greatest effect in G1 and S phases :contentReference[oaicite:36]{index=36}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00962",
   "question": "Which class of anticancer drugs includes trastuzumab?",
   "options": [
      "Monoclonal antibodies",
      "Alkylating agents",
      "Antimetabolites",
      "Microtubule inhibitors"
   ],
   "answer": "Monoclonal antibodies",
   "explanation": "Monoclonal antibodies are a targeted class that includes trastuzumab :contentReference[oaicite:37]{index=37}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00963",
   "question": "Which biologic agent can itself cause cardiotoxicity when combined with anthracyclines?",
   "options": [
      "Trastuzumab",
      "Bevacizumab",
      "Rituximab",
      "Cetuximab"
   ],
   "answer": "Trastuzumab",
   "explanation": "Trastuzumab adds cardiotoxic risk when used with anthracyclines :contentReference[oaicite:38]{index=38}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00964",
   "question": "Which immunomodulatory drugs have antiangiogenic and antiproliferative effects in multiple myeloma?",
   "options": [
      "Lenalidomide and pomalidomide",
      "Bortezomib and carfilzomib",
      "Thalidomide and bleomycin",
      "Cyclophosphamide and ifosfamide"
   ],
   "answer": "Lenalidomide and pomalidomide",
   "explanation": "Lenalidomide and pomalidomide modulate immunity and angiogenesis in multiple myeloma :contentReference[oaicite:39]{index=39}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00965",
   "question": "Patients on bortezomib require which prophylaxis due to zoster reactivation risk?",
   "options": [
      "Antiviral prophylaxis",
      "Antifungal prophylaxis",
      "Antibiotic prophylaxis",
      "No prophylaxis"
   ],
   "answer": "Antiviral prophylaxis",
   "explanation": "Bortezomib increases herpes zoster risk; antiviral prophylaxis is recommended :contentReference[oaicite:40]{index=40}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00966",
   "question": "Which proteasome inhibitor is available as an oral agent?",
   "options": [
      "Ixazomib",
      "Bortezomib",
      "Carfilzomib",
      "Thalidomide"
   ],
   "answer": "Ixazomib",
   "explanation": "Ixazomib is the oral proteasome inhibitor with a profile similar to bortezomib :contentReference[oaicite:41]{index=41}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00967",
   "question": "Which proteasome inhibitor is administered intravenously and often causes fever and fatigue?",
   "options": [
      "Carfilzomib",
      "Bortezomib",
      "Ixazomib",
      "Lenalidomide"
   ],
   "answer": "Carfilzomib",
   "explanation": "Carfilzomib is IV-only and its adverse effects include myelosuppression, fatigue, nausea, diarrhea, and fever :contentReference[oaicite:42]{index=42}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00968",
   "question": "Which alkylating agent must be biotransformed by CYP450 to MTIC?",
   "options": [
      "Dacarbazine",
      "Carmustine",
      "Cyclophosphamide",
      "Busulfan"
   ],
   "answer": "Dacarbazine",
   "explanation": "Dacarbazine is converted by CYP450 to the active methyltriazenoimidazole carboxamide :contentReference[oaicite:43]{index=43}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00969",
   "question": "Which agent crosses the blood–brain barrier and is used for glioblastoma?",
   "options": [
      "Temozolomide",
      "Dacarbazine",
      "Cyclophosphamide",
      "Nitrosoureas"
   ],
   "answer": "Temozolomide",
   "explanation": "Temozolomide crosses the BBB and is used in glioblastomas and metastatic melanoma :contentReference[oaicite:44]{index=44}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00970",
   "question": "Which nitrosourea is given as wafer implants intracranially?",
   "options": [
      "Carmustine",
      "Lomustine",
      "Temozolomide",
      "Dacarbazine"
   ],
   "answer": "Carmustine",
   "explanation": "Carmustine is administered IV and as intracranial wafer implants :contentReference[oaicite:45]{index=45}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00971",
   "question": "Busulfan is most associated with which serious toxicity?",
   "options": [
      "Pulmonary fibrosis",
      "Cardiotoxicity",
      "Neurotoxicity",
      "Hepatotoxicity"
   ],
   "answer": "Pulmonary fibrosis",
   "explanation": "Busulfan can cause “busulfan lung,” a form of pulmonary fibrosis :contentReference[oaicite:46]{index=46}."
},
 {
   "chapter_id": 37,
   "chapter": "Anticancer Drugs",
   "question_id": "00037-00972",
   "question": "Which anthracycline derivative is the 4-demethoxy analog of daunorubicin?",
   "options": [
      "Idarubicin",
      "Mitoxantrone",
      "Epirubicin",
      "Doxorubicin"
   ],
   "answer": "Idarubicin",
   "explanation": "Idarubicin is the 4-demethoxy analog of daunorubicin :contentReference[oaicite:47]{index=47}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00973",
   "question": "Which class of maintenance immunosuppressants includes cyclosporine and tacrolimus?",
   "options": [
      "Calcineurin inhibitors",
      "Costimulation blockers",
      "mTOR inhibitors",
      "Antiproliferatives"
   ],
   "answer": "Calcineurin inhibitors",
   "explanation": "Calcineurin inhibitors such as cyclosporine and tacrolimus block the calcium–calcineurin pathway to impair T-cell activation :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00974",
   "question": "Cyclosporine binds to which intracellular protein to inhibit calcineurin?",
   "options": [
      "FKBP",
      "Cyclophilin",
      "mTOR",
      "IL-2 receptor"
   ],
   "answer": "Cyclophilin",
   "explanation": "Cyclosporine binds to cyclophilin, whereas tacrolimus binds to FKBP, and these complexes inhibit calcineurin activity :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00975",
   "question": "Which adverse effect is the dose-limiting toxicity of calcineurin inhibitors?",
   "options": [
      "Nephrotoxicity",
      "Hepatotoxicity",
      "Ototoxicity",
      "Neurotoxicity"
   ],
   "answer": "Nephrotoxicity",
   "explanation": "Nephrotoxicity is a primary limitation of calcineurin inhibitors, necessitating lower-dose combination regimens :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00976",
   "question": "Belatacept is a recombinant fusion protein that blocks which signal in T-cell activation?",
   "options": [
      "Signal 1",
      "Signal 2 (costimulation)",
      "Signal 3 (IL-2 binding)",
      "Signal 4"
   ],
   "answer": "Signal 2 (costimulation)",
   "explanation": "Belatacept prevents CD28–CD80/86 interaction (signal 2), inhibiting T-cell costimulation :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00977",
   "question": "Which mTOR inhibitor requires therapeutic drug monitoring and can cause hyperlipidemia?",
   "options": [
      "Sirolimus",
      "Mycophenolate mofetil",
      "Azathioprine",
      "Basiliximab"
   ],
   "answer": "Sirolimus",
   "explanation": "Sirolimus (and everolimus) are mTOR inhibitors needing monitoring; they can cause hyperlipidemia, cytopenias, and GI distress :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00978",
   "question": "Azathioprine is a prodrug of which active metabolite?",
   "options": [
      "6-Mercaptopurine",
      "Mycophenolic acid",
      "Thioinosinic acid",
      "Allopurinol"
   ],
   "answer": "6-Mercaptopurine",
   "explanation": "Azathioprine is converted to 6-mercaptopurine and then to thioinosinic acid, which blocks DNA elongation :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00979",
   "question": "Which antiproliferative has largely replaced azathioprine in transplant regimens?",
   "options": [
      "Mycophenolate mofetil",
      "Cyclophosphamide",
      "Methotrexate",
      "Leflunomide"
   ],
   "answer": "Mycophenolate mofetil",
   "explanation": "Mycophenolate has supplanted azathioprine due to a better safety and efficacy profile :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00980",
   "question": "Which agent is an IL-2 receptor antagonist used in induction for kidney transplant?",
   "options": [
      "Basiliximab",
      "Belatacept",
      "Muromonab-CD3",
      "Alemtuzumab"
   ],
   "answer": "Basiliximab",
   "explanation": "Basiliximab is an IL-2 (CD25) receptor antagonist approved for kidney transplant induction :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00981",
   "question": "Muromonab-CD3 depletes which cell type?",
   "options": [
      "CD3+ T cells",
      "B cells",
      "Natural killer cells",
      "Dendritic cells"
   ],
   "answer": "CD3+ T cells",
   "explanation": "Muromonab-CD3 is an anti-CD3 monoclonal antibody that depletes T cells during induction or rejection therapy."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00982",
   "question": "IVIG’s immunomodulatory effects at high doses include:",
   "options": [
      "B-cell apoptosis",
      "Calcineurin inhibition",
      "mTOR activation",
      "IL-2 blockade"
   ],
   "answer": "B-cell apoptosis",
   "explanation": "High-dose IVIG induces B-cell apoptosis and modulates complement activation :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00983",
   "question": "Which corticosteroid adverse effects include hyperglycemia and mood changes?",
   "options": [
      "Prednisone",
      "Cyclosporine",
      "Sirolimus",
      "Tacrolimus"
   ],
   "answer": "Prednisone",
   "explanation": "Prednisone can cause weight gain, acne, insomnia, hyperglycemia, and mood swings :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00984",
   "question": "Switching cyclosporine to tacrolimus reduces the risk of:",
   "options": [
      "Hirsutism",
      "Nephrotoxicity",
      "Gingival hyperplasia",
      "Hypertension"
   ],
   "answer": "Hirsutism",
   "explanation": "Cyclosporine-induced hirsutism is alleviated by switching to tacrolimus :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00985",
   "question": "Which combination should be avoided due to overlapping mechanisms and toxicity?",
   "options": [
      "Cyclosporine and tacrolimus",
      "Tacrolimus and mycophenolate",
      "Cyclosporine and azathioprine",
      "Belatacept and MMF"
   ],
   "answer": "Cyclosporine and tacrolimus",
   "explanation": "Both are calcineurin inhibitors and nephrotoxic; using together is harmful :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00986",
   "question": "Which immunosuppressant avoids the need for therapeutic drug monitoring?",
   "options": [
      "Mycophenolate mofetil",
      "Cyclosporine",
      "Tacrolimus",
      "Sirolimus"
   ],
   "answer": "Mycophenolate mofetil",
   "explanation": "Only mycophenolate does not require routine monitoring :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00987",
   "question": "Acute rejection of a kidney transplant is best treated with:",
   "options": [
      "Antithymocyte globulin",
      "Azathioprine",
      "Basiliximab",
      "Prednisone"
   ],
   "answer": "Antithymocyte globulin",
   "explanation": "Antithymocyte globulin is the most effective antibody for acute rejection :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00988",
   "question": "Which agent increases risk of posttransplant lymphoproliferative disorder?",
   "options": [
      "Belatacept",
      "Sirolimus",
      "Azathioprine",
      "Cyclosporine"
   ],
   "answer": "Belatacept",
   "explanation": "Belatacept carries PTLD risk, especially CNS PTLD, in EBV-seronegative patients :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00989",
   "question": "Which enzyme family metabolizes both cyclosporine and tacrolimus?",
   "options": [
      "CYP3A4/5",
      "CYP2D6",
      "CYP1A2",
      "CYP2C9"
   ],
   "answer": "CYP3A4/5",
   "explanation": "Both are substrates of CYP3A4/5 and P-gp, leading to many drug interactions :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00990",
   "question": "Which monoclonal antibody depletes both T and B cells via CD52 binding?",
   "options": [
      "Alemtuzumab",
      "Rituximab",
      "Basiliximab",
      "Belimumab"
   ],
   "answer": "Alemtuzumab",
   "explanation": "Alemtuzumab binds CD52 causing depletion of T and B cells :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00991",
   "question": "Which agent is contraindicated in EBV-seronegative patients?",
   "options": [
      "Belatacept",
      "Sirolimus",
      "Mycophenolate mofetil",
      "Azathioprine"
   ],
   "answer": "Belatacept",
   "explanation": "Belatacept is contraindicated in EBV-seronegatives due to PTLD risk :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00992",
   "question": "Which maintenance drug class is least likely to require combination therapy?",
   "options": [
      "(None—most regimens use ≥2 agents)",
      "Calcineurin inhibitors",
      "mTOR inhibitors",
      "Antiproliferatives"
   ],
   "answer": "(None—most regimens use ≥2 agents)",
   "explanation": "Maintenance therapy typically uses 2–4 drugs with different mechanisms :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00993",
   "question": "Which adverse effects are unique to cyclosporine compared with tacrolimus?",
   "options": [
      "Hirsutism and gingival hyperplasia",
      "Hyperglycemia and tremor",
      "Hyperlipidemia and anemia",
      "Cataracts and osteoporosis"
   ],
   "answer": "Hirsutism and gingival hyperplasia",
   "explanation": "Hirsutism and gingival hyperplasia are associated with cyclosporine :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00994",
   "question": "Which mTOR inhibitor has a longer half-life than calcineurin inhibitors?",
   "options": [
      "Sirolimus",
      "Everolimus",
      "Tacrolimus",
      "Azathioprine"
   ],
   "answer": "Sirolimus",
   "explanation": "Sirolimus has a longer half-life than calcineurin inhibitors and everolimus :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 38,
   "chapter": "Immunosuppressants",
   "question_id": "00038-00995",
   "question": "Which antiproliferative drug’s toxicity is increased by allopurinol coadministration?",
   "options": [
      "Azathioprine",
      "Mycophenolate mofetil",
      "Sirolimus",
      "Methotrexate"
   ],
   "answer": "Azathioprine",
   "explanation": "Xanthine oxidase inhibitors like allopurinol increase azathioprine toxicity :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-00996",
   "question": "Which generation of H1 antihistamines is least likely to cause sedation?",
   "options": [
      "First-generation",
      "Second-generation",
      "Third-generation",
      "Fourth-generation"
   ],
   "answer": "Second-generation",
   "explanation": "Second-generation H1 antihistamines (e.g., fexofenadine, loratadine, cetirizine) are more polar, don’t readily cross the blood–brain barrier, and thus cause minimal sedation :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-00997",
   "question": "Which enzyme catalyzes the synthesis of histamine from histidine?",
   "options": [
      "Histidine decarboxylase",
      "Monoamine oxidase",
      "Histamine N-methyltransferase",
      "Diamine oxidase"
   ],
   "answer": "Histidine decarboxylase",
   "explanation": "Histidine decarboxylase removes the carboxyl group from histidine to form histamine :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-00998",
   "question": "Which histamine receptor subtype is a ligand-gated ion channel?",
   "options": [
      "H1",
      "H2",
      "H3",
      "H4"
   ],
   "answer": "H1",
   "explanation": "All H1 receptors are G protein–coupled; only 5-HT3 among histamine/serotonin receptors is ligand-gated. None of the histamine receptors are ion channels :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-00999",
   "question": "Which drug is a mast cell stabilizer as well as an H1 antagonist?",
   "options": [
      "Cetirizine",
      "Cyproheptadine",
      "Azelastine",
      "Fexofenadine"
   ],
   "answer": "Azelastine",
   "explanation": "Azelastine blocks H1 receptors and stabilizes mast cells, reducing mediator release :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01000",
   "question": "Diphenhydramine’s motion-sickness effects are due to blockade of H1 and which receptor?",
   "options": [
      "Muscarinic M1",
      "Dopamine D2",
      "Alpha1 adrenergic",
      "Serotonin 5-HT2"
   ],
   "answer": "Muscarinic M1",
   "explanation": "Diphenhydramine’s antiemetic action involves central H1 and M1 muscarinic blockade :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01001",
   "question": "Which second-generation antihistamine is a carboxylated derivative of hydroxyzine?",
   "options": [
      "Fexofenadine",
      "Cetirizine",
      "Loratadine",
      "Desloratadine"
   ],
   "answer": "Cetirizine",
   "explanation": "Cetirizine is the carboxylated form of hydroxyzine, reducing CNS penetration :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01002",
   "question": "Which adverse effect is most common with first-generation H1 blockers?",
   "options": [
      "Headache",
      "Sedation",
      "Tachycardia",
      "Rash"
   ],
   "answer": "Sedation",
   "explanation": "First-generation antihistamines readily cross into the CNS, causing sedation and sometimes paradoxical excitation in children :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01003",
   "question": "Which process terminates serotonin’s action in the synapse?",
   "options": [
      "Monoamine oxidase metabolism",
      "Catechol-O-methyltransferase methylation",
      "Reuptake by the serotonin transporter",
      "Glucuronidation"
   ],
   "answer": "Reuptake by the serotonin transporter",
   "explanation": "Serotonin is cleared via uptake into neurons/platelets and then metabolized primarily by MAO :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01004",
   "question": "Which receptor subtype mediates serotonin-induced emesis in chemotherapy?",
   "options": [
      "5-HT1A",
      "5-HT2A",
      "5-HT3",
      "5-HT4"
   ],
   "answer": "5-HT3",
   "explanation": "5-HT3 is a ligand-gated cation channel on vagal afferents and in the chemoreceptor trigger zone; antagonists prevent CINV :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01005",
   "question": "Triptans exert their antimigraine effect by agonism at which receptor?",
   "options": [
      "5-HT1B/1D",
      "5-HT2C",
      "5-HT3",
      "5-HT4"
   ],
   "answer": "5-HT1B/1D",
   "explanation": "Triptans constrict cranial vessels and inhibit neuropeptide release via 5-HT1B/1D receptor agonism :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01006",
   "question": "Which non-triptan agent selectively targets the 5-HT1F receptor?",
   "options": [
      "Ergotamine",
      "Rimegepant",
      "Ubrogepant",
      "Lasmiditan"
   ],
   "answer": "Lasmiditan",
   "explanation": "Lasmiditan is a selective 5-HT1F agonist without vasoconstrictive effects :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01007",
   "question": "Ergotamine is contraindicated in patients with:",
   "options": [
      "Migraine",
      "Coronary artery disease",
      "Depression",
      "Asthma"
   ],
   "answer": "Coronary artery disease",
   "explanation": "Ergot alkaloids cause vasoconstriction and risk ischemia in CAD or PVD :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01008",
   "question": "Which H2 antagonist is primarily used for peptic ulcer disease and discussed in Chapter 42?",
   "options": [
      "Ranitidine",
      "Famotidine",
      "Cimetidine",
      "Nizatidine"
   ],
   "answer": "Famotidine",
   "explanation": "Famotidine is a potent H2 blocker for acid suppression; Chapter 42 covers H2 antagonists in GI therapy :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01009",
   "question": "Which off-label use of cyproheptadine exploits its serotonin antagonism?",
   "options": [
      "Appetite stimulation",
      "Insomnia",
      "Allergic rhinitis",
      "Asthma"
   ],
   "answer": "Appetite stimulation",
   "explanation": "Cyproheptadine antagonizes serotonin in the appetite center and is used off-label to promote weight gain :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01010",
   "question": "Which adverse effect results from H2-receptor blockade?",
   "options": [
      "Gynecomastia with cimetidine",
      "Sedation",
      "Dry mouth",
      "Bronchospasm"
   ],
   "answer": "Gynecomastia with cimetidine",
   "explanation": "Cimetidine can cause endocrine effects like gynecomastia by inhibiting CYP enzymes and androgen binding :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01011",
   "question": "Which is the primary site of histamine storage in blood?",
   "options": [
      "Neutrophils",
      "Platelets",
      "Erythrocytes",
      "Lymphocytes"
   ],
   "answer": "Platelets",
   "explanation": "Platelets take up and store histamine in granules after release from enterochromaffin cells :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01012",
   "question": "Which histamine receptor subtype modulates neurotransmitter release in the CNS?",
   "options": [
      "H1",
      "H2",
      "H3",
      "H4"
   ],
   "answer": "H3",
   "explanation": "H3 receptors are presynaptic autoreceptors in the CNS, regulating histamine and other neurotransmitters :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01013",
   "question": "Which enzyme inactivates histamine after its release?",
   "options": [
      "Histamine methyltransferase",
      "Histamine N-methyltransferase",
      "Amine oxidase",
      "Monoamine oxidase"
   ],
   "answer": "Amine oxidase",
   "explanation": "Extracellular histamine is degraded by amine oxidases before reaching systemic circulation :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01014",
   "question": "Which topical antihistamine is indicated for allergic conjunctivitis?",
   "options": [
      "Cetirizine",
      "Azelastine",
      "Loratadine",
      "Fexofenadine"
   ],
   "answer": "Azelastine",
   "explanation": "Topical azelastine is approved for allergic conjunctivitis with dual H1 blockade and mast cell stabilization :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01015",
   "question": "Which receptor subtype’s activation in the GI tract increases secretion and motility?",
   "options": [
      "5-HT1",
      "5-HT2",
      "5-HT3",
      "5-HT4"
   ],
   "answer": "5-HT4",
   "explanation": "5-HT4 receptor activation enhances GI motility and secretion; agonists treat postoperative ileus :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01016",
   "question": "Which newer CGRP antagonist is approved for migraine prevention?",
   "options": [
      "Rimegepant",
      "Ubrogepant",
      "Erenumab",
      "Dihydroergotamine"
   ],
   "answer": "Erenumab",
   "explanation": "Erenumab is a monoclonal CGRP receptor antagonist approved for migraine prophylaxis :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 39,
   "chapter": "Histamine and Serotonin",
   "question_id": "00039-01017",
   "question": "Which ergot derivative is available as a nasal spray for cluster headache?",
   "options": [
      "Ergotamine",
      "Dihydroergotamine",
      "Ergonovine",
      "Methylergometrine"
   ],
   "answer": "Dihydroergotamine",
   "explanation": "DHE is used as a nasal spray in acute cluster headache for rapid vasoconstriction :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01018",
   "question": "What is the primary mechanism of action of nonsteroidal anti-inflammatory drugs (NSAIDs)?",
   "options": [
      "Inhibition of cyclooxygenase enzymes",
      "Activation of lipoxygenase pathway",
      "Blockade of leukotriene receptors",
      "Stimulation of prostacyclin synthesis"
   ],
   "answer": "Inhibition of cyclooxygenase enzymes",
   "explanation": "NSAIDs act primarily by inhibiting COX-1 and COX-2, the enzymes catalyzing the first step in prostanoid biosynthesis, leading to decreased prostaglandin synthesis :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01019",
   "question": "Which COX isoform is thought to mediate the anti-inflammatory and analgesic effects of NSAIDs?",
   "options": [
      "COX-1",
      "COX-2",
      "COX-3",
      "COX-4"
   ],
   "answer": "COX-2",
   "explanation": "Inhibition of COX-2, which is induced at sites of inflammation and injury, is believed responsible for NSAIDs’ anti-inflammatory and analgesic actions :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01020",
   "question": "How does aspirin differ from other NSAIDs in its interaction with cyclooxygenase?",
   "options": [
      "It reversibly inhibits COX",
      "It irreversibly acetylates COX",
      "It upregulates COX expression",
      "It has no effect on COX"
   ],
   "answer": "It irreversibly acetylates COX",
   "explanation": "Aspirin irreversibly acetylates and inactivates cyclooxygenase, whereas other NSAIDs are reversible inhibitors :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01021",
   "question": "Which three major therapeutic actions do NSAIDs share?",
   "options": [
      "Antiplatelet, antitumor, and antiviral",
      "Anti-inflammatory, analgesic, and antipyretic",
      "Antihypertensive, diuretic, and antipyretic",
      "Antiviral, anti-inflammatory, and antiplatelet"
   ],
   "answer": "Anti-inflammatory, analgesic, and antipyretic",
   "explanation": "NSAIDs, including aspirin, reduce inflammation, pain, and fever by inhibiting prostaglandin synthesis :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01022",
   "question": "Which NSAID is an exception in providing more potent analgesia for severe pain but only for short durations?",
   "options": [
      "Ibuprofen",
      "Naproxen",
      "Ketorolac",
      "Diclofenac"
   ],
   "answer": "Ketorolac",
   "explanation": "Ketorolac can be used for severe pain but only short term due to its toxicity profile :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01023",
   "question": "How does low-dose aspirin exert cardioprotective effects?",
   "options": [
      "Preferential COX-2 inhibition reducing prostacyclin",
      "Preferential COX-1 inhibition reducing thromboxane A₂",
      "Blocking lipoxygenase pathway",
      "Increasing prostaglandin I₂ synthesis"
   ],
   "answer": "Preferential COX-1 inhibition reducing thromboxane A₂",
   "explanation": "At low doses, aspirin selectively inhibits COX-1, reducing thromboxane A₂, which promotes vasoconstriction and platelet aggregation :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01024",
   "question": "Which prostaglandin analog can be co-administered with NSAIDs to protect the gastric mucosa?",
   "options": [
      "Alprostadil",
      "Bimatoprost",
      "Misoprostol",
      "Epoprostenol"
   ],
   "answer": "Misoprostol",
   "explanation": "Misoprostol, a PGE₁ analog, stimulates receptors on parietal cells to reduce acid secretion and enhances mucus/bicarbonate production, protecting against NSAID-induced ulcers :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01025",
   "question": "What distinguishes acetaminophen’s mechanism from that of NSAIDs?",
   "options": [
      "It is a potent peripheral COX-1 inhibitor",
      "It inhibits prostaglandin synthesis centrally and lacks peripheral anti-inflammatory activity",
      "It selectively blocks COX-2 in inflammatory cells",
      "It irreversibly acetylates COX enzymes"
   ],
   "answer": "It inhibits prostaglandin synthesis centrally and lacks peripheral anti-inflammatory activity",
   "explanation": "Acetaminophen acts in the CNS for analgesic/antipyretic effects but is inactivated peripherally, so it has minimal anti-inflammatory action and no effect on platelets :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01026",
   "question": "Compared to ibuprofen, acetaminophen has:",
   "options": [
      "More GI and CV adverse effects",
      "Less risk for cardiovascular events",
      "Stronger anti-inflammatory effects",
      "Greater antipyretic potency"
   ],
   "answer": "Less risk for cardiovascular events",
   "explanation": "Acetaminophen lacks systemic GI, cardiovascular, and bleeding adverse effects seen with NSAIDs, though it has comparable antipyretic action :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01027",
   "question": "NSAIDs’ analgesic effect is due to decreased synthesis of which mediator?",
   "options": [
      "Bradykinin",
      "Histamine",
      "Prostaglandin E₂",
      "Leukotriene B₄"
   ],
   "answer": "Prostaglandin E₂",
   "explanation": "By inhibiting COX-2, NSAIDs reduce PGE₂ synthesis, which sensitizes nerve endings to pain mediators :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01028",
   "question": "NSAIDs are used in arthritis but do not:",
   "options": [
      "Reduce inflammation",
      "Alleviate pain",
      "Prevent disease progression",
      "Provide analgesia"
   ],
   "answer": "Prevent disease progression",
   "explanation": "NSAIDs inhibit inflammation and pain in arthritis but neither arrest progression nor induce remission :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01029",
   "question": "The antipyretic action of NSAIDs involves inhibition of PGE₂ in which location?",
   "options": [
      "Anterior hypothalamic thermoregulatory center",
      "Peripheral nociceptors",
      "Liver parenchyma",
      "Renal medulla"
   ],
   "answer": "Anterior hypothalamic thermoregulatory center",
   "explanation": "NSAIDs impede PGE₂ synthesis in the hypothalamus, resetting the temperature set-point and lowering fever via vasodilation and sweating :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01030",
   "question": "Which range of toxicity is characteristic of mild salicylate overdose (salicylism)?",
   "options": [
      "Hepatic necrosis and coma",
      "Nausea, hyperventilation, tinnitus, mental confusion",
      "Renal failure and edema",
      "Bone marrow suppression"
   ],
   "answer": "Nausea, hyperventilation, tinnitus, mental confusion",
   "explanation": "Salicylism features GI distress, respiratory stimulation, headache, confusion, and tinnitus :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01031",
   "question": "Celecoxib’s selectivity profile is best described as:",
   "options": [
      "Reversible COX-1 selective inhibitor",
      "Irreversible COX-1 inhibitor",
      "Reversible COX-2 selective inhibitor",
      "Nonselective COX inhibitor"
   ],
   "answer": "Reversible COX-2 selective inhibitor",
   "explanation": "Celecoxib reversibly inhibits COX-2 more than COX-1, aiming to preserve gastric prostaglandins while reducing inflammation :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01032",
   "question": "Which adverse effect is less common with COX-2 selective inhibitors than with nonselective NSAIDs?",
   "options": [
      "Cardiovascular events",
      "Renal toxicity",
      "Gastrointestinal bleeding",
      "Hepatotoxicity"
   ],
   "answer": "Gastrointestinal bleeding",
   "explanation": "COX-2 inhibitors like celecoxib cause less GI bleeding than nonselective NSAIDs, though CV risk remains similar :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01033",
   "question": "NSAID-induced renal effects include all EXCEPT:",
   "options": [
      "Sodium and water retention",
      "Acute kidney injury",
      "Decreased renal blood flow",
      "Enhanced prostaglandin synthesis"
   ],
   "answer": "Enhanced prostaglandin synthesis",
   "explanation": "NSAIDs decrease PG synthesis, causing sodium/water retention, reduced renal perfusion, and potential acute kidney injury :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01034",
   "question": "Which combination with NSAIDs can negate aspirin’s antiplatelet effect?",
   "options": [
      "Aspirin plus warfarin",
      "Aspirin plus ibuprofen taken before aspirin",
      "Aspirin plus acetaminophen",
      "Aspirin plus naproxen"
   ],
   "answer": "Aspirin plus ibuprofen taken before aspirin",
   "explanation": "Ibuprofen can block aspirin’s access to COX-1 if taken first, antagonizing its irreversible platelet inhibition :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01035",
   "question": "What is the primary toxic metabolite responsible for acetaminophen-induced hepatotoxicity?",
   "options": [
      "NAPQI",
      "PGE₂",
      "Thromboxane A₂",
      "Leukotriene B₄"
   ],
   "answer": "NAPQI",
   "explanation": "Acetaminophen is metabolized to N-acetyl-p-benzoquinoneimine (NAPQI), which depletes glutathione and causes liver necrosis in overdose :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01036",
   "question": "Which antidote replenishes glutathione to treat acetaminophen overdose?",
   "options": [
      "N-acetylcysteine",
      "Leucovorin",
      "Mesna",
      "Deferoxamine"
   ],
   "answer": "N-acetylcysteine",
   "explanation": "N-acetylcysteine supplies cysteine for glutathione synthesis to detoxify NAPQI in acetaminophen overdose :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 40,
   "chapter": "Anti-Inflammatory, Antipyretic, and Analgesic Agents",
   "question_id": "00040-01037",
   "question": "Which acute gout therapy is often started with NSAIDs such as indomethacin?",
   "options": [
      "Allopurinol",
      "Probenecid",
      "Indomethacin",
      "Febuxostat"
   ],
   "answer": "Indomethacin",
   "explanation": "Indomethacin and other NSAIDs are first-line for acute gout flares to reduce inflammation and pain :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01038",
   "question": "Which class of drugs irreversibly inhibits the H⁺/K⁺-ATPase in gastric parietal cells?",
   "options": [
      "Proton pump inhibitors",
      "H₂-receptor antagonists",
      "Antacids",
      "Mucosal protectants"
   ],
   "answer": "Proton pump inhibitors",
   "explanation": "PPIs covalently bind and inactivate the proton pump, providing potent and long-lasting suppression of acid secretion :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01039",
   "question": "Which H₂-receptor antagonist has the fewest drug interactions?",
   "options": [
      "Cimetidine",
      "Famotidine",
      "Ranitidine",
      "Nizatidine"
   ],
   "answer": "Famotidine",
   "explanation": "Famotidine does not inhibit cytochrome P450 enzymes, unlike cimetidine, which causes numerous interactions :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01040",
   "question": "Sucralfate promotes ulcer healing primarily by:",
   "options": [
      "Neutralizing gastric acid",
      "Forming a protective barrier over ulcers",
      "Inhibiting H₂ receptors",
      "Stimulating prostaglandin synthesis"
   ],
   "answer": "Forming a protective barrier over ulcers",
   "explanation": "Sucralfate polymerizes in acid to form a viscous, adhesive barrier that protects mucosa and ulcer beds :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01041",
   "question": "Which antacid would most rapidly raise gastric pH after ingestion?",
   "options": [
      "Calcium carbonate",
      "Magnesium hydroxide",
      "Aluminum hydroxide",
      "Sodium bicarbonate"
   ],
   "answer": "Sodium bicarbonate",
   "explanation": "Sodium bicarbonate neutralizes acid immediately on contact, producing rapid pH rise but can cause systemic alkalosis :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01042",
   "question": "Bismuth subsalicylate helps treat H. pylori ulcers by all EXCEPT:",
   "options": [
      "Antimicrobial activity",
      "Inhibiting pepsin",
      "Coating necrotic mucosa",
      "Reducing acid secretion"
   ],
   "answer": "Reducing acid secretion",
   "explanation": "Bismuth protects and coats mucosa, has some antimicrobial and pepsin-inhibitory effects but does not directly reduce acid secretion :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01043",
   "question": "Which 5-HT₃ antagonist has the longest half-life, reducing need for repeat dosing in multiday chemotherapy?",
   "options": [
      "Ondansetron",
      "Granisetron",
      "Dolasetron",
      "Palonosetron"
   ],
   "answer": "Palonosetron",
   "explanation": "Palonosetron’s half-life (~42 h) allows single-dose prophylaxis for CINV without repeated administration :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01044",
   "question": "Metoclopramide’s antiemetic action is due to:",
   "options": [
      "5-HT₃ receptor antagonism",
      "Dopamine D₂ receptor blockade",
      "NK₁ receptor antagonism",
      "Muscarinic receptor blockade"
   ],
   "answer": "Dopamine D₂ receptor blockade",
   "explanation": "Metoclopramide blocks D₂ receptors in the chemoreceptor trigger zone, reducing CINV and promoting gut motility :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01045",
   "question": "Which antiemetic class is effective for both acute and delayed phases of CINV when combined with dexamethasone?",
   "options": [
      "Phenothiazines",
      "5-HT₃ antagonists",
      "Neurokinin-1 antagonists",
      "Benzodiazepines"
   ],
   "answer": "Neurokinin-1 antagonists",
   "explanation": "NK₁ antagonists (e.g., aprepitant) cover delayed CINV and are given with dexamethasone and a 5-HT₃ blocker :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01046",
   "question": "Which corticosteroid is commonly used as an adjunct in CINV protocols?",
   "options": [
      "Prednisone",
      "Hydrocortisone",
      "Dexamethasone",
      "Methylprednisolone"
   ],
   "answer": "Dexamethasone",
   "explanation": "Dexamethasone’s antiemetic mechanism is unclear, but it enhances efficacy of 5-HT₃ and NK₁ antagonists in CINV :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01047",
   "question": "Which anticholinergic is delivered via transdermal patch for PONV prevention?",
   "options": [
      "Scopolamine",
      "Atropine",
      "Glycopyrrolate",
      "Ipratropium"
   ],
   "answer": "Scopolamine",
   "explanation": "Transdermal scopolamine prevents motion-induced and postoperative nausea by blocking muscarinic receptors centrally :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01048",
   "question": "Promethazine’s antiemetic effect is primarily via:",
   "options": [
      "H₁-receptor antagonism",
      "5-HT₃ antagonism",
      "Dopamine antagonism",
      "NK₁ antagonism"
   ],
   "answer": "H₁-receptor antagonism",
   "explanation": "Promethazine blocks H₁ and also some D₂ receptors, but its antiemetic use is based on antihistaminic and anticholinergic action :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01049",
   "question": "Which phenothiazine is used for low-emetogenic chemotherapy prophylaxis?",
   "options": [
      "Prochlorperazine",
      "Ondansetron",
      "Aprepitant",
      "Lorazepam"
   ],
   "answer": "Prochlorperazine",
   "explanation": "Prochlorperazine blocks D₂ in the CTZ and is effective for low-emetogenic regimens but has dose-limiting EPS :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01050",
   "question": "Which antidiarrheal acts on opioid receptors in the gut without central effects at usual doses?",
   "options": [
      "Diphenoxylate",
      "Docusate",
      "Loperamide",
      "Bismuth subsalicylate"
   ],
   "answer": "Loperamide",
   "explanation": "Loperamide is peripherally restricted, activating μ-opioid receptors to slow motility without analgesia :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01051",
   "question": "Diphenoxylate is combined with atropine to:",
   "options": [
      "Enhance opioid effect",
      "Discourage abuse",
      "Increase absorption",
      "Reduce anticholinergic side effects"
   ],
   "answer": "Discourage abuse",
   "explanation": "Atropine is added to deter overdose and abuse of the opioid-like diphenoxylate :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01052",
   "question": "Adsorbents like methylcellulose:",
   "options": [
      "Bind toxins and coat mucosa",
      "Neutralize acid",
      "Inhibit lipoxygenase",
      "Stimulate fluid secretion"
   ],
   "answer": "Bind toxins and coat mucosa",
   "explanation": "Aluminum hydroxide and methylcellulose adsorb irritants/toxins and protect the mucosa, but are less effective than antimotility agents :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01053",
   "question": "Which laxative is a stool surfactant recommended in pregnancy?",
   "options": [
      "Castor oil",
      "Docusate",
      "Bisacodyl",
      "Mineral oil"
   ],
   "answer": "Docusate",
   "explanation": "Docusate is safe in pregnancy for mild constipation; castor oil is contraindicated due to uterine contractions :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01054",
   "question": "Bisacodyl acts as a:",
   "options": [
      "Bulk-forming laxative",
      "Osmotic laxative",
      "Stimulant laxative",
      "Stool softener"
   ],
   "answer": "Stimulant laxative",
   "explanation": "Bisacodyl stimulates enteric nerves to increase peristalsis and fluid secretion in the colon :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01055",
   "question": "Lubiprostone increases intestinal fluid via activation of:",
   "options": [
      "CFTR chloride channels",
      "Type 2 chloride channels (ClC-2)",
      "Guanylate cyclase-C",
      "Sodium–potassium pump"
   ],
   "answer": "Type 2 chloride channels (ClC-2)",
   "explanation": "Lubiprostone opens ClC-2 channels on enterocytes to enhance chloride-rich fluid secretion, easing constipation :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01056",
   "question": "Linaclotide’s mechanism in IBS-C involves:",
   "options": [
      "5-HT₃ antagonism",
      "CGRP blockade",
      "Guanylate cyclase-C activation",
      "Mu-opioid inhibition"
   ],
   "answer": "Guanylate cyclase-C activation",
   "explanation": "Linaclotide binds GC-C on enterocytes, raising cGMP to increase secretion and reduce pain in IBS-C :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01057",
   "question": "Alosetron is restricted to females with severe IBS-D because of risk of:",
   "options": [
      "Ischemic colitis",
      "Pancreatitis",
      "Hepatotoxicity",
      "Nephrolithiasis"
   ],
   "answer": "Ischemic colitis",
   "explanation": "Alosetron’s use is limited by ischemic colitis and severe constipation risk in IBS-D :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 42,
   "chapter": "Gastrointestinal and Antiemetic Drugs",
   "question_id": "00042-01058",
   "question": "Which monoclonal antibody is indicated for moderate-to-severe ulcerative colitis?",
   "options": [
      "Infliximab",
      "Loperamide",
      "Metoclopramide",
      "Linaclotide"
   ],
   "answer": "Infliximab",
   "explanation": "Infliximab, an anti-TNFα, is approved for moderate-to-severe IBD, including ulcerative colitis :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01059",
   "question": "What is the mechanism of action of phosphodiesterase-5 inhibitors in treating erectile dysfunction?",
   "options": [
      "They inhibit degradation of cyclic GMP by blocking PDE-5",
      "They increase calcium influx into smooth muscle",
      "They block alpha-1 receptors in the prostate",
      "They stimulate beta-3 receptors in the bladder"
   ],
   "answer": "They inhibit degradation of cyclic GMP by blocking PDE-5",
   "explanation": "PDE-5 inhibitors prevent degradation of cGMP in the corpus cavernosum, thereby enhancing smooth muscle relaxation and blood flow during sexual stimulation :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01060",
   "question": "Why do PDE-5 inhibitors have no effect in the absence of sexual stimulation?",
   "options": [
      "Because cGMP production is dependent on nitric oxide release during sexual stimulation",
      "Because they require co-administration with nitrates",
      "Because they only act on alpha-adrenergic receptors",
      "Because they need proton pump activation"
   ],
   "answer": "Because cGMP production is dependent on nitric oxide release during sexual stimulation",
   "explanation": "Sexual stimulation triggers NO release and cGMP formation; PDE-5 inhibitors only prolong cGMP action and have no effect without initial NO-mediated cGMP synthesis :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01061",
   "question": "Which agents are first-line therapy for erectile dysfunction due to their efficacy and safety?",
   "options": [
      "Phosphodiesterase-5 inhibitors",
      "Alprostadil suppositories",
      "Penile implants",
      "Testosterone injections"
   ],
   "answer": "Phosphodiesterase-5 inhibitors",
   "explanation": "PDE-5 inhibitors (sildenafil, vardenafil, tadalafil, avanafil) are first-line for ED because of their proven efficacy, ease of oral dosing, and favorable safety profile :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01062",
   "question": "Which PDE-5 inhibitors are also approved for pulmonary hypertension (at different doses)?",
   "options": [
      "Sildenafil and tadalafil",
      "Vardenafil and avanafil",
      "Tadalafil and avanafil",
      "Sildenafil and vardenafil"
   ],
   "answer": "Sildenafil and tadalafil",
   "explanation": "Sildenafil and tadalafil are indicated for erectile dysfunction and, at different dosing regimens, for pulmonary hypertension :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01063",
   "question": "How does food affect the absorption of sildenafil and vardenafil?",
   "options": [
      "High-fat meals delay absorption of both drugs",
      "High-fat meals increase bioavailability of both drugs",
      "Food has no effect on either drug",
      "Food accelerates absorption of both drugs"
   ],
   "answer": "High-fat meals delay absorption of both drugs",
   "explanation": "Sildenafil and vardenafil absorption is delayed by high-fat meals, so they should be taken on an empty stomach for optimal effect :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01064",
   "question": "Which PDE-5 inhibitor has the longest half-life, allowing once-daily dosing and up to 36 hours of effect?",
   "options": [
      "Tadalafil",
      "Sildenafil",
      "Vardenafil",
      "Avanafil"
   ],
   "answer": "Tadalafil",
   "explanation": "Tadalafil’s half-life (~18 h) supports once-daily dosing and an extended 36-hour window of erectile enhancement :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01065",
   "question": "Which PDE-5 inhibitor has the quickest onset of action, suitable when a shorter lead time is desired?",
   "options": [
      "Avanafil",
      "Sildenafil",
      "Tadalafil",
      "Vardenafil"
   ],
   "answer": "Avanafil",
   "explanation": "Avanafil has the fastest onset, with efficacy beginning as soon as 30 minutes after dosing :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01066",
   "question": "Through which metabolic pathway are all PDE-5 inhibitors primarily cleared?",
   "options": [
      "CYP3A4-mediated metabolism",
      "Glucuronidation",
      "Renal excretion unchanged",
      "CYP2D6-mediated metabolism"
   ],
   "answer": "CYP3A4-mediated metabolism",
   "explanation": "All PDE-5 inhibitors are metabolized by CYP3A4 (and some by P-gp), with dosage adjustments needed in hepatic or renal impairment :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01067",
   "question": "Which are the most common adverse effects of PDE-5 inhibitors?",
   "options": [
      "Headache, flushing, dyspepsia, nasal congestion",
      "Bradycardia, hypotension, dry mouth, constipation",
      "Tinnitus, insomnia, weight gain, rash",
      "Renal failure, edema, hyperglycemia, tremor"
   ],
   "answer": "Headache, flushing, dyspepsia, nasal congestion",
   "explanation": "The frequent side effects include headache, flushing, dyspepsia, nasal congestion, and rarely color-vision changes or sudden hearing loss :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01068",
   "question": "Why are PDE-5 inhibitors contraindicated with nitrates?",
   "options": [
      "Because combined vasodilatory effects can cause life-threatening hypotension",
      "Because nitrates induce CYP3A4, reducing PDE-5 levels",
      "Because nitrates block PDE-5 binding sites",
      "Because nitrates increase cGMP independently"
   ],
   "answer": "Because combined vasodilatory effects can cause life-threatening hypotension",
   "explanation": "Co-administration with nitrates potentiates hypotensive effects and is contraindicated to avoid severe low blood pressure :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01069",
   "question": "Which agent is the only PDE-5 inhibitor approved for both erectile dysfunction and benign prostatic hyperplasia?",
   "options": [
      "Tadalafil",
      "Sildenafil",
      "Vardenafil",
      "Avanafil"
   ],
   "answer": "Tadalafil",
   "explanation": "Tadalafil is uniquely approved for ED and BPH due to PDE-5 presence in prostate and bladder smooth muscle :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01070",
   "question": "How do 5α-reductase inhibitors improve symptoms of BPH?",
   "options": [
      "By reducing conversion of testosterone to dihydrotestosterone",
      "By blocking alpha-1 receptors in prostate",
      "By stimulating beta-3 receptors in bladder",
      "By inhibiting prostaglandin synthesis"
   ],
   "answer": "By reducing conversion of testosterone to dihydrotestosterone",
   "explanation": "Finasteride and dutasteride inhibit 5α-reductase, lowering DHT levels, reducing prostate growth over months :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01071",
   "question": "How long do 5α-reductase inhibitors typically take to show clinical benefit in BPH?",
   "options": [
      "6 to 12 months",
      "2 to 4 weeks",
      "1 to 2 days",
      "Immediately"
   ],
   "answer": "6 to 12 months",
   "explanation": "Because prostate shrinkage requires time, finasteride and dutasteride may take 6–12 months to improve symptoms :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01072",
   "question": "Why is combination therapy with an α-blocker and a 5α-reductase inhibitor appropriate in some BPH patients?",
   "options": [
      "To provide both immediate symptom relief and long-term prostate shrinkage",
      "To mitigate PDE-5 inhibitor adverse effects",
      "To treat coexisting overactive bladder",
      "To enhance testosterone levels"
   ],
   "answer": "To provide both immediate symptom relief and long-term prostate shrinkage",
   "explanation": "α-Blockers offer rapid LUTS relief, while 5α-reductase inhibitors reduce prostate volume over months :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01073",
   "question": "Which drugs block both α1A and α1B receptors, and may cause orthostatic hypotension?",
   "options": [
      "Alfuzosin, doxazosin, terazosin",
      "Tamsulosin and silodosin",
      "Finasteride and dutasteride",
      "Sildenafil and tadalafil"
   ],
   "answer": "Alfuzosin, doxazosin, terazosin",
   "explanation": "Nonselective α1-blockers (alfuzosin, doxazosin, terazosin) block α1A/B, causing smooth muscle relaxation but risk orthostatic hypotension :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01074",
   "question": "Which α1-blockers are more selective for prostate α1A receptors, reducing systemic hypotension but increasing risk of ejaculatory dysfunction?",
   "options": [
      "Tamsulosin and silodosin",
      "Alfuzosin and terazosin",
      "Finasteride and dutasteride",
      "Sildenafil and vardenafil"
   ],
   "answer": "Tamsulosin and silodosin",
   "explanation": "Selective α1A antagonists (tamsulosin, silodosin) preferentially relax prostatic smooth muscle with fewer blood pressure effects but more retrograde ejaculation :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01075",
   "question": "What are common adverse effects of α1-adrenergic antagonists in BPH treatment?",
   "options": [
      "Dizziness, orthostatic hypotension, headache, floppy-iris syndrome",
      "Headache, flushing, dyspepsia",
      "Gynecomastia, sexual dysfunction",
      "Dry mouth, constipation, blurred vision"
   ],
   "answer": "Dizziness, orthostatic hypotension, headache, floppy-iris syndrome",
   "explanation": "α1-Blockers can cause dizziness, orthostatic hypotension, headache, and 'floppy-iris syndrome' during cataract surgery :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01076",
   "question": "What is the 'first-dose phenomenon' associated with α1-blockers?",
   "options": [
      "Syncope due to marked orthostatic hypotension after the initial dose",
      "Priapism following first dose",
      "Headache and flushing",
      "Acute urinary retention"
   ],
   "answer": "Syncope due to marked orthostatic hypotension after the initial dose",
   "explanation": "The initial dose may produce profound vasodilation and syncope, so α1-blockers are titrated from a low first dose :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01077",
   "question": "Alprostadil treats erectile dysfunction by what mechanism?",
   "options": [
      "Increasing cAMP in cavernosal tissue to relax smooth muscle",
      "Inhibiting PDE-5 to increase cGMP",
      "Blocking alpha-1 receptors",
      "Stimulating beta-3 receptors"
   ],
   "answer": "Increasing cAMP in cavernosal tissue to relax smooth muscle",
   "explanation": "Alprostadil is a PGE₁ analog that raises cAMP in corpus cavernosum, causing smooth muscle relaxation and arterial dilation :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01078",
   "question": "By which routes can alprostadil be administered for ED?",
   "options": [
      "Intracavernosal injection or intraurethral suppository",
      "Oral tablet or transdermal patch",
      "IV infusion or IM injection",
      "Topical gel or oral capsule"
   ],
   "answer": "Intracavernosal injection or intraurethral suppository",
   "explanation": "Alprostadil is delivered by injection into the corpora cavernosa or intraurethral suppository for ED :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01079",
   "question": "Which surgical option is reserved for ED unresponsive to pharmacotherapy?",
   "options": [
      "Penile prosthesis implantation",
      "Transurethral resection of the prostate",
      "Vasectomy",
      "Nephrectomy"
   ],
   "answer": "Penile prosthesis implantation",
   "explanation": "Penile implants are a third-line ED treatment when pharmacologic and less invasive options fail :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01080",
   "question": "Which PDE-5 inhibitor has both the quickest onset and a minimal food effect?",
   "options": [
      "Avanafil",
      "Sildenafil",
      "Tadalafil",
      "Vardenafil"
   ],
   "answer": "Avanafil",
   "explanation": "Avanafil offers the fastest onset (30 min) and is minimally affected by food, making its timing more flexible :contentReference[oaicite:21]{index=21} :contentReference[oaicite:22]{index=22}."
},
 {
   "chapter_id": 43,
   "chapter": "Drugs for Urologic Disorders",
   "question_id": "00043-01081",
   "question": "What are the elimination half-lives of finasteride and dutasteride, respectively?",
   "options": [
      "6–16 hours and ~5 weeks",
      "2–4 hours and 12 hours",
      "24 hours and 48 hours",
      "30 minutes and 1 hour"
   ],
   "answer": "6–16 hours and ~5 weeks",
   "explanation": "Finasteride’s half-life is 6–16 h; dutasteride’s is ~5 weeks at steady state :contentReference[oaicite:23]{index=23}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01082",
   "question": "What is the primary mechanism by which oral elemental iron corrects iron deficiency anemia?",
   "options": [
      "Supplementation with elemental iron replenishes ferritin stores and supports hemoglobin synthesis",
      "Iron acts as a cofactor for erythropoietin production in the kidney",
      "Iron directly stimulates bone marrow erythroid progenitor proliferation",
      "Iron blocks hepcidin to enhance iron release from macrophages"
   ],
   "answer": "Supplementation with elemental iron replenishes ferritin stores and supports hemoglobin synthesis",
   "explanation": "Oral elemental iron is absorbed in the duodenum, stored as ferritin, transported by transferrin to the marrow, and used for hemoglobin production :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01083",
   "question": "Which signs are characteristic of iron deficiency anemia and guide its initial evaluation?",
   "options": [
      "Pica, koilonychias, and angular cheilitis",
      "Jaundice, splenomegaly, and dark urine",
      "Petechiae, bleeding gums, and epistaxis",
      "Hypertension, headache, and tinnitus"
   ],
   "answer": "Pica, koilonychias, and angular cheilitis",
   "explanation": "Iron deficiency anemia may present with pica (ice or dirt craving), koilonychias (spoon nails), and mouth corner soreness :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01084",
   "question": "What daily oral elemental iron dose does the CDC recommend for treating iron deficiency anemia in nonpregnant adults?",
   "options": [
      "60–120 mg/day in divided doses",
      "10–20 mg/day as a single dose",
      "200–300 mg/day in divided doses",
      "300–400 mg/day as a single dose"
   ],
   "answer": "60–120 mg/day in divided doses",
   "explanation": "The CDC recommends 60–120 mg/day of elemental iron, administered two to three times daily, though lower doses may improve tolerability :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01085",
   "question": "Where and in what form is oral iron primarily absorbed?",
   "options": [
      "In the duodenum as ferrous iron under acidic conditions",
      "In the jejunum as ferric iron under alkaline conditions",
      "In the ileum as heme iron bound to hemoglobin",
      "In the colon as ferritin-bound iron"
   ],
   "answer": "In the duodenum as ferrous iron under acidic conditions",
   "explanation": "Acidic gastric pH keeps iron in the soluble ferrous form, which is absorbed mainly in the duodenum; absorption decreases with larger doses :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01086",
   "question": "Which oral iron formulation contains essentially 100% elemental iron?",
   "options": [
      "Carbonyl iron",
      "Ferrous sulfate",
      "Ferrous gluconate",
      "Ferric ammonium citrate"
   ],
   "answer": "Carbonyl iron",
   "explanation": "Carbonyl iron consists entirely of elemental iron, whereas ferrous sulfate, gluconate, and ferric citrate contain far lower percentages :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01087",
   "question": "Why might lower doses or alternate-day dosing of oral iron improve adherence?",
   "options": [
      "They reduce GI side effects without compromising absorption",
      "They increase hepcidin suppression leading to better uptake",
      "They enhance iron’s bioavailability in the presence of food",
      "They avoid saturating transferrin, preventing toxicity"
   ],
   "answer": "They reduce GI side effects without compromising absorption",
   "explanation": "Lower or every-other-day dosing causes fewer GI adverse effects yet achieves similar absorption and efficacy :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01088",
   "question": "When is parenteral iron indicated over oral iron therapy?",
   "options": [
      "In patients intolerant of oral iron, with malabsorption, ESRD, or ongoing blood loss",
      "In mild iron deficiency with no symptoms",
      "In patients with adequate oral iron absorption",
      "Only when serum ferritin is above normal"
   ],
   "answer": "In patients intolerant of oral iron, with malabsorption, ESRD, or ongoing blood loss",
   "explanation": "Parenteral iron is used when oral formulations are poorly tolerated, inadequately absorbed, or when rapid repletion is needed (e.g., ESRD) :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01089",
   "question": "What precaution is recommended before administering iron dextran?",
   "options": [
      "Give a test dose to monitor for anaphylactoid reactions",
      "Ensure patient is fasting for at least 12 hours",
      "Pre-treat with proton pump inhibitors",
      "Co-administer with vitamin C to enhance absorption"
   ],
   "answer": "Give a test dose to monitor for anaphylactoid reactions",
   "explanation": "Iron dextran can cause severe hypersensitivity; a test dose over 5–30 minutes is given to detect reactions before full dosing :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01090",
   "question": "Which newer parenteral iron formulations have a lower risk of severe reactions than iron dextran?",
   "options": [
      "Sodium ferric gluconate, ferumoxytol, ferric carboxymaltose, and iron sucrose",
      "Ferrous sulfate and ferrous gluconate",
      "Polysaccharide–iron complex and carbonyl iron",
      "Ferric ammonium citrate and ferric chloride"
   ],
   "answer": "Sodium ferric gluconate, ferumoxytol, ferric carboxymaltose, and iron sucrose",
   "explanation": "These formulations are safer than iron dextran, with much lower hypersensitivity risk, though a test dose is still advised :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01091",
   "question": "Folate deficiency causes megaloblastic anemia by impairing synthesis of:",
   "options": [
      "Purines and pyrimidines needed for DNA replication",
      "Hemoglobin chains in red blood cells",
      "Erythropoietin in the kidney",
      "Iron incorporation into heme"
   ],
   "answer": "Purines and pyrimidines needed for DNA replication",
   "explanation": "Folate is required for nucleotide synthesis; its deficiency halts DNA production, leading to large, immature red cells (megaloblasts) :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01092",
   "question": "Why must vitamin B₁₂ deficiency be excluded before empiric folate therapy?",
   "options": [
      "Folate reverses hematologic findings but allows neurologic damage from B₁₂ deficiency to progress",
      "Folate exacerbates B₁₂ malabsorption",
      "Folate increases homocysteine without affecting methylmalonic acid",
      "Folate causes B₁₂-dependent anemia if given alone"
   ],
   "answer": "Folate reverses hematologic findings but allows neurologic damage from B₁₂ deficiency to progress",
   "explanation": "Administering folate alone can mask B₁₂ deficiency anemia while neurologic injury continues; workup of MMA and homocysteine is needed first :contentReference[oaicite:10]{index=10}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01093",
   "question": "What are the usual routes and dosing frequency for cyanocobalamin (vitamin B₁₂) in pernicious anemia?",
   "options": [
      "Daily sublingual or monthly parenteral administration, continued for life",
      "Once-daily oral tablet for one month only",
      "Weekly intramuscular injection for six months",
      "Daily intravenous infusion for two weeks"
   ],
   "answer": "Daily sublingual or monthly parenteral administration, continued for life",
   "explanation": "Cyanocobalamin is given sublingually daily or intramuscularly monthly; lifelong therapy is required in pernicious anemia :contentReference[oaicite:11]{index=11}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01094",
   "question": "Which glycoprotein stimulates red cell progenitors and is produced by the kidney in response to hypoxia?",
   "options": [
      "Erythropoietin (EPO)",
      "Granulocyte-macrophage colony-stimulating factor",
      "Thrombopoietin",
      "Interleukin-3"
   ],
   "answer": "Erythropoietin (EPO)",
   "explanation": "EPO is secreted by renal peritubular cells under hypoxia, driving erythroid differentiation and reticulocyte release :contentReference[oaicite:12]{index=12}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01095",
   "question": "How does darbepoetin differ from epoetin alfa in pharmacokinetics?",
   "options": [
      "It has a half-life about three times longer due to additional carbohydrate chains",
      "It is entirely eliminated renally unchanged",
      "It requires daily dosing due to rapid clearance",
      "It is active only when administered orally"
   ],
   "answer": "It has a half-life about three times longer due to additional carbohydrate chains",
   "explanation": "Darbepoetin’s extra carbohydrate moieties extend its half-life ≈3-fold compared to epoetin alfa :contentReference[oaicite:13]{index=13}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01096",
   "question": "What are common side effects of erythropoiesis-stimulating agents like epoetin alfa?",
   "options": [
      "Hypertension and arthralgia",
      "Hypotension and rash",
      "Bradycardia and constipation",
      "Hyperglycemia and insomnia"
   ],
   "answer": "Hypertension and arthralgia",
   "explanation": "Blood pressure elevation and joint pain may occur, possibly from increased viscosity or vascular resistance :contentReference[oaicite:14]{index=14}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01097",
   "question": "Why is concomitant iron supplementation often necessary when treating with EPO?",
   "options": [
      "To provide substrate for increased red cell production and ensure adequate response",
      "To prevent iron overload by binding free iron",
      "To reduce the half-life of EPO",
      "To antagonize hepcidin and enhance EPO clearance"
   ],
   "answer": "To provide substrate for increased red cell production and ensure adequate response",
   "explanation": "Iron stores must be sufficient to support the EPO-driven rise in hemoglobin; supplementation prevents functional iron deficiency :contentReference[oaicite:15]{index=15}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01098",
   "question": "How does hydroxyurea reduce the frequency of vaso-occlusive crises in sickle cell disease?",
   "options": [
      "By increasing fetal hemoglobin (HbF) through ribonucleotide reductase inhibition",
      "By acting as a P-selectin antagonist on endothelial cells",
      "By chelating free iron and preventing sickling",
      "By blocking calcium channels in red cells"
   ],
   "answer": "By increasing fetal hemoglobin (HbF) through ribonucleotide reductase inhibition",
   "explanation": "Hydroxyurea’s inhibition of ribonucleotide reductase boosts HbF levels, reducing HbS polymerization and crisis events :contentReference[oaicite:16]{index=16}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01099",
   "question": "Which adverse effects are most important to monitor with hydroxyurea therapy?",
   "options": [
      "Bone marrow suppression and cutaneous vasculitis",
      "Nephrotoxicity and ototoxicity",
      "Pulmonary fibrosis and rash",
      "Arrhythmias and tinnitus"
   ],
   "answer": "Bone marrow suppression and cutaneous vasculitis",
   "explanation": "Hydroxyurea can cause cytopenias and rare skin vasculitis, necessitating regular blood counts and skin exams :contentReference[oaicite:17]{index=17}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01100",
   "question": "What is the mechanism of action of crizanlizumab in sickle cell anemia?",
   "options": [
      "It binds P-selectin on endothelial cells and platelets, preventing vaso-occlusion",
      "It increases nitric oxide release in red cells",
      "It inhibits HbS polymerization directly",
      "It chelates iron to reduce oxidative damage"
   ],
   "answer": "It binds P-selectin on endothelial cells and platelets, preventing vaso-occlusion",
   "explanation": "Crizanlizumab blocks P-selectin interactions, reducing sickled cell adhesion and capillary blockade in patients ≥16 years :contentReference[oaicite:18]{index=18}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01101",
   "question": "What are common adverse effects observed with crizanlizumab infusions?",
   "options": [
      "Infusion-related reactions, nausea, arthralgia, back pain, and pyrexia",
      "Hypertension, headache, and rash",
      "Hyperkalemia and bradycardia",
      "Hypoglycemia and tremor"
   ],
   "answer": "Infusion-related reactions, nausea, arthralgia, back pain, and pyrexia",
   "explanation": "Patients may experience infusion reactions plus gastrointestinal and musculoskeletal symptoms :contentReference[oaicite:19]{index=19}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01102",
   "question": "How does voxelotor prevent sickling of red blood cells?",
   "options": [
      "By binding the α-chain of HbS and decreasing deoxy-HbS concentration",
      "By chelating calcium to stabilize membranes",
      "By antagonizing P-selectin like crizanlizumab",
      "By increasing nitric oxide production"
   ],
   "answer": "By binding the α-chain of HbS and decreasing deoxy-HbS concentration",
   "explanation": "Voxelotor inhibits HbS polymerization via α-chain binding, reducing sickling; it is metabolized by CYP3A4 :contentReference[oaicite:20]{index=20}."
},
 {
   "chapter_id": 44,
   "chapter": "Drugs for Anemia",
   "question_id": "00044-01103",
   "question": "Which adverse effects should be monitored in patients taking voxelotor?",
   "options": [
      "Headache, diarrhea, and gastrointestinal upset",
      "Neutropenia and alopecia",
      "Nephrotoxicity and ototoxicity",
      "Hyperglycemia and visual disturbances"
   ],
   "answer": "Headache, diarrhea, and gastrointestinal upset",
   "explanation": "Voxelotor’s most common side effects include headache, diarrhea, and GI complaints :contentReference[oaicite:21]{index=21}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01104",
   "question": "What is the mechanism by which topical retinoids treat acne?",
   "options": [
      "They normalize follicular epithelial desquamation, preventing microcomedone formation",
      "They inhibit 5α-reductase to reduce sebum production",
      "They block bacterial protein synthesis in sebaceous glands",
      "They act as anti-inflammatory agents by inhibiting COX-2"
   ],
   "answer": "They normalize follicular epithelial desquamation, preventing microcomedone formation",
   "explanation": "Topical retinoids modulate gene expression to regulate keratinocyte differentiation, reducing comedone development and promoting turnover :contentReference[oaicite:0]{index=0}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01105",
   "question": "Which topical antibiotic is commonly combined with benzoyl peroxide to reduce Propionibacterium acnes colonization and resistance?",
   "options": [
      "Clindamycin",
      "Mupirocin",
      "Gentamicin",
      "Metronidazole"
   ],
   "answer": "Clindamycin",
   "explanation": "Topical clindamycin plus benzoyl peroxide decreases P. acnes and minimizes emergence of resistant strains by dual mechanisms :contentReference[oaicite:1]{index=1}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01106",
   "question": "What is the first-line systemic therapy for moderate-to-severe plaque psoriasis?",
   "options": [
      "Methotrexate",
      "Acitretin",
      "Cyclosporine",
      "Etanercept"
   ],
   "answer": "Methotrexate",
   "explanation": "Methotrexate inhibits dihydrofolate reductase, reducing hyperproliferation in psoriasis; it remains first-line for many with moderate-to-severe disease :contentReference[oaicite:2]{index=2}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01107",
   "question": "Which biologic agent targets IL-17A for psoriasis treatment?",
   "options": [
      "Secukinumab",
      "Ustekinumab",
      "Etanercept",
      "Infliximab"
   ],
   "answer": "Secukinumab",
   "explanation": "Secukinumab is an anti–IL-17A monoclonal antibody that reduces psoriatic inflammation by blocking a key effector cytokine :contentReference[oaicite:3]{index=3}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01108",
   "question": "How does acitretin differ from isotretinoin in use and pharmacology?",
   "options": [
      "Acitretin is an active metabolite of etretinate with a shorter half-life and used for psoriasis, not acne",
      "Acitretin is used orally for acne with a long half-life in fat tissue",
      "Acitretin is a topical retinoid with no systemic effects",
      "Acitretin directly inhibits 5α-reductase"
   ],
   "answer": "Acitretin is an active metabolite of etretinate with a shorter half-life and used for psoriasis, not acne",
   "explanation": "Acitretin, unlike isotretinoin (for acne), treats psoriasis with teratogenic risk and is metabolized to etretinate only if ethanol is coingested :contentReference[oaicite:4]{index=4}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01109",
   "question": "Which topical agent is first-line for mild to moderate atopic dermatitis due to its immunomodulatory action?",
   "options": [
      "Topical corticosteroids",
      "Topical calcineurin inhibitors (e.g., tacrolimus)",
      "Topical retinoids",
      "Topical antifungals"
   ],
   "answer": "Topical corticosteroids",
   "explanation": "Topical steroids reduce cytokine-mediated inflammation in eczema and remain first-line, with calcineurin inhibitors as steroid-sparing options :contentReference[oaicite:5]{index=5}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01110",
   "question": "What is the primary mechanism of action of topical imiquimod in actinic keratoses and warts?",
   "options": [
      "It activates toll-like receptor 7, inducing local cytokine release and immune-mediated clearance",
      "It inhibits viral DNA polymerase",
      "It blocks keratinocyte proliferation via retinoid receptor activation",
      "It acts as a keratolytic agent"
   ],
   "answer": "It activates toll-like receptor 7, inducing local cytokine release and immune-mediated clearance",
   "explanation": "Imiquimod’s TLR7 agonism stimulates innate immunity and cytokines like interferons to clear premalignant and viral lesions :contentReference[oaicite:6]{index=6}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01111",
   "question": "Which systemic antifungal is DOC for onychomycosis due to dermatophytes?",
   "options": [
      "Terbinafine",
      "Fluconazole",
      "Itraconazole",
      "Griseofulvin"
   ],
   "answer": "Terbinafine",
   "explanation": "Terbinafine inhibits squalene epoxidase, accumulates in nail plate, and has best efficacy for dermatophyte nail infections :contentReference[oaicite:7]{index=7}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01112",
   "question": "What is the mechanism of action of azelaic acid in rosacea?",
   "options": [
      "It has anti-inflammatory and antimicrobial effects, reducing papulopustular lesions",
      "It acts as a retinoid to normalize keratinization",
      "It blocks α-adrenergic receptors in cutaneous vessels",
      "It inhibits melanin synthesis"
   ],
   "answer": "It has anti-inflammatory and antimicrobial effects, reducing papulopustular lesions",
   "explanation": "Azelaic acid inhibits microbial activity and ROS, improving inflammatory rosacea, though flushing requires other therapies :contentReference[oaicite:8]{index=8}."
},
 {
   "chapter_id": 45,
   "chapter": "Drugs for Dermatologic Disorders",
   "question_id": "00045-01113",
   "question": "Which topical agent is indicated for superficial bacterial skin infections like impetigo?",
   "options": [
      "Mupirocin",
      "Clindamycin",
      "Metronidazole",
      "Benzoyl peroxide"
   ],
   "answer": "Mupirocin",
   "explanation": "Mupirocin inhibits bacterial isoleucyl-tRNA synthetase and is effective against S. aureus and Streptococcus spp. in impetigo :contentReference[oaicite:9]{index=9}."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01114",
   "question": "A 2-hour postprandial glucose ≥ 200 mg/dL is diagnostic of diabetes. True or false?",
   "options": [
      "True",
      "False",
      "Only when confirmed with A1C",
      "Only in type 1 diabetes"
   ],
   "answer": "True",
   "explanation": "A 2-hour postprandial (OGTT) glucose ≥ 200 mg/dL (11.1 mmol/L) also qualifies for diabetes diagnosis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01115",
   "question": "A common adverse effect of SGLT2 inhibitors is:",
   "options": [
      "Hypoglycemia",
      "Genital mycotic infections",
      "Pancreatitis",
      "Weight gain"
   ],
   "answer": "Genital mycotic infections",
   "explanation": "By increasing urinary glucose, SGLT2 inhibitors predispose to genital and urinary tract infections."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01116",
   "question": "A fasting plasma glucose of which of the following values is diagnostic of diabetes?",
   "options": [
      "≥ 100 mg/dL",
      "≥ 110 mg/dL",
      "≥ 126 mg/dL",
      "≥ 140 mg/dL"
   ],
   "answer": "≥ 126 mg/dL",
   "explanation": "A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) meets ADA criteria for diabetes diagnosis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01117",
   "question": "A major adverse effect of sulfonylureas is:",
   "options": [
      "Hypoglycemia",
      "Lactic acidosis",
      "Pancreatitis",
      "Diuresis"
   ],
   "answer": "Hypoglycemia",
   "explanation": "By increasing insulin regardless of meal, sulfonylureas commonly provoke hypoglycemia and weight gain."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01118",
   "question": "A patient taking insulin develops symptoms of hypoglycemia. What is the immediate recommended treatment?",
   "options": [
      "Eat a large meal",
      "Inject more insulin",
      "Consume 15–20 grams of fast-acting carbohydrate",
      "Exercise vigorously"
   ],
   "answer": "Consume 15–20 grams of fast-acting carbohydrate",
   "explanation": "Acute hypoglycemia is treated with 15–20 grams of rapid-acting carbohydrates, followed by retesting in 15 minutes."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01119",
   "question": "A patient with newly diagnosed type 2 diabetes has an A1C of 9.5%. What is the most appropriate initial management?",
   "options": [
      "Lifestyle modification only",
      "Metformin monotherapy",
      "Metformin plus another oral agent",
      "Insulin therapy (basal or basal-bolus) with metformin"
   ],
   "answer": "Insulin therapy (basal or basal-bolus) with metformin",
   "explanation": "For A1C > 9%, initiating insulin with metformin is often recommended to rapidly achieve glycemic control."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01120",
   "question": "A patient with type 2 diabetes presents with recurrent urinary tract infections. Which drug class might be contributing?",
   "options": [
      "Metformin",
      "Sulfonylureas",
      "SGLT2 inhibitors",
      "DPP-4 inhibitors"
   ],
   "answer": "SGLT2 inhibitors",
   "explanation": "SGLT2 inhibitors increase urinary glucose excretion, which can increase the risk of genital mycotic infections and urinary tract infections."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01121",
   "question": "A typical starting dose for basal insulin in type 2 diabetes is:",
   "options": [
      "0.1–0.2 units/kg/day",
      "0.3–0.4 units/kg/day",
      "0.5–0.6 units/kg/day",
      "0.7–0.8 units/kg/day"
   ],
   "answer": "0.1–0.2 units/kg/day",
   "explanation": "A common starting dose for basal insulin is 0.1–0.2 units/kg/day, titrated based on fasting glucose."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01122",
   "question": "Acarbose lowers postprandial glucose by:",
   "options": [
      "Inhibiting DPP-4",
      "Blocking α-glucosidase",
      "Stimulating insulin secretion",
      "Blocking SGLT2"
   ],
   "answer": "Blocking α-glucosidase",
   "explanation": "Acarbose and miglitol inhibit intestinal α-glucosidases, delaying carbohydrate breakdown and absorption."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01123",
   "question": "Afrezza is an inhaled insulin formulation. Its onset of action is:",
   "options": [
      "Slower than injected regular insulin",
      "Similar to injected rapid-acting insulin",
      "Faster than injected rapid-acting insulin",
      "Slower than NPH insulin"
   ],
   "answer": "Similar to injected rapid-acting insulin",
   "explanation": "Afrezza, an inhaled insulin, has rapid pharmacokinetics similar to injected rapid-acting insulin, peaking in 15–20 minutes."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01124",
   "question": "An A1C value ≥ 6.5% is consistent with a diagnosis of diabetes according to ADA criteria. True or false?",
   "options": [
      "True",
      "False",
      "Only in type 2 diabetes",
      "Only in gestational diabetes"
   ],
   "answer": "True",
   "explanation": "An A1C ≥ 6.5% is one of the ADA diagnostic thresholds for diabetes in any form."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01125",
   "question": "Dawn phenomenon is characterized by:",
   "options": [
      "Morning hyperglycemia due to growth hormone and cortisol surges",
      "Postprandial hypoglycemia",
      "Nocturnal hypoglycemia",
      "Insulin resistance"
   ],
   "answer": "Morning hyperglycemia due to growth hormone and cortisol surges",
   "explanation": "The dawn phenomenon is morning hyperglycemia caused by overnight surges in growth hormone and cortisol, without antecedent hypoglycemia."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01126",
   "question": "Dawn phenomenon refers to:",
   "options": [
      "Hypoglycemia in the early morning",
      "Increased insulin sensitivity at night",
      "Early morning hyperglycemia due to increased counter-regulatory hormones",
      "Hypoglycemia after dinner"
   ],
   "answer": "Early morning hyperglycemia due to increased counter-regulatory hormones",
   "explanation": "Dawn phenomenon is early morning hyperglycemia due to growth hormone and cortisol surges, increasing glucose production."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01127",
   "question": "Diabetic ketoacidosis (DKA) is characterized by hyperglycemia, metabolic acidosis, and:",
   "options": [
      "Hypokalemia",
      "Ketonemia/ketonuria",
      "Hyponatremia",
      "Respiratory alkalosis"
   ],
   "answer": "Ketonemia/ketonuria",
   "explanation": "DKA is marked by hyperglycemia, metabolic acidosis, and ketonemia/ketonuria resulting from severe insulin deficiency and increased lipolysis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01128",
   "question": "DPP-4 inhibitors improve glycemic control by:",
   "options": [
      "Blocking renal glucose reabsorption",
      "Prolonging incretin hormone action",
      "Stimulating glucose-dependent insulin secretion directly",
      "Enhancing hepatic insulin clearance"
   ],
   "answer": "Prolonging incretin hormone action",
   "explanation": "DPP-4 inhibitors prevent incretin breakdown, increasing postprandial insulin and lowering glucagon."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01129",
   "question": "GLP-1 receptor agonists lower blood glucose by:",
   "options": [
      "Inhibiting gluconeogenesis",
      "Prolonging insulin half-life",
      "Enhancing glucose-dependent insulin secretion and slowing gastric emptying",
      "Blocking SGLT2 in the kidney"
   ],
   "answer": "Enhancing glucose-dependent insulin secretion and slowing gastric emptying",
   "explanation": "GLP-1 RAs enhance meal-stimulated insulin release, slow gastric emptying, increase satiety, and reduce glucagon."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01130",
   "question": "Hyperosmolar hyperglycemic state (HHS) differs from DKA by:",
   "options": [
      "Presence of severe acidosis and ketones",
      "More profound dehydration and absence of significant ketosis",
      "Lower plasma glucose levels",
      "Faster onset of symptoms"
   ],
   "answer": "More profound dehydration and absence of significant ketosis",
   "explanation": "HHS involves extreme hyperglycemia, severe dehydration, and hyperosmolarity without significant ketosis or acidosis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01131",
   "question": "In a patient on insulin therapy, which symptom is characteristic of hypoglycemia?",
   "options": [
      "Increased thirst",
      "Fruity breath odor",
      "Sweating and tremors",
      "Frequent urination"
   ],
   "answer": "Sweating and tremors",
   "explanation": "Hypoglycemia often presents with adrenergic symptoms like sweating, tremors, and palpitations."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01132",
   "question": "In a patient with insulin resistance, which drug class directly addresses this pathology?",
   "options": [
      "Sulfonylureas",
      "Thiazolidinediones",
      "DPP-4 inhibitors",
      "SGLT2 inhibitors"
   ],
   "answer": "Thiazolidinediones",
   "explanation": "Thiazolidinediones directly improve insulin sensitivity by activating PPARγ."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01133",
   "question": "In a patient with newly diagnosed type 2 diabetes and established atherosclerotic cardiovascular disease, which agent should be considered first-line after metformin?",
   "options": [
      "Insulin glargine",
      "Sitagliptin",
      "Liraglutide",
      "Glimepiride"
   ],
   "answer": "Liraglutide",
   "explanation": "For T2DM patients with ASCVD, GLP-1 RAs or SGLT2 inhibitors with proven CV benefit are recommended as add-on therapy."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01134",
   "question": "In a patient with type 2 diabetes and chronic kidney disease, which agent requires careful dose adjustment or avoidance?",
   "options": [
      "Metformin",
      "Linagliptin",
      "Empagliflozin",
      "Pioglitazone"
   ],
   "answer": "Metformin",
   "explanation": "Metformin requires dose adjustment or is contraindicated in CKD depending on eGFR due to lactic acidosis risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01135",
   "question": "In a patient with type 2 diabetes and established cardiovascular disease, which SGLT2 inhibitor has demonstrated cardiovascular and renal benefits?",
   "options": [
      "Canagliflozin",
      "Dapagliflozin",
      "Empagliflozin",
      "All of the above"
   ],
   "answer": "All of the above",
   "explanation": "Canagliflozin, dapagliflozin, and empagliflozin have all shown cardiovascular and renal protective effects in trials."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01136",
   "question": "In type 1 diabetes, the primary defect is:",
   "options": [
      "Insulin resistance",
      "Impaired insulin secretion",
      "Absolute insulin deficiency",
      "Increased hepatic glucose production"
   ],
   "answer": "Absolute insulin deficiency",
   "explanation": "Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01137",
   "question": "Insulin is classified by its:",
   "options": [
      "Onset and duration of action",
      "Source of origin",
      "Method of administration",
      "Cost"
   ],
   "answer": "Onset and duration of action",
   "explanation": "Insulins are primarily categorized by their pharmacokinetic profiles (onset, peak, duration)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01138",
   "question": "Lipodystrophy at injection sites can cause:",
   "options": [
      "Improved insulin absorption",
      "Variable insulin absorption",
      "Increased local pain",
      "Reduced need for insulin"
   ],
   "answer": "Variable insulin absorption",
   "explanation": "Repeated injections in the same site can cause lipodystrophy (lipoatrophy or lipohypertrophy), leading to inconsistent insulin absorption."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01139",
   "question": "Meglitinides carry a similar risk of hypoglycemia as sulfonylureas. True or false?",
   "options": [
      "True",
      "False",
      "Only with renal impairment",
      "Only if combined with metformin"
   ],
   "answer": "True",
   "explanation": "Meglitinides share the insulinotropic mechanism of sulfonylureas, so hypoglycemia is common."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01140",
   "question": "Metformin is contraindicated in patients with an eGFR < 30 mL/min/1.73 m² due to risk of:",
   "options": [
      "Lactic acidosis",
      "Hypoglycemia",
      "Pancreatitis",
      "Hepatotoxicity"
   ],
   "answer": "Lactic acidosis",
   "explanation": "Severe renal impairment increases metformin’s risk of lactic acidosis, so it must be avoided if eGFR < 30 mL/min/1.73 m²."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01141",
   "question": "Metformin lowers blood glucose primarily by:",
   "options": [
      "Stimulating insulin release",
      "Reducing hepatic gluconeogenesis",
      "Inhibiting DPP-4",
      "Blocking SGLT2 in the kidney"
   ],
   "answer": "Reducing hepatic gluconeogenesis",
   "explanation": "Metformin’s main action is suppression of hepatic glucose production via decreased gluconeogenesis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01142",
   "question": "NPH insulin is classified as a(n):",
   "options": [
      "Rapid-acting insulin",
      "Short-acting insulin",
      "Intermediate-acting insulin",
      "Long-acting insulin"
   ],
   "answer": "Intermediate-acting insulin",
   "explanation": "NPH is an intermediate-acting insulin, taking effect in 2–4 hours with 10–16 hours duration."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01143",
   "question": "Pramlintide is administered by which route?",
   "options": [
      "Oral",
      "Intravenous",
      "Subcutaneous injection",
      "Intramuscular"
   ],
   "answer": "Subcutaneous injection",
   "explanation": "Pramlintide is an injectable peptide, given subcutaneously."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01144",
   "question": "Pramlintide, used in type 1 and type 2 diabetes, is an analog of:",
   "options": [
      "Insulin",
      "Amylin",
      "GLP-1",
      "GIP"
   ],
   "answer": "Amylin",
   "explanation": "Pramlintide is a synthetic amylin analog that complements insulin by slowing gastric emptying and reducing postprandial glucagon."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01145",
   "question": "SGLT2 inhibitors lower plasma glucose by:",
   "options": [
      "Inhibiting hepatic glucose production",
      "Blocking renal glucose reabsorption",
      "Delaying carbohydrate absorption",
      "Enhancing insulin receptor sensitivity"
   ],
   "answer": "Blocking renal glucose reabsorption",
   "explanation": "SGLT2 inhibitors prevent proximal tubular glucose reabsorption, increasing glucosuria."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01146",
   "question": "Sulfonylureas lower blood glucose by:",
   "options": [
      "Inhibiting hepatic glucose production",
      "Enhancing peripheral insulin sensitivity",
      "Stimulating pancreatic β-cell insulin secretion",
      "Delaying carbohydrate absorption"
   ],
   "answer": "Stimulating pancreatic β-cell insulin secretion",
   "explanation": "Sulfonylureas bind β-cell K_ATP channels, causing depolarization and insulin release."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01147",
   "question": "The incretin effect refers to:",
   "options": [
      "Increased insulin secretion after oral glucose vs. intravenous glucose",
      "Decreased glucagon secretion after a meal",
      "Enhanced insulin sensitivity in peripheral tissues",
      "Delayed gastric emptying"
   ],
   "answer": "Increased insulin secretion after oral glucose vs. intravenous glucose",
   "explanation": "The incretin effect describes the greater insulin response to oral glucose compared to intravenous glucose, due to gut hormones."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01148",
   "question": "The primary goal of insulin therapy in type 1 diabetes is to:",
   "options": [
      "Prevent weight gain",
      "Achieve an A1C < 7%",
      "Eliminate all hypoglycemic episodes",
      "Mimic physiologic insulin secretion"
   ],
   "answer": "Mimic physiologic insulin secretion",
   "explanation": "Insulin regimens in T1DM aim to replicate the body’s natural basal and bolus insulin release."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01149",
   "question": "The primary mechanism by which glucagon increases blood glucose is by:",
   "options": [
      "Increasing insulin secretion",
      "Stimulating hepatic glycogenolysis and gluconeogenesis",
      "Decreasing peripheral glucose uptake",
      "Inhibiting gastric emptying"
   ],
   "answer": "Stimulating hepatic glycogenolysis and gluconeogenesis",
   "explanation": "Glucagon’s main action is to raise blood glucose by stimulating the liver to break down glycogen and produce new glucose."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01150",
   "question": "The primary site of action for α-glucosidase inhibitors is the:",
   "options": [
      "Liver",
      "Pancreas",
      "Kidney",
      "Small intestine"
   ],
   "answer": "Small intestine",
   "explanation": "α-glucosidase inhibitors act locally in the small intestine to delay carbohydrate digestion."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01151",
   "question": "The Somogyi effect is characterized by:",
   "options": [
      "Morning hyperglycemia following nocturnal hypoglycemia",
      "Persistent morning hyperglycemia without nocturnal hypoglycemia",
      "Increased insulin resistance in the evening",
      "Rapid glucose drop after a meal"
   ],
   "answer": "Morning hyperglycemia following nocturnal hypoglycemia",
   "explanation": "Somogyi effect is rebound hyperglycemia after an unmanaged nocturnal hypoglycemia, triggering counter-regulatory hormones."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01152",
   "question": "The Somogyi effect refers to:",
   "options": [
      "Morning hyperglycemia due to rebound from nocturnal hypoglycemia",
      "Persistent hyperglycemia despite increasing insulin doses",
      "Dawn phenomenon",
      "Postprandial hyperglycemia"
   ],
   "answer": "Morning hyperglycemia due to rebound from nocturnal hypoglycemia",
   "explanation": "The Somogyi effect is nocturnal hypoglycemia stimulating counterregulatory hormones, causing rebound morning hyperglycemia."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01153",
   "question": "Thiazolidinediones are contraindicated in:",
   "options": [
      "Heart failure",
      "Chronic kidney disease",
      "Gastroparesis",
      "Pancreatitis"
   ],
   "answer": "Heart failure",
   "explanation": "By causing fluid retention, TZDs worsen symptomatic heart failure and are thus contraindicated."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01154",
   "question": "Thiazolidinediones improve glycemic control by:",
   "options": [
      "Activating PPARγ to enhance insulin sensitivity",
      "Stimulating insulin secretion",
      "Inhibiting α-glucosidase",
      "Blocking renal glucose reabsorption"
   ],
   "answer": "Activating PPARγ to enhance insulin sensitivity",
   "explanation": "TZDs (pioglitazone, rosiglitazone) activate PPARγ, increasing adipocyte insulin sensitivity."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01155",
   "question": "What is a common strategy to minimize gastrointestinal side effects of metformin?",
   "options": [
      "Take it on an empty stomach",
      "Increase the dose rapidly",
      "Start with a low dose and titrate slowly with meals",
      "Take it only once daily"
   ],
   "answer": "Start with a low dose and titrate slowly with meals",
   "explanation": "To minimize GI side effects, metformin should be started at a low dose and titrated slowly, taken with meals."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01156",
   "question": "What is the most common adverse effect of insulin therapy?",
   "options": [
      "Weight gain",
      "Hypoglycemia",
      "Lipoatrophy",
      "Injection site reactions"
   ],
   "answer": "Hypoglycemia",
   "explanation": "Hypoglycemia is the most frequent and serious adverse event of insulin therapy; weight gain and lipohypertrophy are also common."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01157",
   "question": "What is the most common adverse effect of α-glucosidase inhibitors?",
   "options": [
      "Weight gain",
      "Flatulence",
      "Hypoglycemia",
      "Pancreatitis"
   ],
   "answer": "Flatulence",
   "explanation": "By increasing carbohydrate fermentation in the colon, these drugs cause flatulence, diarrhea, and cramping."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01158",
   "question": "What is the primary concern when combining sulfonylureas with insulin?",
   "options": [
      "Weight loss",
      "Increased risk of lactic acidosis",
      "Increased risk of hypoglycemia",
      "Fluid retention"
   ],
   "answer": "Increased risk of hypoglycemia",
   "explanation": "Both sulfonylureas and insulin promote insulin secretion, so their combination significantly increases the risk of hypoglycemia."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01159",
   "question": "What is the primary diagnostic test for gestational diabetes?",
   "options": [
      "Fasting plasma glucose",
      "A1C",
      "Oral glucose tolerance test (OGTT)",
      "Random plasma glucose"
   ],
   "answer": "Oral glucose tolerance test (OGTT)",
   "explanation": "Gestational diabetes is diagnosed by an oral glucose tolerance test (OGTT)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01160",
   "question": "What is the recommended approach for initiating bolus insulin in type 2 diabetes?",
   "options": [
      "Start with a single prandial dose before the largest meal",
      "Start with three prandial doses immediately",
      "Start with NPH twice daily",
      "Start with a fixed dose of rapid-acting insulin"
   ],
   "answer": "Start with a single prandial dose before the largest meal",
   "explanation": "Bolus insulin can be started with a single dose before the largest meal, then advanced to multiple meals if needed."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01161",
   "question": "Which adverse effect is more common with SGLT2 inhibitors compared to other oral antidiabetic agents?",
   "options": [
      "Hypoglycemia",
      "Diabetic ketoacidosis (euglycemic)",
      "Weight gain",
      "Pancreatitis"
   ],
   "answer": "Diabetic ketoacidosis (euglycemic)",
   "explanation": "SGLT2 inhibitors can cause euglycemic DKA, especially with illness or reduced insulin, requiring patient education."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01162",
   "question": "Which adverse effect is most commonly associated with metformin?",
   "options": [
      "Weight gain",
      "Hypoglycemia",
      "Gastrointestinal upset",
      "Fluid retention"
   ],
   "answer": "Gastrointestinal upset",
   "explanation": "Metformin frequently causes GI symptoms (diarrhea, nausea, cramping) which can be mitigated by dose titration and taking with food."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01163",
   "question": "Which agent, often used in combination with insulin, is known to reduce postprandial glucose excursions by slowing gastric emptying and suppressing postprandial glucagon?",
   "options": [
      "Metformin",
      "Pramlintide",
      "Sitagliptin",
      "Empagliflozin"
   ],
   "answer": "Pramlintide",
   "explanation": "Pramlintide, an amylin analog, slows gastric emptying and suppresses glucagon, primarily reducing postprandial glucose."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01164",
   "question": "Which anti-diabetic agent is associated with a risk of bladder cancer?",
   "options": [
      "Pioglitazone",
      "Sitagliptin",
      "Canagliflozin",
      "Exenatide"
   ],
   "answer": "Pioglitazone",
   "explanation": "Pioglitazone has a potential link to increased bladder cancer risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01165",
   "question": "Which class of diabetes drugs can cause an increased risk of amputations, particularly with canagliflozin?",
   "options": [
      "GLP-1 receptor agonists",
      "DPP-4 inhibitors",
      "SGLT2 inhibitors",
      "Sulfonylureas"
   ],
   "answer": "SGLT2 inhibitors",
   "explanation": "Canagliflozin, an SGLT2 inhibitor, has been associated with an increased risk of lower limb amputations in some studies, leading to a boxed warning."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01166",
   "question": "Which class of diabetes drugs can cause weight loss?",
   "options": [
      "Sulfonylureas",
      "Thiazolidinediones",
      "GLP-1 receptor agonists",
      "Insulin"
   ],
   "answer": "GLP-1 receptor agonists",
   "explanation": "GLP-1 RAs and SGLT2 inhibitors are associated with weight loss, unlike sulfonylureas, TZDs, and insulin, which often cause weight gain."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01167",
   "question": "Which class of diabetes drugs primarily works by increasing urinary glucose excretion?",
   "options": [
      "Metformin",
      "Sulfonylureas",
      "SGLT2 inhibitors",
      "DPP-4 inhibitors"
   ],
   "answer": "SGLT2 inhibitors",
   "explanation": "SGLT2 inhibitors block glucose reabsorption in the kidney, leading to glucose excretion in urine."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01168",
   "question": "Which class of drugs is known to cause dose-dependent weight gain?",
   "options": [
      "Metformin",
      "SGLT2 inhibitors",
      "Sulfonylureas",
      "GLP-1 receptor agonists"
   ],
   "answer": "Sulfonylureas",
   "explanation": "Sulfonylureas cause dose-dependent weight gain due to increased insulin secretion."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01169",
   "question": "Which class of drugs is preferred for initial monotherapy in most patients with type 2 diabetes?",
   "options": [
      "Sulfonylureas",
      "Metformin",
      "DPP-4 inhibitors",
      "Insulin"
   ],
   "answer": "Metformin",
   "explanation": "Metformin remains the preferred first-line agent for most patients with type 2 diabetes."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01170",
   "question": "Which class of oral antidiabetic agents is associated with a risk of pancreatitis?",
   "options": [
      "Metformin",
      "Sulfonylureas",
      "DPP-4 inhibitors",
      "Thiazolidinediones"
   ],
   "answer": "DPP-4 inhibitors",
   "explanation": "DPP-4 inhibitors have been linked to a potential risk of pancreatitis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01171",
   "question": "Which diabetes drug class has the highest risk of hypoglycemia when used as monotherapy?",
   "options": [
      "SGLT2 inhibitors",
      "GLP-1 receptor agonists",
      "DPP-4 inhibitors",
      "Sulfonylureas"
   ],
   "answer": "Sulfonylureas",
   "explanation": "Sulfonylureas like glyburide increase insulin irrespective of blood glucose and thus carry the greatest hypoglycemia risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01172",
   "question": "Which DPP-4 inhibitor does NOT require renal dose adjustment?",
   "options": [
      "Sitagliptin",
      "Saxagliptin",
      "Alogliptin",
      "Linagliptin"
   ],
   "answer": "Linagliptin",
   "explanation": "Linagliptin is primarily hepatically cleared and does not need renal dosing adjustments."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01173",
   "question": "Which drug class is contraindicated in patients with a history of medullary thyroid carcinoma or MEN 2 syndrome?",
   "options": [
      "Sulfonylureas",
      "GLP-1 receptor agonists",
      "DPP-4 inhibitors",
      "SGLT2 inhibitors"
   ],
   "answer": "GLP-1 receptor agonists",
   "explanation": "GLP-1 RAs carry a boxed warning due to a risk of thyroid C-cell tumors in rodents, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01174",
   "question": "Which drug class is generally weight-neutral or associated with modest weight loss?",
   "options": [
      "Sulfonylureas",
      "Thiazolidinediones",
      "Metformin",
      "Insulin"
   ],
   "answer": "Metformin",
   "explanation": "Metformin is typically weight-neutral or can lead to modest weight loss, unlike some other classes."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01175",
   "question": "Which drug for type 2 diabetes is associated with a lower risk of hypoglycemia compared to sulfonylureas and insulin?",
   "options": [
      "Glyburide",
      "Repaglinide",
      "Sitagliptin",
      "NPH insulin"
   ],
   "answer": "Sitagliptin",
   "explanation": "DPP-4 inhibitors like sitagliptin have a low risk of hypoglycemia when used as monotherapy because their action is glucose-dependent."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01176",
   "question": "Which feature distinguishes type 1 from type 2 diabetes?",
   "options": [
      "Absolute insulin deficiency",
      "Obesity-associated insulin resistance",
      "Onset in middle age",
      "Strong family history"
   ],
   "answer": "Absolute insulin deficiency",
   "explanation": "Type 1 diabetes is characterized by autoimmune destruction of β-cells leading to absolute insulin deficiency."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01177",
   "question": "Which GI side effect is most common with GLP-1 receptor agonists?",
   "options": [
      "Constipation",
      "Diarrhea",
      "Nausea",
      "Abdominal cramping"
   ],
   "answer": "Nausea",
   "explanation": "Nausea (with vomiting and diarrhea) is the predominant adverse effect of GLP-1 RAs."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01178",
   "question": "Which GLP-1 receptor agonist is administered once weekly?",
   "options": [
      "Exenatide (Byetta)",
      "Lixisenatide (Adlyxin)",
      "Dulaglutide (Trulicity)",
      "Byetta (twice daily)"
   ],
   "answer": "Dulaglutide (Trulicity)",
   "explanation": "Dulaglutide, semaglutide, and exenatide extended-release are once-weekly GLP-1 RAs."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01179",
   "question": "Which GLP-1 receptor agonist is available in both oral and injectable formulations?",
   "options": [
      "Dulaglutide",
      "Lixisenatide",
      "Exenatide",
      "Semaglutide"
   ],
   "answer": "Semaglutide",
   "explanation": "Semaglutide is unique in offering both weekly injectable and once-daily oral forms."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01180",
   "question": "Which GLP-1 receptor agonist is given as a daily injection?",
   "options": [
      "Dulaglutide",
      "Semaglutide (oral)",
      "Liraglutide",
      "Exenatide extended-release"
   ],
   "answer": "Liraglutide",
   "explanation": "Liraglutide (Victoza) and lixisenatide are daily injectable GLP-1 RAs."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01181",
   "question": "Which insulin analog is ultra-long-acting, lasting over 40 hours?",
   "options": [
      "Glargine",
      "Detemir",
      "Degludec",
      "NPH"
   ],
   "answer": "Degludec",
   "explanation": "Insulin degludec is an ultra-long-acting basal insulin that lasts >40 hours with less day-to-day variability than glargine."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01182",
   "question": "Which insulin formulation is an intermediate-acting insulin that requires mixing before injection?",
   "options": [
      "Lispro",
      "Regular insulin",
      "NPH insulin",
      "Degludec"
   ],
   "answer": "NPH insulin",
   "explanation": "NPH is an intermediate-acting cloudy suspension that requires gentle agitation before use and provides 10–16 hours of action."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01183",
   "question": "Which insulin has an intermediate duration of action and is often used for basal coverage twice daily?",
   "options": [
      "Insulin lispro",
      "Regular insulin",
      "NPH insulin",
      "Insulin degludec"
   ],
   "answer": "NPH insulin",
   "explanation": "NPH insulin is an intermediate-acting insulin often given twice daily for basal coverage."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01184",
   "question": "Which insulin has the fastest onset of action?",
   "options": [
      "Regular insulin",
      "NPH insulin",
      "Insulin glulisine",
      "Insulin detemir"
   ],
   "answer": "Insulin glulisine",
   "explanation": "Rapid-acting insulins (lispro, aspart, glulisine) have the fastest onset (5–15 min)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01185",
   "question": "Which insulin preparation provides basal insulin coverage for up to 24 hours?",
   "options": [
      "Regular insulin",
      "NPH insulin",
      "Glargine",
      "Lispro"
   ],
   "answer": "Glargine",
   "explanation": "Glargine and detemir provide up to 24 hours of basal insulin coverage with no peak, mimicking physiologic basal release."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01186",
   "question": "Which insulin product is a concentrated formulation that may reduce injection volume for patients requiring high doses?",
   "options": [
      "Insulin NPH",
      "Insulin glargine U-300",
      "Insulin lispro",
      "Regular insulin"
   ],
   "answer": "Insulin glargine U-300",
   "explanation": "Insulin glargine U-300 (Toujeo) is a more concentrated formulation of glargine, allowing for smaller injection volumes for high-dose needs."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01187",
   "question": "Which insulin provides a “peakless” basal insulin level?",
   "options": [
      "Insulin glargine",
      "Regular insulin",
      "NPH insulin",
      "Insulin lispro"
   ],
   "answer": "Insulin glargine",
   "explanation": "Glargine and detemir provide relatively peakless basal insulin coverage."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01188",
   "question": "Which is a potential side effect of GLP-1 receptor agonists and DPP-4 inhibitors?",
   "options": [
      "Lactic acidosis",
      "Pancreatitis",
      "Fluid retention",
      "Visual field defects"
   ],
   "answer": "Pancreatitis",
   "explanation": "Both GLP-1 RAs and DPP-4 inhibitors have been associated with a potential risk of pancreatitis."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01189",
   "question": "Which is an appropriate combination therapy for type 2 diabetes?",
   "options": [
      "Metformin and sulfonylurea",
      "Metformin and insulin",
      "Metformin and GLP-1 receptor agonist",
      "All of the above"
   ],
   "answer": "All of the above",
   "explanation": "Various combinations are effective, but some (e.g., sulfonylurea + insulin) increase hypoglycemia risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01190",
   "question": "Which long-acting insulin analog allows for once-daily dosing due to its prolonged duration?",
   "options": [
      "Insulin regular",
      "Insulin NPH",
      "Insulin detemir",
      "Insulin lispro"
   ],
   "answer": "Insulin detemir",
   "explanation": "Insulin detemir and glargine are long-acting insulins that provide prolonged basal coverage, allowing once-daily dosing."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01191",
   "question": "Which medication for type 2 diabetes has a cardiovascular benefit of reducing major adverse cardiovascular events?",
   "options": [
      "Pioglitazone",
      "Saxagliptin",
      "Liraglutide",
      "Glipizide"
   ],
   "answer": "Liraglutide",
   "explanation": "GLP-1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01192",
   "question": "Which of the following adverse effects is commonly associated with thiazolidinediones?",
   "options": [
      "Lactic acidosis",
      "Fluid retention and edema",
      "Hypoglycemia",
      "Gastrointestinal upset"
   ],
   "answer": "Fluid retention and edema",
   "explanation": "TZDs commonly cause fluid retention, leading to edema and worsening heart failure."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01193",
   "question": "Which of the following best describes the action of incretin hormones?",
   "options": [
      "Decrease insulin secretion and increase glucagon secretion",
      "Increase glucose absorption from the gut",
      "Increase glucose-dependent insulin secretion and suppress glucagon secretion",
      "Promote hepatic glucose production"
   ],
   "answer": "Increase glucose-dependent insulin secretion and suppress glucagon secretion",
   "explanation": "Incretin hormones (GLP-1, GIP) enhance glucose-dependent insulin release and suppress glucagon after meals."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01194",
   "question": "Which of the following can be used to treat both type 1 and type 2 diabetes?",
   "options": [
      "Metformin",
      "Sulfonylureas",
      "Insulin",
      "DPP-4 inhibitors"
   ],
   "answer": "Insulin",
   "explanation": "Insulin is essential for type 1 diabetes and often used in type 2 diabetes when other agents are insufficient."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01195",
   "question": "Which of the following can worsen heart failure?",
   "options": [
      "Metformin",
      "GLP-1 receptor agonists",
      "SGLT2 inhibitors",
      "Thiazolidinediones"
   ],
   "answer": "Thiazolidinediones",
   "explanation": "Thiazolidinediones cause fluid retention and are contraindicated in patients with symptomatic heart failure."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01196",
   "question": "Which of the following classes carries minimal risk of hypoglycemia?",
   "options": [
      "Sulfonylureas",
      "Meglitinides",
      "DPP-4 inhibitors",
      "Insulin"
   ],
   "answer": "DPP-4 inhibitors",
   "explanation": "DPP-4 inhibitors enhance glucose-dependent insulin release, resulting in a low hypoglycemia risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01197",
   "question": "Which of the following classes carries minimal risk of hypoglycemia?",
   "options": [
      "Sulfonylureas",
      "Meglitinides",
      "DPP-4 inhibitors",
      "Insulin"
   ],
   "answer": "DPP-4 inhibitors",
   "explanation": "DPP-4 inhibitors, GLP-1 RAs, and TZDs have low hypoglycemia risk as monotherapy."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01198",
   "question": "Which of the following factors increases a patient’s risk of hypoglycemia with insulin?",
   "options": [
      "Increased carbohydrate intake",
      "Increased physical activity",
      "Hyperglycemia",
      "Insulin resistance"
   ],
   "answer": "Increased physical activity",
   "explanation": "Increased physical activity, reduced food intake, renal/hepatic impairment, and alcohol increase hypoglycemia risk."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01199",
   "question": "Which of the following insulins can be administered intravenously?",
   "options": [
      "NPH insulin",
      "Insulin glargine",
      "Regular insulin",
      "Insulin detemir"
   ],
   "answer": "Regular insulin",
   "explanation": "Regular insulin is the only insulin formulation suitable for intravenous administration."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01200",
   "question": "Which of the following insulins is a suspension and must be gently rolled before administration?",
   "options": [
      "Insulin lispro",
      "Insulin glargine",
      "NPH insulin",
      "Insulin detemir"
   ],
   "answer": "NPH insulin",
   "explanation": "NPH insulin is a cloudy suspension that requires resuspension before injection."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01201",
   "question": "Which of the following is a benefit of GLP-1 receptor agonists in addition to glucose lowering?",
   "options": [
      "Weight gain",
      "Hypoglycemia",
      "Cardiovascular risk reduction",
      "Fluid retention"
   ],
   "answer": "Cardiovascular risk reduction",
   "explanation": "Several GLP-1 receptor agonists have demonstrated significant cardiovascular benefits, including a reduction in major adverse cardiovascular events."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01202",
   "question": "Which of the following is a common symptom of uncontrolled type 1 diabetes?",
   "options": [
      "Weight gain",
      "Bradycardia",
      "Polyuria",
      "Hypotension"
   ],
   "answer": "Polyuria",
   "explanation": "Polyuria, polydipsia, and weight loss are classic symptoms of uncontrolled diabetes, especially type 1."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01203",
   "question": "Which of the following is a key component of patient education for individuals on insulin therapy?",
   "options": [
      "Avoiding all carbohydrates",
      "Injecting insulin into scarred areas for better absorption",
      "Monitoring blood glucose regularly and recognizing hypoglycemia symptoms",
      "Increasing insulin dose without consulting a healthcare provider"
   ],
   "answer": "Monitoring blood glucose regularly and recognizing hypoglycemia symptoms",
   "explanation": "Patient education should emphasize blood glucose monitoring, recognizing and treating hypoglycemia, and proper injection technique."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01204",
   "question": "Which of the following is a long-acting insulin analog that has no pronounced peak?",
   "options": [
      "NPH insulin",
      "Insulin glargine U-100",
      "Regular insulin",
      "Insulin lispro"
   ],
   "answer": "Insulin glargine U-100",
   "explanation": "Insulin glargine U-100 (Lantus) provides a relatively peakless basal insulin profile."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01205",
   "question": "Which of the following is a potential side effect of SGLT2 inhibitors related to their mechanism of action?",
   "options": [
      "Hyponatremia",
      "Increased blood pressure",
      "Genital yeast infections",
      "Hypothyroidism"
   ],
   "answer": "Genital yeast infections",
   "explanation": "Increased glucose in urine due to SGLT2 inhibition can lead to increased risk of genital mycotic infections."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01206",
   "question": "Which of the following is a potential side effect of sulfonylureas that distinguishes them from metformin?",
   "options": [
      "Weight loss",
      "Lactic acidosis",
      "Weight gain",
      "Nausea"
   ],
   "answer": "Weight gain",
   "explanation": "Sulfonylureas commonly cause weight gain due to increased insulin levels, a contrast to metformin’s weight neutrality or modest loss."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01207",
   "question": "Which of the following is a rapid-acting insulin analog that should be given shortly before or with a meal?",
   "options": [
      "Insulin glargine",
      "NPH insulin",
      "Insulin lispro",
      "Insulin detemir"
   ],
   "answer": "Insulin lispro",
   "explanation": "Rapid-acting insulin analogs (lispro, aspart, glulisine) are administered around mealtime due to their quick onset."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01208",
   "question": "Which of the following is a symptom of severe hypoglycemia that requires immediate medical attention?",
   "options": [
      "Mild sweating",
      "Confusion or loss of consciousness",
      "Increased hunger",
      "Blurred vision"
   ],
   "answer": "Confusion or loss of consciousness",
   "explanation": "Severe hypoglycemia can lead to confusion, disorientation, seizures, or loss of consciousness, requiring immediate intervention."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01209",
   "question": "Which of the following is an advantage of metformin therapy?",
   "options": [
      "Causes weight gain",
      "Low risk of hypoglycemia",
      "Requires frequent glucose monitoring",
      "Is an injectable medication"
   ],
   "answer": "Low risk of hypoglycemia",
   "explanation": "Metformin does not stimulate insulin secretion, thus has a low risk of hypoglycemia as monotherapy."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01210",
   "question": "Which of the following is an ultra-long-acting insulin, lasting over 40 hours?",
   "options": [
      "Insulin glargine U-300",
      "Insulin degludec",
      "Insulin detemir",
      "Insulin glulisine"
   ],
   "answer": "Insulin degludec",
   "explanation": "Insulin degludec has a duration of action beyond 40 hours, making it an ultra-long-acting basal insulin."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01211",
   "question": "Which of the following is an ultra-rapid acting insulin that can be used at the start of a meal or up to 20 minutes after starting a meal?",
   "options": [
      "Insulin aspart",
      "Insulin lispro",
      "Insulin glulisine",
      "Insulin Fiasp (faster-acting insulin aspart)"
   ],
   "answer": "Insulin Fiasp (faster-acting insulin aspart)",
   "explanation": "Faster-acting insulin aspart (Fiasp) has an even quicker onset than traditional rapid-acting insulins, allowing for dosing during or after a meal."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01212",
   "question": "Which of the following is NOT one of the ADA’s recognized clinical classifications of diabetes?",
   "options": [
      "Type 1 diabetes",
      "Type 2 diabetes",
      "Gestational diabetes",
      "Maturity-onset diabetes of the young"
   ],
   "answer": "Maturity-onset diabetes of the young",
   "explanation": "The ADA recognizes type 1, type 2, gestational diabetes, and diabetes due to other specific causes; maturity-onset diabetes of the young is a monogenic form but not a primary ADA category."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01213",
   "question": "Which of the following oral agents primarily targets insulin resistance?",
   "options": [
      "Sulfonylureas",
      "Meglitinides",
      "Thiazolidinediones",
      "DPP-4 inhibitors"
   ],
   "answer": "Thiazolidinediones",
   "explanation": "Thiazolidinediones directly enhance insulin sensitivity, addressing insulin resistance."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01214",
   "question": "Which of the following produces only modest A1C reductions by an unknown mechanism?",
   "options": [
      "Bromocriptine",
      "Metformin",
      "Sitagliptin",
      "Liraglutide"
   ],
   "answer": "Bromocriptine",
   "explanation": "Bromocriptine (a dopamine agonist) and colesevelam lower A1C modestly but their exact actions are unclear."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01215",
   "question": "Which of the following statements about insulin absorption is true?",
   "options": [
      "Absorption is fastest from the thigh",
      "Absorption is slowest from the abdomen",
      "Heat and exercise can increase absorption",
      "Massage at the injection site decreases absorption"
   ],
   "answer": "Heat and exercise can increase absorption",
   "explanation": "Heat, massage, and exercise can increase blood flow to the injection site, accelerating insulin absorption."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01216",
   "question": "Which of these agents also shows proven benefit in heart failure with reduced ejection fraction?",
   "options": [
      "Empagliflozin",
      "Exenatide",
      "Rosiglitazone",
      "Saxagliptin"
   ],
   "answer": "Empagliflozin",
   "explanation": "Empagliflozin and other SGLT2 inhibitors reduce HF hospitalizations and mortality in HFrEF."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01217",
   "question": "Which of these is a long-acting insulin with a flat, prolonged action profile, typically given once daily?",
   "options": [
      "Insulin regular",
      "Insulin NPH",
      "Insulin glargine",
      "Insulin lispro"
   ],
   "answer": "Insulin glargine",
   "explanation": "Insulin glargine (Lantus, Basaglar) is a long-acting insulin designed to provide steady, peakless basal insulin levels for 24 hours or more."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01218",
   "question": "Which of these is a meglitinide (short-acting insulin secretagogue)?",
   "options": [
      "Pioglitazone",
      "Repaglinide",
      "Sitagliptin",
      "Empagliflozin"
   ],
   "answer": "Repaglinide",
   "explanation": "Repaglinide (and nateglinide) are meglitinides that stimulate rapid, short-duration insulin release."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01219",
   "question": "Which oral agent helps lower postprandial glucose by slowing carbohydrate digestion and absorption?",
   "options": [
      "Metformin",
      "Glyburide",
      "Acarbose",
      "Sitagliptin"
   ],
   "answer": "Acarbose",
   "explanation": "Acarbose and miglitol are alpha-glucosidase inhibitors that delay carbohydrate absorption in the gut."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01220",
   "question": "Which oral agent is preferred as initial therapy for type 2 diabetes?",
   "options": [
      "Glyburide",
      "Metformin",
      "Pioglitazone",
      "Sitagliptin"
   ],
   "answer": "Metformin",
   "explanation": "Metformin’s efficacy, safety, low cost, and benefits make it first-line for type 2 diabetes."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01221",
   "question": "Which oral agent works by enhancing the effects of endogenous incretins?",
   "options": [
      "Metformin",
      "Glyburide",
      "Sitagliptin",
      "Pioglitazone"
   ],
   "answer": "Sitagliptin",
   "explanation": "DPP-4 inhibitors like sitagliptin enhance the action of naturally occurring incretin hormones."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01222",
   "question": "Which oral antidiabetic drug is known to cause weight gain and fluid retention, and is contraindicated in heart failure?",
   "options": [
      "Metformin",
      "Glyburide",
      "Pioglitazone",
      "Sitagliptin"
   ],
   "answer": "Pioglitazone",
   "explanation": "Thiazolidinediones like pioglitazone cause weight gain and fluid retention and are contraindicated in heart failure."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01223",
   "question": "Which rapid-acting insulin analog has the fastest onset and shortest duration of action?",
   "options": [
      "Lispro",
      "Regular insulin",
      "NPH insulin",
      "Glargine"
   ],
   "answer": "Lispro",
   "explanation": "Lispro, aspart, and glulisine are rapid-acting insulins with a quick onset (15–30 min) and short duration (3–5 hr)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01224",
   "question": "Which rapid-acting insulin analog has the quickest onset of action?",
   "options": [
      "Insulin lispro",
      "Insulin aspart",
      "Insulin glulisine",
      "All have similar quick onset"
   ],
   "answer": "All have similar quick onset",
   "explanation": "Lispro, aspart, and glulisine are all rapid-acting analogs with similar quick onsets (5–15 minutes)."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01225",
   "question": "Which SGLT2 inhibitor has also shown renal protective benefits in patients with type 2 diabetes and chronic kidney disease?",
   "options": [
      "Dapagliflozin",
      "Canagliflozin",
      "Empagliflozin",
      "All of the above"
   ],
   "answer": "All of the above",
   "explanation": "All SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) have demonstrated renal benefits in T2DM with CKD."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01226",
   "question": "Which type of insulin is considered 'basal insulin'?",
   "options": [
      "Insulin lispro",
      "Regular insulin",
      "Insulin glargine",
      "NPH insulin"
   ],
   "answer": "Insulin glargine",
   "explanation": "Insulin glargine is a long-acting basal insulin, providing relatively constant insulin levels over 24 hours."
},
 {
   "chapter_id": 24,
   "chapter": "Drugs for Diabetes",
   "question_id": "00024-01227",
   "question": "Why is regular insulin often used in insulin drips for diabetic ketoacidosis?",
   "options": [
      "It has the longest duration of action",
      "It can be given intravenously",
      "It causes minimal hypoglycemia",
      "It is the cheapest option"
   ],
   "answer": "It can be given intravenously",
   "explanation": "Regular insulin’s ability to be administered intravenously makes it suitable for continuous infusions in DKA."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01228",
   "question": "Common local adverse effects of ICS include:",
   "options": [
      "Systemic hypertension",
      "Oral candidiasis and dysphonia",
      "Osteoporosis",
      "Adrenal suppression"
   ],
   "answer": "Oral candidiasis and dysphonia",
   "explanation": "Local deposition can cause thrush (oral candidiasis) and hoarseness (dysphonia)."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01229",
   "question": "In stable COPD management, the mainstay of bronchodilator therapy is:",
   "options": [
      "Short-acting β₂ agonists only",
      "Long-acting muscarinic antagonists and/or LABAs",
      "Mast cell stabilizers",
      "IV corticosteroids"
   ],
   "answer": "Long-acting muscarinic antagonists and/or LABAs",
   "explanation": "COPD guidelines recommend LAMAs (e.g., tiotropium) and/or LABAs as baseline maintenance bronchodilators."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01230",
   "question": "Inhaled corticosteroids (ICS) reduce asthma exacerbations by:",
   "options": [
      "Directly bronchodilating airways",
      "Suppressing airway inflammation",
      "Inhibiting bacterial growth",
      "Increasing mucociliary clearance"
   ],
   "answer": "Suppressing airway inflammation",
   "explanation": "ICS are first-line long-term controllers in asthma due to their potent anti-inflammatory effects."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01231",
   "question": "Inhaled or intranasal administration of drugs for respiratory conditions aims primarily to:",
   "options": [
      "Increase systemic exposure",
      "Target lung tissue and minimize systemic effects",
      "Enhance first-pass metabolism",
      "Prolong half-life"
   ],
   "answer": "Target lung tissue and minimize systemic effects",
   "explanation": "Inhaled or intranasal delivery targets diseased tissues while reducing systemic adverse effects."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01232",
   "question": "Ipratropium, a short-acting muscarinic antagonist (SAMA), causes bronchodilation by:",
   "options": [
      "Activating β₂-receptors",
      "Blocking M₃ muscarinic receptors in airways",
      "Inhibiting phosphodiesterase",
      "Reducing histamine release"
   ],
   "answer": "Blocking M₃ muscarinic receptors in airways",
   "explanation": "Ipratropium blocks cholinergic (M₃) receptors, preventing acetylcholine-induced bronchoconstriction."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01233",
   "question": "LABA monotherapy in asthma is contraindicated because it:",
   "options": [
      "Causes excessive sedation",
      "Increases risk of asthma-related death",
      "Induces tolerance rapidly",
      "Has no bronchodilator effect"
   ],
   "answer": "Increases risk of asthma-related death",
   "explanation": "LABA monotherapy in asthma is associated with an increased risk of severe exacerbations and asthma-related death."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01234",
   "question": "Leukotriene receptor antagonists (LTRAs) like montelukast are effective in asthma by:",
   "options": [
      "Blocking histamine receptors",
      "Inhibiting leukotriene synthesis or receptor binding",
      "Activating β₂-receptors",
      "Suppressing IgE production"
   ],
   "answer": "Inhibiting leukotriene synthesis or receptor binding",
   "explanation": "Montelukast and zafirlukast block CysLT1 receptors, reducing leukotriene-mediated bronchoconstriction and inflammation."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01235",
   "question": "Long-acting β₂ agonists (LABAs) should never be used as monotherapy in asthma primarily because they:",
   "options": [
      "Increase the risk of asthma-related death",
      "Cause tolerance quickly",
      "Are less effective than SABAs",
      "Lead to excessive systemic side effects"
   ],
   "answer": "Increase the risk of asthma-related death",
   "explanation": "LABA monotherapy in asthma is associated with an increased risk of severe exacerbations and asthma-related death."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01236",
   "question": "Nebulized dornase alfa is used in cystic fibrosis to:",
   "options": [
      "Bronchodilate airways",
      "Reduce viscosity of sputum",
      "Inhibit bacterial growth",
      "Improve nutrient absorption"
   ],
   "answer": "Reduce viscosity of sputum",
   "explanation": "Dornase alfa (recombinant human DNase) cleaves extracellular DNA in sputum, reducing its viscosity."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01237",
   "question": "Omalizumab is a monoclonal antibody used in severe persistent allergic asthma that targets:",
   "options": [
      "IL-5",
      "IgE",
      "TNF-α",
      "IL-4"
   ],
   "answer": "IgE",
   "explanation": "Omalizumab binds to free IgE, preventing its binding to mast cells and reducing mediator release."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01238",
   "question": "Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, is used in severe COPD to:",
   "options": [
      "Cause bronchodilation",
      "Reduce inflammation and exacerbations",
      "Increase mucociliary clearance",
      "Directly suppress cough"
   ],
   "answer": "Reduce inflammation and exacerbations",
   "explanation": "Roflumilast selectively inhibits PDE4, increasing cAMP and reducing inflammation, leading to fewer COPD exacerbations."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01239",
   "question": "Short-acting β₂ agonists (SABAs) relieve acute asthma symptoms by:",
   "options": [
      "Reducing airway inflammation",
      "Bronchodilation via smooth muscle relaxation",
      "Suppressing mucus production",
      "Inhibiting mast cell degranulation"
   ],
   "answer": "Bronchodilation via smooth muscle relaxation",
   "explanation": "SABAs stimulate β₂-adrenergic receptors in airway smooth muscle, causing relaxation and bronchodilation."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01240",
   "question": "Theophylline’s bronchodilating effect is mediated by:",
   "options": [
      "Inhibiting phosphodiesterase and blocking adenosine receptors",
      "Stimulating β₂-receptors directly",
      "Blocking muscarinic receptors",
      "Increasing cyclic GMP"
   ],
   "answer": "Inhibiting phosphodiesterase and blocking adenosine receptors",
   "explanation": "Theophylline inhibits PDE (increasing cAMP) and blocks adenosine, leading to bronchodilation and anti-inflammatory effects."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01241",
   "question": "Tiotropium, a long-acting muscarinic antagonist (LAMA), is preferred over ipratropium for COPD maintenance because it:",
   "options": [
      "Has a faster onset of action",
      "Provides sustained 24-hour bronchodilation",
      "Is less expensive",
      "Causes fewer side effects"
   ],
   "answer": "Provides sustained 24-hour bronchodilation",
   "explanation": "Tiotropium offers once-daily dosing due to its prolonged M₃ receptor binding, providing sustained bronchodilation in COPD."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01242",
   "question": "Which adverse effect is a rare but serious concern with omalizumab?",
   "options": [
      "Hypoglycemia",
      "Anaphylaxis",
      "Hyperkalemia",
      "Thrombosis"
   ],
   "answer": "Anaphylaxis",
   "explanation": "Omalizumab has a boxed warning for anaphylaxis, requiring administration in a healthcare setting."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01243",
   "question": "Which adverse effect is common with roflumilast, particularly early in therapy?",
   "options": [
      "Weight gain",
      "Insomnia and weight loss",
      "Fluid retention",
      "Hypoglycemia"
   ],
   "answer": "Insomnia and weight loss",
   "explanation": "Nausea, diarrhea, weight loss, and neuropsychiatric effects (e.g., insomnia) are common."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01244",
   "question": "Which adverse effect is commonly associated with SABA use?",
   "options": [
      "Bradycardia",
      "Hypoglycemia",
      "Tremor and tachycardia",
      "Sedation"
   ],
   "answer": "Tremor and tachycardia",
   "explanation": "Activation of β₂-receptors in skeletal muscle and the heart can lead to tremor and tachycardia."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01245",
   "question": "Which LTRA is also approved for seasonal allergic rhinitis?",
   "options": [
      "Montelukast",
      "Zafirlukast",
      "Zileuton",
      "Pranlukast"
   ],
   "answer": "Montelukast",
   "explanation": "Montelukast is approved for both asthma and the relief of seasonal allergic rhinitis symptoms."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01246",
   "question": "Which mediator is primarily responsible for bronchoconstriction in asthma?",
   "options": [
      "Leukotrienes",
      "Prostaglandins",
      "Histamine",
      "Bradykinin"
   ],
   "answer": "Histamine",
   "explanation": "Histamine released from mast cells is a potent bronchoconstrictor in allergic asthma."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01247",
   "question": "Which of the following factors can increase theophylline levels, potentially leading to toxicity?",
   "options": [
      "Smoking",
      "Phenobarbital use",
      "Ciprofloxacin use",
      "High-protein diet"
   ],
   "answer": "Ciprofloxacin use",
   "explanation": "Ciprofloxacin and other CYP1A2 inhibitors (e.g., cimetidine, erythromycin) can increase theophylline levels."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01248",
   "question": "Which of the following is a common anticholinergic adverse effect of muscarinic antagonists?",
   "options": [
      "Bronchospasm",
      "Dry mouth",
      "Diarrhea",
      "Bradycardia"
   ],
   "answer": "Dry mouth",
   "explanation": "Dry mouth is common due to M₃ receptor blockade in salivary glands."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01249",
   "question": "Which of the following is a key feature of asthma, but not chronic obstructive pulmonary disease (COPD)?",
   "options": [
      "Chronic airflow limitation",
      "Irreversible airway obstruction",
      "Airway hyperresponsiveness and reversibility",
      "Neutrophilic inflammation"
   ],
   "answer": "Airway hyperresponsiveness and reversibility",
   "explanation": "Asthma is distinguished by reversible airflow limitation and airway hyperresponsiveness to various stimuli."
},
 {
   "chapter_id": 41,
   "chapter": "Drugs for Disorders of the Respiratory System",
   "question_id": "00041-01250",
   "question": "Which of the following is typically used for rapid relief of acute bronchospasm in COPD?",
   "options": [
      "Salmeterol",
      "Tiotropium",
      "Albuterol",
      "Fluticasone"
   ],
   "answer": "Albuterol",
   "explanation": "Albuterol (a SABA) is the rescue medication of choice for acute COPD exacerbations."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01251",
   "question": "A child with absence seizures and attention interruption should be treated with:",
   "options": [
      "Carbamazepine",
      "Diazepam",
      "Ethosuximide",
      "Phenytoin"
   ],
   "answer": "Ethosuximide",
   "explanation": "Ethosuximide is the first-line therapy for childhood absence seizures, whereas carbamazepine may worsen them."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01252",
   "question": "All women planning pregnancy on antiseizure medications should receive high-dose folic acid (1–5 mg) to prevent:",
   "options": [
      "Cardiac defects",
      "Neural tube defects",
      "Gastrointestinal atresia",
      "Limb deformities"
   ],
   "answer": "Neural tube defects",
   "explanation": "High-dose folic acid reduces neural tube defect risk in fetuses exposed to ASMs during early pregnancy."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01253",
   "question": "Atonic seizures, also known as drop attacks, are characterized by:",
   "options": [
      "Brief staring spells",
      "Sudden loss of muscle tone",
      "Continuous muscle contraction",
      "Rapid muscle jerks"
   ],
   "answer": "Sudden loss of muscle tone",
   "explanation": "Atonic seizures cause a sudden loss of muscle tone, leading to falls or “drop attacks”."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01254",
   "question": "Eslicarbazepine acetate is a prodrug of oxcarbazepine’s active metabolite and differs by:",
   "options": [
      "Being more potent enzyme inducer",
      "Exhibiting linear pharmacokinetics",
      "Blocking GABA uptake",
      "Inhibiting NMDA receptors"
   ],
   "answer": "Exhibiting linear pharmacokinetics",
   "explanation": "Eslicarbazepine shows linear kinetics and is converted to S-licarbazepine, offering more predictable levels than oxcarbazepine."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01255",
   "question": "Ethosuximide is most effective for which type of seizure?",
   "options": [
      "Focal seizures",
      "Absence seizures",
      "Generalized tonic–clonic seizures",
      "Atonic seizures"
   ],
   "answer": "Absence seizures",
   "explanation": "Ethosuximide reduces abnormal thalamic T-type calcium currents, making it the treatment of choice for absence seizures."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01256",
   "question": "In women of childbearing potential, which antiseizure drug is preferred due to lower teratogenic risk?",
   "options": [
      "Valproate",
      "Barbiturates",
      "Lamotrigine",
      "Phenobarbital"
   ],
   "answer": "Lamotrigine",
   "explanation": "Lamotrigine has a lower teratogenicity profile compared to valproate and barbiturates and is often chosen before conception."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01257",
   "question": "Lamotrigine dosing must be conservative when co-administered with valproate because valproate:",
   "options": [
      "Induces lamotrigine metabolism",
      "Inhibits lamotrigine clearance",
      "Competes for GABA uptake",
      "Blocks sodium channels"
   ],
   "answer": "Inhibits lamotrigine clearance",
   "explanation": "Valproate inhibits lamotrigine glucuronidation via UGT, doubling its half-life; conservative titration minimizes rash risk."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01258",
   "question": "Monotherapy is preferred in newly diagnosed epilepsy because combination therapy generally results in:",
   "options": [
      "Better adherence and fewer side effects",
      "Higher seizure rates",
      "Lower efficacy",
      "Increased drug interactions"
   ],
   "answer": "Better adherence and fewer side effects",
   "explanation": "New patients on monotherapy show better adherence and fewer adverse effects compared to polytherapy."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01259",
   "question": "Myoclonic seizures are best described as:",
   "options": [
      "Brief loss of muscle tone",
      "Short episodes of muscle contractions",
      "Continuous tonic contraction",
      "Brief absence of awareness"
   ],
   "answer": "Short episodes of muscle contractions",
   "explanation": "Myoclonic seizures consist of brief, recurrent muscle contractions, often occurring after awakening."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01260",
   "question": "Perampanel’s antiseizure action involves antagonism at which receptor, with a warning for psychiatric reactions?",
   "options": [
      "GABA_A",
      "AMPA glutamate",
      "NMDA",
      "SV2A protein"
   ],
   "answer": "AMPA glutamate",
   "explanation": "Perampanel selectively antagonizes AMPA receptors, reducing excitatory neurotransmission, but carries a boxed warning for serious psychiatric and behavioral reactions."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01261",
   "question": "Phenytoin’s nonlinear pharmacokinetics lead to disproportionate increases in plasma levels with dose changes, contributing to:",
   "options": [
      "Hepatotoxicity only",
      "Variable seizure control",
      "Gingival hyperplasia and toxicity risk",
      "No adverse effects"
   ],
   "answer": "Gingival hyperplasia and toxicity risk",
   "explanation": "Phenytoin exhibits saturation kinetics, so small dose increases can cause toxicity and adverse effects like gingival hyperplasia."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01262",
   "question": "Rufinamide is indicated as adjunctive therapy for seizures in which syndrome?",
   "options": [
      "Dravet syndrome",
      "Lennox–Gastaut syndrome",
      "Benign rolandic epilepsy",
      "Absence epilepsy"
   ],
   "answer": "Lennox–Gastaut syndrome",
   "explanation": "Rufinamide acts on sodium channels and is approved for Lennox–Gastaut syndrome in children ≥1 year and adults."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01263",
   "question": "Status epilepticus is first treated with a fast-acting benzodiazepine followed by which slower-acting agent?",
   "options": [
      "Levetiracetam",
      "Ethosuximide",
      "Phenytoin",
      "Lamotrigine"
   ],
   "answer": "Phenytoin",
   "explanation": "Initial management of status epilepticus uses IV benzodiazepines, then phenytoin (or fosphenytoin, divalproex, levetiracetam) to maintain seizure control."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01264",
   "question": "Stiripentol’s use is limited to Dravet syndrome patients co-administered with which benzodiazepine?",
   "options": [
      "Diazepam",
      "Clobazam",
      "Clonazepam",
      "Lorazepam"
   ],
   "answer": "Clobazam",
   "explanation": "Stiripentol enhances GABA_A function and is approved only in Dravet syndrome when given with clobazam, raising clobazam levels significantly."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01265",
   "question": "Tiagabine’s antiseizure effect is mediated by blocking:",
   "options": [
      "GABA uptake into neurons",
      "GABA transaminase",
      "SV2A protein",
      "NMDA receptors"
   ],
   "answer": "GABA uptake into neurons",
   "explanation": "Tiagabine inhibits presynaptic GABA reuptake, increasing extracellular GABA; it’s adjunctive for focal seizures but not indicated outside epilepsy due to risk of provoked seizures."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01266",
   "question": "Topiramate’s mechanisms include sodium channel blockade, carbonic anhydrase inhibition, and:",
   "options": [
      "GABA-T inhibition",
      "Calcium channel blockade",
      "SV2A binding",
      "NMDA antagonism"
   ],
   "answer": "Calcium channel blockade",
   "explanation": "Topiramate blocks Na⁺ channels, high-voltage Ca²⁺ currents, inhibits carbonic anhydrase, and may modulate NMDA receptors; it’s also migraine-preventive."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01267",
   "question": "Valproate therapy requires frequent monitoring of which organ function due to rare hepatotoxicity?",
   "options": [
      "Renal function",
      "Liver enzymes",
      "Thyroid function",
      "Pancreatic enzymes"
   ],
   "answer": "Liver enzymes",
   "explanation": "Valproate inhibits multiple metabolic pathways and can cause hepatotoxicity, so liver enzymes must be checked regularly."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01268",
   "question": "Valproate’s mechanisms include sodium channel blockade, GABA transaminase inhibition, and T-type calcium channel action, making it effective for:",
   "options": [
      "Only focal seizures",
      "Only absence seizures",
      "Broad spectrum epilepsy",
      "Status epilepticus only"
   ],
   "answer": "Broad spectrum epilepsy",
   "explanation": "Valproate/divalproex acts on Na⁺ channels, GABA-T, and Ca²⁺ channels, providing broad efficacy in focal and generalized epilepsies."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01269",
   "question": "Which adjunctive antiseizure agent carries a risk of shortened QT interval and is contraindicated in familial short QT syndrome?",
   "options": [
      "Rufinamide",
      "Brivaracetam",
      "Phenobarbital",
      "Ethosuximide"
   ],
   "answer": "Rufinamide",
   "explanation": "Rufinamide may shorten QT interval and should not be used in patients with familial short QT syndrome."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01270",
   "question": "Which anticonvulsant is a prodrug converted to phenytoin and is preferred for IV or IM administration to avoid tissue damage?",
   "options": [
      "Fosphenytoin",
      "Phenytoin",
      "Phenobarbital",
      "Valproate"
   ],
   "answer": "Fosphenytoin",
   "explanation": "Fosphenytoin is rapidly converted to phenytoin in blood, allowing safe IM/IV use, whereas phenytoin sodium causes tissue necrosis if given IM."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01271",
   "question": "Which antiseizure drug blocks sodium channels, induces its own metabolism, and is contraindicated in absence seizures?",
   "options": [
      "Carbamazepine",
      "Lamotrigine",
      "Ethosuximide",
      "Topiramate"
   ],
   "answer": "Carbamazepine",
   "explanation": "Carbamazepine inhibits Na⁺ channels, autoinduces CYP and UGT enzymes, and can worsen absence seizures; it also causes hyponatremia in some patients."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01272",
   "question": "Which antiseizure drug competes at the glycine site of NMDA receptors and is reserved for refractory epilepsy due to aplastic anemia risk?",
   "options": [
      "Felbamate",
      "Perampanel",
      "Phenobarbital",
      "Lamotrigine"
   ],
   "answer": "Felbamate",
   "explanation": "Felbamate blocks multiple targets including NMDA glycine site; its use is limited by rare but serious aplastic anemia and hepatic failure."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01273",
   "question": "Which antiseizure drug may cause oligohidrosis and hyperthermia in children?",
   "options": [
      "Carbamazepine",
      "Topiramate",
      "Lamotrigine",
      "Ethosuximide"
   ],
   "answer": "Topiramate",
   "explanation": "Topiramate’s carbonic anhydrase inhibition can lead to reduced sweating (oligohidrosis) and heat intolerance."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01274",
   "question": "Which antiseizure drug’s use is limited by risk of serious rash progressing to Stevens–Johnson syndrome?",
   "options": [
      "Lamotrigine",
      "Phenytoin",
      "Topiramate",
      "Gabapentin"
   ],
   "answer": "Lamotrigine",
   "explanation": "Lamotrigine requires slow titration, especially when combined with valproate, to minimize risk of life-threatening rash."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01275",
   "question": "Which antiseizure drugs induce hepatic enzymes and may decrease efficacy of hormonal contraceptives?",
   "options": [
      "Valproate, ethosuximide",
      "Phenytoin, carbamazepine",
      "Levetiracetam, gabapentin",
      "Lamotrigine, vigabatrin"
   ],
   "answer": "Phenytoin, carbamazepine",
   "explanation": "Enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital, topiramate, oxcarbazepine) increase contraceptive metabolism and risk failure."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01276",
   "question": "Which antiseizure medication exhibits nonlinear kinetics due to saturable gut transport and is eliminated unchanged by kidneys?",
   "options": [
      "Gabapentin",
      "Levetiracetam",
      "Oxcarbazepine",
      "Valproate"
   ],
   "answer": "Gabapentin",
   "explanation": "Gabapentin’s absorption is saturable, causing nonlinear kinetics; it’s excreted unchanged renally and has minimal interactions."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01277",
   "question": "Which antiseizure medication has high affinity for synaptic vesicle protein 2A but an unknown exact mechanism?",
   "options": [
      "Levetiracetam",
      "Carbamazepine",
      "Phenobarbital",
      "Ethosuximide"
   ],
   "answer": "Levetiracetam",
   "explanation": "Levetiracetam’s efficacy is linked to SV2A binding; its precise antiseizure mechanism remains unclear, and it is renally excreted unchanged, minimizing interactions."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01278",
   "question": "Which antiseizure medication is approved as a liquid formulation with sesame oil for Dravet, without psychoactive effects?",
   "options": [
      "Cannabidiol",
      "Clobazam",
      "Stiripentol",
      "Fenfluramine"
   ],
   "answer": "Cannabidiol",
   "explanation": "Cannabidiol is formulated as a sesame oil liquid for Lennox–Gastaut and Dravet syndromes; it has no psychoactivity but can raise liver enzymes."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01279",
   "question": "Which antiseizure medication is associated with weight loss, paresthesias, and potential kidney stones?",
   "options": [
      "Zonisamide",
      "Levetiracetam",
      "Carbamazepine",
      "Vigabatrin"
   ],
   "answer": "Zonisamide",
   "explanation": "Zonisamide can cause somnolence, weight loss, paresthesias, and nephrolithiasis due to carbonic anhydrase activity."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01280",
   "question": "Which antiseizure therapy requires biannual echocardiograms due to risk of valvulopathy and pulmonary hypertension?",
   "options": [
      "Fenfluramine",
      "Stiripentol",
      "Levetiracetam",
      "Tiagabine"
   ],
   "answer": "Fenfluramine",
   "explanation": "Fenfluramine, indicated in Dravet syndrome, carries valvular and pulmonary hypertension risks, necessitating echocardiographic monitoring."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01281",
   "question": "Which class of drugs suppresses seizures by blocking voltage-gated sodium or calcium channels, enhancing GABAergic impulses, or inhibiting excitatory glutamate transmission?",
   "options": [
      "Anxiolytics",
      "Antidepressants",
      "Antiseizure medications",
      "Antipsychotics"
   ],
   "answer": "Antiseizure medications",
   "explanation": "Antiseizure medications act via multiple mechanisms—blocking Na⁺/Ca²⁺ channels, enhancing GABA, or reducing glutamate—to suppress seizures without curing epilepsy."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01282",
   "question": "Which drug binds GABA_A receptors to reduce neuronal firing and is reserved primarily for emergency seizure treatment?",
   "options": [
      "Clonazepam",
      "Phenobarbital",
      "Phenytoin",
      "Ethosuximide"
   ],
   "answer": "Clonazepam",
   "explanation": "Benzodiazepines like clonazepam bind GABA_A receptors to enhance inhibition; chronic use leads to tolerance, so they’re reserved for acute seizures."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01283",
   "question": "Which drug irreversibly inhibits GABA transaminase, increasing GABA levels but carries a risk of visual field defects?",
   "options": [
      "Tiagabine",
      "Vigabatrin",
      "Valproate",
      "Gabapentin"
   ],
   "answer": "Vigabatrin",
   "explanation": "Vigabatrin irreversibly inhibits GABA-T, raising GABA; however, it’s associated with visual field loss in many patients and requires REMS monitoring."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01284",
   "question": "Which drug is approved for focal-onset seizures and adjunctive therapy for primary generalized tonic-clonic seizures, with minimal drug interactions?",
   "options": [
      "Phenytoin",
      "Levetiracetam",
      "Carbamazepine",
      "Valproate"
   ],
   "answer": "Levetiracetam",
   "explanation": "Levetiracetam binds SV2A, is excreted unchanged, and has few interactions; it’s approved for focal and adjunctive generalized seizure treatment."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01285",
   "question": "Which home rescue medication is most appropriate for a patient with seizure clusters 1 hour from hospital?",
   "options": [
      "Topical cannabidiol lotion",
      "Intranasal diazepam",
      "Oral clonazepam",
      "Oral lamotrigine"
   ],
   "answer": "Intranasal diazepam",
   "explanation": "Intranasal or rectal diazepam provides rapid seizure control at home; topical cannabidiol formulations are unregulated and oral agents are slower."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01286",
   "question": "Which new antiseizure drug binds CRMP-2 protein in addition to stabilizing sodium channels?",
   "options": [
      "Lacosamide",
      "Perampanel",
      "Ethosuximide",
      "Phenobarbital"
   ],
   "answer": "Lacosamide",
   "explanation": "Lacosamide enhances Na⁺ channel slow inactivation and binds CRMP-2, though its role in seizure control is not fully understood."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01287",
   "question": "Which seizure type involves continuous tonic muscle contraction followed by rapid clonic jerks and is often followed by confusion?",
   "options": [
      "Myoclonic seizures",
      "Tonic–clonic seizures",
      "Absence seizures",
      "Atonic seizures"
   ],
   "answer": "Tonic–clonic seizures",
   "explanation": "Tonic–clonic seizures start with tonic stiffening then clonic jerking and are often followed by a postictal period of confusion."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01288",
   "question": "Which seizure type is characterized by a brief loss of consciousness with a 3-Hz spike-and-wave discharge on EEG, most commonly in children aged 3 to 5 years?",
   "options": [
      "Focal seizures",
      "Tonic–clonic seizures",
      "Absence seizures",
      "Clonic seizures"
   ],
   "answer": "Absence seizures",
   "explanation": "Absence seizures present with a sudden, self-limiting loss of consciousness and are defined by a 3-Hz spike-and-wave pattern."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01289",
   "question": "Which sulfonamide derivative antiseizure drug is approved for focal epilepsy but may cause kidney stones and oligohidrosis?",
   "options": [
      "Zonisamide",
      "Oxcarbazepine",
      "Ethosuximide",
      "Tiagabine"
   ],
   "answer": "Zonisamide",
   "explanation": "Zonisamide blocks Na⁺ and T-type Ca²⁺ channels, has carbonic anhydrase activity, and can cause kidney stones and decreased sweating."
},
 {
   "chapter_id": 19,
   "chapter": "Drugs for Epilepsy",
   "question_id": "00019-01290",
   "question": "Which type of seizure originates in a specific area of one cerebral hemisphere and may progress to bilateral generalized tonic–clonic seizures?",
   "options": [
      "Focal seizures",
      "Tonic–clonic seizures",
      "Absence seizures",
      "Atonic seizures"
   ],
   "answer": "Focal seizures",
   "explanation": "Focal seizures involve only a portion of one hemisphere and can spread to both hemispheres, differentiating them from primary generalized seizure types."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01291",
   "question": "Administration of high-dose iodide in thyroid storm works by:",
   "options": [
      "Inhibiting thyroid hormone release",
      "Stimulating TSH secretion",
      "Enhancing hormone synthesis",
      "Blocking peripheral T4–T3 conversion"
   ],
   "answer": "Inhibiting thyroid hormone release",
   "explanation": "Pharmacologic iodide exerts the Wolff–Chaikoff effect, blocking thyroid hormone release."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01292",
   "question": "Adrenocorticotropic hormone (ACTH) primarily stimulates:",
   "options": [
      "Cortisol release",
      "Thyroid hormone release",
      "Growth hormone release",
      "Prolactin release"
   ],
   "answer": "Cortisol release",
   "explanation": "ACTH from the pituitary controls adrenal cortisol production in stress response."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01293",
   "question": "Central diabetes insipidus results from deficiency of:",
   "options": [
      "Antidiuretic hormone",
      "Growth hormone",
      "Thyroid-stimulating hormone",
      "Luteinizing hormone"
   ],
   "answer": "Antidiuretic hormone",
   "explanation": "Loss of ADH (vasopressin) secretion from the posterior pituitary causes DI."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01294",
   "question": "Continuous administration of the GnRH analog leuprolide initially causes a transient rise in which hormone?",
   "options": [
      "Follicle‐stimulating hormone",
      "Luteinizing hormone",
      "Testosterone",
      "Estrogen"
   ],
   "answer": "Testosterone",
   "explanation": "Leuprolide initially stimulates LH (and thus testosterone) release before receptor downregulation suppresses gonadotropin production."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01295",
   "question": "Desmopressin is preferred over vasopressin for treating nocturnal enuresis primarily because it:",
   "options": [
      "Has minimal V1 receptor activity",
      "Is not metabolized by the liver",
      "Is administered intravenously",
      "Has a shorter duration of action"
   ],
   "answer": "Has minimal V1 receptor activity",
   "explanation": "Desmopressin is a selective V2 agonist with minimal V1 (pressor) activity, reducing vasoconstrictive side effects."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01296",
   "question": "Levothyroxine is preferred over liothyronine for hypothyroidism because it:",
   "options": [
      "Has a longer half‐life",
      "Is more potent per microgram",
      "Does not require TSH monitoring",
      "Is only metabolized to T3"
   ],
   "answer": "Has a longer half‐life",
   "explanation": "Levothyroxine (T4) has a long half‐life (7–10 days), allowing once‐daily dosing."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01297",
   "question": "Methimazole inhibits thyroid hormone synthesis by:",
   "options": [
      "Blocking thyroid peroxidase",
      "Inhibiting deiodinase",
      "Binding to thyroxine‐binding globulin",
      "Antagonizing T3 receptors"
   ],
   "answer": "Blocking thyroid peroxidase",
   "explanation": "Methimazole blocks thyroid peroxidase, preventing iodination of tyrosines on thyroglobulin."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01298",
   "question": "Octreotide may be used in bleeding esophageal varices because it:",
   "options": [
      "Inhibits growth hormone",
      "Causes splanchnic vasoconstriction",
      "Increases portal flow",
      "Blocks acetylcholine release"
   ],
   "answer": "Causes splanchnic vasoconstriction",
   "explanation": "Octreotide constricts splanchnic vessels, reducing portal pressure and variceal bleeding."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01299",
   "question": "Oxytocin is clinically used to:",
   "options": [
      "Induce labor",
      "Treat diabetes insipidus",
      "Suppress prolactin",
      "Inhibit uterine contractions"
   ],
   "answer": "Induce labor",
   "explanation": "Oxytocin induces uterine contractions and is used to stimulate labor."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01300",
   "question": "Posterior pituitary hormones include:",
   "options": [
      "Vasopressin and oxytocin",
      "Growth hormone and TSH",
      "ACTH and prolactin",
      "FSH and LH"
   ],
   "answer": "Vasopressin and oxytocin",
   "explanation": "The neurohypophysis stores and releases vasopressin and oxytocin synthesized in the hypothalamus."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01301",
   "question": "The most sensitive laboratory test to monitor hypothyroidism therapy is:",
   "options": [
      "TSH",
      "T3",
      "T4",
      "TRH"
   ],
   "answer": "TSH",
   "explanation": "TSH levels are used to assess adequacy of levothyroxine therapy, measured 6–8 weeks after dose change."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01302",
   "question": "The Wolff–Chaikoff effect refers to:",
   "options": [
      "Iodide-induced inhibition of thyroid hormone release",
      "Iodide-induced increase in T4 synthesis",
      "Iodide-induced goiter formation",
      "Radioiodine-induced tissue destruction"
   ],
   "answer": "Iodide-induced inhibition of thyroid hormone release",
   "explanation": "The Wolff–Chaikoff effect is the transient block of hormone release by high iodide."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01303",
   "question": "Thyroid-stimulating hormone (TSH) exerts its effects on the thyroid gland via which second messenger?",
   "options": [
      "cAMP",
      "IP₃",
      "DAG",
      "Calcium"
   ],
   "answer": "cAMP",
   "explanation": "TSH receptor activation increases cAMP, stimulating iodide uptake and hormone synthesis."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01304",
   "question": "Which adverse effect is commonly seen with long-term octreotide therapy?",
   "options": [
      "Cholesterol gallstones",
      "Hyponatremia",
      "Hyperglycemia",
      "Constipation"
   ],
   "answer": "Cholesterol gallstones",
   "explanation": "Long-term somatostatin analog use delays gallbladder emptying, causing gallstones."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01305",
   "question": "Which adverse effect is most associated with oral iodide therapy?",
   "options": [
      "Sore mouth and throat",
      "Weight gain",
      "Hyperglycemia",
      "Skin rash"
   ],
   "answer": "Sore mouth and throat",
   "explanation": "High-dose iodide can cause oral mucous membrane ulcerations and throat swelling."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01306",
   "question": "Which GnRH antagonist can be used in controlled ovarian stimulation protocols?",
   "options": [
      "Cetrorelix",
      "Octreotide",
      "Methimazole",
      "Lanreotide"
   ],
   "answer": "Cetrorelix",
   "explanation": "Cetrorelix blocks GnRH receptors, suppressing LH surge during IVF."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01307",
   "question": "Which hormone released by the posterior pituitary increases water reabsorption in the kidney?",
   "options": [
      "Vasopressin",
      "Oxytocin",
      "Thyrotropin‐releasing hormone",
      "Adrenocorticotropic hormone"
   ],
   "answer": "Vasopressin",
   "explanation": "Vasopressin (antidiuretic hormone) binds V2 receptors in the kidney to increase water permeability and reabsorption."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01308",
   "question": "Which long-acting somatostatin analog is available as a depot injection every 4 weeks?",
   "options": [
      "Lanreotide",
      "Octreotide",
      "Leuprolide",
      "Desmopressin"
   ],
   "answer": "Lanreotide",
   "explanation": "Lanreotide depot allows monthly dosing due to its prolonged half-life."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01309",
   "question": "Which of the following is a common symptom of hyperthyroidism?",
   "options": [
      "Tachycardia",
      "Cold intolerance",
      "Weight gain",
      "Fatigue"
   ],
   "answer": "Tachycardia",
   "explanation": "Hyperthyroidism accelerates metabolism and often presents with tachycardia."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01310",
   "question": "Which of the following pituitary-secreted hormones are glycoproteins?",
   "options": [
      "TSH, FSH, LH",
      "Growth hormone, prolactin",
      "ACTH, α-MSH",
      "Oxytocin, vasopressin"
   ],
   "answer": "TSH, FSH, LH",
   "explanation": "TSH, FSH, and LH are glycoprotein hormones secreted by the anterior pituitary."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01311",
   "question": "Which synthetic analog of somatostatin is used to treat acromegaly?",
   "options": [
      "Octreotide",
      "Leuprolide",
      "Methimazole",
      "Levothyroxine"
   ],
   "answer": "Octreotide",
   "explanation": "Octreotide is a long‐acting somatostatin analog used in acromegaly and carcinoid syndrome."
},
 {
   "chapter_id": 23,
   "chapter": "Pituitary and Thyroid",
   "question_id": "00023-01312",
   "question": "Which thyroid hormone is most active at its receptor?",
   "options": [
      "T3",
      "T4",
      "Reverse T3",
      "MIT"
   ],
   "answer": "T3",
   "explanation": "T3 is the biologically active form of thyroid hormone that binds nuclear receptors."
}
]